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Abstract 
 
Functional characterization of the phenotypic consequences of genetic variants 
increasingly constitutes the rate-limiting step in the study  of  biochemical  genetics. 
This thesis  presents the application  of  metabolic  profiling technologies, including 
Nuclear Magnetic Resonance (NMR) spectroscopy and Mass Spectrometry (MS), to 
identify  metabolic  perturbations resulting from inborn erors  of  metabolism, 
congenital diseases afecting the kidney, and animal models of both genetic mutations 
and renal  pathology. In the case of newborn screening for enzyme deficiencies, two 
mass spectrometric assays, traditional tandem  mass spectrometry (MS/MS)  with 
multiple reaction  monitoring and  direct injection  nanospray  high resolution  mass 
spectrometry (ns-HR-MS), were applied to profile dried blood spot (DBS) samples of 
over  6,000  newborns and identify the  metabolic  perturbations resulting from  24 
congenital disorders of metabolism.  
To study  genetic  mutations  with  more complex  phenotypic consequences 
afecting the  kidney,  urinary  metabolic  profiles  were evaluated for four congenital 
kidney  diseases.   The  natural  history  of cystinosis, showing changes in the  urinary 
profile of cystinosis  patients  over time and with age,  glomerular filtration rate, drug 
therapy, and transplantation, and a comparison of urinary perturbations seen in these 
human  Mendelian  disorders to the  perturbations induced  by region specific 
nephrotoxins characterize the  urinary  metabolic associations  with these renal 
phenotypes. Finaly, new computational approaches for analyzing metabolic profiling 
data are  presented and evaluated, including for improving  biomarker identification 
with two-dimensional  NMR and increasing  metabolomic coverage  with  high-
resolution  mass spectrometry.Integrating  metabolic and  genetic  diagnostics should 
enhance understanding of the relationship between genes and health and mechanisms 
by which genetic variations manifest as inheriteddisease. 
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c number of model components (scalar) 
d Distance (scalar) 
δ NMR chemical shift (ppm) 
n number of observations (scalar) 
p number of descriptor variables (scalar) 
Q2 test set goodness-of-fit (scalar) 
R2 training set goodness-of-fit (scalar) 
r Corelation coeficient (scalar) 
T  Matrix of scores, [n x c] 
U  Matrix of loadings, [p x c] 
ω NMR frequency domain 
X Matrix of descriptors, [n x p] 
Y Vector of responses, [n x 1] 
 
 
 
 
 
 
 
 
 
 
 14 
 
 
 
 
List of Figures 
 
1.1. Identification of genotype-phenotye associations in Mendelian 
disease is accelerating ....................................... 21 
1.2. Genes with known Mendelian phenotypes mapped onto KEGG 
human metabolic pathways ................................... 22 
1.3. Three experimental designs integrating genomic and metabolomic 
analysis .................................................. 24 
2.  
2.1. Nuclear magnetic resonance spectroscopy ....................... 31 
2.2. Pulse sequence diagrams for 1D and 2D NMR spectroscopy 
experiments ............................................... 35 
2.3. Schematic of preprocessing operations in metabolomics ............ 39 
2.4. Visualization of normalization efects ........................... 41 
2.5. Visualization of scaling efects ................................ 43 
2.6. Strategy for unknown compound identification using statistical 
spectroscopy and spectral databases ............................ 53 
3.  
3.1. Overal strategy of Hierarchical Alignment of Two-Dimensional 
Spectra ................................................... 60 
3.2. Outline of mvaDANS operations............................... 63 
3.3. Alignment results for P. redivivus (Pre) and P. pacificus (Ppa) 
TOCSY spectra of flow-through fractions from C18 solid phase 
extractions ................................................ 68 
3.4. Comparison of normalization on ful-resolution 2D NMR data on 
bin integrals ............................................... 69 
3.5. Efects of normalization on Principal Component Analysis of 2D 
NMR spectra .............................................. 70 
 15 
3.6. Human  mitochondrial  and  peroxisomal  β-oxidation with 
homologous C. elegans pathway ............................... 72 
3.7. Statistical analysis of C. elegans mutant strain dqfCOSY spectra 
and confirmation of long chain ascarosides (VLCA) in daf-22 
exudates .................................................. 73 
3.8. Statistical analysis of urinary TOCSY spectra and identification of 
metabolic disruptions from a single pedigree Fanconi Syndrome ...... 77 
3.9. Elevated succinate and fumarate in ADFS1 urinary profiles ......... 79 
4.  
4.1. Detection frequencies and coeficients of variation for isotopicaly 
labeled internal standards by nS-HR-MS ........................ 88 
4.2. Analysis of Variance (ANOVA) by batch for internal standards ...... 89 
4.3. Changes in batch median internal standard intensity over time ....... 90 
4.4. Detection frequencies for measured analytes in nS-HR-MS .......... 91 
4.5. Distributions of log-fold-change vs. median feature for set of one 
hundred control samples ..................................... 92 
4.6. Reduction of batch efects by median centering ................... 93 
4.7. Corelations between nS-HR-MS and MS/MS measurements for 34 
metabolites detected by both techniques ......................... 94 
4.8. nS-HR-MS vs. MS/MS measurements of Phenylalanine for PKU 
positive samples, HPA samples, and non-PKU/HPA positives ....... 95 
4.9. Receiver operating characteristic (ROC) curves for PKU diagnosis 
by phenylalanine ........................................... 96 
4.10. Classification of PKU test-set samples based on stepwise logistic 
regression model ........................................... 98 
4.11. Receiver operating characteristic (ROC) curves for MCADD 
diagnosis by octanoylcarnitine ................................ 99 
4.12. Classification of MCADD test-set samples by stepwise logistic 
regression model .......................................... 100 
4.13. Classification of independent MCADD samples by stepwise 
logistic regression model .................................... 101 
4.14. Biomarkers of PKU ........................................ 103  
4.15. Biomarkers of MCADD .................................... 105 
 16 
4.16. Metabolites outside of normal ranges for 24 inborn erors by nS-
HR-MS .................................................. 106 
4.17. Metabolites outside of normal ranges for 24 inborn erors by 
MS/MS .................................................. 107 
4.18. Biomarkers of MSUD mapped onto KEGG ..................... 109 
5.  
5.1. Metabolic profiling of Fanconi Syndrome in cystinosis urine 
samples by NMR spectroscopy ............................... 119 
5.2. Confirmation of tartrate in the urine of cystinosis patients .......... 120 
5.3. Clinical phenotypes observed in congenital kidney diseases ........ 123 
5.4. Urinary excretion of metabolites elevated in Fanconi Syndromes 
relative to controls ......................................... 124 
5.5. Metabolites diferentiating congenital Fanconi Syndromes ......... 125 
5.6. Urinary citrate, acetate, and inositol excretion in ERS patients and 
unafected controls ......................................... 126 
5.7. Metabolic perturbations observed in congenital kidney diseases ..... 128 
5.8. Analysis of cystinosis natural history metadata variables ........... 129 
5.9. Statistical analysis of metabolites from cystinosis urinary NMR 
data ..................................................... 131 
5.10. Corelations between metabolites excreted by cystinosis patients .... 133 
5.11. Significant associations between urinary metabolites and cystinosis 
patient metadata variables identified by regression analysis ......... 134 
5.12. Changes in key urinary metabolites by time from transplantation .... 136 
5.13. Urinary NMR signals of glucose, TMAO and succinate over time 
from a single cystinosis patient ............................... 138 
5.14. Urinary excretion of metabolites significantly altered in animals 
exposed to model nephrotoxins relative to controls ............... 140 
5.15. Trajectories of key metabolites over nephrotoxin exposure time-
course ................................................... 142 
 
 
 
 
 
 17 
 
 
 
 
List of Tables 
2.  
2.1. Frequently measured nuclei in biomolecular Nuclear Magentic 
Resonance ................................................. 29 
2.2. Characteristics of commonly used mass analyzers .................. 37 
2.3. Data definition tools in NMR and MS ........................... 40 
2.4. Binary classification confusion matrix ........................... 51 
4.  
4.1. Inborn errors of metabolism profiled by nS-HR-MS and MS/MS 
dried blood spot analysis ..................................... 84 
4.2. Logistic regression models for prediction of PKU class by nS-HR-
MS and MS/MS ............................................ 97 
4.3. Logistic regression models for prediction of MCADD class by nS-
HR-MS and MS/MS ........................................ 100 
5.  
5.1. Cystinosis patient characteristics .............................. 113 
5.2. Assignments of urinary NMR signals integrated for targeted 
analysis .................................................. 118 
 
 
 
 
 
 
 
 
 
 
 
 18 
 
 
 
 
List of Published Papers 
 
Papers in Appendix B (I-I), C (II) and D (IV) are directly related to work presented 
in  Chapters  3-5 in this thesis, respectively.   Papers in  Appendix  E(V-VII) were 
published  during  my tenure as a  PhD candidate at Imperial and are related to 
thebackground theory, and perspectives reflected in Chapters 1, 2, and 6 but are not 
directly related to the  work  presented inChapters  3-5.   Reproduction  permission for 
work from these  papers is included in  Appendix  F and as a result figures and text 
from these papers appear throughout Chapters 1-6.  
 
Appendix B 
 
I. Izrayelit Y†, Robinete SL†, Bose N, von Reuss SH, Schroeder FC. 2D NMR-
based  metabolomics  uncovers interactions  between conserved  biochemical 
pathways in the  model  organism Caenorhabditis elegans.  ACS  Chem  Biol, 
2012. 8(2):314-319. doi:10.1021/cb3004644. †equal contribution 
I. Robinete SL, Ajredini R, Rasheed H, Zeinomar A, Schroeder FC, Dossey AT, 
Edison  AS.  Hierarchical  Alignment and  Ful  Resolution  Patern  Recognition 
of  2D  NMR  Spectra:  Application to  Nematode  Chemical  Ecology. Anal 
Chem, 2011. 83(5):1649-1657. 
 
Appendix C 
 
II. Dénes J,  Szabó  E,  Robinete  SL,   Szatmári   I,   Szőnyi   L   ,   Kreuder   JG,  
Rauterberg EW, Takáts Z. Metabonomics of Newborn Screening Dried Blood 
Spot Samples: A Novel Approach in the Screening and Diagnostics of Inborn 
Erors  of  Metabolism. Anal  Chem,  2012.  84(22):10113-10120. 
doi:10.1021/ac302527m 
 
 19 
Appendix D 
 
IV. Jaureguiberry G, De la  Dure-Mola M, Pary  D, Quentric M, Himmerkus N, 
Koike T, Poulter J, Klootwijk E,  Robinete SL, Howie AJ, Patel V, Figueres 
ML,  Stanescu  HC, Issler  N,  Nicholson JK,  Bockenhauer  D,  Laing  C,  Walsh 
SB,  McCredie  DA,  Povey  S,  Asselin  A,  Picard  A,  Coulomb  A,  Medlar  AJ, 
Baileul-Forestier I, Verloes A, Le Caignec C, Roussey G, Guiol J, Isidor B, 
Logan  C,  Shore  R, Johnson  C, Inglehearn  C,  Al-Bahlani  S,  Schmitbuhl  M, 
Clauss F, Huckert M, Laugel V, Ginglinger E, Pajarola S, Spartà G, Bartholdi 
D,  Rauch  A,  Addor  MC,  Yamaguti  PM,  Safatle  HP,  Acevedo  AC,  Marteli-
Júnior  H,  E  Dos  Santos  Netos  P,  Coleta  RD,  Gruessel  S,  Sandmann  C, 
Ruehmann  D,  Langman  CB,  Scheinman  SJ,  Ozdemir-Ozenen  D,  Hart  TC, 
Hart  PS,  Neugebauer  U,  Schlater  E,  Houilier  P,  Gahl  WA,  Vikkula  M, 
Bloch-Zupan  A,  Bleich  M,  Kitagawa  H,  Unwin  RJ,  Mighel  A,  Berdal  A, 
Kleta R.  Nephrocalcinosis (Enamel Renal Syndrome) Caused by Autosomal 
Recessive  FAM20A  Mutations. Nephron  Physiol,  2012.  122(1-2):1-6.  doi: 
10.1159/000349989. 
 
Appendix E 
 
V. Robinete  SL,  Lindon J,  Nicholson JK.  Statistical  Spectroscopic  Tools for 
Biomarker Discovery and Systems Medicine.Anal Chem, 2013. 85(11):5297-
303. 
VI. Robinete SL, Holmes E, Nicholson JK, Dumas ME. Genetic Determinants of 
Metabolism in  Health and  Disease:  From  Biochemical  Genetics to  Genome-
Wide Associations. Genome Med, 2012. 4:30. doi:10.1186/gm329 
VI. Robinete  SL,  Brüschweiler  R,  Schroeder  F,  Edison  AS.   Metabolomics and 
Natural  Products  Research:  Two  Sides  of the  Same  Coin.  Acc  Chem  Res, 
2011. 45(2):288–297. 
VII. Veselkov KA, Vingara LK, Masson P,  Robinete SL, Want E, Li JV, Barton 
RH,  Claire  BN,  Walther  B,  Ebbels  TM,  Pelczer I,  Holmes  E,  Lindon JC, 
Nicholson JK.  Optimized  pre-processing  of  UPLC-MS  urinary  metabolic 
profiles for improved information recovery. Anal  Chem,  2011.  83(15):5864-
5872. 
 20 
 
 
 
 
CHAPTER 1 
INTRODUCTION AND BACKGROUND 
 
Rapid advances in the  genomic sciences enabling the rapid acquisition  of 
genome-wide  gene-expression  profiles,  polymorphisms and,  more recently,  whole 
genome sequences  have contributed to a  dramatic increase in the  number  of  known 
and suspected associations  between  genetic  variations and  human  disease.   As the 
costs of genomic sequencingfal, functional genomic analysis – the characterization of 
the phenotypic consequences of genetic variants–wil increasingly constitute the rate-
limiting step in the study  of  biochemical  genetics.   Genes - ‘upstream’   blueprints  
controling  dynamic  biological  processes - and  metabolites - capturing  both  genetic 
and  environmental  ‘downstream’  efects  - are intrinsicaly co-informational, shedding 
light  on complementary  biological  processes.   Thus, applying  metabolic  profiling 
technologies to identify the metabolic perturbations resulting from genetic mutations 
wil likely  help to annotate  genes  of  unknown function, identify  genetic controls  of 
metabolism, and characterize mechanisms of disease. 
 
1.1 Background 
 
1.1.1 Characterizing the role of rare variants in human disease 
 
The potential for genetic mutations to disrupt metabolic processes and result in 
human  disease  has  been  known since the  discovery  of alkaptonuria  by  Archibald 
Garod in the early  20th  Century [1].   In the folowing century,  hundreds  of these 
diseases, termed inborn erors  of  metabolism  or  Mendelian  diseases  due to their 
typicaly single-gene  origins and  Mendelian inheritance  paterns,  were identified. 
Folowing the introduction of molecular cloning and Sanger sequencing technologies, 
the  molecular  basis  of these  diseases  began to  be  uncovered [2,  3].  Advances in 
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sequencing technology and drastic reductions in the cost of genome sequencing have 
accelerated the identification  of the  genetic  background  underlying these rare 
congenital diseases, and the molecular bases of inborn erors first described by Garod 
are stil being uncovered [4]. Statistics from the Online Mendelian Inheritance in Man 
(OMIM) database show an accelerating rate of growth in the number of known genes 
for which there is a described Mendelian phenotype (Fig.1.1). 
 
 
Figure 1.1. Identification of genotype-phenotye associations in Mendelian disease is accelerating. The 
rate of discovery for genotype-phenotype associations has increased year-on-year from the late 1980s 
to the  present (red  bar).   This  has resulting in a  growing set  of  genes  with  known  Mendelian 
phenotypes, which is now approaching 3,000. Data from omim.org. 
 
Folowing the sequencing of the human genome [5] atention shifted from rare 
variants and rare  diseases to common  variants and common  diseases.   However, 
common single-nucleotide  polymorphisms and  genome-wide associations studies 
showed  missing  heritability in common  diseases [6] and  weak associations  with a 
large number of genes [7]. As a result, there is once again growing appreciation for 
the importance  of rare  variants and aleles  of large efect in  both rare and common 
diseases,  with some leading  groups suggesting that common  disease  may in fact  be 
overlapping  phenotypes resulting from a large set  of rare  diseases [8].   Curent 
statistics from OMIM (Fig.1.1) show that of known and suspected human Mendelian 
diseases, molecular bases have been identified for over 4,800 phenotypes, with ~3000 
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known genes associated with described Mendelian phenotypes (htp:/omim.org/) [9]. 
Mapping these genes onto human metabolic pathways (Fig.1.2) show that mutations 
that result in an identifiable  human  phenotype afect  nearly al  known  metabolic 
pathways.   These findings indicate the central importance  of  genetic  variation, 
especialy rare variation, in human disease. 
 
 
 
Figure 1.2. Genes with known Mendelian phenotypes mapped onto KEGG human metabolic pathways.  
Of the ~3,000 genes with known Mendelian phenotypes in OMIM, >450 of these matched genes in the 
KEGG global human metabolic pathway database (hsa01100). The distribution of these genes, ploted 
in red, indicates that  known  human  Mendelian  diseases affect the  majority  of  human  metabolic 
pathways. Data from omim.org and kegg.jp. 
 
1.1.2 Identifying genetic and metabolic covariation. 
 
Since the  discovery  of alkaptonuria  by  Archibald  Garod in the early  20th 
Century, the measurement of metabolites has been used as a proxy to identify human 
genetic diseases, especialy inborn erors of metabolism. Uniform newborn screening 
for multiple inborn erors of metabolism, including urea cycle disorders and amino- 
and organic acidurias, using heel-prick testing with MS/MS exemplifies the power of 
 23 
targeted metabolomic analysis to diagnose these diseases and enable the interuption 
of  pathological  processes resulting from  genetic  mutations [10].   Untargeted 
metabolic profiling of biofluids, especialy urine and serum, is a powerful technique 
for  diagnosing inborn erors  of  metabolism  with  often  non-specific clinical 
presentation as metabolic intermediates accumulated in biofluid compartments can be 
easily identified [11,  12].   Untargeted  NMR and  MS  have  been  used to  diagnose 
known inborn erors [13-16], identify novel inborn erors using biofluid profiling [17, 
18]and identify complex  downstream  metabolic consequences [19-21] and 
biomarkers of organ pathology resulting from genetic mutations [22-24]. 
While mutations in enzymes and transporters can often be readily diagnosed 
by  biofluid  profiling and a strong  mechanistic link is easily inferred  between the 
disruption  of a  metabolic  pathway and resulting accumulation  or  depletion  of 
metabolic intermediates,  many  Mendelian  diseases result in  more complex, 
progressive  organ specific  or  multi-organ  pathology [25].  In these cases,  metabolic 
profiling  has  been applied to identify sites  of lesions,  describe  progression, and 
atempt to identify  proxy smal  molecular  biomarkers  of  disease.   Examples  of this 
include the identification of markers of autosomal dominant polycystic kidney disease 
[24], comparison  of the  urinary  profiles  of several  genetic forms  of renal  Fanconi 
syndrome [23], and description of abnormal brain metabolism in Smith-Lemli-Optiz 
syndrome [22].   Additionaly,  metabolite flux analysis  using isotopicaly labeled 
metabolites suggests an additional  way to apply  metabolic  profiling techniques to 
study the impact of genetic mutations [25].  
The genomic corolary of using metabolic profiling to study Mendelian genes 
is  quantitative trait loci (QTL)  mapping  of single  metabolic traits.   The advent  of 
whole-genome SNP analysis and the use of QTL mapping for quantitative traits, such 
as  height [26] led to interest in identifying  genetic loci associated  with  quantitative 
variation in individual metabolite levels [27].  Examples of this include  mapping of 
serum leptin levels to genes on human chromosome 2 in multiple human populations 
[28,  29], associations  with  plasma triglyceride levels [30,  31], and identification  of 
genetic variants associated with high-density lipoprotein levels [32, 33]. 
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Figure  1.3.  Three experimental  designs integrating  genomic and  metabolomic analysis.   Metabolic 
profiling applied to the diagnosis and study  of human Mendelian diseases frequently identifies direct, 
causal relationships between genetic variants and downstream accumulation or deficiency of metabolic 
intermediates, which may vary or progress over time.  QTL mapping of single quantified metabolites 
can identify strong associations  between  metabolite concentration and  polymorphisms, though 
frequently additional,  weaker associations  with  other aleles are  discovered as  wel.   mQTL and 
mGWAS studies are conceptualy similar to  QTL studies  of individual  metabolites,  but search for 
associations between many metabolites and many genes, frequently yielding a larger set of associations 
between genetic polymorphisms and metabolite concentrations or ratios.  
 
Recently, genome-wide single nucleotide polymorphism (SNP) measurements 
have been combined with metabolomics to identify a large number of gene-metabolite 
associations at once. In these studies, individuals are genotyped and metabotyped in 
paralel and the resulting  genome-wide and  metabolome-wide  profiles are then 
quantitatively corelated.  This approach, first termed  metabolic  Quantitative  Trait 
Loci  mapping (mQTL),  was  demonstrated in  plants [34,  35] and then in animal 
models [36, 37].   Folowing these successes, the  mQTL approach  was  quickly 
folowed by the development of metabolomic or metabolome-wide GWAS in humans 
cohorts [38-45]. These approaches have led to the identification of a growing number 
of  gene-metabolite associations,  particularly  between  genes encoding enzymes and 
transporters and their  metabolic substrates.   Figure  1.3  outlines the associations 
identified  by  metabolic  profiling  of  Mendelian  disease,  QTL analysis  of  metabolic 
traits, and mQTL/mGWAS.  
  
1.1.3 Mendelian disease diagnostics: genotypes or metabotypes? 
 
While inborn erors  of  metabolism  were initialy considered to  be 
idiosyncratic "chemical individuality",  growing  understanding  of  neonatal  diseases 
and the identification  of  pathological inborn errors such as  phenylketonuria (PKU) 
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lead to eforts to implement  population-wide  newborn screening  programs as early 
diagnosis enabled intervention, such as dietary restriction of phenylalanine in the case 
of  PKU, that  disrupted the  progression  of the  disease.   Early  newborn screening 
programs, such as Robert Guthrie's PKU screening protocol [46], relied on bacterial 
inhibition assays, but in the 1990s the introduction of tandem mass spectrometry for 
the  measurement  of smal  molecule  biomarkers  of inborn erors [46-48]  gave 
screening programs a much more sensitive and specific analytical  platform.  Today, 
targeted  metabolic  profiling  based  on  MS/MS is the  main  primary screening 
technique for detection of the 31 diseases included in the US Recommended Uniform 
Screening Panel for neonatal screening [49]. 
As clinical genetics, including whole exome and genome sequencing [50-52], 
expands the set  of  known inborn erors it is likely that screening  programs  wil 
include a larger number  of diseases in the future.  At the same time, new screening 
methods  based  on  genotype rather than  metabotype  have appeared, including  pre-
implantation  genetic  diagnosis (PGD) [50-54],  parental carier testing [55,  56], and 
recently diagnostics based on fetal genome reconstructions from maternal sequencing 
[57].  These tests  provide risk assessment and prenatal diagnostics, information that 
arguably has much greater utility than the neonatal diagnostics provided by metabolic 
testing.   However,  genetic  backgrounds for even single  gene  disorders are  highly 
heterogenous,  with  multiple  variants including  point  mutations, indels, and copy 
number variants of varying deleteriousness contributing to a spectrum of phenotypic 
consequences [58-60].  While a comprehensive catalog of these genotypes and their 
phenotypic consequences  may enable  purely  genetic screening,  both characterizing 
the spectrum of genotype-phenotype relationships and screening in the near term wil 
require continued metabolic profiling.  
 
1.2 Scope of thesis 
 
Clearly,  metabolic  profiling  has a continuing role to  play in the study  of 
biochemical  genetics.   This thesis  presents the application  of  metabolic  profiling 
technologies, including  Nuclear  Magnetic  Resonance and  Mass  Spectrometry, to 
identify  metabolic  perturbations resulting from inborn erors  of  metabolism, 
congenital diseases afecting the kidney, and animal models of both genetic mutations 
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and renal pathology. While MS based newborn screening for inborn errors is a major 
application  of  metabolic  profiling  used in the clinic and  would likely  benefit from 
broader  metabolomic coverage, these  diseases are typicaly  quite simple in their 
mechanisms and  progression.  Congenital  diseases  of the  kidney, though also 
monogenic in  origin, constitute a  greater chalenge and  greater  opportunity for 
contribution from metabolic profiling. Additionaly, data from these studies are used 
to introduce and evaluate  modified analytic  methods for  metabolic  profiling that 
mitigate some  of the chalenges involved in  biochemical  genetics, such as smal 
sample sizes, unknown or novel chemical structures, and the chalenge  of providing 
broader metabolomic coverage.  
1D NMR is frequently used for metabolic profiling, but while 2D1H-1H NMR 
spectra require additional colection time they are  wel suited to smal sample sizes 
and assignment chalenges  due to  unexpected compounds and increased spectral 
complexity  due to accumulation  of  metabolic intermediates  or shunt  metabolites. 
Data processing methods for 2D NMR spectral  dataset are introduced, including for 
signal alignment, binning, and patern recognition and evaluated using data colected 
from closely related nematode species, C. elegans, and humans. Increased structural 
information aids identification of accumulating long-chain intermediates produced by 
a peroxisomal β-oxidation  defect in C. elegans and increased spectral resolution 
enhances analysis  of  Fanconi  Syndrome (FS) resulting from a  peroxisomal β-
oxidation traficking defect in a single human pedigree. 
While tandem mass spectrometry (MS/MS) is used to diagnose inborn errors 
from  dried  blood spot samples in the  majority  of  newborn screening  programs, 
targeted analysis  by  MS/MS typicaly involves  measurement  of a smal subset  of 
metabolites  present in  human  blood.   As a result,  diagnosis typicaly requires 
additional confirmatory  metabolic  measurements, and the identification  of  global 
metabolic perturbations resulting from Mendelian diseases is limited. To investigate 
whether broader metabolomic coverage could yield improved diagnostic accuracy and 
additional  biomarkers,  MS/MS  data from  ~6,000  newborns  was compared  with a 
recently introduced direct injection nanospray high resolution mass spectrometry (nS-
HR-MS) assay providing coverage of >200 metabolites for newborns both unafected 
and afected by 24 congenital disorders of metabolism. 
Inborn erors of metabolism are typicaly considered to result from mutations 
in enzymes and transporters, and these can  often  be readily  diagnosed  by  biofluid 
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profiling as a strong  mechanistic link is easily infered  between the  disruption  of a 
metabolic  pathway and resulting accumulation  or  depletion  of  metabolic 
intermediates.   However,  many  Mendelian  diseases result in  more complex, 
progressive, organ specific or multi-organ pathology. The final chapter of this thesis 
presents urinary metabolic profiles from patients  with one of four related congenital 
kidney  diseases and the comparison  of these  profiles  with each  other and  with 
unafected family  members.   While these  disorders result from  distinct  genetic 
mutations afecting diferent  genes, pathways, and celular and metabolic processes, 
they present with an overlapping set of clinical phenotypes. As a result, some of the 
features   of   patients’   metabolic   profiles   are   shared,   while   others are  distinct,  helping 
unravel the complex set  of  phenotypes  observed in these  disorders.   Additionaly, a 
time course analysis  of the  natural  history  of  one  of these  disorders, cystinosis, is 
presented from samples colected over a 15-year period. The metabolic perturbations 
observed in these human diseases are compared to those observed in animal studies of 
model nephrotoxins afecting an overlapping set of kidney structures.  
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CHAPTER 2 
THEORY AND METHODS 
 
The work presented in this thesis is the result of applications of a diverse set of 
analytical and computational techniques  which  when applied in conjunction are 
typicaly refered to as metabolomics [61], metabonomics [62], or metabolic profiling. 
Details of experimental design, sample colection, data acquisition and analysis can be 
found in the individual chapters, as the tools  used  difer  based  on application. 
Protocols for  metabolomics research for  both  major analytical  platforms –  Nuclear 
Magnetic Resonance (NMR) [63] and Mass Spectrometry (MS) [64-66] – as wel as 
for data analysis [67, 68] and compound identification [69] are available. As a result 
this chapter focuses  on introducing the theory  of  NMR and  MS as  wel as  data 
preparation, statistical analysis, and  biomarker identification approaches applied in 
this thesis.   The  purpose  of this chapter is to introduce the family  of techniques 
frequently used in metabolomics research and to discuss their strengths and pitfals to 
clarify the analytical and computational strategies employed in the folowing chapters. 
 
2.1 Data acquisition – analytical chemistry of biological fluids 
 
2.1.1 Nuclear Magnetic Resonance (NMR) Spectroscopy 
 
Nuclear  magnetic resonance (NMR) is a  powerful and almost  universal 
detector  due to its ability to analyze essentialy al types  of  molecules at atomic 
resolution.  NMR spectroscopy  has been applied continuously in organic chemistry, 
structural  biology, and metabolic analysis for the past  50  years and as a result there 
are many comprehensive guides to both the theory and practice of NMR [70-72]. In 
smal  molecule research,  NMR spectroscopy  has a long  history  of application in 
organic chemistry for structural identification and is  used extensively in 
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metabolomics.  NMR spectroscopy is characterized  by the folowing  key  properties: 
(i)  high  dynamic range,  with several  biological  nuclei, such as 1H, 13C, 15N  or 31P, 
being accurately measured over a large range of concentrations; (i) high linearity of 
signal intensity with concentration; and (ii) high reproducibility. 
While  NMR and  MS  were  used  most frequently for the structural 
characterization of organic and inorganic chemical structures, beginning in the 1980s 
these techniques began to be used as biochemical sensors with changes in the paterns 
of complex mixtures measured to assess biological rather than structural changes[73]. 
In  particular, 1H  NMR spectroscopy is robust,  provides a  high  degree  of structural 
information for  both  one-dimensional 1H and two-dimensional 1H-1H  NMR, and is 
flexibly applied to extracts,  biofluids and solid tissues  using  high-resolution  magic 
angle spinning, and in  vivo  using  magnetic resonance spectroscopy.  Technological 
advancements in  magnetic field strength  with the introduction  of  600,  800 and, 
recently,  1,000  MHz  NMR spectrometers,  pulse sequence experiments, and 
cryogenicaly cooled  probes  have increased the sensitivity and coverage for smal- 
molecular-weight metabolites from urine, plasma, serum and tissue samples [63]. 
 
2.1.1.1 Principles of NMR spectroscopy 
 
Nuclear spin is a fundamental quantum property of atomic nuclei, and nuclei 
with spin  quantum  number  1/2 (Table  2.1)  have two  possible  orientations 
coresponding to m = +1/2 and m = -1/2. While these spin states are degenerate in the 
absence of magnetic field, when an atomic nucleus with non-zero spin is placed in an 
ambient magnetic field B0 the energetic consequences are determined by equation 2.1. 
 
Table 2.1. Frequently measured nuclei in biomolecular Nuclear Magentic Resonance [74] 
Isotope Spin Natural Abundance Gyromagentic ratio (γ ; rad/s·T) 
1H ½ ~100% 267.52 × 106 
13C ½ ~1.1% 67.28 × 106 
15N ½ ~0.37% −27.13 × 106 
19F ½ ~100% 251.82 × 106 
31P ½ ~100% 108.39 × 106 
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0BmE                       (2.1) 
 
Here, B0 is the strength of the magnetic field, m is the nuclear spin,  is the 
reduced Planck constant ( = 1.054571726 × 10-34 J·s),  and  γ  is  the  gyromagnetic  
ratio of the nucleus, values of which for typical NMR nuclei can be seen in Table 2.1. 
By convention, m  = +1/2 is the lower energy orientation, and as a result the energy 
diference  between the two spin  1/2 states is shown in eq.  2.2, and the energy 
diferential between these two states wil lead to net polarization of the population of 
nuclear spins as the equilibrium between spin +1/2 and spin -1/2 states shifts to favor 
the lower energy state. The ratio of these spin states is determined by equation 2.3. 
 
0BE       (2.2) 
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Here, N-/N+ is the ratio of nuclei in the high energy to low energy spin state, 
∆E  is  the  energy  diference  from  equation  2,  k is Boltzmann's constant (1.3806488 × 
10-23 J/K) and T is temperature in Kelvin. The sum of these magnetic moments yields 
a net or "bulk" magnetization aligned with the orientation of B0 - typicaly refered to 
as the  Z axis (Fig.  2.1A).  In the absence  of external sources  of electromagnetic 
radiation,  magnetic  moments  wil  precess (spin) around the  orientation  of  B0 at a 
frequency given by equation 2.4. This precession frequency (the Larmor frequency) is 
equal to the frequency which must be applied to equal the energy diferential between 
spin states (eq. 2.5).  
 
00 B      (2.4) 
 
/0 E       (2.5) 
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Figure  2.1.  Nuclear  magnetic resonance spectroscopy.   Bulk  magnetization (M, red arow) resulting 
from the polarization of nuclear spins in an ambient magnetic field (B0) is reoriented in the XY plane 
by a radio frequency pulse B1 (A).  Precession of nuclear spins and relaxation processed yield a free 
induction  decay (FID)  by inducing an electric current in the  detection coil (B).   Frequency  domain 
NMR spectra result when a Fourier Transform is applied to the time-domain FID (C).   The resulting 
signals, including chemical shifts, J-couplings, and integrals alow the assignment  of chemical 
structures, shown here for EtOH.  
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When   electromagnetic   radiation   at   the   frequency   ω0 (radio frequency for the 
nuclei and field strengths typicaly used in NMR spectroscopy, 800 MHz for 1H at a 
B0  of  18.8  T) is applied to the  population  of  nuclear spins,  bulk  magnetization is 
rotated in the  XY  plane, frequently in increments  of  90  or  180  degrees,  which are 
refered to as 90° or 180°pulses (Fig 2.1A).   
 
)cos(1 tB       (2.6) 
 
The component  of  bulk  magnetization in the  XY  plane is  given  by equation 
2.6  where  B1 is   the   strength   of   the   radio   frequency   field,   ω   is   the   frequency   of   the  
pulse (ω ≠  ω0) and t is its  duration.   Thus, folowing a  90°pulse the entirety  of the 
bulk magnetization is in the XY plane, while after a 180°pulse bulk magnetization is 
aligned along -Z. Folowing an RF pulse, magnetic moments wil resume precession 
around  B0 at the  Larmor frequency,  but the  oscilation  of the  bulk  magnetization  of 
the  XY  plane can  now  be  detected as an induced current in the  detector coil  of an 
NMR  probe,  yielding a free induction  decay (FID)  which is the  basis  of  NMR 
spectroscopy (Fig. 2.1B). The "decay" in FID refers to the gradual loss of signal due 
to spin-latice (T1) and spin-spin (T2) relaxation which reduce the component of net 
magnetization in the XY plane as equilibrium returns to alignment with  B0 (T1) and 
due to reduced precession coherence (T2).  
If al nuclei were to precess at exactly the same Larmor frequency, only one 
frequency  would  be  detected in the  FID and  no chemical information  would  be 
present. However, electrons surounding a given nucleus have the effect of shielding 
it from B0, and as a result the magnetic field and precession frequency experienced is 
slightly different for nuclei in difering chemical environments.  As such, frequency 
diferences  given  by equation  2.7 can  be  detected in the  FID,  yielding information 
about the chemical environment experienced by the atomic nuclei present in a sample.  
 
610
ref
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v
vv     (2.7) 
 
Here δ is the chemical shift in  parts-per-milion (ppm), as the  difference 
between ν and νref is measured in Hz while the Larmor frequency νref is measured in 
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MHz. This has the added benefit of freeing the chemical shift scale from dependence 
on field strength, so that measurements from spectrometers with difering B0 can be 
compared.   While the  FID is in the time  domain, chemical shifts are typicaly 
measured in the frequency domain, which is obtained by applying a Fourier transform 
to the FID (Fig. 2.1C). 
The energy levels experienced by atomic nuclei are further complicated by J-
coupling - changes in resonance frequency  due to  nearby  nuclei  with  non-zero spin 
states.   The  presence  of a two adjacent spin  1/2  nuclei  wil result in two  distinct 
energy levels for each  nucleus  depending  on the spin state  of the adjacent  nucleus, 
which results in "spliting" in the resulting  NMR spectrum.   These splitings, also 
refered to as multiplicity or fine structure, yield signals whose intensities are defined 
by  Pascal's triangle,  which contain additional information about the chemical 
environment experienced by a given nucleus and thus aid characterization of chemical 
structures.  
 
2.1.1.2 NMR Pulse Sequences 
 
The  number, timing,  orientation, frequency, and sequence  of  RF  pulses 
determine the information  generated  by an  NMR experiment.   Over the  past forty 
years a large number of these experimental protocols, refered to as pulse sequences, 
have  been  developed and  many  have  been implemented in commercial  NMR 
platforms.  In  metabolomics research,  pulse sequences for  1D 1H,  2D 1H-1H 
homonuclear, and  2D 1H-13C  heteronuclear experiments are  widely  used.   Figure  2 
shows pulse sequence diagrams for prototypical versions of these experiments. 
The  1D "pulse-acquire" sequence (Fig.  2.2A) is arguably the simplest  NMR 
pulse sequence.   Here, a  90°pulse is folowed  by  detection  of the  FID.   A  delay is 
typicaly added  before the  pulse to alow for  T1 relaxation  processes to return  bulk 
magnetization to the Z-axis. This sequence can be repeated in series as a number of 
"scans" and the resulting signals averaged in  order to improve the signal-to-noise 
ratio.   Urine and serum spectra typicaly are acquired in an aqueous  medium, so a 
low-power, selective presaturation pulse is frequently added during the delay before 
the pulse to iradiate water and dampen the signal from the water protons.  Variants 
of this experiment used frequently include use of the  nuclear Overhauser efect [75] 
(1D  Nuclear  Overhauser  Efect  SpectroscopY,  NOESY) for signal enhancement,  T2 
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filtering (Car–Purcel–Meiboom–Gil,  CPMG) to suppress signals from large 
molecules, and gradient pulses for improved solvent presaturation [63]. 
Two-dimensional  NMR spectroscopy is arguably the  most important 
spectroscopic technique for the elucidation  of  novel  or  unexpected structures [76]. 
Two-dimensional  NMR spectra are  unique in that they  provide  direct evidence for 
atom connectivity (through-bond connectivity) and spatial arrangements (through-
space connectivity).   Sequences for  generalized 1H-1H  homonuclear experiments 
include  preparation, evolution,  mixing and  detection  phases, a schematic for  which 
can be seen in Figure 2.2B. The second dimension is created by colecting multiple 
increments with varying values for the t1 delay between pulses, and a second Fourier 
transform is typicaly applied to  generate  data in two frequency  domain axes. 
Corelations are  generated  by  magnetization transfer through  bonds  by J-coupling 
(COrelation  SpectroscopY,  COSY [77];  Total  COrelation  SpectroscopY,  TOCSY 
[78])  or through space  by  dipolar coupling (2D  Nuclear  Overhauser  Efect 
SpectroscopY,  NOESY;  Rotating-frame  Nuclear  Overhauser  Effect  SpectroscopY, 
ROESY).   The  double  quantum filtered (dqf) COSY alows for  greater  visible fine 
structure in 2D crosspeaks as it is phase sensitive.  
Heteronuclear experiments (Fig.  2.2C) alow for  observation  of couplings 
between 1H and additional nuclei(typicaly 13C in metabolomics) by pulsing on both 
1H and 13C frequency channels. Frequently applied sequences include Heteronuclear 
Single Quantum Corelation spectroscopy (HSQC) and Heteronuclear Multiple-Bond 
quantum  Corelation spectroscopy (HMBC) [79].While  2D  NMR experiments 
generaly  provide  greater signal  dispersion and increased chemical information, the 
main drawback of 2D Fourier transform (FT) NMR spectroscopy is the time required 
to colect the indirect second dimension at high digital resolution.  Additionaly, the 
use of natural abundance 13C (Table 2.1) in heteronuclear NMR also limits sensitivity. 
As such,  2D  NMR are frequently  used for compound identification rather than 
metabolic  profiling, though for limited sample experiments  or  mixtures  with a  high 
degree of chemical complexity, variation, or expected novel structures, 2D profiling 
can provide a substantial advantage (see Chapter 3).  
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Figure 2.2. Pulse sequence diagrams for 1D and 2D NMR spectroscopy experiments. A simple pulse-
acquire sequence (A)  yields a  1D  NMR spectrum,  while a two-pulse sequence in  which scans are 
colected  with incremental  values  of t1 (B)  yields a  2D  homonuclear spectrum.   2D  heteronuclear 
spectra can be acquired by pulsing at the Larmor frequencies of multiple nuclei (C). 
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2.1.1.3 Sample preparation and acquisition considerations 
 
Nuclear  Magnetic  Resonance requires relatively litle sample  preparation, 
especialy as the sample  does  not come into contact  with the instrument.   High 
volume, low concentration samples can be dried under N2 or freeze-dried to increase 
solute concentration,  but  mammalian  biological fluids are typicaly analyzed raw  or 
with the addition  of a smal amount  of  HPLC  grade  water in the case  of limited 
volume samples.   5mm  glass  waled  NMR tubes are frequently  used, and require 
approximately 500 µL of sample to achieve good magnetic field homogeneity across 
the sample, but  2.5 and  1.7  mm tubes can be used with smaler volumes.  Aqueous 
samples typicaly require the addition  of  D2O for a signal lock and a chemical 
reference, such as  3-trimethylsilyl-  2,2,3,3-tetradeuteropropionate (TSP), to set the 
chemical shift axis.   Dried samples can  be resuspended in  pure  D2O  or another 
deuterated solvent such as  methanol-d4 (CD3OD)  or chloroform-d (CDCl3).   As 
temperature,  pH, and  osmolality al afect smal  molecular chemical shifts,  urine 
samples are typicaly bufered at pH 7.4 by the addition of phosphate bufer and al 
experimental spectra are colected at the same temperature, typicaly 298 or 300K.  
1H NMR spectra are colected over a spectral width of at least 10 ppm, and up 
to  20  ppm in  order to  observe the ful range  of chemical shifts.   Relaxation  delays 
(RD) must be long enough to alow adequate T1 relaxation and optimal RD=5·T1 can 
be experimentaly identified  by the  use  of inversion recovery experiments.   For 
TOCSY spectra, the amount  of  magnetization transfer and thus the intensity  of 
crosspeaks is  dependent  on  mixing time, though  60ms and  90ms are typical  values 
and should  be  kept consistent to compare  between spectra.   Receiver  gain affects 
signal intensities, but receiver gain values are typicaly set automaticaly which, along 
with concentration variance frequently necessitates normalization as a post-processing 
step.   Fourier transforms,  window functions, zero-filing, spectral  phasing,  baseline 
corection, and referencing, are typicaly required  before spectra  may  be compared, 
though these may be performed on the console instrument. 
 
2.1.2 Mass Spectrometry (MS) in Metabolomics 
 
Mass spectrometry (MS), coupled to either liquid (LC)  or  gas (GC) 
chromatography, is also frequently applied to profile the metabolome [64, 65,80]. LC- 
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and GC-MS both boast high sensitivity to low-concentration analytes, as wel as high- 
resolution chromatographic separation. While these techniques have faced chalenges 
in compound identification, reproducibility and  bias towards certain compound 
functional groups, the rapid pace of technological development in MS has sought to 
address  many  of these chalenges.  Advances in chromatography, including  ultra- 
high-performance liquid chromatography (UPLC) and  multidimensional  gas 
chromatography (GC×GC,  3D-GC),  have increased the speed and reproducibility  of 
chromatography-coupled  MS [81].  Additionaly, advances in  MS, including  high-
resolution time-of-flight (ToF) and  quadrupole time-of-flight (qTOF) instruments, 
along  with serial ion fragmentation (MS/MS,  MSn)  have improved resolution, 
coverage and identification of low-molecular-weight species [82]. 
Modern mass spectrometry is  dependent  on the generation of molecular ions 
and the  detection  of these ions  by a  mass  detector.   While electrospray ionization 
(ESI) and matrix assisted laser-desorption ionization (MALDI) have been the major 
methods  used to  generate  molecular ions for  decades [83], advances  have alowed 
increasingly low volumes to be nebulized in ESI [84]and location based rasterization 
for imaging of solids, including whole tissues, by MALDI [85]. ESI is typicaly used 
in conjunction with liquid chromatogprahy and can operate in both  positive (+) and 
negative (-) ionization  modes as  metabolites  may ionize  preferentialy in a single 
mode.   While  LC,  GC, capilary electrophoresis (CE) and  other chromatographic 
techniques can be used to separate metabolites upstream of ionization and detection, 
ESI can also be applied to directly injected samples, which is frequently used to save 
time in high-throughput, targeted MS assays [86].  
 
Table 2.2.Characteristics of commonly used mass analyzers.[87] 
 HR-ToF Orbitrap FT-ICR 
Resolution (m/Δm50%) <60,000 <100,000 <1,000,000 
Scan rate 500 scan/s 10 scan/s 1 scan/s 
Mass range  50-500,000 50-4000 50-4000 
 
Molecular ions are separated according to  mass/charge (m/z) ratio in a  mass 
analyzer and m/z values for the detected ions are recorded in each scan colected by 
the  mass  detector.   The  major features  diferentiating  mass  detectors are  mass 
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resolution, typicaly calculated as  peak  width at  half  max in fractions  of an atomic 
mass  unit, and scan rate, the amount  of time required  between scan colection.   A 
tradeof typicaly exists between mass resolution and scan rate, as can be seen in the 
typical values for major mass analyzers shown in Table 2.2. As such, time-of-flight 
(ToF)  detectors are frequently  used in conduction  with chromatography,  while 
Orbitrap and  FT-ICR instruments  ofer  greater resolution  when scan rate is less 
critical, such as with direct injection [87]. Quadrupole instruments, including triple-
quadruples and  quadrupole-time-of-flight (qToF) instruments are  generaly  used to 
fragment  molecular ions to improve  detection sensitivity, specificity, and  provide 
additional structural information. 
 
2.2 Dataset preparatory analysis 
 
The basic premise of a metabolomics study is that spectral variables - be they 
NMR, MS, or generated by another detection technique, can be directly compared to 
identify  qualitative and  quantitative changes in the chemical composition  of a 
biological  mixture such as  urine, serum,  or an extract.   The two assumptions that 
underlie this  premise are  1) that signal intensity is related to compound abundance, 
and  2) that the spectral signal(s) arising from a compound are  present in the same 
position in the spectrum.  Were these assumptions not  generaly valid, spectroscopy 
would be of litle use in analytical chemistry and the general principle that the same 
compound  wil  give the same spectrum  underpins the  utility  of the spectroscopic 
approach.  Despite this, various forms of instrumental and experimental noise afect 
the spectra  of  biological  mixtures and complicate the  direct comparison  of these 
spectra in metabolomics.  
Preprocessing techniques  have  been  developed to account for these 
complications and are now widely used in urinary metabolomics [88-90]. While the 
adoption and progressive development of preprocessing methodologies has advanced 
the art of data analysis in metabolomics, preprocessing techniques are stil evolving 
and there is a  high  degree  of  heterogeneity in the  preprocessing algorithms and the 
extent to  which these techniques are applied.   Despite  variations in the  workflow 
depending  on instrumentation and experimental  design,  preprocessing in 
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metabolomics  generaly includes signal  detection  or alignment (Fig  2.3A), 
normalization (Fig 2.3B), and variance stabilization (Fig 2.3C). 
 
 
 
Figure 2.3. Schematic of preprocessing operations in metabolomics. Signal definition (shown here as 
signal alignment, left) resolves  positional  variation and ensures comparability  of spectral  variables. 
Normalization (center) scales al spectral datapoints to corect for global intensity variation.  Finaly, 
variance scaling or stabilization scales individual datapoints to alow the comparison of high and low 
intensity signals. 
 
 
2.2.1 Data definition – resolving positional variation 
 
Data  definition  methods, including  peak  picking,  binning,  bucketing, signal 
alignment, integration, and fiting serve to ensure that measured variables reflect the 
abundance   of   the   same   metabolites   across   a   set   of   samples.      In   NMR,   “positional  
noise”   is   caused   by   variation   in   observed  chemical shifts  due to temperature,  pH, 
osmolality, and the interaction  of  mixture components.  In  mass spectrometry, 
measured m/z values vary within a range related to the resolution of the mass detector, 
while in  LC-MS retention time  drift is frequently  observed  due to  unpredictable 
changes in column conditioning.   While  many  methods  have  been  presented to 
resolve this  positional  variation, these  methods typicaly fal into  one  of four 
categories combining either targeted or untargeted signal detection withful-resolution 
or condensed processing (Table 2.3).  
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Table 2.3. Data definition tools in NMR and MS. 
 Targeted Untargeted 
 
Ful- 
resolution 
 
rNMR [91] 
 
Signal alignment (NMR) [90, 92-95] 
Profile mode detection (MS) 
 
 
Condensed 
Chenomx, targeted profiling [96] 
BATMAN [97] 
Multiple reaction monitoring 
(MRM MS) 
Integration and fiting (NMR/MS) 
 
XCMS [82, 98, 99] 
MAVEN [100] 
Adaptive binning (NMR) [101, 102] 
 
Targeted  methods atempt to identify signals coresponding to a set  of 
metabolites defined a priori and transform a set of spectra into a matrix of metabolite 
abundances, while untargeted methods consideras many spectral features as possible 
and reserve identification  until after statistical analysis,  usualy for a subset  of 
features. Ful-resolution methods seek to preserve spectral line-shapes, and are more 
frequently  used in  NMR  where lineshapes contain additional structural information, 
while condensed  methods reduce a set  of spectral  datapoints to a single  variable 
reflecting the level of a given feature. Table 2.3 shows the breakdown of frequently 
used techniques in both NMR and MS into these categories.  
 
2.2.2 Normalization 
    
Signal intensities in  NMR and  mass spectra are affected  by a  number  of 
variables, including biological factors such as sample concentration and instrumental 
factors such as receiver  gain, ion suppression,  pulse angle, signal averaging, and 
more.   While single compound  measurements frequently  use calibration curves to 
enable absolute  quantification, in  metabolomics these factors are frequently  held 
constant  where  possible and comparison  between  metabolic  variables is  based  on 
relative changes between measurements.  In order to make quantitative comparisons 
between spectra, some form  of  data  normalization is typicaly required.   These 
include normalization to a chemical internal standard such as an isotopicaly labeled 
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standard  or chemical reference, to a  biological internal standard such as  urinary 
creatinine,  or a statistical  method such as total area  or  probabilistic  quotient 
normalization [88].  
Each of these methods have strengths and weaknesses- the chemical standard 
can be added at a fixed concentration, but cannot corect for variable dilution in the 
sample.    Biological   “standards”  are  valuable  so   long  as  they   are  not   afected  by  the  
experimental  design – the equivalent  of  using a constitutively expressed 
“housekeeping”  protein as a loading control in a  western  blot.    Statistical 
normalization typicaly performs wel, and while probabilistic quotient (median fold-
change)  normalization is  more robust to smal  numbers  of  highly  variable signals, 
these methods can stil be compromised by coordinated changes in large numbers of 
metabolite abundances.   Normalization efects can  be evaluated  by  visualizing 
histograms of log-fold-change vs. median for al spectra (Figure 2.4) as these indicate 
samples for  which a large  percentage  of  datapoints are relatively  high  or relatively 
low compared to the dataset median.  
 
 
Figure 2.4. Visualization of normalization effects. Box plots indicate distributions of log-fold-change 
vs. median feature before and after normalization. These plots indicate the extent to which systematic 
changes in  metabolite intensities  by sample (normalization) are  present  between samples. 
Normalization reduces these effects.  
 
2.2.3 Centering and scaling 
 
Smal  molecules in  human  biofluids are  present in a range  of concentrations 
spanning multiple orders of magnitude from mM (urea in urine, glucose in serum and 
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CSF) to sub-nM (hormones). While the limit of detection in most NMR experiments 
is  approximately  10  μM,  the  concentration  range  of  NMR  detectable  smal  molecules  
stil spans approximately  3-4  orders  of  magnitude [103], and for  MS experiments 
dynamic range can  be  much  greater.   Despite the fact that changes in the 
concentration of al metabolites are potentialy of interest, the much higher variance 
of  high concentration compounds can lead to the signals arising from these 
compounds  dominating  multivariate  models and  masking  more significant relative 
changes in low intensity peaks. This is compounded by analytical variance in which 
instrumental  noise increases  with signal intensity as  wel- a  heteroscedastic  noise 
structure [104].   Data centering is also typicaly applied to identify  positive and 
negative associations, and this can be done by centering variables to either a mean or 
median value.  
Recognition  of this chalenge  has lead to the adoption  of  variance 
stabilization,  or  “scaling”  methods  that  atempt  to  corect  for  this  efect  [89]. While 
unit  variance scaling,  or autoscaling, (eq  2.8) is frequently applied, this  method 
penalizes  variables  with  multimodal  distributions, the identification  of  which is 
typicaly a  goal  of  metabolomics research.   As such, the log transformation  may  be 
beter suited for  both clinical  metabolomics and the two-class experimental  designs 
commonly used in the field. Equations 2.8, 2.9 and 2.10 show variance stabilization 
by unit variance scaling (eq. 2.8), log-fold-change vs. median (eq. 2.9) and ofset log-
fold-change vs. median (eq. 2.10). Here, X is a stabilized version of the spectrum S in 
a dataset of n spectra with m datapoints, Sm is the standard deviation of each column 
m, and f is a scalar ofset.  
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The efects  of  variance stabilization can  be  demonstrated  by  ploting  peak 
variance against peak intensity rank (Figure 2.5). For un-scaled data, this produces a 
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characteristic  “hockey  stick”  plot  with  variance  dominated  by  high  intensity  variables.    
While log-fold change  without an  ofset can lead to  high  variance for low intensity 
variables, inappropriate scaling  of  noise can  be avoided  by adding an  ofset (f)  of 
approximately  10x the standard  deviation  of the  noise (eq  2.10).   By avoiding 
intensities near zero, the log fold change transformed noise values fal below those of 
true signals. The choice of the ofset does make a diference - choice of offset values 
that are too low wil fail to compensate for noise scaling, while ofset values that are 
too  high and approach signal intensities wil not stabilize variances and scaling  wil 
have no efect. This method has been applied in both metabolomics and microaray 
analysis and strategies for  offset selection reviewed  previously [104-106].  Log-
scaling also  has the added  benefit  of transforming  highly skewed  distributions, as 
many frequentist statistical tests assume approximate normality [107]. 
 
 
 
Figure  2.5.  Visualization  of scaling effects.   Rank  vs.  variance  plots indicate the  distribution  of 
variance between high intensity (high rank) and low intensity (low rank) variables. Scaling, such as to 
unit variance or by log-transform distribute dataset variance more equaly between high and low rank 
variables.   
 
2.3 Statistical data analysis 
 
Data  preparatory analysis,  or  preprocessing, transforms a set  of  biological 
NMR or mass spectra into a data matrix Xnp in which N rows represent the metabolic 
profile of a single sample n and P columns represent the metabolic or spectroscopic 
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variable p.  Relationships  between samples and  variables in X can then be analyzed 
using exploratory  or "unsupervised" statistical  methods.   Alternately, relationships 
between X and a(n) independent  variable(s) Y can  be analyzed  with "supervised" 
methods.  In  metabolomics research, Y is typicaly a  biological response  variable 
which can take the form  of dummy variables such as [0, 1] for control and afected 
samples, integers [1, N] for classes such as individual, location, or response group, or 
quantitative response  data [-∞,∞]   with   data   from   an   assay   response   or   biological  
measurement.   These supervised  methods are typicaly  used for regression  or 
classification,  predicting  unknown Y  on the  basis  of X,  or for feature selection, 
identifying variables p significantly associated with Y. 
 
2.3.1 Methods for unsupervised data analysis 
 
Unsupervised methods atempt to identify relationships between variables and 
uncover sources  of  variation that  may  or  may  not  be captured  by the independent 
variables. Methods in this family do not make use of a Y vector, and as such there is 
typicaly  no  objective function  or fit  metric to evaluate their  performance.   Many 
unsupervised methods depend on the choice of a distance function that measures the 
similarity (or  distance)  between  vectors Xn  or Xp.  In  metabolomics research, the 
corelation coeficient is frequently  used as a  metric  of similarity, and in statistical 
spectroscopy corelations are  used to  preprocess spectral  datasets, identify 
biomarkers, and interpret metabolic co-regulation. 
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Equation 2.11 shows how the corelation coefficient rmn is calculated for two 
vectors xim and xin  where m and n are column indices  of Xp.  In the context  of 
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statistical spectroscopy, rmn is the corelation coeficient between the intensities x of 
signal m and signal n across al spectra i through j,  where these signals  have  mean 
intensity and  and standard deviations mx and nx . When signals m and n arise 
from the same chemical structure, rmn  wil tend to approach  unity.  When signals m 
and n arise from  diferent chemical structures, the  magnitude  of rmn  wil  depend  on 
the extent to  which the metabolites giving rise to signals m and n are subject to the 
same metabolic perturbations (e.g. pathway connectivity) [108, 109]. As a result, the 
corelation coeficient rmn can  be  used to assess  both structural and  pathway 
connectivity, though in the case  of strong  metabolic  perturbations  or  poor signal 
resolution there  may  be ambiguity  between the  underlying  origin  of corelations. 
When xim and xin are vectors of intensities rmn is the Pearson corelation coeficient, 
and  when xim and xin are  vectors  of rank  orders rmn is the  Spearman corelation 
coeficient.   Corelation coeficients [-1,  1] can also  be converted to corelation 
distances dmn [0, 2] by equation 2.12.  
Equation  2.13 is  mathematicaly equivalent to equation  2.11,  but the  matrix 
notation emphasizes  diferences  between  datasets rather than signals.   Here, R is a 
matrix of corelation coeficients between two autoscaled datasets X1 and X2, each of 
which is composed of j observations. When X1 and X2 take the form Xnp, R wil be 
the corelation  matrixRpp  between al  metabolic  variables, and  when X1 and X2 take 
the form Xpn R wil be the correlation matrix Rnn between al samples. When X1 and 
X2 are the same  matrix, R is  homo-spectroscopic.  When X1 and X2 are  matrices 
derived from  diferent analytical techniques, such as  heteronuclear  NMR  or  mass 
spectrometry, R is hetero-spectroscopic. The framework of statistical spectroscopy is 
flexibly extended in cases in which X2 is data derived from genomics, proteomics, or 
transcriptomics as  wel.  In these cases R  wil reflect  metabolite –  non-metabolite 
associations as opposed to the traditional metabolite – metabolite associations. 
Underlying structure in Xnp can then be identified by applying cluster analysis 
to  distance  matrix Dpp, Dnn,  or  both.   While there are  many techniques for cluster 
analysis, including  k-means clustering,  density  or  distribution  based clustering, and 
related  dimensionality reduction  methods that can  be applied to D such as 
multidimensional scaling,  hierarchical clustering is among the  more frequently  used 
clustering tools in metabolomics research [110, 111].  
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Hierarchical cluster analysis (HCA)  depends  on the sequential (typicaly 
greedy) grouping of variables into clusters on the basis of distance. HCA can either 
build  up clusters from individual  variables (agglomerative  HCA),  or split clusters 
from the ful set of variables (divisive HCA). The sequence of splits is then recorded 
in a tree,  or  dendrogram.   The results  of  HCA  depend  on the choice  of  distance 
metric, such as the Pearson or Spearman corelation, and the linkage method, which 
determines how distances between clusters are calculated. The unweighted pair group 
method  with arithmetic  mean (UPGMA) algorithm for  HCA applies agglomerative 
clustering with average-linkage, in which the distance between clusters is the average 
of the distance between al  variables in the given clusters (eq.  2.14).  Equation 2.14 
shows the average-linkage  distance  between clusters a and b  given  distances dmn. 
Other linkage methods include single, complete, and weighted linkages. 
Alternately, Principal Component Analysis (PCA) [112] can project X into a 
lower  dimensionality space to identify  major sources  of  variance in X.   When p<n, 
PCA is typicaly calculated based on the singular value decomposition of X (eq. 2.15). 
Here, U and V are eigenvector  matrices  of the covariance  matrices XTX and XXT 
respectively and S is a rectangular diagonal matrix. When X is autoscaled, XTX and 
XXT are the  Pearson corelation  matrices Rpp and Rnn.   While in singular  value 
decomposition, elements  of the  diagonal  matrix S  go from low to  high, in  PCA the 
direction  of S is reversed so that elements  go from  high to low, and U and V are 
reordered to match S. In the context of PCA, the coefficients of U are refered to as 
“loadings”,  and  the  matrix  T (eq.  2.16)  as  “scores”.     
 
USVX                      (2.15) 
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However,  when p  >  n, the covariance  matrix XTX  may  be singular and as a 
result singular  value  decomposition is  not  used.  In this case, an iterative algorithm 
such as non-linear iterative partial least squares (NIPALS) [112] it typicaly used to 
calculate U and T.  In this case only a subset of the eigenvectors of U may be used 
and as a result there is a residual matrix E such that 
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The scores matrix T is then an (n x c) matrix and the loadings matrix U is a (p 
x c) matrix where c is the number of principal components used to reconstruct X to a 
certain level of precision (frequently 95% percent of variance). As such, for a given 
principal component (PC) c, there is a set of n scores and p loadings. In the context of 
metabolomics, the loadings p  describe the  metabolic  patern  which  give rise to the 
clustering patern seen in the distances between the n scores. As such, PCA is used to 
identify the  major sources  of  variation  present in a  dataset and the relationships 
between samples and metabolic variables induced by these sources.  
 
2.3.2 Methods for supervised data analysis 
 
Unlike unsupervised techniques, supervised methods make use of a biological 
response  vector Y that can  be categorical  or continuous.  These supervised  methods 
perform two main functions in metabolomics data analysis - classification and feature 
selection.  In the context  of  metabolomics in  medicine, classification is related to 
diagnosis- for example,  patients can  be classified as either "healthy"  or "diseased" 
(binary categorical Y), as a grade of disease severity (multiple categorical Y), or on a 
scale (continuous Y) on the basis of detected metabolite levels. Feature selection then 
provides a tool for "biomarker discovery"- the goal of which is to identify metabolites 
that are  most associated  with  biological response captured in Y.  Like  unsupervised 
methods, supervised methods can be either univariate (i.e. analysis of a single variable 
at a time) or multivariate (analysis of multiple variables at once).  
 
2.3.2.1 Univariate tests 
 
Univariate tests can be applied to categorical and continuous Y. If Y is binary 
categorical, the t-statistic can be used to identify diferences between the means of the 
two groups. Here, the t-statistic t is calculated from group means ,  and variances
, where a and b are  groups  of size na ,nb  with  difering  values Y.   Typicaly, 
when Y is  binary categorical it is represented  by  dummy  variables Y =  0 and Y =  1   
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with a representing the group Y = 1 and b representing the group Y = 0. Thus, if t is 
positive, x is positively associated with Y and if t is negative x is negatively associated 
with Y.  
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 If Y is multiple categorical, analysis of variance (ANOVA) testing can used to 
identify  differences  between  group  means across  multiple  groups.   The  F-statistic 
calculated in  ANOVA compares  between-group  mean squares (MSB)  with  within-
group mean squares (MSW), which are calculated from group means and variances
while taking into account the number of groups a, the number of observations in 
each  group na and the total  number  of  observations N.   When a =  2,  ANOVA and 
Student’s  t-test are equivalent with F = t2. 
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Finaly, if Y is continuous, corelation coefficients can be used in a supervised 
manner by taking the correlation between X and Y as in equation 2.23. As previously, 
R is a matrix - or vector if Y is (n x 1) - of corelation coeficients between datasets X 
and Y, each  of  which is composed  of j  observations and  where  both are autoscaled. 
Regression analysis can also  be applied to single  variables as  wel as  multiple 
variables, as discussed below.  
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2.3.2.2 Multivariate supervised methods 
 
Like univariate tests, multivariate supervised methods can be applied to both 
categorical and continuous Y.   When p < n,  generalized linear  model regression 
techniques can  be  used,  which estimate a set p  of regression coeficients,  or 
predictors, β  based  on equation  2.24.   Generalized linear  models are refered to as 
“generalized”  because  the  choice  of  model  is  based  on  the  distribution  of  Y. When Y 
is continuous, the coresponding  model is  ordinary least squares (OLS) regression, 
and predictions, denoted by , can be made on the basis of β by equation 2.25, where 
k is a constant intercept  value.   When  Y is  binary categorical, the coresponding 
model is multiple logistic regression, where  is evaluated based on equation 2.26. 
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As  with singular  value  decomposition,  generalized linear  models  depend  on 
the inversion of the XTX covariance matrix and so are limited to cases where p < n.  
When p > n, iterative methods such as NIPALS [112] or SIMPLS [113] can be used 
to calculate β by Partial Least Squares (PLS). Like PCA, PLS calculates a number of 
components c  where c < p  which are  used to reconstruct X.   The choice c  must  be 
optimized based on fit parameters (see 2.2.3), typicaly using cross-validation.  Like 
generalized linear models, PLS can be applied to both continuous Y (termed partial-
least-squares regression  or  PLS-R) and categorical Y (termed  partial-least-squares 
discriminant analysis  or  PLS-DA)  where  predictions  are evaluated  by equations 
2.25 and 2.26 respectively.  
 
 
2.3.3 Evaluating supervised models 
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Interpreting feature selection  methods and classification  models typicaly 
depends  on evaluating  quality  metrics such as significance, classification accuracy, 
and goodness-of-fit. Especialy in the case of supervised methods where p > n, such 
as PLS, overfiting is concern and must be guarded against by various cross-validation 
and  permutation testing strategies.   While the  methods  discussed  here are linear, 
parametric  models, the application  of  non-linear  or  non-parametric  models and 
machine learning techniques requires even  greater  vigilance in evaluating  model 
performance.  
 
2.3.3.1 Evaluating feature significance 
 
When  using  univariate  tests  such  as  Student’s  t-test,  ANOVA,  and  Pearson’s  
corelation coeficient, significance levels can typicaly  be ascribed to test statistics 
such as t-values  or  F-values  by referring to coresponding t- and  F-distributions. 
Here, p-values refer to the probability of observing a test statistic by chance given the 
degrees  of freedom and the resulting  probability  density function.   While the 
significance threshold α  is typicaly set at α  =  0.05, since  p-values refer to the 
probability  of  observing a test statistic  by chance the  occurence  of false-positive 
associations is expected to increase when multiple features (hypotheses) are evaluated 
by univariate methods. To corect for this multiple hypothesis testing, a corection is 
typicaly applied to the  p-values calculated after  multiple tests  by the  number  of 
measured  variables m.   Methods for estimating a revised threshold p include 
Bonferoni corection (eq.  2.27), Šidák corection (eq.  2.28), and the  Benjamini-
Hochberg false discovery rate (FDR, eq. 2.29) [114, 115]where d is the largest index 
of sorted p-values for which equation 2.29 holds true.  
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2.3.3.2 Evaluating classification performance 
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Given a  binary categorical Y and a  binary categorical  resulting from 
predictive  modeling, it is  possible to  have four  possible classification  outcomes as 
shown in the confusion matrix in Table 2.4.  These are refered to as true-positives, 
true-negatives, false-positives and false-negatives.  Clearly, the  goal  of any 
classification  method is to  maximize the true  predictions and  minimize the false 
predictions. However, total positives and total negatives tend to be inversely related 
as they are  based  on the selection  of a classification threshold.   As a result, 
classification accuracy tends to  be reported in terms  of sensitivity (eq.  2.30) and 
specificity (eq. 2.31), which are percentage values.  
 
Table 2.4.Binary classification confusion matrix. Here n is the absolute number of true-positives (nTP), 
false-positives (nFP), true-negatives (nTN) and false-negatives (nFN). 
 Y = 0 Y = 1 
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 In receiver operating characteristic (ROC) analysis, classification sensitivities 
and specificities are evaluated at classification thresholds at al  values  of x, and an 
area-under-curve (AUC) is evaluated  by integrating the curve resulting from 
calculating sensitivity as a function of (1-specificity). An AUC of 1 indicates perfect 
classification while and AUC of 0.5 indicates random classification. 
 In the case  of  overfiting,  however, classification can  be  highly accurate for 
the  dataset  used to construct a  model β,  but essentialy random for an independent 
dataset.  To avoid this, datasets are frequently split into training and test sets  where 
the training set is  used to construct a  predictive  model and the test set is  used to 
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evaluate the classification performance of the model. Training and test sets can also 
be  defined iteratively,  with  multiple  models constructed  based  on  diferent 
permutations of training and test set assignment.  These methods include leave-one-
out cross-validation (LOOCV), in which a test set of n = 1 is used to evaluate model 
peformance for al nN, k-fold cross validation in  which k test-sets  of size n = k/N 
are used, and k-fold Monte-Carlo cross validation (MCCV) in which test-sets of size 
n = k/N are used but membership in the test and train set is randomly permuted such 
that a given sample may be assigned to the train set multiple times [116, 117].  
While sensitivity, specificity, and  AUC are  useful  metrics  of classification 
accuracy, these metrics do not indicate goodness-of-fit. For example, even in logistic 
regression or PLS-DA,  is continuous on a range of [0,1] and for continuous Y the 
concept  of classification accuracy  does  not  make as  much sense.  In these cases, 
goodness-of-fit metrics R2 (or ) and Q2(or ) are used to report the  goodness-
of-fit for train and test sets respectively, as shown in equations 2.32 and 2.33 [118]. 
Recent work has also atempted to assess model significance by randomly permuting 
Y and evaluating the percentage of random models with greater Q2 values [119]. 
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2.4 Compound identification and verification 
 
Interpretation  of  metabolic  profiling  data requires that spectral signals  be 
related to  known chemical species.   This  process, referred to as assignment  or 
compound/biomarker identification,  has  historicaly  been a significant chalenge in 
metabolomics research [120].  In targeted analysis, assignment is typicaly  done 
before quantitative analysis while in untargeted analysis it is done only for a subset of 
signals  highlighted  by statistical analysis.   Beter characterization  of the  makeup  of 
typical  human metabolic profiles and a growing literature together with advances in 
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statistical spectroscopy and spectral  databases  have reduced the complexity  of the 
assignment workflow. 
 
 
 
Figure  2.6.  Strategy for  unknown compound identification  using statistical spectroscopy and spectral 
databases. Signals of interest are identified from an experimental dataset (A). Statistical spectroscopy 
tools, such as STOCSY and SHY, are used to identify correlations between the signal of interest and 
additional signals in the same  or  other spectral  datasets colected from the same set  of samples (B). 
Candidate compounds are identified using database search tools to match the set of correlated spectral 
features with structures (C). A candidate compound is confirmed by spiking a solution of the candidate 
into the original mixture (D). 
 
In the case  of  unknown  or  unexpected compounds that are  not  novel 
compounds, a four-stage approach to  biomarker and compound identification, 
represented schematicaly in Figure 2.6, may be used to assign these signals. In the 
first stage, spectral features are corelated with a given biological state or response by 
applying  patern recognition analysis to individual  datasets  generated  by  NMR 
spectroscopy  or  mass spectrometry (Fig  2.6A).   Subsequently,  STOCSY,  SHY, and 
other statistical spectroscopy tools are then used to associate masses, fragments, and 
NMR spectral features (Fig  2.6B).  In a third stage, the set  of corelated features, 
including mass, retention time, fragmentation  paterns, chemical shifts, and through-
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bond corelations are searched in-silico for  matching compounds  using  metabolite 
libraries and reference spectral data (Fig 2.6C).  
While individual  MS m/z  values and single  NMR chemical shifts are  often 
non-specific, only a smal number of structural isomers wil give rise to similar NMR 
spectra andMS/MS fragments.  To conclusively  verify  database  matches,  metabolite 
candidates of interest may be confirmed by direct spiking of pure chemical standards 
into the biological matrix for NMR, or comparison of parent masses, retention times, 
and fragmentation  paterns  of  pure standards  by  mass spectrometric analysis (Fig 
2.6D).   Several  web-based computational tools support  biomarker and compound 
identification, including  Metlin,  XCMS  Online, the  BMRB and  HMDB  databases, 
and MetaboAnalyst, [69, 99, 121-123]. In cases where database matches or chemical 
standards are not available, 2D NMR can be used to conclusively identify structural 
isomers [120].  
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CHAPTER 3 
2D  NMR  METABOLIC  PROFILING IN 
BIOCHEMICAL GENETICS 
 
3.1 Introduction and aims 
 
Nuclear  Magnetic  Resonance (NMR) spectroscopy is a  powerful and almost 
universal  detector  due to its ability to analyze essentialy al types  of  molecules at 
atomic resolution. Recently it has been applied extensively to metabolic profiling in 
studies  of  human and animal  biofluids [124,  125], celular  biochemistry [126,  127], 
and  non-mammalian chemical ecology [128,  129].  While  one-dimensional (1D) 1H 
NMR spectra  have  been  used in the  majority  of  NMR-based  metabolic  profiling 
studies, resonance  overlap and lack  of structural corelations can limit the  utility  of 
the 1D approach. In contrast, powerful multidimensional NMR methods are routinely 
used in structural biology and natural products studies but have been used much less 
frequently for metabolomics. Two dimensional (2D) homonuclear (such as TOCSY 
and  COSY) and  heteronuclear (such as  HSQC and  HMBC) spectra  ofer increased 
dispersion  of signals in two  dimensions that can  overcome the  problem  of signal 
overlap, which often limits the use of 1D 1H NMR spectra. 
 While the  use  of  2D  NMR  data is expected to  be  broadly  useful in 
metabolomics, the advantages  of  2D  NMR are  particularly  helpful in  overcoming 
specific chalenges sometimes posed by metabolic profiling in biochemical genetics. 
The information  provided  by these  2D experiments through specific atomic 
corelations can assist in the identification and assignment  of  known  molecules and 
the structural elucidation of unknown smal molecules that may be significant to the 
underlying  biology.   The  presence  of  novel,  uncharacterized smal  molecules in 
complex  biological  mixtures is a frequent  occurence, especialy in  metabolic 
profiling experiments in  both  human and  non-mammalian  biochemical  genetics, 
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where significant  perturbations  may  be expected  or a  priori  knowledge  of the 
metabolome is  often incomplete.   Assignment chalenges are exacerbated  by 
increased spectral complexity such as in cases  where a large  number  of similar 
compounds are  present in  biological samples  due to accumulation  of  metabolic 
intermediates or shunt metabolites produced by atypical metabolism of accumulating 
intermediates.  In  human  biochemical  genetics, characterization  of the  metabolic 
efects  of a  genetic  variation frequently  depends  on analysis  of a smal  number  of 
samples, sometimes from a single  pedigree [130].   2D  NMR experiments,  which 
require more time to colect but provide additional information relative to 1D datasets, 
are  wel suited to smal sample sizes.   Finaly, investigations  of the  metabolic 
consequences of mutation are wel established in other fields such as natural products 
research, where 2D NMR is an important and established tool [126, 131]. 
While it is clear that metabolic profiling research as a field would benefit from 
more extensive use of 2D NMR spectra, there is a lack of suitable 2D versions of the 
computational approaches applied to  1D  NMR and  MS spectra in  metabolomics 
[132].  Methods such as signal alignment,  detection,  patern recognition and 
visualization tools for multiple 2D spectra have lagged behind similar methods for 1D 
NMR and  mass spectra [133].  This chapter  presents  methods for  hierarchical 
alignment and signal  detection from sets  of  2D  NMR spectra, thereby enabling 
efective normalization and patern recognition using both ful-resolution data and bin 
integrals. These tools are then applied to identify shunt metabolites of peroxisomal β-
oxidation in a C. elegans model of human peroxisomal biogenesis defects and human 
urinary solutes lost due to proximal tubule defects in a novel form  of renal  Fanconi 
syndrome in a single family.  
 
3.2 Results – Method development 
 
This section presents the theoretical framework of the new methods developed 
for  preprocessing  2D 1H-1H  NMR spectra.   These include  guided alignment, 
presented as  Hierarchical  Alignment  of  Two-Dimensional  Spectra (HATS), 
automated crosspeak identification and integration,  presented as  multivariate 
Diferential  Analysis  of  NMR  Spectra (mvaDANS), and adapted chemometric 
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methods including normalization, scaling and patern recognition for analysis of this 
data [94, 102].  
 
3.2.1 Automated crosspeak identification and integration in 2D NMR 
 
Spectral segments are  detected from a representative  pseudo-spectrum-  here, 
an average spectrum calculated from the  mean along the third  dimension  of the 
spectral stack (ω1,   ω2,N).   To identify segments  of the  pseudo-spectrum 
coresponding to crosspeak regions, a local  noise surface is calculated  using the 
AUTOPSY [134]method (equations  3.1-3.4).   AUTOPSY calculates a  point-wise 
estimation of underlying noise as folows. 
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Here, dx and dy are noise values for each slice x and y in the direct and indirect 
dimensions of the 2D NMR spectrum, respectively. The noise value for a given slice 
x or y is calculated by spliting the slice up into 16 regions of size n=F1/16 for the 
direct  dimension and n=F2/16 for the indirect  dimension.  The  noise for that sliceis 
then the standard  deviation  of the region  with the  minimum standard  deviation as 
shown in equations  3.1 and  3.2.  Each  point p in the spectrum is intersected  by two 
slices x and y whose noise values are dx and dy. The noise at point pxy combines the 
noise in slice x  with the  noise in slice yand  with a  baseline  noise  value b as in 
equations 3.3 and 3.4. This method of calculating noise is very wel suited to the noise 
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structure  of  2D  NMR  data,  which is characterized  by  vertical  noise such as  T1 and 
water noise. 
Once the  noise surface pxy  has  been calculated,  peaks can  be  detected  by 
identifying local  maxima above a certain  multiple  of the  noise surface.   While the 
exact threshold can  vary and is a  parameter that  must  be  modified for appropriate 
processing of any individual dataset, values of 5-10 detect the large majority of cross-
peaks. Segments are then defined as regions adjacent to detected peaks.  
Initial spectral segments are identified as regions within 0.04 ppm of a peak in 
the 1H dimension of homonuclear spectra. In the case of multiplicity, local maxima 
are grouped together into a single initial segment. Each segment is then labeled with 
a  unique integer  value and iterated  minimum and  maximum filtering expand these 
initial segments. Min/max filtering has the efect of growing the segments until they 
encounter another spectral segment or until they reach a maximum frequency range of 
approximately  0.2  ppm for 1H.   This  procedure creates spectral segments  with  non-
rectangular bounds that are bounded by nearby resonances yet avoid close cropping of 
cross-peak line shapes.  These segments are then integrated  using a trapezoidal 
numerical integration.  
 
3.2.2 Hierarchical Alignment of Two-Dimensional Spectra (HATS) 
 
The  HATS alignment  method  presented  here  makes  use  of a  guide tree to 
structure the alignment  process.   While  many existing  1D alignment  methods  have 
atempted to align each spectrum in a dataset to a single consensus spectrum [90, 92, 
135],   the   quality   of   these   “star   alignments”   can   sufer   if   there   is   wide   chemical  
diversity  between spectra, as any individual spectrum chosen as a star  may  not 
include the ful complement of metabolites present in the other datasets. The use of 
guide trees  was a significant advance for  multiple sequence alignment in sequence 
bioinformatics, and  methods such as  CLUSTAL-W [136]  have enjoyed  widespread 
popularity in  nucleic acid and  protein sequence alignment.   The  use  of a  guide tree 
should  be  helpful in the alignment  of  2D spectra as corelation spectra are  often 
colected  when significant  metabolic  diversity is expected and the assumptions 
underlying star alignments may not be appropriate.  
The  UPGMA agglomerative  hierarchical clustering  method  was  used to 
construct the initial  guide tree for the subsequent  pairwise alignment  of spectral 
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groups. The  squared  distance  of  Pearson’s  corelation  coeficient  was applied here as 
a metric for clustering (equations 3.5 and 3.6), and the resulting dendrogram specifies 
the order in which alignment of the spectra proceeds.  
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Here, rmn is the corelation coeficient  between the reshaped  vectors (1  x 
F1F2) of spectra Sm and Snwith mean values and , standard deviations and
, and dmn is a distance version of the corelation value. At each branch point in the 
dendrogram, the set  of spectra specified  by the  branches are aligned.   For the 
alignment ilustrated in Figure 3.1, the two red spectra are aligned first, folowed by 
the two blue spectra, then the two blue spectra are aligned with the black spectrum, 
and finaly the two red spectra are aligned with the three blue and black spectra.  If 
there are  multiple spectra in an alignment  group,  positional adjustments are  made 
equaly to al spectra in the group. 
The alignment at each branch point of the guide tree consists of two parts: a 
global alignment in  which al spectral  datapoints are shifted equaly and a local 
alignment in  which specific crosspeak regions are shifted individualy.   The  global 
alignment step seeks to corect defects such as mis-calibration or referencing, which 
produce chemical shift diferences across the entire spectrum.  One of the groups of 
spectra is  passed over the other  group as a mask in a point-wise manner in  both  F1 
and  F2  dimensions, and at each  positional step xand ythe alignment  quality is 
expressed as rxy, the mean corelation between groups (equation 3.7). 
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Figure  3.1.  Overal strategy  of  Hierarchical  Alignment  of  Two-Dimensional  Spectra.   Before 
alignment, the  HATS algorithm  produces a  guide tree  by the  UPGMA agglomerative  hierarchical 
clustering algorithm from a  matrix  of  pairwise correlation  distances.   This  guide tree is  used to 
structure the alignment  process.    At each intersection  of  branches in the  guide tree, the spectra 
specified by the two branches are aligned globaly and localy. For the alignment tree shown here, the 
two red spectra are aligned first, folowed  by the two  blue spectra.   The two  blue spectra are then 
aligned with the black spectrum, and finaly the three blue and black spectra are aligned with the red 
spectra. 
 
Here, a is the number of spectra in  group 1 and b is the number in  group 2, 
and rmn is the corelation coeficient between the reshaped vectors of spectrum m in 
group  1 and spectrum n in  group  2.   Spectra in the  mask  group are shifted to the 
pointsmand n producing the maximal mean correlation which is identified by a simple 
gradient ascent algorithm.While  global alignment can resolve factors afecting al 
resonances equaly, it is  not capable  of resolving  diferences in specific resonances 
caused  by conditions such as  pH, temperature,  metal ion concentration, and 
osmolality.  To resolve local chemical shift  variation, crosspeak regions  must  be 
aligned individualy.  To identify segments  of the spectrum coresponding to 
crosspeak regions, a local noise surface is calculated for each spectrum, as outlined in 
the previous section [134]. This procedure creates spectral segments that are bounded 
by  nearby resonances  yet avoid close cropping  of crosspeak lineshapes.   Each 
crosspeak segment is then aligned individualy  by  maximizing the  mean cross-
corelation of crosspeak segments between alignment groups in the same way as the 
global alignment  but treating each crosspeak segment independently (equation  3.7, 
where rxy is the lineshape vector for a single crosspeak region rather than the entire 
spectrum) 
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3.2.3 Chemometrics applied to 2D NMR 
  
3.2.3.1 Unfolding and refolding of ful resolution data  
 
Folowing alignment, Principal Component Analysis (PCA) and Partial Least 
Squares  Discriminant  Analysis (PLS-DA) are applied for ful resolution spectral 
patern recognition.  Each  principal component consists  of  N scores and  P loadings, 
where scores identify relationships  between  observations (here,  TOCSY spectra 
colected from individual samples) and loadings represent the  patern  of features 
(here,  2D  NMR chemical shifts)  underlying the relationships identified  by scores. 
The NIPALS algorithm [112] was applied to calculate principal components given the 
impracticality  of  using singular  value  decomposition  methods for  P>>N  matrices. 
While PCA avoids the problem of over-fiting by taking an unsupervised approach to 
patern recognition, it is  not  optimized for class separation.   Partial least squares 
methods such as PLS-DA are often the supervised method of choice for the analysis 
of metabolic diferentials.  The SIMPLS [113] PLS-DA algorithm  was used to  help 
clarify the  metabolic  differential identified  by  PCA  while avoiding  over-fiting  by 
using  4-fold cross-validation and reporting  performance statistics for the  PLS-DA 
model. 
Each  of the  4096  x  1024  TOCSY  data  matrices  were reshaped to a  1  x 
4194304  vector  before the application  of  PCA  or  PLS.   This is a  necessary step 
because it creates an  NxP  matrix,  where  P=F1F2  data  points  on  which  patern 
recognition algorithms can  operate.   To  visualize the resulting  1xP loadings, the 
loadings vectors for each principal component were reshaped back into a 4096 x 1024 
data matrix. Contours were defined by multiplying the univariate scaled loadings by 
the standard  deviation along the third  dimension  of the  original  TOCSY stack (ω1, 
ω2,N), a procedure known as back-scaling or back-projection [137]. Contour colors 
were then defined by the loading values themselves divided by the maximum absolute 
loading coefficient to  produce a range  of -1 to  1.   This strategy  produces loading 
spectra  which  have cross-peak line shapes similar to traditional  TOCSY spectra  but 
include sign and intensity information related to the relationships  between spectra 
specified  by the coresponding  PCA scores.   PLS-DA results are  presented in a 
similar  manner,  but instead  of specifying scores and loadings  only the  predictive 
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feature  vector is shown, along  with  performance statistics for the  model.  This  2D 
NMR  unfolding and refolding approach  has recently  been applied successfuly to 
HSQC spectra and  provides a simple  methodology to apply statistical  patern 
recognition approaches to 2D NMR spectra [138, 139]. 
 
3.2.3.2  Mapping integrated  bins –  multivariate  Differential  Analysis  NMR 
Spectroscopy (mvaDANS) 
 
Integration  of  detected spectral segments transforms the  2D  NMR  dataset 
from a three-dimensional stack  of ful resolution 2D   spectra   (ω1,   ω2,N) to a two-
dimensional  matrix  of features (N,P)  where  P is the  number  of  detected segments. 
Patern recognition methods such as PCA, PLS, and derivatives of these methods can 
be applied directly to the bin matrix, though inclusion of intermediate normalization 
and stabilization steps applied to the bin matrix rather than the ful resolution spectra 
improve  patern recognitions results [88,  104].   As in  3.2.3.1, the result  of  patern 
recognition is, for each component in the  model, a set  of  N scores showing the 
similarity of the samples to each other and a vector of P coefficients (refered to as 
loadings  or  predictors) that indicate the contribution  of each  bin to the separation 
between the samples.   However, as a result  of  binning the  number  of  variables (P) 
modeled is much lower than the ful spectral resolution.  
To interpret the  model and identify important  metabolites, coeficients are 
back projected onto the ful resolution spectra by using the spectral segments.  For al 
segments in the ful resolution matrix, the data points within the segment are replaced 
with the  value  of the coeficient from  patern recognition  of the  bin extracted from 
that segment to produce a ful resolution loadings matrix. For stabilized data, loading 
coeficients are independent of signal intensity and thus peak shape is not visible. To 
produce ful-resolution  back-projected loadings that resemble 2D NMR spectra, this 
matrix is then  multiplied  point-wise  by the standard  deviation along the third 
dimension of the 2D NMR stack (ω1,  ω2,N). As with the ful resolution data, contour 
lines are  defined  by the  back-projected loadings, and the colors  of these lines are 
defined  by the coefficients themselves.   Figure  3.2  outlines this approach, termed 
multivariate  Diferential  Analysis  NMR  Spectroscopy (mvaDANS), as applied to a 
representative dqfCOSY spectrum of the C. elegans wild-type metabolome.  
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Figure 3.2. Outline of mvaDANS operations. A) 1-3 ppm region of phase-sensitive dqfCOSY spectrum 
of C. elegans wild-type metabolome. (B) Same NMR spectrum processed in magnitude mode prior to 
automatic binning. (C) Contour plot of NMR spectrum from (B) ploted with boundaries of bin regions 
identified by mvaDANS. (D) Back-projected pseudo-spectrum derived from Principal Component 1 of 
the C. elegans  wild-type/daf-22 comparison NMR dataset.  Crosspeak colors indicate the normalized 
PC 1 loading coeficient of the region bin. 
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3.3 Data Sets 
 
3.3.1 Nematode species diferentiation: P. pacificus and P. redivivus 
 
 P.  pacificus and P. redivivus strains  were  obtained from the  Sternberg 
laboratory at  Caltech.  2.5  milion semi-synchronized J2 P.  pacificus  were  grown to 
adult stage  on  S-complete  medium supplemented  with  3%  HB101 and incubated at 
22°C at  250 rpm shaker.  A  mixed  population  of P. redivivus  with  worm  density  of 
10,000  worms/mL  were incubated in  250  mL  of  S-complete  medium supplemented 
with 3% HB101. P. redivivus were cultured for 12 days and 3% HB101 was added 
every  3rd  day.   Worms from this culture  were then  put  onto a sucrose  gradient to 
remove  bacteria and  placed in  M9  bufer for  30  minutes to clear their  gut.   Worms 
were washed three times with double-distiled water (ddH20) and then incubated for 1 
h in  ddH20  with  density  of  ~30,000  worms/mL to colect  worm exudates.   Worm 
exudates   were   filtered   with   a   0.2   μm   nylon   syringe   filter   and   stored   at  -80°C for 
further analysis.  
 P.  pacificus and P. redivivusexudates  were each fractionated  by  C18 solid 
phase extraction (Varian  Mega  BE  C18). P.  pacificus and P. redivivusexudateswere 
then added to individual columns and the flow-through was colected. The columns 
were washed with 25 mL of ddH2O and then eluted with 25 mL of 50% methanol and 
25  mL  of  90%  methanol.  The flow-through fractions  were lyophilized,  dissolved in 
500  µL  of  99.9%  D2O (Cambridge Isotope  Labs), and transferred into  5-mm  NMR 
tubes.   The  50%  MeOH fractions  were lyophilized,  dissolved in  110  µL  of  99.95% 
methanol d4 (Cambridge Isotope Labs), and transfered into 2.5-mm NMR tubes.  
1D 1H and  2D  TOCSY spectra  were colected  on a  Bruker  Avance I 
spectrometer operating at 600.23 MHz using a 5-mm TXI cryoprobe. NMR data were 
colected  with spectral  widths  of  11  ppm at a sample temperature  of about  300  K. 
TOCSY spectra were colected with the DIPSI-2 mixing sequence [140] with 60 or 90 
ms mixing times and iradiation of residual water for the 50% MeOH or flow-through 
fractions, respectively. TOCSY data were colected with 2048 and 256 complex data 
points in the  direct and indirect  dimensions, respectively.   TOCSY  data  were zero 
filed to 2048 F2 and 1024 F1 datapoints, Fourier transformed, phased, and baseline 
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corected in  Topspin  2.0 (Bruker)  before  being transfered to  Matlab  2009b for 
alignment and patern recognition analysis. 
 
3.3.2 Animal model of peroxisomal disorder: daf-22 C. elegans 
 
Wild-type C. elegans (N2) as  wel as daf-22 (m130) and daf-22 (ok693) 
mutant strains were obtained from the Caenorhabditis Genetics Center (CGC). Strains 
were maintained at 20 °C on NGM plates with bacteria (E. coli OP50) as food. 
Liquid cultures were grown as previously reported [141]. Briefly, wild-type or 
daf-22  mutant  worms  were  grown for two  generations  on  NGM  plates seeded  with 
OP50.  Three crowded  6 cm  NGM  plates  were  washed into  100  mL solution  of  S-
medium in a 500 mL Erlenmeyer flask and grown at 22°C and 220 pm. Concentrated 
OP50 from 1 L bacterial cultures, grown over-night, were given on day 1 and day 3. 
On  day  5 the liquid culture  was split into two  500  mL  Erlenmeyer flasks and the 
growth media volume was maintained at 100 mL. An additional 1 L OP50 pelet was 
given as food upon spliting. The cultures were harvested on day 7 by centrifugation 
at  4750 rpm.  The supernatant  was lyophilized and the residue extracted  with  95% 
ethanol (300 mL) at room temperature for 12 h. The resulting suspension was filtered 
and evaporated in  vacuo at room temperature to  yield the crude extracts. In this 
manner four extracts each  of  wild-type (N2), daf-22 (m130), and daf-22 (ok693) 
cultures were prepared. 
 In  preparation for  NMR-spectroscopic analysis, the crude extracts  were 
suspended in  1:8  methanol (MeOH):dichloromethane (DCM),  using  7.5  mL  of this 
solvent mixture per 1 gram of crude extract. Folowing centrifugation, 2 mL aliquots 
of supernatant of each sample were filtered over 1 g of silica (EMD Chemicals Inc.) 
using 10 mL of 1:8 MeOH:DCM for elution. The filtrate was evaporated to dryness in 
vacuo prior to analysis.  For  NMR spectroscopic analysis, 10-20 mg of the resulting 
metabolite extracts was used.  
NMR samples were prepared by dissolving 10–20 mg portions of metabolite 
extract (see above) in  0.6  mL  of  CD3OD.  Samples  were analyzed  using a  Varian 
INOVA  600  MHz  NMR spectrometer.  Nongradient  phase-cycled  dqfCOSY spectra 
were truncated at 0.4 s and acquired using the folowing parameters: 0.8 s acquisition 
time,  600 complex increments,  16 scans  per increment.  For  processing  with 
mvaDANS, spectra were zero-filed to 2048 × 1024 data points, a sine-square-shaped 
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window function was applied in both dimensions prior to Fourier transformation, and 
spectra  were converted to  magnitude  mode  prior to transfer to  Matlab 
(Mathworks).For  detailed analysis in  phase-sensitive  mode,  dqfCOSY spectra  were 
zero-filed to 8192 × 4096 data points and a cosine bel-shaped window function was 
applied in  both  dimensions  before  Fourier transformation.NMR spectra  were 
processed  using  TopSpin (Bruker),  VNMR (Varian),  MestReC (MestreLabs), and 
MNova (MestreLabs) software  packagesbefore  being transferred to  Matlab  2009b 
(Mathworks) for mvaDANS and patern recognition analysis. 
 
3.3.3  Genotype-metabotype  association in  a single  pedigree:  Autosomal 
Dominant Fanconi Syndrome I (ADFS1) 
 
Seven  members  of a family  with  generalized  Fanconi  Syndrome (FS)  were 
admited to the  NIH  Clinical  Center and enroled in clinical  protocol  76-HG-0238, 
“Diagnosis   and   Treatment   of   Patients   with   Inborn   Erors   of   Metabolism   and   Other  
Genetic Defects”.  Other  family  members  (N=11) were seen localy. Al gave writen, 
informed consent.  The  diagnosis  of  FS  was established  by routine laboratory 
investigations of urine and blood.  Al investigations, including genetic studies, were 
approved by the NHGRI Institutional Review Board and conducted according to the 
principles of the Declaration of Helsinki. 
Glomerular function, as evidenced by plasma creatinine levels, was considered 
normal, even in the afected  74-year  old  matriarch (plasma creatinine  1.4  mg/dl). 
Proteinuria in the afected  was  up to  1.2  g/day and  was  not associated  with renal 
failure.Eighteenafected individuals in this family, aged  1 to  74  years,  had an 
uneventful  gestation,  birth and infancy.  The  primary clinical  manifestation  was 
rickets,  with  bowing  of legs from early childhood  on.  Al  known causes  of  FS  had 
been previously excluded. Urine samples were colected from (N=5) afected family 
members and from and additional (N=5) unafected family members and analyzed by 
NMR spectroscopy. 
250  μL  aliquots  of  filtered,  centrifuged  urine  were  combined  with  150  μL  of  
HPLC grade water (Sigma) and  100μL  of  NMR  bufer  of D2O and 1mM TSP (Sigma) 
and  3mM  NaN3 in  5mm  NMR tubes (Wilmad). Spectra  were colected  on a  Bruker 
Avance II spectrometer operating at 800.32 MHz using a 5 mm cryoprobe. Spectra 
were acquired at 300K with a resolution of 64k data points and a spectral width of 20 
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ppm  using a  1D  pulse-acquire sequence  with  direct  presaturation  of residual  water 
and a relaxation  delay  of  30 s to accommodate ful  T1 relaxation  of  urinary 
metabolites.   2D 1H-1H  TOCSY spectra  were acquired  using a  DIPSI-2  pulse 
sequence with MLEV and WATERGATE [140]. Al data were Fourier transformed, 
phased, and  baseline corected in  XWinNMR (Bruker)  before  being transfered to 
Matlab  R2010b (Mathworks) for  preprocessing, including  normalization to  urinary 
creatinine, and patern recognition. 
 
3.4 Results and Discussion 
 
3.4.1 Improved information recovery from 2D NMR spectra 
 
Guided alignment by the HATS approach reduces positional variation by first 
clustering al  of the spectra through a  guide tree, as shown in  Figure  3.3A.   The 
problem  of  positional  variation is easily seen in the  TOCSY spectra from the P. 
redivivus and P. pacificus nematode samples.  An expansion of the anomeric region 
of the sugars from the flow-through fractions is shown in Figures 3.3B and 3.3C. In 
the  unaligned  data (Figure  3.3B), local  diferences in resonance frequency  of the 
anomeric protons affect multiple spectra of both P. redivivus and P. pacificus samples 
and   result   in   a   general   “bluriness”   that   significantly   impacts   subsequent   statistical  
analyses. Removing this variation is clearly desirable, but the close proximity (~.03 
ppm) and similar paterns and lineshapes of the P. pacificus glucose and P. redivivus 
trehalose crosspeaks raise the possibility of inappropriate alignment of the glucose to 
the trehalose crosspeaks.   The  use  of the  HATS-PR  guide tree (Figure  3.3A)  helps 
avoid this  possibility  by aligning the  most similar  before the less similar spectra. 
Using this approach, the  glucose and trehalose resonances are  not compared for 
alignment until they have been wel aligned separately. As shown in Figure 3.3C, this 
results in the corection  of  positional  variation  within  both  glucose and trehalose 
crosspeaks and rejection of the inappropriate alignment of the two sugars. 
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Figure  3.3.  Alignment results for P. redivivus (Pre) and P.  pacificus (Ppa)  TOCSY spectra  of flow-
through fractions from  C18 solid  phase extractions.   A)  The  guide tree  produced  by  HATS  groups 
spectra from the same species, resulting in intra-species alignment before inter-species alignment. The 
utility of a guide tree based alignment is exemplified by the anomeric crosspeaks of glucose, sucrose, 
and trehalose in the TOCSY spectra (B, C).  By aligning spectra with similar composition first, false 
positive alignments of nearby but unrelated crosspeaks, such as the anomeric crosspeaks shown above, 
are avoided.     Arrows indicate  poorly aligned signals for  which  positional  variation is correctly 
resolved by HATS. 
 
As 2D NMR data are frequently used in a qualitative rather than quantitative 
manner,  preprocessing steps such as  normalization and  variance stabilization  or 
scaling are  not frequently applied to  2D  datasets.  However, as in  1D  NMR, signal 
intensity in  2D  NMR reflects solute concentration in the sample  being  measured. 
While cross-peak integrals are  not absolutely  quantitative  due to efects such as 
incomplete  magnetization transfer and the  number  of  bonds  between the coupled 
nuclei  giving rise to the crosspeak as  wel as  other  detection and  processing 
parameters, integrals are relatively quantitative in that changes in solute concentration 
should result in linear changes in the integral value. Additionaly, 2D NMR spectra, 
like  1D spectra, are afected  by random  dilution especialy in the case  of  urinary 
spectra. 
Unlike 1D data where a majority of the colected data points have a substantial 
contribution from signal  with few  variables  dominated  by  noise,  2D corelation 
spectroscopy  data is  highly sparse.   Even  with the  narower spectral  widths (10-12 
ppm) common for  TOCSY and  COSY spectra, cross-peaks are  present in less than 
10% of spectral  data points as determined by comparing detected spectral  bins  with 
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the ful resolution data, even for crowded spectra such as the C. elegans extracts and 
human urine. As a result, normalization to the median fold change of al spectral data 
points  does  not rectify the linear changes in signal intensity caused  by  variable 
dilution. Figure 3.4 compares the efect of normalizing on the ful resolution data and 
just the spectral  bin integrals for the  Autosomal  Dominant  Fanconi  Syndrome  1 
(ADFS1) human urinary data. 
 
 
 
Figure  3.4.  Comparison  of  normalization  on ful-resolution  2D  NMR  data  on  bin integrals.   These 
panels show histograms of fold-change vs. median for al (N=10) TOCSY spectra from ADFS1 urine 
samples  when  normalization is  performed  on ful resolution  or crosspeak  bins and the  dilution 
correction calculated by normalization is evaluated for the ful resolution data or crosspeak bins. While 
the  normalization  protocol shifts the  median fold-change to 1, the  botom left  panel shows that the 
sparseness of the ful-resolution data under-normalizes the signal component of the data.  
 
Here,  normalizing  on the ful resolution  data and evaluating the fold change 
distributions of the data show a distribution centered at 1 as expected. However, this 
distribution is  very  broad, as increased  variance is to  be expected  when taking the 
ratio  of  noise  values sampled randomly from a  distribution centered at zero. 
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Estimating  dilution factors from the ful resolution  data  does  not center the 
distribution  of  bin integrals.   Normalizing the  bin integrals  directly  does corect for 
the effects  of random  dilution  on cross-peak intensity.   Estimating  dilution factors 
from the  median  of the  distribution  of  bin integral fold changes for  2D corelation 
spectra is the equivalent  of  doing  peak  probabilistic  quotient  normalization for  1D 
spectra [88]. However, the increased sparseness of the 2D data makes normalization 
using signal values only even more important than for 1D data.  
 
 
 
Figure 3.5. Efects of normalization on Principal Component Analysis of 2D NMR spectra. Principal 
Component  Scores (top) and  Loadings (botom) for  un-normalized (left) and  normalized (right) C. 
elegans TOCSY spectra.  After mean-centering but before normalization, PC1 scores do not separate 
worm strains and loading coeficients are  positive (red) for  nearly al spectral signals, indicating 
variance induced  by  dilution effects.   Normalization corrects for this effect, leading to  good strain 
separation and loadings that are interpretable as quantitative diferences in metabolite levels.  
 
  Dilution efects are  wel  known in  human  urine, and the  necessity  of 
normalization to overcome variable dilution for human urinary data is established in 
 71 
urinary metabolic profiling [104]. However, urine is not the only sample matrix that 
shows  variable  dilution efects, and these can  be  observed in extracts as  wel even 
when sample preparation atempts to standardize concentration by sample volume or 
dried mass. Dilution efects are shown in Figure 3.5 for the C. elegans daf-22 and N2 
spectra.  
While final concentrations for  NMR  were roughly  on the same  order  of 
magnitude due to the preparation of 10-20 mg of filtered extract in 600 uL CD3OD, 
this variation is stil great enough that the variance in Principal Component Analysis 
is  dominated  by linear changes in signal intensity shown  by the  positive loading 
coeficients for nearly al spectral signals in PC1 of the un-normalized data, indicating 
that concentration effects are the primary source of variation in the raw data. While 
this would not be a significant complication to interpreting the data qualitatively, only 
folowing normalization is the dataset able to be interpreted in a quantitative manner 
using patern recognition tools. These results indicate that the preprocessing methods 
developed for 2D NMR datasets presented here improve the interpretability of these 
data  by adapting and extending the framework  of the  methodology applied to  1D 
NMR and mass spectral data in metabolomics.  
 
3.4.2 Identification  of β-oxidation intermediates in  a C. elegans  model  of 
peroxisomal disorders 
 
C. elegans is an established model organism in biochemical genetics, studies 
of  which  have  yielded important insights into  metabolic  pathways and regulation 
[142-144].  Recent analyses  of the C. elegans metabolome revealed a family  of 
structuraly  diverse smal  molecules, the ascarosides, as  products  of conserved 
peroxisomal   β-oxidation [131,  145,146].  Mass spectrometry-based comparative 
metabolomics characterizedthe functions of three enzymes in ascaroside biosynthesis, 
the acyl-CoA  oxidase  ACOX-1, the enoyl-CoA  hydratase  MAOC-1, and the  3-
hydroxyacyl-CoA dehydrogenase DHS-28[146]. 
Figure 3.6 shows the C. elegans peroxisomal  β-oxidation pathway responsible 
for ascaroside  biosynthesis  with the  homologous  human long-chain lipid catabolic 
pathway.    The fourth enzyme in the C. elegans peroxisomal   β-oxidation cascade, 
encoded  by the  gene daf-22, is a close  homologue  of  mammalian  3-keto-acyl-CoA 
thiolases(human SCP2, 83% homology), but its predicted thiolase activity could  not 
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be confirmed in previous work because no accumulating metabolic intermediates had 
been found. 
 
 
 
Figure 3.6. Human  mitochondrial  and  peroxisomal  β-oxidation with homologous C. elegans pathway. 
While  the   underlying  biochemistry  of   β-oxidation is highly conserved between organeles and across 
substrates and species, a diverse set of enzymes in the mitochondrion catabolizes shorter chain lengths 
primarily for energetic purposes, while the peroxisome handles more structuraly diverse compounds to 
supply  processed faty acids for  both  mitochondrial  metabolism and  diverse structural and  metabolic 
roles.  
 
Identification  of shunt  metabolites in daf-22 mutant exo-metabolome  would 
help confirm the  biochemical function  of this enzyme and  provide insight into 
interactions  with  other  biochemical  pathways.   To search for these  metabolites, the 
daf-22 metabolome  was investigated  using  2D  NMR spectroscopy-based 
metabolomics using the multivariate Diferential Analysis by 2D NMR Spectroscopy 
(mvaDANS) methodology outlined previously in section 3.2. These tools enabled the 
automated  processing and comparative computational analysis  of  2D  NMR spectra 
from  metabolome extracts  obtained from two  diferent daf-22 aleles (m130, ok693) 
and wild-type C. elegans, including four independent biological replicates of each. 
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Figure 3.7. Statistical analysis of C. elegans mutant strain dqfCOSY spectra and confirmation of long 
chain ascarosides (VLCA) in daf-22 exudates. (a) Principal Component  Analysis. PC 1 distinguishes 
wild-type from mutant worms, while PC2 separates the two daf-22 mutant aleles. (b) Back-projection 
of  PC  1 loadings  onto  magnitude  mode  dqfCOSY spectra identify crosspeaks increased (red)  or 
decreased (blue) in wild-type spectra relative to mutant spectra. (c-e) Example for data interpretation 
and identification of known compound (ascr#5) whose biosynthesis has previously been shown to be 
daf-22 dependent. (c) Loading coeficients indicate N2 upregulation, (d) phase-sensitive crosspeak aids 
assignment  of (e) ascr#5 structure. (f-h)  Partial structures inferred from analysis  of daf-22-specific 
crosspeaks  that  suggest  α-methyl  branched  faty  acids  and  β-keto faty acid ethanolamides. (i) Partial 
structure  of  methionine  derivatives  whose abundance is  greatly increased in daf-22  background. (j) 
HPLC−MS  analysis  conﬁrms  long-chain ascarosides and ethanolamides in the daf-22 metabolome that 
are absent in  wild-type. (k) daf-22  mutant-speciﬁc   VLCAs identiﬁed   via   mvaDANS   and   subsequent  
HPLC−MS  analysis. 
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Automatic crosspeak identification and binning prepared the dqfCOSY spectra 
colected from  wild-type and  mutant C. elegans for statistical analysis  via  Principal 
Component  Analysis, which clustered the  data  by  genotype (Figure  3.7A). 
Coeficients from the PCA loadings were back-projected onto the dqfCOSY spectra 
as  outlined  previously (Figure  3.2), revealing a large  number  of crosspeaks that are 
up-  or  downregulated in daf-22 mutants relative to  wild-type (Figure  3.7B). 
Excluding crosspeaks also present in the E. coli food source, analysis of the remaining 
strongly daf-22-upregulated crosspeaks suggested a series  of  partial structures, 
including   methyl   ketones,   α-methyl  branched faty acids, and coresponding 
ethanolamides,  as  wel  as  β-keto faty acid derivatives (Figure 3.7 F-I). Fractionation 
of the daf-22 metabolome guided by the signals indicated in the PCA loadings led to 
the isolation and ful characterization  of  very long-chain ascarosides (VLCA) that 
account for al  of the  predicted structural features (Figure 3.7K), and  HPLC–MS 
analysis confirmed the absence  of these components in  wild-type samples 
(Figure 3.7J). 
  The accumulation  of  VLCAs in daf-22  mutant  C. elegans  matches 
observations  of accumulated  very long chain faty acids (VLCFAs) in  human β-
oxidation  defects, including  peroxisomal β-oxdation  defects in the  Zelweger 
spectrum  of  disorders and in  mitochondrial β-oxidation  defects such as  VLCAD 
deficiency.  The chain lengths (23- to  27-carbon)  of the daf-22 mutant-upregulated 
VLCAs in C. elegans are similar to those  of  very long-chain faty acids that are 
oxidized solely in the human peroxisome [147] and accumulate in human disorders 
involving   defects   in   peroxisomal   β-oxidation [148].  While  D-bifunctional  protein 
and  SCPx are considered the  main  biosynthetic β-oxidation enzymes in the  human 
peroxisome,  metabolizing  phytanic acid,  bile acid intermediatesdi- and 
trihydroxycholestanoic acid (DHCA and THCA), recent evidence suggests that these 
enzymes also serve as a backup system for oxidizing some straight-chain faty-acids 
[148]. The co-occurence of straight chain and methyl-branched derivatives among 
the daf-22 mutant-specific  VLCAs suggests that like  SCPx, DAF-22 is involved in 
processing both branched and straight chain faty acids. 
The  dual roles  of β-oxidation in  both energetics and  biosynthesis can  be 
observed in the differential pathology of defects to these systems. Mitochondrial β-
oxidation  defects (VLCAD,  MCAD, and  SCAD  deficiency) are among the  most 
common inborn erors or metabolism, and while these are considered leading causes 
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of sudden infant  death syndrome (SIDS), efects are typicaly  only  observed  upon 
fasting [149].   However,  peroxisomal β-oxidation  defects are typicaly  much  more 
complex.   Classical  Zelweger syndrome, caused  by  mutations in  PTS1 and  PTS2 
targeting signals, results in  defective  peroxisomal  biogenesis, the absence  of 
peroxisomes in the liver and  kidney, and a  host  of clinical consequences including 
cranial malformation, hypotonia, failure to thrive, and hepatic dysfuction [148]. 
While several  patients  with  LBP and  peroxisomal  3-ketoacyl-CoA thiolase 
deficiency  have  been  described [150,  151], reinvestigation  of these  patients 
folowing the  discovery  of the second  peroxisomal β-oxidation  pathway indicated 
that these  patients  were actualy  deficient in  DBP [152,  153].  These  patients show 
cerebro-hepato-renal  phenotypes similar to those  observed in  Zelweger syndrome. 
There have been no further reported cases of true LBP deficiency, suggesting it may 
be asymptomatic as due to partial compensation by DBP. Investigation of knockout 
mice showed that  while  LBP -/-  mice showed  no  gross  phenotypic abnormalities, 
DBP -/-  mice showed significant  growth retardation and  postnatal  mortality [154]. 
As daf-22 is  homologous  with  human SCP2 (BLAST e-value  4e-30,  83% 
homology), it is  unsurprising that daf-22  plays a role in  biosynthesis.   While it is 
unknown  whether C. elegans  has a separate  peroxisomal β-oxidation  pathway for 
non-ascaroside faty-acids,  previous investigations  of maoc-1 and dsh-28  mutant 
C.elegans did not show significant phenotypic effects such as those observed in DBP 
deficiency [146], suggesting this is a possibility.  
  Understanding  of the  metabolic role  of the  peroxisome, especialy the 
enzymology of peroxisomal β-oxidation, has evolved significantly in the past decade. 
These results, together  with analyses  of the C. elegans  peroxisomal β-oxidation 
pathway [146] expand the  known roles  of  peroxisomal β-oxidation to include 
biosynthesis of signaling compounds. While C. elegans has been used as a model in 
genetics, relatively few atempts have been made to use common animal models such 
as C. elegans and D.  melanogaster to study  human inborn erors  of  metabolism, 
though  what  work  has  been  done  with these  models indicates their  potentialy 
significant  utility [143,  155-157].   Given the availability  of large libraries  of C. 
elegans mutant strains and mature RNAi protocols, and the increasing demands for 
functional  genomic analysis resulting from increasing  variant  discovery in clinical 
genetics, C. elegans models may be useful tools in human biochemical genetics.  
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3.4.3 Identification  of renal tubular transporter  and  TCA cycle substrates in 
Autosomal Dominant Fanconi Syndrome I probands 
 
Fanconi Syndrome (FS) is a proximal tubular cel dysfunction that renders the 
renal tubule unable to recover smal molecule solutes from the ultrafiltrate leading to 
the  urinary loss  of solutes including  glucose, amino acids, and ions including 
phosphate, calcium, sodium,  potassium, and  bicarbonate.  While the  most common 
cause of Fanconi Syndrome in children is cystinosis [158], FS results froma range of 
Mendelian diseases [23], from toxicity to the proximal tubule [159], and from various 
idiopathic origins. As the active transport processes of the renal tubule are among the 
most energeticaly intensive  processes in the  body,  mitochondrial stress and 
disruptions to energetic  metabolism frequently result in  Fanconi  Syndrome as  wel. 
Fanconi Syndrome with an autosomal dominant inheritance patern was identified in a 
five-generation  African  American family, (Figure  3.8A) [160].   Genetic linkage 
studies subsequently  mapped this  phenotype to chromosome  3 and sequencing 
subsequently identified a heterozygous missense mutation in EHHADH that created a 
de  novo  mitochondrial targeting  motif leading to  mistraficking  of  L-Bifunctional 
Protein, an enzyme involved in  peroxisomal faty acid  oxidation (Figure  3.6) to the 
mitochondrion. 
To connect the renal  phenotype  with the EHHADH  variant  genotype, 
untargeted  urinary  metabolic  profiling  was  performed  using  1D and  2D  NMR 
spectroscopy for (N=10) family  members,  with equal  numbers  of affected and 
unafected individuals. While both 1D 1H and 2D 1H-1H TOCSY spectra of afected 
individuals clearly showed the  glucosuria and  generalized aminoaciduria 
characteristic  of  Fanconi  Syndrome, the  1D 1H spectra  were  observed to  be  highly 
complex and  overlapped  given the intense  glucose and amino acid signals in these 
spectra. Additionaly, the low number of samples complicated untargeted analysis by 
reducing the statistical  power  of significance testing  given the large  number  of 
variables in ful resolution  NMR and the  unsuitability  of  binning for  overlapped 
signals.  
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



 
 
 
 78 
To mitigate these chalenges and identify urinary signatures of ADFS1 from a 
single family,  2D  TOCSY spectra  were subjected to automatic crosspeak 
identification and  binning  using the  mvaDANS algorithm  presented above.   To 
identify significantly  variable  metabolites, crosspeak  bins  were transformed  by log2 
fold-change  vs.  median and analyzed  using two-way  hierarchical cluster analysis, 
PLS-DA, and significance testing  using two-way,  unpaired t-tests  with  Bonferoni 
corection for multiple hypothesis testing (Figure 3.8B). Hierarchical cluster analysis 
and  PLS-DA clearly separate afected and  unafected individuals,  with  PLS-DA 
showing an R2 of 0.94 and a Q2 or 0.88 under four-fold Monte Carlo cross validation 
using a single PLS component explaining 61% of dataset variance. A manhatan plot 
identifies aset  of  69 crosspeak  bins  with  p-values less than the threshold set  by 
Bonferoni corection (p < 1.71 x 10-04).  The clustered heatmap of log-fold-change 
vs. median values showing these significant features indicate that, as expected from a 
urinary solute loss  phenotype, al are  more abundant in the  urine  of affected than 
unafected individuals. 
To identify the metabolites represented by these signals, PLS-DA coefficients 
were  back-projected  onto the ful-resolution  NMR  data and  bin  boundaries  of 
significant features outlined in black, which were assigned using reference data from 
spectra  of  pure compounds (Figure  3.8C).   These results show a  preponderance  of 
signals from  glucose and amino acids, especialy  branch-chain amino acids,  proline, 
and  hydroxyproline.   While increased lactate, threonine, and alanine excretion  were 
observed and indicated  by  positive  PLS-DA coeficients for these signals, the 
presence  of these  metabolites in the  urinary spectra  of  unaffected individuals  meant 
they  did  not  pass the threshold for significance testing  by  untargeted analysis. 
Additionaly, citrate and malate were significantly increased in the urine  of afected 
individuals.  
While the  observation  of  glucosuria and  generalised aminoaciduria  matches 
previous identification of Fanconi Syndrome in the family [160], the identification of 
significantly increased urinary citrate and malate suggest a more direct connection to 
the  genotype.  Increased  urinary excretion  of  TCA cycle intermediates is  known to 
accompany  mitochondrial  pathology [161-163].  Interpreting  urinary excretion  of 
these metabolites is complicated by the multiple roles of many of these metabolites, 
especialy citrate, in the  kidney [164].  However, evidence from screening clinics 
suggest that malate and fumarate are sensitive and specific indicators of mitochondrial 
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disease [163], and coordinated loss  of  multiple  TCA cycle intermediates  would 
support this assertion. While only citrate and malate were identified in the 2D NMR 
dataset, several  TCA cycle intermediates are  present as singlets in  NMR spectra, 
which  would  preclude their identification  by  mvaDANS as the algorithm  does  not 
consider signals along the diagonal of TOCSY or COSY spectra. Of the TCA cycle 
intermediates that present as singlets in the coresponding 1D spectra (cis-Aconitate, 
succinate, fumarate, and  oxaloacetate), signals from succinate and fumarate  were 
observed to  be elevated in  ADFS1  urinary  1D spectra,  with fumarate elevation 
especialy notable (Figure 3.9).  
 
 
 
Figure  3.9.  Elevated succinate and fumarate in  ADFS1  urinary  profiles.    1D 1H  NMR signals 
corresponding to succinate (left) and fumarate (right) are  ploted for afected (red) and  unafected 
(blue) family  members.  1H  NMR indicates elevations  of these  metabolites, especialy fumarate, in 
ADFS1 patients.  
 
These results connect the identified EHHADH  variant  genotype to the 
phenotypic  observation  of renal  Fanconi  Syndrome in a single family  by  providing 
additional evidence for energetic  disruption in the renal  proximal tubule.   Proximal 
tubular cels are among the  most energeticaly  demanding in the  body, relying  on 
mitochondrial  beta-oxidation to  meet the requirements for  ATP  dependent active 
solute transport across the tubular lumen [165].   The  observation  of renal tubular 
transporter substrates and  TCA cycle intermediates in the  urine  of  ADFS1  patients 
matches  observations  of impaired  oxidative  phosphorylation in cels expressing 
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mutant EHHADH. While the low sample numbers and high complexity of rare renal 
disease pose a chalenge for metabolic profiling, these results show that the use of 2D 
NMR  data  with the  methods introduced  here are  useful for relating  genotype and 
phenotype in rare genetic disease cohorts.  
 
3.5 Conclusions 
 
This chapter introduced new methods for signal alignment and detection from 
sets of 2D NMR spectra. These methods were then used to enable normalization and 
patern recognition  of  2D  NMR  datasets  using  both  bin integrals and ful-resolution 
data.   To  demonstrate the  utility  of these  methods, results  were shown for the 
application of these tools to identify the metabolic consequences of disruptions to β-
oxidation in the peroxisome and mitochondrion in a C. elegans mutant strain and in a 
novel human form of renal Fanconi syndrome in which LBP mistraficking results in 
human urinary solutes lost due to proximal tubule defects in a single family. 
Untargeted comparative  metabolomics  has  become an important tool for 
investigating  human and  model  organism  biochemistry.  While  most  metabolic 
profiling is  performed  using  1D 1H  NMR  or  mass-spectrometry, the  methods for 
analysis of 2D NMR data presented here, including HATS [94] and mvaDANS [102] 
extend the scope  of  2D  NMR-based  metabolomic analysis by introducing 
computational tools for cross-peak identification, alignment, integration and  patern 
recognition. Whereas patern recognition techniques have been applied previously to 
2D NMR spectra, these approaches have either relied on manual peak selection [132], 
parametric approaches [166], or used spectral unfolding/refolding techniques without 
alignment [139].  While the routine application  of  2D  NMR is limited  mainly  by 
acquisition time requirements, advances in single scan  2D  NMR [167,  168], 
covariance  NMR [169,  170], and  non-uniform sampling [171]  wil contribute to 
reduced acquisition time.   We expect that advances in  metabolic  profiling and 
statistical spectroscopy  wil continue to accelerate the structural and functional 
characterization  of smal  molecules, and that the  use  of  2D  NMR  wil constitutean 
important component of this work. 
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CHAPTER 4 
METABOLIC  PROFILE  SCREENING  AND 
BIOMARKER IDENTIFICATION  FOR 
INBORN ERRORS OF METABOLISM 
 
4.1 Introduction and aims 
 
Inborn errors  of  metabolism (IEMs)  have  been studied since their 
identification by Sir Archibald Garrod in the early 1900s. While these defects were 
initialy considered to  be  non-pathological idiosyncrasies  of  metabolism resulting 
from "chemical individuality",  growing  understanding  of  neonatal  diseases and the 
identification  of  pathological inborn erors such as  phenylketonuria (PKU) lead to 
eforts to implement population-wide newborn screening programs.  Early screening 
programs, such as the PKU screening pioneered by Robert Guthrie, relied on bacterial 
inhibition assays [46], but in the 1990s screening programs  were given a significant 
boost  by the introduction  of  ESI-MS/MS for the  measurement  of smal  molecule 
biomarkers of inborn erors [47, 48]. Today, MS/MS is the main primary screening 
technique [86] for  detection  of the  plurality  of the  31  diseases included in the 
Recommended  Uniform  Screening  Panel for  neonatal screening [49] 
(htp:/www.hrsa.gov/advisorycommitees/mchbadvisory/heritabledisorders/recomme
ndedpanel/).  
While the introduction  of  ESI-MS/MS significantly improved the sensitivity 
and specificity of many screening assays, diagnostic algorithms for these assays stil 
typicaly classify  patients as  positive  or  negative  on the  basis  of cutof  values for a 
single metabolite or smal number of metabolites and metabolite ratios [172]. Cutof 
values are typicaly selected by individual screening labs in order to minimize false-
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negatives, resulting in  greater  numbers  of false-positive samples  which  must  be 
folowed  up  by secondary and sometimes tertiary tests [173].      Additionaly, the 
measurement  of these  metabolites  by  MS/MS can require extensive sample 
preparation including derivitization,  quantificationby reference toisotopicaly labeled 
standards  which represent a significant  variable cost in screening, and the  use  of 
multiple reaction  monitoring (MRM) involves a trade-of  between sensitivity and 
acquisition time [174]. 
In addition to analytical chalenges, screening labs  wil likely face 
chalenges in the future as screening programs expand in scope. While the American 
Colege of Medical Genetics lists 31 diseases in the Uniform Screening Panel, curent 
estimates suggest that as  many as  ~6,500 congenital  diseases resulting from rare 
genetic  mutations  may exist (htp:/omim.org/statistics/entry) [9].   As clinical 
genetics, including whole exome and genome sequencing [50-52], expands the set of 
known inborn erors it is likely that screening programs wil include a larger number 
of diseases in the future. An expanded panel wil thus pose chalenges to diagnostic 
sensitivity and specificity as more diseases are included.  
Improving  diagnostic sensitivity and specificity  while reducing cost and 
complexity are important goals for newborn screening programs. Greater coverage of 
the  metabolome  may also  provide important  phenotypic context for the increased 
genomic knowledge provided by expanded sequencing programs. Identification of a 
broader set of metabolic markers of inborn errors could not only limit second-tier tests 
but also aid the study of biochemical genetics by identifying metabolic perturbations 
associated  with  mutations.   Recent  work simulating the  metabolic consequences  of 
enzyme  deficiencies [175] and connecting serum and  urinary  metabolite 
concentrations  with single  nucleotide  polymorphisms [38,  39,  44,  176] suggest 
expanded  metabolic coverage in  newborn screening  may improve  understanding  of 
genotype-phenotype corelations for geneticaly heterogeneous conditions.  
Expanding  measurement to  provide  greater analytical coverage  of the 
metabolome from dried blood spot (DBS) samples should alow many tests to be done 
in  paralel, rather than in series.  In addition, the  use  of  multivariate regression to 
build  models that  predict  disease  on the  basis  of  measurements  of  multiple 
metabolites should also provide improved sensitivity and specificity relative to cutof 
values. While MS/MS is not incompatible with broader measurement and multivariate 
regression,  newer  methods such as  direct injection  nanospray  high resolution  mass 
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spectrometry (nS-HR-MS) [173]  may  be able to  provide reduced time, cost, and 
complexity  while expanding  metabolome coverage and  maintaining sensitivity and 
specificity.  
This chapter compares MS/MS and single stage nS-HR-MS measurement and 
analysis  of  DBS samples for  6,050  unafected and  102  newborns afected  by  24 
congenital  disorders  of  metabolism (Table  4.1).    For  both  MS/MS and  nS-HR-MS 
measurements, sparse logistic regression models were built for identification of PKU 
and MCADD positive samples and the sensitivity and specificity of these models was 
evaluated for independent test sets.   These regression  based  methods show 
comparable  or  greater sensitivity and specificity than canonical cutof  based 
algorithms. Finaly, the expanded metabolomic coverage of nS-HR-MS was used to 
identify a  broader range  of  perturbed  metabolites for  phenylketonuria (PKU), 
medium-chain acyl-CoA dehydrogenase deficiency (MCADD), and the 22 additional 
disorders.   While re-designing screening  methodologies  wil require analysis  of a 
much larger affected population, expanded analytical coverage of the metabolome and 
multivariate regression  has the  potential to  both increase  diagnostic accuracy and 
provide important metabolic context for inborn errors.  
 
4.2 Materials and Methods 
 
4.2.1 Sample colection 
 
Anonymous  DBS samples  were  provided for  6050  healthy  newborns  by the 
Hesse Screening Center (Giessen, Germany). Ethical permission was provided by the 
clinical laboratory and  by the  National  Research  Ethics  Service in the 
UK(12/SC/0634).   73 true  positive samples  were  provided  by the  Hesse  Screening 
Center and  29 samples  were  provided  by the  Hungarian  Screening  Laboratory 
(Budapest, Hungary).  Characteristics of these samples are shown in Table 4.1.  For 
al samples ESI-MS/MS data was colected in the original screening laboratories and 
provided along with codes matching the anonymous DBS samples. An additional 36 
samples including  9  MCADD true-positive,  3 false-positive, and  24 true  negative 
were  provided  by the  National Institute for  Health  Data and  Disease  Control 
(Copenhagen,  Denmark) as an independent test for the  MCADD regression  model. 
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Al  MS/MS  data from screening facilities  was  provided as tab-delimited  data files 
reporting metabolite levels rather than raw spectral data. 
 
Table 4.1. Inborn errors of metabolism profiled by nS-HR-MS and MS/MS dried blood spot analysis. 
OMIM 
Phenotype ID 
Inborn Error of Metabolism  Samples 
(N) 
 Inborn errors of fatty acid metabolism  
201450 Medium-chain acyl-coA dehydrogenase deficiency (MCADD) 20 
201475 Very long-chain acyl-CoA dehydrogenase deficiency (VLCADD) 5 
609016 Long-chain 3-hydroxyacyl-coA dehydrogenase deficiency (LCHADD) 2 
212140 Carnitine transporter deficiency 2 
201470 Short-chain acyl-coenzyme A dehydrogenase deficiency (SCADD) 1 
 Organic Acidurias  
606054 Propionic acidemia (PA) 4 
243500 Isovaleric acidemia (IVA) 4 
210200 3-Methylcrotonyl-CoA carboxylase deficiency (3MCC) 4 
251000 Methylmalonic acidemia (MMA) 2 
231670 Glutaric acidemia type 1 (GA I) 1 
231680 Glutaric acidemia type 2 (GA II) 1 
248600 Maple syrup urine disease (MSUD) 1 
 Amino acid metabolism defects  
261600 Phenylketonuria (PKU) 18 
233910 Hyperphenylalaninemia (HPA) 16 
276700, 
613018, 276710 
Tyrosinemia 2 
250850 Methionine adenosyltransferase deficiency 1 
 Urea cycle defects  
215700 Citrulinemia 2 
311250 Ornithine transcarbamylase deficiency 2 
207900 Argininosuccinate lyase deficiency 1 
608300 N-Acetylglutamate synthase deficiency (NAGS) 1 
 Carbohydrate metabolism disorders  
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230400 Galactosemia 1 
 Other  
193090 Cobalamin deficiency 5 
275200 Hypothyroidism 4 
 Non-ketotic hyperglycinemia (NKH) 2 
 
4.2.2 Sample preparation 
 
  3.2  mm  punches  of  dried  blood spot samples  were  placed in  96-wel filter 
plates (Milipore) and extracted with 100 µL HPLC grade methanol (Sigma-Aldrich). 
An additional 100 µL methanolic solution of 20 isotopicaly labeled internal standards 
(Cambridge Isotope Laboratories, Appendix ATable 1) was pipeted onto the samples 
and the plates  were shaken for 35 minutes at room temperature to extract the blood 
spot samples. The resulting extract was filtered by centrifugation at 2000 rpm for 2 
minutes into a second 96-wel plate (Greiner Bio-One) and diluted with 50 µL HPLC 
grade  water (Sigma-Aldrich).   Plates  were sealed  with  heat seal foils (ABgene) and 
analyzed by mass spectrometry.  
 
4.2.3 Mass spectrometry and data preparation 
 
High-resolution  mass spectrometry  was  performed  using an  Exactive 
instrument (Thermo) equipped with TriVersa NanoMate ion source (Advion). Chip-
based   infusion   mode   measurements   were   performed   using   5   μm   nominal   internal  
diameter  nozzle  chips,  and  a  sample  volume  of  5  μL  was  injected.    Mass  spectra  were  
recorded in ful scan mode over a mass range of 70-600 for both positive and negative 
ion modes at a nominal resolution of 100.000. Total data acquisition time was 2 min, 
1 min in negative ion mode and 1 min in positive ion mode with automatic polarity 
switching.  Al mass spectra were recorded in Giessen, Germany with the exception 
of the samples provided by the National Institute for Health Data and Disease Control 
lab, which were recorded in London, UK.  
  Ful scan  mode .RAW files (Thermo)  were converted to  XML encoded text 
files  using the  MSConvert  package  of  ProteoWizard.    The resulting  MS  data, 
including intensities, m/z ratios, and detection mode, were extracted for each scan in 
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Matlab 2012b (Mathworks). Positive and negative scans were separated, interpolated 
with a resolution  of  0.0001  mass  units to  generate consistent m/z  domains  between 
scans, and averaged for each  data file.  Intensities coresponding to isotopicaly 
labeled internal standards (Appendix  A,  Table  1) and  238 selected  molecular ions 
assigned in  previous  work [173] (Appendix  A,  Table  2) in  positive and  negative 
detection modes were extracted by identifying local maxima within 0.0025 mass units 
of the expected ion m/z.  Internal standard and analyte intensities for al  detected 
[M+H]+, [M+Na]+, and [M-H]- adducts along  with  mass  deviation in  ppm  were 
exported in CSV format for each processed spectrum.  
 
4.2.4 Data processing and analysis 
 
 Ion intensities for each detection mode were imported from CSV format into 
Matlab and ion intensities were averaged according to eq. 4.1 to generate a consensus 
intensity for each compound across both detection modes.  
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Here, the intensities (IS)  of  N  positive  mode ions and  M  negative  mode ions are 
averaged first by mode, and then across modes to give a single intensity (I) for a given 
compound.   Samples  were considered  poor  quality runs and excluded from further 
analysis if less than  half  of internal standards  or less than  half  of  metabolites  were 
detected.329 such samples were identified and excluded out of the set of 6050 control 
samples, while none of the afected samples were excluded. 
nS-HR-MS data was preprocessed for relative quantitation  prior to statistical 
analysis.   Compound intensities  were  normalized  using  probabilistic  quotient 
normalization [88], stabilized by an ofset log2 fold-change vs. median with an ofset 
of  10%  of the  dataset  median  value, and  median centered  by  batch.  Absolutely 
quantitative  measurements from  MS/MS  were  not  modified and  nS-HR-MS and 
MS/MS data were matched by anonymous sample ID. MS/MS data was available for 
5627 of the 5721 high quality nS-HR-MS spectra. 
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Predictive  models  were  developed for  PKU and  MCADD.   Control and 
afected samples  were split into training and test sets  of equal size  with equal 
alocation  of affected samples to train and test sets.   Significant  variables  were 
identified by a two-way, one-tailed, one (PKU or MCADD) vs. al (controls and non-
PKU/MCADD afected) t-test  with  Bonferoni corection for  multiple testing.   Log 
ratios for significant variables vs. al other variables were then calculated according to 
eq. 4.2 for MS/MS and eq. 4.3 for nS-HR-MS. 
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Here, X and Y are the  measured levels  of two compounds  X and  Y, and Z is a 
preprocessing factor derived from normalization, scaling, and median centering. For 
each significant compound, the ratio with the lowest p-value by a two-way, two-tailed 
one vs. al t-test with Bonferoni corection using the number of ratios tested for each 
compound was included in the set of filtered variables.  
  Sparse logistic regression  models  were then  built for the filtered set  of 
compounds and compound ratios using multivariate logistic regression with forward 
stepwise variable selection. Models were selected on the basis of the deviance of an 
internal test set using 4-fold cross validation and evaluated using the external test set. 
Stepwise regression produces sparse models in which the coeficients for the majority 
of variables are set to 0 and prediction is based on a smal number of compounds and 
ratios.  For MCADD, these models were validated with an additional set of positive 
and control samples from the  Danish screening lab,  which  were analyzed and 
preprocessed separately.  
  Compounds  were considered to  be  markers for  one  of the  24  disorders if a 
two-way, two-tailed one vs. al t-test with Bonferroni correction for the samples of a 
single  disorder  vs. samples from al  other  disorders  was significant (p  <2.1e-04 for 
nS-HR-MS and p <0.0015 for MS/MS) and if the median level  of the compound in 
the afected samples was in the extreme 1% of the levels of al control samples. 
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4.3 Results – Characterizing the nS-HR-MS method 
 
4.3.1 Isotopicaly labeled internal standards 
 
As  previously  noted, a  methanolic solution  with a fixed concentration  of 
twenty isotopicaly labeled standards (Appendix  A,  Table  1)  was added to the  DBS 
extracts.  In a  previous  pilot study [173], these standards  were  used to calculate 
concentration  values for endogenous  metabolites.   Preliminary results  with an 
expanded set  of  238 endogenous  metabolites showed  unexpected  variation in these 
concentration  values, and to identify the source  of this  variation the  detection and 
variance of the internal standards was investigated.  
 
 
 
Figure  4.1.   Detection frequencies and coeficients  of  variation for isotopicaly labeled internal 
standards  by  nS-HR-MS. Internal standard  detection frequencies (top) and coeficients  of  variation 
(botom) are shown the [M+Na]+, [M+H]+, and [M-H]- adducts  detected for each  of the internal 
standards. Coefficients of variation of up to 360% are unexpected for internal standards.  
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Figure  4.1 shows  detection frequencies and coeficients  of  variation for the 
major [M+H]+, [M+Na]+, and [M-H]- adducts for each of the 20 isotopicaly labeled 
standards. Detection frequencies are typicaly high, especialy for [M+Na]+, and [M-
H]-, with the exception of acylcarnitine standards which are not detected in negative 
ionization  mode and 2H3-Aspartate and 2H3-Glutamate,  which appear to  have low 
ionization eficiencies in positive ionization mode. However, coefficients of variation 
for the detected masses (excluding samples in which a given adduct was not detected) 
range from  40% to  360%.   These  values are  high, considering that the standards 
should be present at a fixed concentration in DBS extracts.  
 
 
 
Figure  4.2.Analysis  of  Variance (ANOVA)  by  batch for internal standards.   Log10  between  batch 
(black) and  within  batch (magenta) shows that  variation  between  batches is  greater than  variation 
within batches for al internal standards (top). These differences are significant, as shown by the log10 
p values calculated by ANOVA (botom).  
 
Consensus intensities for internal standards and endogenous metabolites were 
calculated by averaging intensities of adducts in each mode as shown in equation 4.1. 
Using this  method, consensus intensities  were calculated for each  of the  20 
isotopicaly labeled internal standards and the  variance  of these intensities  by  batch 
 90 
was investigated  using  balanced,  one-way analysis  of  variance (ANOVA).   For al 
standards, between-batch variance was  greater than within-batch variance, as shown 
by the log10 variance and  p-values calculated  by  ANOVA analysis (Figure  4.2). 
Notably, the  difference  between  between-batch and  within-batch  variance  does  not 
seem to be related to the absolute level of variance.  
 
 
 
Figure  4.3.  Changes in  batch  median internal standard intensity  over time.Isotopicaly labeled amino 
acid internal standards (2H3-Methionine, top)  with  high  variation  between  batches show  decreasing 
median detection intensity over time, while isotopicaly labeled acylcarnitines (2H3-Palmitoylcarnitine) 
with less significant batch efects show a slower decrease in median intensity. 
 
As between-batch variance can be highly afected by a single or smal number 
of batches, median intensities for a high variance internal standard and a low variance 
internal standard were calculated and ploted by the acquisition date of a given batch 
(Figure  4.3).   For the  high  variance internal standard (2H3-Methionine),  median 
intensities appear to decay over time as batches run later in time show lower median 
intensities. Linear regression shows a slope of greater magnitude and a beter fit for 
the  high-variance internal standard.  These results suggest that  variance in internal 
standard intensities  may introduce  noise into the  measurement  of endogenous 
metabolites.   As a result, evaluating  preprocessing  methods for the  nS-HR-MS  data 
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should compare both endogenous metabolite intensities relative to internal standards 
and the endogenous metabolite intensities alone. 
 
4.3.2 Dried blood spot (DBS) metabolites 
 
As  with the internal standards, consensus intensities for the  238  metabolites 
listed in Appendix A, Table 2 were calculated from ions in both positive and negative 
mode according to eq. 4.1. Detection frequencies for metabolites approach 100% for 
over half of the metabolites targeted, but these frequencies drop to below 10% for a 
smal  number (Figure  4.4).  While  many  mass spectrometry analysis  packages 
exclude ions with low detection frequencies [98], some long-chain acylcarnitines that 
are important biomarkers for inborn erors have detection frequencies below 10%, as 
would be expected for sensitive and specific biomarkers of rare diseases.  
 
 
 
Figure  4.4.  Detection frequencies for  measured analytes in  nS-HR-MS.   The  majority  of these  238 
compounds are detected in an overwhelming majority of samples, shown here including both positive 
and control samples,  but low frequency  metabolites include  disease  biomarkers including long chain 
acylcarnitines which are important not to exclude from analysis.  
 
Normalization is an important component  of  pre-processing  metabolomics 
data, and to assess  various  normalization  methods for  nS-HR-MS  data  100 samples 
were randomly selected from the 5721 good quality control samples. Distributions of 
log-fold-change  vs.  median  were assessed for these  100 samples for the internal 
standard intensities alone, DBS metabolite / single internal standard ratios, where the 
reference internal standard was selected using the results from the pilot study [173], 
for  metabolite /  median internal standard, and for  metabolite intensities alone.   Box 
plots  of these  distributions are shown in  Figure  4.5, applying the  methodology to 
assess normalization discussed in Chapter 2. Here, sample distributions centered at 0 
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are roughly normalized, while samples with widely varying ranges show increased or 
decreased intensities for a large number of compounds. 
 
 
 
 
Figure  4.5.   Distributions  of log-fold-change  vs.  median feature for a set  of  one  hundred control 
samples.   These  plots indicate the extent to  which systematic changes in  metabolite intensities  by 
sample (normalization) affect  various  preprocessing  methods.   Substantial  normalization  diferences 
can be seen for the internal standards (top), while the metabolite intensities themselves show much less 
variation in normalization between control samples.  
 
These results show that while the internal standard levels tend to vary within a 
smaler range for each sample, there is large variance between samples. When DBS 
metabolite / internal standard ratios are calculated, the  varying  normalization  of the 
internal standards impacts the  normalization  of the ratio.   Strikingly, the  DBS 
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metabolites themselves are roughly measured within the same ranges across the set of 
samples, and a standard  probabilistic  quotient  normalization [88] applied to these 
intensities resolves the remaining normalization effects.  
While  processing the  DBS  metabolites  without the internal standards  does 
reduce  variation  between samples,  batch efects are stil a source  of substantial 
variation, as  ANOVA analysis  by  batch for the  238 compounds included in the 
targeted analysis show (Figure 4.6). To reduce these effects, the stabilized compound 
abundances were median centered by batch. Batch mean centering is an established 
technique in microarray analysis [177, 178]- batch median centering serves the same 
purpose  while increasing the robustness  of the  method to the  outlying  observations 
expected in rare disease screening. Substantial reductions in between-group variation 
after  median-centering indicates that  while this corection  does  not resolve  batch 
efects for al compounds, it  does  mitigate the efects  of  batch acquisition  on the 
resulting data.  
 
 
 
Figure 4.6. Reduction of batch efects by median centering. Analysis of variance (ANOVA) of analyte 
intensities  by  batch shows  highly significant  batch effects  on these intensities for  both the raw and 
normalized intensities, which are reduced by median centering batches.  
 
These results suggest that  while the  use  of internal standards  may alow a 
calculation of metabolite concentration in the original blood spot, high variance in the 
internal standard measurements reduce the utility of absolute quantification. Instead, 
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relative quantification as used in many metabolomics experiments yields more stable 
data. 
 
4.3.3 Comparison of nS-HR-MS and MS/MS measurements 
 
While the  disparate approaches to the acquisition and  processing  of the  nS-
HR-MS and MS/MS data preclude direct, absolutely quantitative comparison, the nS-
HR-MS and  MS/MS  data  must  both  be sensitive to relative changes in compound 
levels for a sensitive and specific assay. Both MS/MS and nS-HR-MS methods detect 
a set of 34 metabolites, and corelations between the MS/MS and nS-HR-MS methods 
were assessed for al  5627 control and  102  positive samples  with  paired 
measurements. Figure 4.7 shows the correlations for control (red) and positive (blue) 
measurements  by the two  methods for each  of the  34 compounds.  Pearson  product-
moment corelations are calculated for the  untransformed abundances – 
concentrations for MS/MS and compound intensities (equation 4.1) for nS-HR-MS. 
 
 
 
Figure 4.7.  Correlations between nS-HR-MS and MS/MS  measurements for 34 metabolites detected 
by  both techniques.  Pearson correlation coefficients are  generaly low for control samples (red),  but 
high when the inclusion of positive samples (blue) expands the range of detection.  
 
Corelations between the reported  MS/MS levels and  nS-HR-MS levels  vary 
from  no correlation to  near  perfect corelation (0.99).   Pearson corelations  of raw 
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abundances are high when the variance in the metabolite concentration is high, such 
as  when the  metabolite level is affected  by  one  of the conditions included in the 
dataset, and low when the variance is low. Relative corelations, including log-fold-
change vs. median and rank corelations (not shown) are more stable, indicating that 
nS-HR-MS and MS/MS measurements agree on a relative rather than absolute scale. 
 
 
 
Figure  4.8. nS-HR-MS  vs.  MS/MS  measurements  of  Phenylalanine for  PKU  positive samples,  HPA 
samples, and non-PKU/HPA positives. While the correlation between Phe measurements tends to be 
low for  both  PKU and  non-PKU samples alone,  when  PKU and  non-PKU  measurements are taken 
together, agreement tends to be good especialy for relative metrics such as log-fold-change vs. median 
(left). 
 
To investigate the efects  of increased  metabolic  variance  on the corelation 
between MS/MS and nS-HR-MS data, Phe measurements were ploted for PKU (red), 
hyperphenylalaninemia (HPA,  magenta), and  other afected samples (blue) (Figure 
4.8).  While the corelation  between  Phe  measurements tends to  be lower for  both 
PKU (red line) and  non-PKU (blue line) samples alone,  when  PKU and  non-PKU 
measurements are taken together (black line), agreement tends to  be  good.   This 
means that  both  platforms reflect significant elevations  or reductions in abundances 
due to  metabolic  perturbations.  Notably, the slope for the fit line  of the log-fold-
change  vs.  median  data  was  1.   While the raw abundances are  on  diferent scales 
(concentration vs. intensity), it appears that the MS/MS data separates the PKU, HPA, 
and other afected samplesmore accurately based on Phe levels alone than the nS-HR-
MS  data.   This could  be  due to  non-linearity in  detection  or the  detection  of  other 
isobaric ions by nS-HR-MS. 
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4.4 Results and Discussion 
 
4.4.1 Predictive modeling of PKU and MCADD 
 
While IEM prevalence and the diseases included in screening programs  vary 
between countries,  phenylketonuria (PKU) and  medium-chain acyl-CoA 
dehydrogenase  deficiency (MCADD) are the  most common inborn erors  of amino 
acid metabolism and of mitochondrial faty acid oxidation and screening programs for 
these  diseases are in  place in  many countries internationaly [179,  180].   These 
screening programs typicaly rely on MS/MS analysis of DBS samples combined with 
cutof  values for a smal set  of  metabolites to identify affected individuals.   These 
clinical algorithms are frequently set  by individual screening centers,  but  published 
decision  parameters include (Phe  >120   μmol/L,  Phe / tyr  >  2) for  phenylketonuria 
[180] and (C8>1uM,  C8/C10>1) for  MCADD [181].   While some  groups  have 
proposed standardizing diagnostic algorithms and replacing cutoff values [172, 182], 
many labs stil set these thresholds individualy and modify them over time to capture 
previous positive and negative samples [172, 182, 183].  
 
 
 
Figure  4.9.  Receiver  operating characteristic (ROC) curves for  PKU  diagnosis  by  phenylalanine. 
Identification  of  PKU  positive samples  by  measured  phenylalanine levels are shown for  nS-HR-MS 
(left) and  MS/MS (right).  Sensitive and specific identification  of  PKU  positives  by  MS/MS 
phenylalanine measurements leads to high area under the curve (AUC) values.  
 
  Newborn screening by serum metabolite measurement is arguably one of the 
first  metabolomic tests to reach routine clinical  use [184],  but advances in 
metabolomics  have  paired advanced  mass spectrometric  measurement  with 
multivariate  data analysis to classify samples and identify  biomarkers.   Even recent 
 97 
cutof-free  methods [182]  have relied  on  percentile ranges and composite scores 
rather than patern recognition. Here, sparse logistic regression methods are used to 
identify maximaly predictive compounds and build models that predict the class of a 
sample based on the measurements of these markers by nS-HR-MS and MS/MS.  
  As  Figure  4.8 shows,  PKU,  HPA, and  other  disorders are  wel separated  by 
Phe concentration. As a result, receiver operating characteristic (ROC) curves for the 
classification  of  PKU samples  by  Phe concentration show  high sensitivity and 
specificity across a range  of  Phe cutoff  values resulting in an area  under the curve 
(AUC) approaching unity (Figure 4.9). In ROC analysis, AUCs of 0.5 reflect random 
classification, while AUCs of 1 reflect perfect classification [185]. Phe measurements 
by  both  MS/MS and  nS-HR-MS show  high  AUCs, though as  noted  previously the 
MS/MS measurements separate PKU, HPA, and unafected samples more sensitively 
and specificaly than nS-HR-MS data alone. High AUCs for PKU mean that a range 
of cutof  values result in  high sensitivities and specificities,  which alows for some 
choice in the precise value of a cutof. Cutof values suggested in the literature [180] 
yield a sensitivity and specificity of 100% and  99.8% for these samples.  While the 
optimal cutof value for these samples would be (Phe > 260 μmol/L), this estimation 
is  only  useful for ilustration as it  would  have to  be cross-validated  using an 
independent test set.  
 
Table 4.2.Logistic regression models for prediction of PKU class by nS-HR-MS and MS/MS. 
Model Intercept Coefficients Metabolites 
nS-HR-MS (LFC) -87.48 -3.97 C6DC / Phenylpyruvic acid 
  48.71 Phenylalanine / (Leu + Ile) 
MS/MS (μmol / L) -418.48 1.34 Phenylalanine 
  1.08 Ornithine 
 
 
  Separating the set of 5627 control and 102 positive samples into test and train 
sets  of equal size and applying forward logistic regression as outlined previously to 
training sets for nS-HR-MS and MS/MS yield the models shown in Table 4.2 and 4.3.  
Results of the application of these predictive models to test sets are shown in Figure 
4.10 and  4.12.  In  Figure  4.10,  box  plots show the test set ranges for the  variables 
 98 
included in the forward  variable selection  process for true  PKU (red), true  HPA 
(magenta) and true controls and  non-PKU/HPA afected (blue).   ROC curves for 
classification  by log-odds  prediction for the test-set show that  both  nS-HR-MS and 
MS/MS  yield  highly sensitive and specific classification  with  AUC  >  0.999.   At 
100% sensitivity these models both yield specificities of 99.8% for the test set. It is 
notable that both variables selected by forward logistic regression were ratios for nS-
HR-MS and single compound abundances for  MS/MS, and that the  use  of ratios in 
classification for  nS-HR-MS closes the sensitivity and specificity  gap relative to 
MS/MS based on Phe measurements alone.  
 
 
 
Figure  4.10.  Classification  of  PKU test-set samples  by stepwise logistic regression  model.  Box  plots 
(top) for  metabolites and ratios selected  by forward logistic regression for  PKU true  positives (red), 
HPA samples (magenta) and non-PKU samples (blue) for nS-HR-MS (left) and MS/MS (right).  
 
  While PKU is detected with high sensitivity and specificity on the basis of a 
single  marker,  medium-chain acyl-CoA  dehydrogenase  deficiency (MCADD) 
presents a more chalenging case. Octanoylcarnitine (C8) is frequently measured by 
MS/MS to identify MCADD, with characteristic elevations in hexanoylcarnitine (C6), 
octanoylcarnitine (C8), decanoylcarnitine (C10), and decenoylcarnitine (C10:1) [186]. 
Alternate tests for  of  MCADD  have  been  proposed, including a test for leukocyte 
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MCAD enzymatic activity [187] and for urinary hexanoylglycine [188]. Although the 
primary  genetic  background in clinicaly  diagnosed  MCADD is c.985A>G 
homozygosity, the  genetic  background  of  MCADD is  heterogeneous  with the 
c.985A>G mutation making up only 55% percent of the screening population and less 
in non-European populations [189], yielding genetic screens potentialy less sensitive 
than metabolic screns.  
 
 
 
Figure  4.11.  Receiver  operating characteristic (ROC) curves for  MCADD  diagnosis  by 
octanoylcarnitine. Identification  of  MCADD  positive samples  by  measured  octanoylcarnitine (C8) 
levels are shown for nS-HR-MS (left) and MS/MS (right). 
 
  Figure  4.11 shows the  ROC curves for the classification  of  MCADD  DBS 
samples on the basis of C8 levels alone for nS-HR-MS and MS/MS. While MS/MS 
stil does show a high AUC > 0.97, even the optimal cutof value of (C8>0.1) for this 
dataset  gives a false positive rate of 13.2% (specificity 86.8%) and this is biased by 
seting the cutof without an independent test set. Published cutof values (C8>1uM, 
C8/C10>1, [181]) yield a sensitivity of 65% and a specificity of 100% for the MS/MS 
data colected here. Applying forward logistic regression to test and train sets for nS-
HR-MS and MS/MS data for MCADD generates the model shown in Table 4.3, and 
application of this predictive model to the test set yields the results shown in Figure 
4.12.   As  with  Figure  4.10,  box  plots show the test set ranges for  variables in the 
logistic regression model for true MCADD (red) and true non-MCADD (blue). Both 
models yield AUCs wel above those from classification based on C8 alone for their 
respective measurement platforms. At 100% sensitivity, the nS-HR-MS model yields 
a specificity of 91.1% and the MS/MS model yields an impressive 99.9%, indicating 
both  models  give fewer false  positives than either  published cutof  values  or the 
optimal cutof for C8 across the test and train sets.  
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Figure  4.12.  Classification  of  MCADD test-set samples  by stepwise logistic regression  model.   Box 
plots (top) for metabolites and ratios selected by forward logistic regression for MCADD true positives 
(red) and non-MCADD samples (blue) for nS-HR-MS (left) and MS/MS (right).  
 
Table 4.3.Logistic regression models for prediction of MCADD class by nS-HR-MS and MS/MS. 
Model Intercept Coefficients Metabolites 
nS-HR-MS (LFC)
 -7.9881 0.13 C10 / C14:2 
  -1.42 C5DC / C6 
  3.78 C6 / C20:2 
MS/MS (μmol / L) -11.4964 95.48 C6 
  61.46 C10:1 
 
  An external test-set of 36 samples including 9 MCADD true-positive, 3 false-
positive, and 24 true negative were provided by National Institute for Health Data and 
Disease  Control (Copenhagen,  Denmark).These samples constitute a truly 
independent test set as they represent diferent neonatal nationality, different sample 
colection locations, and the  data  was  preprocessed independently from the set  of 
control and afected samples from the German and Hungarian centers. Prediction of 
MCADD positives based on the model in Table 4.3 yields 100% corect classification 
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for both true positives and true negatives, as wel as for samples which were identified 
as positives by MS/MS screening in Denmark but were later found to be unafected. 
Box plots in Figure 4.13 indicate ranges for the predictive variables for MCADD true 
positive (red), MS/MS false positives (magenta), and true negatives (blue). 
 
 
 
Figure  4.13.   Classification  of independent  MCADD samples  by stepwise logistic regression  model. 
These results show the accurate classification  of the independent set  of  MCADD samples from the 
Danish screening center in Copenhagen by the model built on MCADD samples from the German and 
Hungarian screening centers.  Box  plots for  metabolites and ratios selected  by forward logistic 
regression for MCADD true positives (red), false-positives (magenta) identified by MS/MS and non-
MCADD samples (blue) for nS-HR-MS.  
 
  While  models  based  on a smal  number  of afected individuals – (n=18) for 
PKU and (n=19) for MCADD – must be validated by larger sample sizes and across a 
broader set  of screening facilities and  populations, these results indicate that 
predictive  modeling for  both  nS-HR-MS and  MS/MS  measurements can improve 
upon the cutof  based  methods that are currently standard in screening centers 
internationaly.   Additionaly, though  non-parametric  patern recognition  methods 
such as random forest classification, neural networks, or support vector machines may 
improve upon logistic regression [190], logistic regression based on a smal number 
of features  was applied  here as it is  wel  understood, routinely applied in  medicine 
[191] and  does  not  greatly exceed the current  measurement capabilities  of  many 
screening facilities.  Multivariate  methods  based  on  predictive  modeling should 
substantialy aid the search for cutoff-free methods for newborn screening [182].  
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4.4.2 Biomarker identification 
 
  Broader  metabolomic coverage in  newborn screening  has the  potential to 
improve the sensitivity and specificity of diagnostic tests, but identification of a more 
comprehensive set  of  metabolic  perturbations resulting from  genetic  defects could 
contribute greatly to the understanding of genetics, metabolism, and the relationships 
between genes and metabolites in health and disease [192]. Understanding the impact 
of genetic variation on health and disease is a critical task in modern medicine and life 
sciences.   Mammalian  metabolism is afected  by  genes, environment,  nutrition, 
microbiota, andmetabolite levels in  biofluids are afected  by al these factors [193]. 
This   complexity   poses   a   significant   chalenge   for   “botom   up”   prediction   of   the  
efects  of  genetic  variation at the systems level [194], and as  genomic advances 
increasingly shed light  on  human  genetic  diversity functional annotation  of  variants 
has become one of the main chalenges in genetic research [154, 195]. 
  While several atempts  have  been  made to connect  genetic  variants to 
metabolic  perturbations through computational  modeling [175] and regression  of 
single-nucleotide  polymorphisms (SNPs) against  biofluid  metabolite levels [38,  39, 
44, 176], as of 2012 there were approximately 3,500 known Mendelian diseases for 
only  ~20,000  known  human  genes [51].  Recent statistics  discussed in  Chapter  1 
suggests this  number  wil continue to rise.   Even  neglecting these  new  Mendelian 
diseases that  wil  be  discovered as sequencing eforts expand,  potential functional 
analysis of nearly 20% of the human genome provides a strong rationale for studying 
the functional consequences  of  Mendelian  disease.   Additionaly,  while the term 
“Mendelian  disease”  suggests  single  genetic  cause,  there  is  growing  appreciation  for  
the   importance   of   “modifier”   variations  [196] and for the  genetic  heterogeneity  of 
even straightforward single-gene diseases [58, 197].  While these efects complicate 
genetic screening for inborn errors, genetic folow up in conjunction with metabolic 
screening could  help clarify the complex  genetics  of IEMs and aid functional 
assessment of rare variation.  
  The expanded set of metabolites measured by nS-HR-MS, the large number of 
control samples, and the number of diseases included in the newborn screening data 
presented  here  provides an  opportunity to identify a  broader set  of  perturbed 
metabolites specific to a range  of inborn erors.   Figure  4.14 shows the results  of a 
two-way, two-tailed  one  vs. al t-test  of PKU  positive samples  vs. al  other  positive 
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samples for  nS-HR-MS and  MS/MS  measurements.  Manhatan  plots  of log10(p) 
values are shown for nS-HR-MS (top) and MS/MS (middle) datasets. The blue line 
denotes the significance threshold from Bonferoni corection (p <2.1e-04 for nS-HR-
MS and  p  <0.0015 for  MS/MS) - red  markers indicate significant  variables  with  p 
values less than these thresholds.   Boxplots in the  botom  panel indicate the 
distribution  of significant  metabolites for  PKU (red) and  non-PKU (blue) samples. 
While  both  MS/MS and  nS-HR-MS identify the  main  biomarker for  PKU, 
Phenylalanine,  nS-HR-MS identifies additional  metabolites in the  phenylalanine 
metabolic pathway. 
 
 
 
Figure 4.14. Biomarkers of PKU. Manhatan plots of -log10(p) values from PKU (N=18) vs. al non-
PKU afected (N=84) evaluated  by two-way  unpaired t-test are shown for  nS-HR-MS (top) and 
MS/MS (middle)  datasets.  Boxplots in the  botom  panel indicate the  distributions  of significant 
metabolites for PKU (red) and non-PKU (blue) samples. 
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Phenylketonuria results from mutations in the PAH gene, the enzyme product 
of which, phenylalanine hydoxylase, converts phenylalanine to tyrosine. As a result, 
phenylalanine is elevated in serum and urine, and phenylpyruvic acid and phenlylactic 
acid are produced as shunt metabolites by transamination [198]. N-acetyl amino acids 
have been observed in several aminoacidurias [199, 200], and N-acetylphenylalanine 
is  produced  by  N-acetylation  of  phenylalanine in  PKU [200].   While  N-
acetylphenylalanine is considered a hazardous amphipathic metabolite, previous work 
has shown it is eliminated by renal filtration and as a result appears in large quantities 
in the urine of PKU patients [199].  
Medium-chain acyl-CoA  dehydrogenase (MCAD) catalyzes the rate-limiting 
step in mitochondrial beta-oxidation for faty acids with chain lengths between 6 and 
12 carbons [201].   MCAD  deficiency can result in faty acid  oxidation failure 
folowing fasting, metabolic decompression, and as a result is a major cause of sudden 
infant death syndrome [179]. Figure 4.15 shows the results of a two-way, two-tailed 
one vs. al t-test of MCADD positive samples vs. al other positive samples for  nS-
HR-MS and  MS/MS  measurements.  MS/MS shows characteristic elevations  of 
hexanoylcarnitine (C6),  octanoylcarnitine (C8),  decanoylcarnitine (C10), and 
decenoylcarnitine (C10:1) [179], as wel as some shorter chain acylcarnitines.  
 In addition to the primary acylcarnitines, nS-HR-MS detects acylglycines and 
faty acids. Acylglycines are produced by glycine conjugation of acyl-CoAs and the 
C6 and C8 acylglycines suberylglycine and hexanoylglycine have been detected in the 
urine of MCADD patients [202], and these have been proposed as additional tests for 
MCADD screening [188].   Additionaly,  C8 faty acids are  detected, including 
hydoxy-octanoic acids and  keto-octanoic acids.   While the  position  of the  hydoxyl 
and carbonyl cannot be verified based on parent mass, 3-, 6- and 7-hydroxyoctanoic 
acids have been identified as products of faty acid metabolism [203] and have been 
identified as elevated in patients with abnormal faty acid metabolism [204]. Previous 
reports identify increased medium-chain faty acids, dicarboxylic acids, acylglycines, 
and medium-chain acylcarnitines in plasma and urine as shunt metabolites of elevated 
medium-chain acyl-CoA esters [205].  
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Figure 4.15. Biomarkers of  MCADD.  Manhatan plots of -log10(p) values from MCADD (N=19) vs. 
al non-MCADD affected (N=83) evaluated by two-way unpaired t-test are shown for nS-HR-MS (top) 
and  MS/MS (middle)  datasets.  Boxplots in the  botom  panel indicate the  distributions  of significant 
metabolites for MCADD (red) and non-MCADD (blue) samples.  Abbreviations: C2, acetylcarnitine; 
C3-DC,  malonylcarnitine;  C4,  butrylcarnitine;  C6,  hexanoylcarnitine;  C8,  octanoylcarnitine;  C10, 
decanoylcarnitine; C10:1, decenoylcarnitine. 
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MCADD and PKU are among the most common inborn erors of metabolism, 
and the resulting availability of a greater number of samples yields greater statistical 
power to identify  perturbed  metabolites.   To  detect  potential  markers for the less 
common IEMs, a  dual filtering strategy  was  used.   Metabolites  were considered a 
potential marker of an individual IEM if its p-value by one vs. al two-way two-tailed 
t-test passed a Bonferoni significance level and if the median level of the compound 
in the afected samples  was in the extreme  1%  of the levels  of al control samples. 
The markers identified for each of the IEMs in Figure 4.16 for nS-HR-MS and Figure 
4.17 for MS/MS. 
 
 
 
Figure 4.16. Metabolites outside of normal ranges for 24 inborn errors by nS-HR-MS. Red metabolites 
are significantly increased vs. al other inborn errors and the median disease range is greater than the 
99th percentile of the normal range.  Blue metabolites are significantly decreased vs. al other inborn 
errors and the median disease range is less than the 1st percentile of the normal range.  
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In these matrices, red elements denote an elevated metabolite for a given IEM, 
while blue elements denote a metabolite with decreased levels relative to controls and 
other IEM affected patients. 
 
 
 
Figure 4.17. Metabolites outside of normal ranges for 24 inborn errors by MS/MS. Red metabolites are 
significantly increased vs. al other inborn errors and the median disease range is greater than the 99th 
percentile of the normal range. No decreased metabolites were detected by MS/MS.  
 
Results of note include the detection of perturbed mitochondrial faty acid β-
oxidation and resulting elevation of acylcarnitines for MCADD, very long-chain acyl-
CoA  dehydrogenase (VLCAD)  deficiency, and long-chain  3-hydroxyacyl-CoA 
dehydrogenase (LCHAD) deficiency. For MCADD and VLCADD, chain-lengths of 
the  perturbed  metabolites corespond to the  major activities  of the  MCAD and 
VLCAD enzymes. The presence of 3-hydroxylated acylcarnitines is characteristic of 
LCHAD deficiency, as LCHAD is a critical component of mitochondrial trifunctional 
enzyme (MTP) along  with the long-chain enoyl-CoA  hydratase (LCEH) and  3-
ketoacyl-CoA thiolase.   While HADHA encodes for the  protein  with  both  LCHAD 
and  LCEH activities, the  majority  of afected  patients show  primarily  LCHAD 
deficiency [206].   Markers  of short-chain acyl-CoA  dehydrogenase (SCAD) 
deficiency include  C4 and  C6,  which  were likely  not  detected  due to low sample 
numbers.  
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Priopionic academia (PA), resulting from  propionyl-CoA carboxylase 
deficiency, and  3-methylcrotonyl-CoA carboxylase (3MCC)  deficiency are  both 
inborn erors  of  branch chain amino acid  degradation  of  valine and isoleucine (PA) 
and leucine (3MCC  deficiency).   Both  PA and  3MCC  deficiency show elevated  3-
methylcrotonylglycine and 3-hydroxyisovalerate.   Both are direct shunt metabolites 
of  3-methylcrotonyl-CoA,  where  unmetabolised  3-methylcrotonyl-CoA is converted 
to  3-methylcrotonylglycine  by  glycine-N acetyltransferase and to  3-
hydroxyisovaleryl-CoA  by enoyl-CoA  hydratase and then to  3-hydroxyisovalerate 
[207].   These and  other  metabolic intermediates  of  branch chain amino acid 
degradation  have  previously  been  observed in  propionic academia [208]. 
Coresponding acylcarnitines –  3-hydroxyisovalerylcarnitine (C5OH) for  3MCC 
deficiency and  propionylcarnitine (C3) for  PA –  were also elevated.   Patients  with 
isovaleric academia, another inborn eror  of  branch-chain amino acid  degradation, 
showed increased isovalerylcarnitine (C5)  by  both  nS-HR-MS and  MS/MS. 
Branched-chain  keto acid  dehydrogenase is the second step in the  degradation  of 
leucine, isoleucine and  valine, and  deficiencies in this enzyme cause  Maple  Syrup 
Urine  Disease (MSUD) [209].   MSUD is characterized  by  urinary excretion  of 
branch-chain amino acids and their keto-acid derivatives, al of which were identified 
as elevated by either MS/MS or nS-HR-MS. Figure 4.18 shows the accumulation of 
the compounds  detected  by  MS/MS and  nS-HR-MS  due to  branched-chainalpha-
ketoaciddehydrogenase  deficiency in  MSUD  mapped  onto  human  metabolic 
pathways from KEGG (hsa01100). 
Tyrosinemia is an inborn eror caused by deficiencies in one of three enzymes 
in the tyrosine  degradation  pathway [210].   Tyrosinemia type  1, caused  by 
fumarylacetoacetate (FAA)  hydrolase  deficiency, and tyrosinemia type  3, caused  by 
4-hydroxyphenylpyruvate dioxygenase deficiency, lead to increased urinary excretion 
of  4-hydroxyphenypyruvate  derivates including  hydroxyphenylactic acid,  while 
tyrosinemia type  2,  which is caused  by inability  of tyrosine aminotransferase to 
catalyze the first step in tyrosine metabolism, does not [211, 212]. Hypertyrosinemia 
was detected by MS/MS, and elevated hydroxyphenylactic acid was detected by nS-
HR-MS.  Interestingly,  nS-HR-MS also identified elevated ascorbate sulfate, a 
metabolite of the vitamin C supplements used to treat neonatal tyrosinemia [213]. A 
similar finding  was elevated citrate, administered to citrulinemia  patients [214], 
detected by MS/MS.  
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Figure 4.18. Biomarkers of MSUD mapped onto KEGG. Metabolites elevated in the dried blood spot 
samples of maple syrup urine disease identified by MS/MS and nS-HR-MS. The Kyoto Encyclopedia 
of Genes and Genomes (KEGG) map of human metabolic pathways (hsa01100) shows the relationship 
between these accumulating intermediates and the enzyme deficiency characteristic of MSUD.  
 
While most of the perturbed metabolites identified here were elevated, a smal 
number were decreased relative to the control population and the other inborn errors. 
Eicosapentaenoic acid (EPA) lower than  99%  of the control  population for the 
glutaric acidemia type  2  patient,  which could  be  due to impaired faty acid 
biosynthesis due to multiple acyl-CoA deficiency. Also potentialy informative is the 
decreased creatine found  by  nS-HR-MS for the  methionine adenosyltransferase 
deficiency  patient.   While  hypermethioninemia, the classic  marker  of  methionine 
adenosyltransferase  deficiency,  was identified  by  MS/MS,  decreased creatine  been 
postulated as a metabolic consequence of methionine adenosyltransferase deficiency 
as creatine synthesis  by  guanidinoacetate  methyltransferase (GAMT)requires  S-
adenosylmethionine [215].   Though  decreased creatine  has  not  been  previously 
detected in individuals  with  methionine adenosyltransferase  deficiency, the 
identification  of  GAMT  deficiency and impaired  neurological  development  due to 
impaired creatine synthesis suggested a  possibility for a role in impaired creatine 
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synthesis in the analogous  neurological impairment seen in  methionine 
adenosyltransferase patients [16, 215, 216]. 
 
4.5 Conclusions 
 
Metabolic profiling is an important component of national newborn screening 
programs and is an increasingly important tool for the functional characterization of 
genetic  variants.   This chapter evaluates the applications  of two  mass spectrometric 
assays, traditional electrospray ionization tandem  mass spectrometry (ESI-MS/MS) 
with  multiple reaction  monitoring and a  new  direct injection  nanospray  high 
resolution mass spectrometry (nS-HR-MS), to classification and biomarker discovery 
for inborn errors  by  dried  blood spot (DBS) analysis.   While a larger  number  of 
afected  patient samples  wil  be  necessary to assess  diagnostic accuracy at a level 
comparable to the studies  performed  by international  newborn screening  programs 
[172], results for phenylketonuria (PKU) and medium chain acyl-CoA dehydrogenase 
deficiency (MCADD) indicate that increased  metabolic coverage together  with 
predictive modeling can improve upon cutof based diagnostics for these diseases.  
Additionaly, while the combination of expanded coverage metabolic profiling 
and  predictive  modeling  holds  promise for improving  diagnostic tests for  newborn 
screening, a second  major  benefit  of expanding  metabolic coverage in screening 
assays is the  opportunity to identify  metabolic changes incidental to and associated 
with the  main  metabolic lesion.   Examples  of these identified in this  work include 
shunt metabolites for acyl-CoA dehydrogenase deficiencies and erors of amino acid 
degradation and  metabolites  with  decreased  blood levels relative to  unafected 
newborns. Identifying these secondary perturbations could improve understanding of 
mechanisms of pathology, help clarify spectrums of clinical and genetic variation, and 
aid the functional assessment of rare variants.  
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CHAPTER 5 
METABOLOMIC INVESTIGATION OF 
CONGENITAL DISEASES OF THE 
KIDNEY 
 
 
5.1 Introduction and aims 
 
Mutations in enzymes and transporters can often be readily diagnosed by 
biofluid profiling and a strong mechanistic link is easily inferred between the 
disruption of a metabolic pathway and resulting accumulation or depletion of 
metabolic intermediates. However, many Mendelian diseases result in more complex, 
progressive organ specific or multi-organ pathology [25]. Examples include 
transporter deficiencies, organelle disorders such as lysosomal and peroxisomal 
storage diseases, congenital cancers, mistrafficking, or signalling disorders.  While 
these complex phenotypes frequently have systemic effects, individual organs or 
tissue types may be affected to varying degrees.  In these cases, metabolic profiling 
may be applied to identify sites of lesions, describe progression, and attempt to 
identify proxy small molecular biomarkers of the disease [22-24]. 
The utility of urinary metabolic profiling in nephrology has long been noted in 
both the metabolomics and nephrological communities [217-219].  Urinary metabolic 
profiling has been applied to study uremic toxins [220], acute kidney injury induced 
by exposure to nephrotoxins [161, 221-224], diabetic nephropathy [225-227], 
polycystic kidney disease [24, 228], renal Fanconi Syndrome [23], renal cell 
carcinoma [229, 230], and to monitor kidney transplantation [217, 231, 232].  In 
addition to using metabolic profiling to identify urinary compounds differentiating 
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nephrologicaly stressed  humans and animals from controls,  metabolic  profiling  has 
been  used to identify characteristic  urinary changes resulting from region specific 
acute toxicity [233, 234]. This work has shown that characteristic urinary metabolic 
profiles  diferentiate renal tubular toxins from renal  medulary toxins, for example. 
While it has been suggested that studying inborn erors may aid toxicological research 
[235], metabolomics studies of nephrotoxins suggest the reverse is true as wel. 
This chapter  presents a comparison  of the  urinary  metabolic  profiles  of four 
congenital  kidney  diseases, a  natural  history study showing changes in the  urinary 
profile of cystinosis patients over time and with age, glomerular filtration rate (GFR), 
drug therapy, and transplantation, and a comparison of the urinary perturbations seen 
in these  human  Mendelian  disorders to the  perturbations induced  by region specific 
nephrotoxins.   While the  human renal  disorders  discussed  here  have  quite  distinct 
genetic causes, they result in an  overlapping set  of  phenotypic consequences 
including  Fanconi  Syndrome (FS),  progressive renal failure,  nephrocalcinosis, and 
myopathy. These phenotypes suggest pathology afecting at least the renal proximal 
tubule,  glomerulus, and renal interstitium.   This chapter characterizes  urinary 
metabolic associations  with these  phenotypes  by comparing these conditions and 
investigating changes over time as these phenotypes develop. 
 
 
5.2 Materials and Methods 
 
5.2.1 Molecular biology and patients 
 
5.2.1.1 Cystinosis 
 
Cystinosis is an autosomal recessive lysosomal storage disease caused by loss-
of-function  mutations in the CNTS  gene encoding cystinosin, the lysosomal 
membrane transport protein responsible for the efflux of cystine from lysosomes [158, 
236-238]. As a consequence, intra-lysosomal cystine accumulates in many cel types, 
most of which contain crystals. Clinicaly, renal tubular cel death and FS develop in 
the first  year  of life,  manifesting as  polyuria,  phosphaturia,  glucosuria, and 
generalized aminoaciduria [239].  Cystinosis  historicaly resulted in fatal end-stage 
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renal disease, but renal transplantation and treatment with the cystine-depleting agent, 
cysteamine, have significantly increased the lifespan of cystinosis patients [240-242]. 
Twenty-two cystinosis patients were investigated at the Clinical Center of the 
National Institutes  of  Health,  USA,  between  1995 and  2010 as  part  of clinical 
protocol  78-HG-0093, approved  by the  NICHD and  NHGRI IRBs.  Patients  or their 
parents  gave writen, informed consent. Twenty-four hour urines were colected and 
aliquots stored at -30C. Sample colections and analyses were performed according to 
Imperial  Colege  Research  Ethics  Commitee (ICREC)  protocols approved  by 
Imperial Colege London.Patient data, including transplantation status, are included in 
Table 5.1. Between 7 and 15 samples were colected from each patient over this time 
period, with urines colected from patients between the ages of 3 weeks and 49 years; 
the  mean age at sample colection  was  13  years.  Of the  22  patients included in the 
study, 12 ultimately underwent renal transplantation  during the period of colection. 
Folowing  diagnosis, al  patients  were  prescribed  CystagonR (cysteamine  bitartrate), 
generaly at a  dose  of  60-90  mg/kg/day  divided  q6h.  After transplantation, anti-
rejection medications such as mycophenolic acid were given. 
 
Table 5.1. Cystinosis patient characteristics 
Patients N=22 
Age 3 wks – 49 years (mean 13 years) 
Gender 11 Male, 11 Female 
Samples per Patient 7 – 15 (mean 9 samples) 
Patients with pre-transplant samples N=19 
Patients with post-transplant samples N=12 
Cystagon prescribed dose  75 – 850 mg (mean 437 mg) 
Glomerular filtration rate 7– 176 mL/min (mean 59 mL/min) 
 
5.2.1.2 Autosomal Dominant Fanconi Syndrome 1 (ADFS1) 
 
Fanconi Syndrome is a proximal tubular cel dysfunction that renders the renal 
tubule  unable to recover smal  molecule solutes from the  ultrafiltrate leading to the 
urinary loss of solutes including glucose, amino acids, and ions including phosphate, 
calcium, sodium,  potassium, and  bicarbonate.  While the  most common cause  of 
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pediatric  Fanconi  Syndrome is cystinosis [158],  FS results from  other  known 
Mendelian  diseases, including  Oculocerebrorenal  Syndrome  of  Lowe [243],  Dent 
disease,  Wilson  disease, and tyrosinemia.   While these  diseases  generaly show an 
autosomal recessive inheritance  patern,  Fanconi  Syndrome  with an autosomal 
dominant inheritance  patern  was recently identified in a five-generation  African 
American family [160]. Afected family members presented with FS but without the 
glomerular  kidney failure  observed in cystinosis.   Genetic linkage studies 
subsequently mapped this phenotype to chromosome 3 and sequencing subsequently 
identified a  heterozygous  missense  mutation in EHHADH that created a  de  novo 
mitochondrial targeting motif leading to mistrafficking of L-Bifunctional Protein, an 
enzyme originaly involved in peroxisomal faty acid oxidation, to the mitochondria. 
Urine samples  were colected from a total  of (N=10)  patients and family 
members from a five-generation  African  American family  with isolated autosomal 
dominant  FS. Seven members of a family with  generalized FS were admited to the 
NIH  Clinical  Center and enroled in clinical  protocol  76-HG-0238.   Urine samples 
were colected from 5 of these patients. Eleven unafected family members were seen 
localy, and urine samples were colected from 5 family members. Al  gave writen, 
informed consent.  The  diagnosis  of  FS  was established  by routine laboratory 
investigations of urine and blood.  Al investigations, including genetic studies, were 
approved by the NHGRI Institutional Review Board and conducted according to the 
principles of the Declaration of Helsinki. 
 
5.2.1.3 Autosomal Dominant Fanconi Syndrome 2 (ADFS2) 
 
A second  phenotype also  presenting  with renal  Fanconi  Syndrome and an 
autosomal  dominant inheritance  patern  was studied in  members  of four  unrelated 
families, yet did not show the EHHADH mutations characteristic of ADFS1 patients. 
Clinical  work-up identified abnormal looking  mitochondria in afected family 
members, suggesting a mitochondrial dysfunction distinct from other observed forms 
of  Fanconi  Syndrome.  As such, this as  yet  geneticaly  uncharacterised form  of 
Fanconi  Syndrome  was termed  Autosomal  Dominant  Fanconi  Syndrome type  2 
(ADFS2). 
Urine samples were colected from a total of 12 members of these families, of 
which (N=8) afected individuals provided samples. One afected individual provided 
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an additional sample at a later colection date.Participants were either admited to the 
NIH  Clinical  Center in the  USA and enroled in clinical  protocol  76-HG-0238  or 
enroled   in   the   protocol   “Identification   of   genes   involved   in   renal   and   electrolyte  
disorders”  and  seen  in  the  United  Kingdom.  Al  gave  written, informed consent. The 
diagnosis  of  FS  was established  by routine laboratory investigations  of  urine and 
blood.  Al investigations, including  genetic studies,  were approved  by the  NHGRI 
Institutional  Review  Board  or  Royal  Free  Hospital  Research and  Development and 
conducted according to the principles of the Declaration of Helsinki. 
 
5.2.1.4 Enamel Renal Syndrome (ERS) 
 
Enamel Renal Syndrome (ERS), resulting in amelogenesis imperfecta (AI)and 
nephrocalcinosis (NC) is an autosomal recessive  disorder  of calcium  homeostasis 
caused  by  mutations in the FAM20A  gene [244-247].  FAM20A, together  with 
FAM20B and FAM20C, are involved in  glycosaminoglycan synthesis, and 
experimental evidence suggests that loss  of FAM20A function results in 
overabundance  of chondroitin sulfate in the extracelular  matrix.  Clinicaly,  ERS 
patients show abnormal enamel formation and tooth eruption as wel as calcifications 
in the  kidney, teeth, and  gingival.   Unlike  other forms  of  nephrocalcinosis such as 
Barter’s  syndrome,  Dent’s  Disease,  and  hypophosphataemia with nephrolithiasisthat 
involve defects in calcium transport from the renal tubule to the interstitium and result 
in  hypercalciuria [248], the  neprocalcinosis in  ERS is results from increased 
sequestration  of ionized calcium in the interstitium  by chondroitin sulfate rich 
glycosoaminoglycans [246]. 
Urine samples were colected from a total of (N=14) patients examined as part 
of the international genetic characterization of ERS [246]. Patients and families were 
identified in rare  disease renal tubular  or  dental / craniofacial reference centers and 
gave informed consent. Al patients had NC confirmed by either ultrasound, X-ray or 
CT, and al showed  pathognomonic teeth findings  with  AI and  delayed  or  missing 
tooth eruption. This study was approved by the institutional review boards and ethics 
commitees  of the  various centers,  details  of  which  have  been  previously  published 
[246].  
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5.2.2 Samples and data acquisition 
 
5.2.2.1 Comparison of congenital kidney diseases 
 
Spot urines were colected and aliquots stored at -30C. Sample colections and 
analyses  were  performed according to Imperial  Colege  Research  Ethics  Commitee 
(ICREC)  protocols  approved  by  Imperial  Colege  London.  250  μL  aliquots  of  filtered,  
centrifuged urine  were  combined  with  150  μL  of  HPLC  grade  water  (Sigma) and 100 
μL  of  D2O NMR bufer containing 1 mM TSP (Sigma-Aldrich) and 3 mM NaN3 in 5 
mm  NMR tubes (Wilmad).   Aliquots  were taken from  urine samples  of (N=10) 
cystinosis patients and prepared as above. 1D 1H spectra were colected on a Bruker 
Avance II spectrometer operating at 800.32 MHz using a 5 mm cryoprobe. Spectra 
were acquired at 300K with a resolution of 64k data points and a spectral width of 20 
ppm  using a  1D  pulse-acquire sequence  with  direct  presaturation  of residual  water 
and a relaxation  delay  of  30s to accommodate ful  T1 relaxation  of  urinary 
metabolites.  Al  data  were  Fourier transformed,  phased, and  baseline corected in 
XWinNMR (Bruker)  before  being transfered to  Matlab  R2010b (Mathworks) for 
preprocessing and data analysis. 
 
5.2.2.2 Urinary metabolic natural history of cystinosis 
 
For al  200 cystinosis  urine samples,  500  uL aliquots  of filtered, centrifuged 
urine  were  combined  with  100  μL  of  NMR  bufer  containing  D2O and 1 mM TSP (3-
trimethylsilyl-  2,2,3,3-tetradeuteropropionate,  Sigma-Aldrich) and  3  mM  NaN3 in  5 
mm NMR tubes (Wilmad). 1D 1H NMR spectra were colected for al samples on a 
Bruker  Avance spectrometer  operating at  600.44  MHz  using a  5  mm  BBI  probe at 
300K. Samples were run using an automated sample changer with a randomized run 
order. Spectra were acquired at a resolution of 64k data points and a spectral width of 
20  ppm  using a  1D  pulse acquire sequence  with  gradient  pulses and excitation 
sculpting for presaturation of water. For select samples, 1D 1H spectra were colected 
using a pulse-acquire sequence with iradiation of residual water and TOCSY spectra 
were colected using a 90 ms mixing time DIPSI-2 sequence with gradient pulses and 
excitation sculpting on a Bruker Avance spectrometer operating at 800.32 MHz. Al 
data were Fourier transformed, phased, and baseline corrected in XWinNMR (Bruker) 
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before being transfered to Matlab R2010b (Mathworks) for preprocessing and patern 
recognition. One spectrum was left out of statistical evaluation due to spectral quality, 
leaving (N=199) for further analysis. 
 
5.2.2.3 Animal studies of nephrotoxin exposure 
 
1D 1H NMR metabonomic datasets were colected from the urine samples of 
Sprague-Dawley rats exposed to the model nephrotoxins cisplatin, mercuric chloride 
(HgCl2), and  2-bromoethanamine (BEA) studied as  part  of the  Consortium for 
Metabonomic  Toxicology,  COMET [249,  250].   Animal selection and treatment 
folowed the standard  COMET  protocol, as  detailed elsewhere [250].  At the  0  hour 
time  point, animals in each  group  were administered an intraperonital injection  of 
vehicle (0.9% saline)  with toxin  dosages selected to induce  overt toxicity  without 
significant  mortality (HD,  10  ml/kg cisplatin,  2  ml/kg  HgCl2,  5  ml/kg  BEA,  N=10 
each)  or saline  vehicle alone (C,  N=10 for each study).  In al experimental  groups 
half of the animals were euthanized at 48 h and the remaining animals at 168 h after 
dosing. Urine samples were colected at -16, 0, 8, 24, 48, 72, 96, 120, 144, and 168 h 
postdosing and 1D 1H NMR spectra were acquired and processed for each colected 
sample using standard COMET procedures [63, 251]. 
 
5.2.3 Data analysis 
 
NMR spectra  were referenced to  TSP at  0.00  ppm  before the removal  of 
residual water signal from  4.5 – 5.2 ppm.  Assignment of observed NMR  peaks was 
achieved by reference to previously assigned urinary NMR spectra[110], to spectra of 
pure compounds and  2D 1H-1H  TOCSY spectra  were acquired for selected samples 
for further confirmation of urinary metabolites. Figure 5.1 shows an aliphatic region 
of a  600  MHz  NMR spectrum typical for a  pre-transplant cystinosis  urine sample. 
Tartratewas confirmed  by  LC-MS and spiking  of an authentic standard, as it is  not 
frequently observed at high levels in urinary NMR spectra (Figure 5.2). 
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Table 5.2. Assignments of urinary NMR signals integrated for targeted analysis. Abbreviations: s, 
singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; m, multiplet; AB, AB doublet. 
Metabolite Integrated signal Other signals 
Glucose 3.90 (dd) 
3.26 (dd), 3.43 (m), 3.49 (m), 3.55 (dd), 3.73 (m), 
3.85 (m), 4.66 (d), 5.24 (d) 
Lactate 1.33 (d) 4.12 (q) 
Glutamine 2.45 (m) 2.14 (m), 3.78 (t) 
Lysine 1.73 (m) 1.48 (m), 1.93 (m), 3.05 (t), 3.78 (t) 
Leucine 0.96 (t) 1.73 (m), 3.74 (m) 
Isoleucine 1.02 (d) 0.94 (t), 1.26 (m), 1.47 (m), 1.99 (m) 
Valine 0.99 (d) 1.04 (d), 2.30 (m), 3.63 (d) 
Threonine 4.26 (m) 1.33 (d), 3.59 (d) 
Alanine 1.48 (d) 3.78 (q) 
Tyrosine 6.91 (d) 3.06 (dd), 3.2 (dd), 3.94 (dd), 7.2 (d) 
TMAO 3.27 (s)  
Acetate 1.92 (s)  
Creatine 3.93 (s) 3.04 (s) 
Creatinine 4.06 (s) 3.05 (s) 
Citrate 2.54 (AB) 2.66 (AB) 
Glycine 3.57 (s)  
Tartrate 4.34 (s)  
Formate 8.46 (s)  
Carnitine 3.23 (s) 2.44 (dd), 3.43 (m), 4.59 (m) 
Dimethylamine 2.73 (s)  
Methylamine 2.61 (s)  
Dimethylglycine 2.93 (s)  
Hippurate 7.56 (t) 3.97 (d), 7.64 (t), 7.84 (d) 
Acetone 2.33 (s)  
Succinate 2.40 (s)  
Fumarate 6.52 (s)  
Prolinebetaine 3.11 (s) 3.31 (s) 
Hypotaurine 3.36 (t) 2.66 (t) 
Myo-inositol 4.04 (t) 3.63 (dd), 3.53 (dd), 3.28 (t) 
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Figure  5.1.  Metabolic  profiling  of  Fanconi  Syndrome in cystinosis  urine samples  by  NMR 
spectroscopy.  Assignments in  both  1D 1H (top) and  2D 1H-1H  TOCSY spectra show  urinary loss  of 
sugars and amino acids characteristic  of renal  Fanconi  Syndrome, as  wel as increased excretion  of 
lactate, acetate, and trimethylamine-N-oxide.  1D 1H spectrum shows resonance frequencies  of 
individual protons,  while 2D  TOCSY shows off-diagonal crosspeaks between coupled protons in the 
same  metabolite.  Abbreviations:  BCAA,  branch-chain amino acids;  Gln,  glutamine;  Suc, succinate; 
MA, methylamine; DMA, dimethylamine; DMG, dimethylglycine; Pb, proline-betaine; Carn, carnitine; 
TMAO, trimethylamine-N-oxide; Cre, creatine; Crn, creatinine. 
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Figure 5.2. Confirmation of tartrate in the urine of cystinosis patients. While the NMR urinary profiles 
of cystinosis and  ADFS1  patients (A) are  highly similar, the singlet at  4.34  ppm is  present at  high 
levels in the urinary spectra of cystinosis patients.  Spiking a sample of pure, authentic tartrate into a 
urinary sample colected from a cystinosis patient (B) shows a specific increase increase in the singlet 
at  4.34  ppm.  Extracted ion chromatograms  of m/z 149.0000 –  149.2000 (C) and  mass spectra at  47 
seconds (D) from negative mode LC-MS match the observation of high levels of tartrate excreted by 
cystinosis patients.  
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Spectral signals representing  29  metabolites  with  wel-resolved  peaks  were 
quantified by fiting Lorentzian lineshapes to the NMR multiplets indicated in Table 
5.2 according to equation 5.1.  
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wsi
    
(5.1) 
 
Here, iδ is the intensity of the Lorentzian lineshape at chemical shift position δ 
given  peak  half-width at  half-max w and  peak  positions δ0,  multiplied  by a scaling 
factor s as the  Lorentzian function  gives  values  between  0 and  1.  Peak  positions δ0 
were  detected  by  peak  picking the spectral lineshapes and  values for s and w  were 
optimized by grid search between the ranges of (0 < s < 1  iδ0) and (0.25 Hz < w < 3 
Hz)  using the residual  of the  NMR lineshape after subtraction  of iδ as an  objective 
function.    Lorentzian fiting  generates a  matrix  of  N samples  by  M  metabolites, 
which was normalized to the CRN singlet at 4.06 ppm for the spectra in 5.2.2.1 and 
5.2.2.3 in  order to compare across  phenotypic  groups and  by  probabilistic  quotient 
normalization [88] for the spectra in  5.2.2.2 as  CRN excretion is afected  by the 
independent variables of age, gender, GFR, and transplantation status which vary in 
the natural history study. The normalized abundances were log10 scaled to meet the 
normality criterion of the Liliefors test [252]. 
The data matrices of 5.2.2.1 and 5.2.2.3 were subjected to unpaired, two-sided 
t-tests  between  disease and toxicological  groups and the resulting  p-values  were 
corected using the Benjamini-Hochberg False Discovery Rate [114, 115] for multiple 
testing.   Missing  values (<10%  of independent  variables)  were estimated  using 
regression  based  multiple imputation [253]. PCA  using the  NIPALS algorithm  was 
applied to the  data  matrix  of  5.2.2.2 folowing  mean centering and scaling to  unit 
varianceand partial corelations between metabolites were calculated independent  of 
age,  gender,  GFR,  Cystagon  dose and transplantation status.  One-way analysis  of 
variance (ANOVA) was used to compare the variance between and within individual 
patients for  both independent  variables and  metabolite levels.  Associations  between 
single independent variables and metabolite levels were identified by linear or logistic 
regression after corection for confounders  by  multivariable adjustment for  other 
independent variables [254]. Associations were considered significant if regression p-
values  were less than a threshold calculated  by  Bonferoni corection.   For time 
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courses in data sets 5.2.2.2 and 5.2.2.3 mean values and standard eror of the means 
were calculated at each time  point to show changes in  metabolite levels  over time. 
While animal samples  were colected at regular intervals,  human samples  were 
colected at irregular intervals and to compare these  measurements  by time-to-
transplant values were taken for the nearest year pre- or post-transplant.  
 
5.3 Results and Discussion 
 
5.3.1 Comparison of congenital kidney diseases 
 
Renal Fanconi Syndrome is a consensus phenotype resulting from the loss of 
transporter activity in the renal proximal tubule that is caused by inherited conditions 
as wel as chemical insult [255, 256]. This renders the renal tubule unable to recover 
smal  molecule solutes from the  ultrafiltrate.  Hence, FS is characterized  by  marked 
glucosuria and  generalized aminoaciduria, as  wel as the loss  of ions such as 
phosphate, calcium, sodium,  potassium, and  bicarbonate [23].   Renal  Fanconi 
Syndrome can be isolated, as in the case of idiopathic FS, or it can be one aspect of a 
systemic condition as in the case of cystinosis.  
In  order to identify  urinary  perturbations resulting from FS and  distinguish 
them from those resulting from systemic  or  non-tubule renal  pathology,  urinary 
profiles  of cystinosis and three forms  of congenital renal  pathology  with recently 
characterized  genetic causes  were compared.   The  presentation  of these syndromes 
partialy  overlaps  with that  of cystinosis, alowing  metabolites that  discriminate 
between these similar phenotypes to be identified.  
Figure 5.3 shows the clinical phenotypes associated with each of the diseases 
analyzed in this section.   While autosomal  dominant  Fanconi  Syndrome type I 
(ADFS1), autosomal dominant Fanconi Syndrome type I (ADFS2), and cystinosis al 
present with Fanconi Syndrome, there is no apparent renal failure in ADFS1 patients. 
Additionaly,  neither  ADFS1  nor  ADFS2  patients  have the  muscle  weakness and 
progressive deterioration observed in cystinosis. Finaly, comparison to controls and 
patients  with a  novel form  of  nephrocalcinosis (ERS) should  provide controls for 
comparison against a  normal  urinary  baseline and against a significantly  difering 
renal phenotype.  
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Figure 5.3. Clinical phenotypes observed in congenital kidney diseases. 
 
Given the similarity  of the clinical  phenotypes  of  ADFS1,  ADFS2, and 
cystinosis, some  portion  of the  urinary  metabolic changes associated  with these 
diseases are expected to  be common to al three,  with another  portion specific 
individual diseases.  Figure 5.4 shows urinary abundances of metabolites relative to 
creatinine for the Fanconi Syndromes and for unafected family members. For al of 
the  metabolites shown in the top  panel,  urinary abundances for al three sets  of 
afected  patients are significantly  greater than  unafected controls,  but  not 
significantly  diferent from the  other  diseases.  Glucose, lactate and amino acid 
excretion (top panel) are halmarks of Fanconi Syndrome [257-259], and these results 
suggest they are al affected  by each  of the  various forms  of  Fanconi  Syndrome 
included in this analysis. 
While the set of conserved urinary perturbations common to ADFS1, ADFS2, 
and cystinosis are useful to identify associations  between metabolic phenotypes and 
damage to the renal tubule,  diferential  perturbations indicate features specific to 
individual  diseases  which  both identify  unique  pathological  developments and 
associations  between  metabolites and afected tissues.   These  differential  metabolic 
perturbations were identified as the set of urinary metabolites for which abundances 
were not only significantly diferent from controls, but also from one or more of the 
other Fanconi Syndromes. 
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Figure  5.4.   Urinary excretion  of  metabolites elevated in  Fanconi  Syndromes relative to controls. 
White bars reflect values from unaffected family members (N=15),  and black from affected patients 
(ADFS1,  N=5;  ADFS2,  N=9;  CYS,  N=10).   The  height  of the  bars is the  mean  of the log10 relative 
concentration  vs.  CRN.  Error  bars,  SEM;  *P<0.05,  **P<0.005,  ***P<0.0005,  unpaired t-test, 
Benjamini-Hochberg  FDR correction.  Abbreviations:  TMAO, trimethylamine-N-oxide;  DMG, 
dimethylglycine. 
 
Figure 5.5 shows urinary abundances of metabolites relative to creatinine for 
each  of the  kidney  diseases that  present  with  Fanconi  Syndrome and for  unafected 
family members for the metabolites that show significant diferences not just between 
afected patients and controls,  but  between patients  with individual diseases.  These 
metabolites that discriminate between patient groups should indicate unique features 
of the pathology of these diseases.  
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Figure 5.5. Metabolites diferentiating congenital Fanconi Syndromes. White bars reflect values from 
unaffected family  members (N=15), and  black from affected  patients (ADFS1,  N=5;  ADFS2,  N=9; 
CYS, N=10).  The height of the bars is the mean of the log10 relative concentration vs. CRN.   Error 
bars, SEM; *P<0.05, **P<0.005, ***P<0.0005, unpaired t-test, Benjamini-Hochberg FDR correction. 
Significance noted above individual bar plots denote tests relative to controls, while significance noted 
by marker bars denote tests between afected patients.  
 
Citrate and fumarate are significantly increased in ADFS1 individuals relative 
to ADFS2 individuals (citrate, p = 0.036; fumarate, p = 0.035) as wel as to controls 
(citrate,  p  =  0.0066; fumarate,  p  =  1.91  x  10-4).   Elevated excretion  of these  TCA 
cycle intermediates, along with succinate (Figure 4) are likely indicative of the TCA 
cycle  disruption caused  by the  underlying  genetic  defect in  ADFS1  patients as 
increased urinary excretion of TCA cycle intermediates has frequently been observed 
to accompany  mitochondrial  pathology [161-163].  Retrospective analyses  have 
suggested fumarate is a sensitive and specific indicators  of  mitochondrial  disease 
[163], and coordinated loss of multiple TCA cycle intermediates in  ADFS1 patients 
would support this assertion.  Cystinosis  patients also show elevations in citrate, 
fumarate, and succinate levels, and  while citrate is also supplemented to alkalinise 
pre-transplant cystinosis  patients, elevated fumarate and succinate suggest the 
energetics efects postulated as a cause renal Fanconi Syndrome in cystinosis patients 
[260-262] and sync  with  observations  of altered  mitochondrial appearance in 
proximal tubule cels of cystinosis patients [263].  
The  observation  of elevated creatine excretion  observed in  ADFS1 and 
cystinosis patients relative to controls (ADFS1, p = 0.015; cystinosis, p = 1.44x 10-4) 
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and ADFS2 individuals (ADFS1, p = 0.0029; cystinosis, p = 4.70 x 10-6) may also be 
a result  of an energetic  defect in these  diseases.   Cystinosis  patients  present  with 
progressive  myopathy [264,  265],  which is absent in  ADFS2  patients, and elevated 
urinary creatine/CRN ratios are an established biomarker of steroid induced myopathy 
[266].  While the  muscle  weakness and  wasting characteristic  of  myopathy  was  not 
identified clinicaly in ADFS1 patients, there is no reason to suspect mistraficking of 
LBP is limited to the  kidney, and as a result  pathology  of tissues  with significant 
energetic requirements, including both muscle and the renal tubule, is consistent. 
 
 
 
Figure  5.6.  Urinary citrate, acetate, and inositol excretion in  ERS  patients and  unaffected controls. 
White bars reflect values from control samples (N=15), and black from affected patients (N=14). The 
height of the bars is the mean of the log10 relative concentration vs. CRN. Error bars, SEM; *P<0.05, 
**P<0.005, unpaired t-test, Benjamini-Hochberg FDR correction. 
 
Elevated carnitine,  hypotaurine, and tartrate and excretion  by cystinosis 
patients are  most likely the result  of therapeutic interventions rather than a  primary 
metabolic perturbation. L-Carnitine is frequently supplemented in cystinosis patients, 
and while absence of cysteamine in the urine of cystinosis patients confirms its pre-
renal catabolism [267], hypotaurine has been identified as an excreted metabolite of 
cysteamine in animal  models [268].   Tartrate is a  minor  metabolite  known to  be 
excreted folowing fruit consumption [269],  however the extreme elevations in 
tartrate excretion by cystinosis patients relative to controls and to ADFS1 and ADFS2 
patients indicated excretion  of  unmetabolised tartrate resulting from cysteamine 
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therapy  under the cysteamine-bitartrate (Cystagon) formulation.   While elevated 
methylamine excretion  by cystinosis  patients could  be related to  L-carnitine 
supplementation, studies  of the  origin  of  urinary  methylamine  have indicated a 
primarily endogenous  origin  with  only  minor contributions from  dietary sources 
[270]. 
ERS  urinary  profiles,  unlike those  of the  Fanconi  Syndromes, show few 
diferences relative to controls.   The  metabolites that are significantly  modulated, 
citrate, acetate and  myo-inositol,  were also  observed to  be  perturbed in the  Fanconi 
Syndromes.   However,  while citrate excretion  by  ADFS1,  ADFS2 and cystinosis 
patients was elevated relative to controls, citrate excretion by ERS patients is reduced 
across the cohort- especialy so in six individuals for which the citrate signal is below 
the limit  of  detection.   Given the complex role citrate  plays in the  kidney, it is 
unsurprising that its excretion is  modulated  by  very  diferent  phenotypes.  In  ERS 
patients, reduced citrate excretion likely indicates the  disruption  of calcium 
homeostasis underlying the nephrocalcinosis in these patients rather than a TCA cycle 
defect.   Hypocitraturia  has  been  noted in instances  of renal calcium  precipitation, 
especialy  nephrolithiasis [271], and citrate supplementation is an established 
treatment for stone forming disorders, including hypercalciuric nephrolithiasis [272]. 
Hypocitraturia is also considered a major risk factor for nephrocalcinosis in neonates 
[273].  
Figure  5.7 shows a summary  of the  urinary  perturbations identified for the 
diseases investigated here. These findings both support and clarify work in the study 
of congenital  kidney  diseases, renal transplantation, and  nephrotoxicity, and add 
important context to the folowing investigations  of renal  metabolism in cystinosis 
and pathology of structures of the kidney due to toxin exposure.  
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Figure  5.7.  Metabolic  perturbations  observed in congenital  kidney  diseases.  Abbreviations:  Gluc, 
glucose;  Lac, lactate;  AAs, amino acids;  TMAO, trimethylamine-N-oxide;  DMG,  dimethylglycine; 
H2TA, tartaric acid; HTAU, hypotaurine. 
 
5.3.2 Urinary metabolic natural history of cystinosis 
 
Despite  detailed  knowledge about the  genetic and  molecular features  of 
cystinosis (see section 5.2.1.1), the mechanisms by which defective lysosomal cystine 
transport leads to renal tubular  pathology are largely  unknown [274].  Clinical 
chemistry metrics such as urine glucose and creatinine clearance are routinely used to 
monitor disease progression, but a broader complement of urinary metabolites is not 
routinely  measured.  Nuclear  Magnetic  Resonance (NMR),  with its capacity for 
targeted and  untargeted identification and  quantification  of a  broad range  of smal, 
soluble analytes, is  wel suited for  urinalysis and  has  been applied to study renal 
physiology, disease, and multiple inborn erors of metabolism [14, 17, 19, 217, 218, 
275, 276]. 
Longitudinal  monitoring  of  urine composition  over the  natural  history  of 
cystinosis  may  provide  higher resolution and  more  detailed information about the 
celular and  metabolic changes in  proximal tubular cels.  To achieve this  goal,  we 
performed a prospectively designed NMR metabolic profiling study on 200 archived 
samples from 22 cystinosis patients colected over a period of 15  years (Table  5.1). 
This design captured key features of cystinosis pathology and treatment, including the 
urinary loss  of  TCA cycle intermediates (citrate, succinate, fumarate), the 
development  of  Fanconi  Syndrome (with  glucosuria, aminoaciduria) and elevated 
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levels  of excreted trimethylamine-N-oxide (TMAO) as  wel as the efects  of  oral 
cysteamine therapy and kidney transplantation. 
The natural history of nephropathic cystinosis is characterized by a number of 
factors, changes in which are likely to afect urinary metabolite levels. These include 
factors which are specific features of cystinosis, including renal failure, drug therapy 
with cysteamine bitartrate, and transplantation, and general factors that are known to 
afect  urinary  metabolic  profiles including age,  gender and  diferences  between 
individuals [277, 278]. In order to determine the relationships between the folowing 
variables- transplantation status, age,  prescribed  Cystagon  dosage,  gender, and 
glomerular filtration rate (GFR) and their relationships to  urinary  metabolite levels, 
corelations between these variables, fit to urinary metabolite levels, and diferences 
between individuals were assessed (Figure 5.8).  
 
 
Figure 5.8. Analysis of cystinosis  natural  history  metadata  variables.   R2 fit of transplantation status, 
age,  prescribed  Cystagon  dosage,  gender, and  glomerular filtration rate to the  urinary  metabolic 
profiles  of cystinosis  patients (top), significant correlations  between these  variables (botom), and –
log10(p) values from ANOVA by individual for each variable. 
 
Figure 5.8 shows the R2 fit of linear regression modeling of each variable to 
the ful set  of  urinary  metabolite levels, a  heatmap showing significant corelations 
between  variables, and a  Manhatan representation  of  ANOVA  p-values comparing 
variance  between  patients  with  variance  within individual  patients.   These results 
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show that transplantation  has the greatest efect  on the urinary metabolic profiles of 
cystinosis  patients, and  while age  has a substantial efect as  wel it is significantly 
corelated  with al  other  variables except  gender.   One-way analysis  of  variance 
(ANOVA)  by individual shows the efects  of capturing  metabolic  profiles from 
individuals at varying points in the natural history of cystinosis. Despite an average 
of  9 samples  per individual  patient  over the  15-year  period in  which samples  were 
colected, these timepoints do not capture the entire progression of cystinosis for any 
individual  patient and as a result  ANOVA reports significant  diferences  between 
individuals especialy for age.  
Statistical analysis  of  urinary  metabolites  over the set  of  pre- and  post-
transplant NMR spectra indicate while transplantation may be the dominant source of 
variation among the set  of  variables captured in  Figure  5.8,  Fanconi  Syndrome 
accounts for a  greater share  of the  variation in the cystinosis  urinary  profiles 
(Figure5.9).  Principal  Component  Analysis  decomposes the  data  matrix  of  199 
samples and 29 metabolites into N scores (Figure 5.9A) and P loadings (Figure 5.9B, 
5.9C) for a number of Principal Components (PCs) coresponding to major sources of 
variation in the  overal  dataset.  Principal  Component  1, representing  24.9%  of the 
total variance in these metabolites, is dominated by the urinary abundances of glucose 
and amino acids characteristic of Fanconi Syndrome (Figure 5.9B). 
Principal  Component  2 (10.8%  of  variance) shows some separation  between 
pre-transplant (blue) and  post-transplant (red) (Figure  5.9A),  but the  PC  2 loadings 
(Figure  5.9C) indicate a  dominant contribution from  TCA cycle intermediates 
succinate, fumarate, and citrate.   This could indicate that after the  development  of 
Fanconi Syndrome, energetic stress as observed in section 5.3.1 is the major source of 
urinary metabolic variance in the natural history of cystinosis. Energetic stress to the 
native renal tubule would experience would result in corelations with transplantation, 
but may not miror the direct efects of transplantation. 
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Figure 5.9. Statistical analysis of metabolites from cystinosis urinary NMR data. Principal Component 
Analysis and ANOVA identify renal Fanconi Syndrome and the loss of TCA cycle intermediates as the 
major sources  of  variation in  urinary  NMR  data from cystinosis  patients.  A)  Principal component 
scores for each  urinary  NMR spectrum  both  before (blue) and after transplantation (red).  B)  PC1 
loading coefficients for each  metabolite indicate that characteristic renal  Fanconi  Syndrome 
metabolites are primary contributors to variance in principal component 1. C) PC2 loading coefficients 
for each  metabolite indicate a  plurality  of the  variance resulting from  TCA cycle intermediates 
succinate, fumarate, and citrate. D) Log10 variance of metabolite abundances between (blue) and within 
(green) individual  patient samples as identified  by  one-way  ANOVA analysis after correction for 
transplantation status, age, prescribed Cystagon dosage, gender, and GFR 
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To identify whether Fanconi Syndrome shows greater variability from patient 
to  patient  or across the set  of  observations  of a single  patient,  one-way analysis  of 
variance (ANOVA) testing  was  performed  using  patient IDs as sub-groups after 
corection for confounding  variables  of transplantation status, age,  prescribed 
Cystagon  dosage,  gender, and  GFR  which  were shown to  be significantly  diferent 
between individuals (Figure  5.8).  ANOVA results indicate that for the  majority  of 
characteristic  Fanconi  Syndrome  metabolites (including  glucose, lactate, alanine, 
lysine,  valine, leucine, and isoleucine),  variance  between individual  patients 
exceedsthe variance within patients to a greater extent than most urinary metabolites 
(Figure 5.9D). 
Multiple forms  of  membrane  proteins in the solute carier (SLC) family  of 
transporters at the luminal and  basolateral faces  of the renal  proximal tubule are 
responsible for the recovery of solutes, included separate transporters for  positively, 
negatively, and  neutraly charged amino acids [279].  While some congenital  kidney 
diseases including  Hartnup  disease, iminoglycinuria, and cystinuria are caused  by 
mutations in single solute carier genes, renal Fanconi Syndrome is characterized by a 
generalized aminoaciduria that does not appear to be transporter-specific. Across the 
board reduction in transporter activity would be expected to generate high corelations 
between the excreted levels of actively transported solutes.  
Clustered  partial correlations  between excreted  metabolites independent  of 
transplantation status, age,  prescribed  Cystagon  dosage,  gender, and  GFR  (Figure 
5.10) show significant, positive corelations between the actively transported solutes 
glucose, lactate,  myo-inositol, and  uncharged,  polar,  branch-chain, and  negatively 
charged amino acids.  Lower  baseline excretion  of these amino acids and spectral 
crowding may be responsible for the reduced correlations of tyrosine, threonine, and 
glutamine, though significant  positive corelations  between these amino acids and 
other transporter substrates  were stil  observed.   The  observation  of significant 
positive corelations  between the  urinary loss  of these  metabolites supports 
observations  of reduced intercelular  ATP concentration in cystine-loaded cels and 
resulting coordinated loss  of transporter activity [262].   The clustering  of succinate, 
fumarate, and citrate,  which are frequently  observed to  be excreted in the  urine in 
mitochondrial  disorders [280], suggest  disrupted  mitochondrial  ATP  production in 
renal tubular cels could result in the  observed coordinated excretion  of actively 
transported solutes.  
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Figure  5.10.  Correlations  between  metabolites excreted  by cystinosis  patients.  Partial correlations 
between  metabolite levels independent  of transplantation status, age,  prescribed  Cystagon  dosage, 
gender, and  glomerular filtration rate are  displayed as a  heatmap.   These  metabolites are clustered 
using an average linkage agglomerative  hierarchical clustering applied to the  partial correlations. 
Insignificant correlations are not shown.  
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Figure  5.11.  Significant associations  between  urinary  metabolites and cystinosis  patient  metadata 
variables identified by regression analysis. Stem plots show –log10(p) Manhatan representations of p-
valuesfrom regression analysis after correction for  other  metadata  variables and  multiple  hypothesis 
testing.   The sign  of the t-statistic indicates  whether  metabolite levels are  positively  or  negatively 
associated. Urinary metabolites for which (p<0.0017, Bonferroni correction) are indicated in red, and 
the ±log10 Bonferroni threshold is ploted as a dashed blue line.  
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As indicated  by  Figure  5.8, the  variables  of transplantation status, age, 
prescribed  Cystagon  dosage,  gender, and  glomerular filtration rate (GFR) afect the 
urinary  metabolic  profile  of cystinosis  patients.  In  order to identify associations 
between these independent  variables and  metabolite levels, regression analysis  was 
applied to  model  metabolite excretion as a function  of each  of these  variables, 
corecting for al  other  variables as confounders.   Associations  were considered 
significant if regression p-values were less than a threshold calculated by Bonferroni 
corection (p  =  0.0017).   Figure  5.11 shows the results  of linear regression  vs. age, 
Cystagon  dose, and  GFR and logistic regression  vs.  dummy  variables for 
transplantation status (pre-transplant,  0;  post-transplant,  1) and  gender (female,  0; 
male,  1).   Here, the  Manhatan representation  of  p-values for each  metabolite from 
regression analysis and the  Bonferroni threshold indicate significant associations 
between  metabolites and transplantation status, age,  Cystagon  dosage,  gender, and 
GFR. 
Increases in creatinine excretion folowing transplantation match expectations 
of increased creatinine clearance, and reductions in  TMAO levels relative to  pre-
transplant fit with observations of accumulating TMAO produced in end stage renal 
disease as a counter-osmolyte  by the renal  medula [281] and changes in  TMAO 
excretion  during transplantation folow-up [217,  282].  Interestingly,  TMAO and 
carnitine excretion  was associated  with  gender as  higher levels  were  observed in 
males.  It is  known that  L-carnitine is  metabolized to  TMAO  by the  gut  microflora 
[283-285],  which could explain the association  between carnitine and  TMAO.   The 
efect of L-carnitine supplementation on renal physiology and the cause of increased 
L-carnitine levels in males, however, is an area for further inquiry.  
Hypotaurine and tartrate, excreted  metabolites  of cysteamine-bitartrate 
(Cystagon), would be expected to associate with prescribed Cystagon dosage. While 
there is a  positive correlation  between  hypotaurine and tartrate excretion and 
Cystagon dosage, this association is not significant. Interestingly, it is the TCA cycle 
intermediates succinate and citrate that are significantly associated  with  Cystagon 
dosage.   While citrate is supplemented to some cystinosis  patients, lower succinate 
excretion with increased Cystagon dose suggests a reduction in  mitochondrial stress 
in the renal tubule with cysteamine therapy. Citrate and tartrate are both significantly 
corelated with GFR, and cysteamine therapy has been shown on several occasions to 
promote  maintenance  of  glomerular function and  postpone transplantation [237, 
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240,242]. Interestingly, no single metabolites were significantly associated with age 
after corection for the other variables, despite the relatively high fit of age to urinary 
metabolic profiles overal (Figure 5.8). This, together with the significant corelations 
of age with transplantation status, Cystagon dose, and GFR suggest that the efects of 
age  on the cystinosis  urinary  metabolic  profile are  due to changes in  other factors 
corelated with age rather than growth and development alone.  
 
 
 
Figure 5.12. Changes in key urinary metabolites by time from transplantation. Mean values (dark line) 
and standard error of the  mean (SEM, lighter region) for glucose (blue), TMAO (red), and succinate 
(magenta) show differing trajectories over time from 13 years pre-transplant to 7 years post-transplant. 
A dashed black line indicates the period between the last pre-transplant sample and first post-transplant 
sample.  
 
In order to investigate the changes in key metabolic parameters, mean glucose, 
TMAO and succinate levels were compared by time before and after transplantation 
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for the (N=9) cystinosis patients for whom both pre- and post-transplantation samples 
were available.  As urine samples were colected during routine visits that were not 
necessarily scheduled at fixed intervals, time from transplantation was rounded to the 
nearest  year to compare  between individuals.   Figure  5.12 shows  mean (dark lines) 
and standard eror  of the  mean (SEM, lighter regions) for  glucose,  TMAO, and 
succinate levels over the range of times from transplantation captured over the natural 
history study.   Glucose levels show  gradual increase from  8  years  before 
transplantation and a slow decline folowing transplantation, and are characterized by 
high  variation  between individuals at al time  points  both  before and after 
transplantation.  TMAO excretion is  high pre-transplant,  but  drops immediately and 
shows low  variance folowing transplantation.   Succinate excretion is  high long 
before transplantation  but  drops in the  years approaching renal failure and 
transplantation.  Interestingly, succinate excretion climbs folowing transplantation 
before declining to the low levels seen immediately pre-transplant. Figure 5.13 shows 
these trends represented in the urinary NMR signals of these metabolites from a single 
patient  preceding and folowing transplantation.   Again, the  notable characteristics 
include a  gradual  decline in  glucose excretion, a rapid  drop in  TMAO, and  pre-
transplant declines in succinate excretion folowing by a post-transplant spike.  
These results suggest a  model for renal tubular  damage in  nephropathic 
cystinosis characterized  by early  mitochondrial stress leading to elevations in  TCA 
cycle intermediates.   Associations  between  TCA  metabolite excretion and  Cystagon 
dosage suggest that cysteamine therapy  may retard  or  mitigate this  process.   As 
mitochondrial  pathology leads to energetic stress in the renal tubule, the activity  of 
transporters in the  proximal renal tubule  declines, resulting in increases in solute 
excretion including highly corelated losses of glucose, lactate, and amino acids. The 
decreases in succinate excretion observed approaching transplantation could suggest 
the  majority  of  mitochondrial stress in the renal tubule  occurs early, leaving lower 
levels  of  TCA cycle  metabolites remaining to  be lost  by the tubule.   TMAO levels, 
indicating counter-osmotic action  by the  kidney and  potential  metabolism from  L-
carnitine,  drop folowing transplantation,  but  native  kidneys  not surgicaly removed 
continue to lose lower levels of transporter substrates into the urine.  An interesting 
line  of further investigation  would  be  whether the  post-transplant spike in succinate 
excretion indicates  proximal tubular  damage to the transplanted  kidneys  or residual 
excretion from the native kidneys. 
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Figure 5.13. Urinary NMR signals of glucose, TMAO and succinate over time from a single cystinosis 
patient.   Urinary  NMR spectra  over a  defined chemical shift range showing  glucose (blue),  TMAO 
(red), and succinate (magenta) show changes in the excretion  of these metabolites at different patient 
ages.  A  dashed  black line indicates the  period  between the last  pre-transplant sample and first  post-
transplant sample.  
 
5.3.3 Animal studies of nephrotoxin exposure 
 
For the past twenty years, toxicological studies in animals have been a major 
source  of information connecting changes in  metabolic  profiles  with  organ- and 
tissue-specific  pathology [161,  231,  233,  286, 287].   Comparative  metabolomics 
studies of large numbers of toxins have shown that it is possible to identify toxicity to 
specific regions in the  kidney and liver  on the  basis  of  urinary  metabolic  profiles 
[234]. In order to help interpret the urinary metabolic perturbations identified in the 
human congenital  kidney  diseases, animal  urinary  metabolic  profiles colected 
folowing exposure to three  model  nephrotoxins – cisplatin,  mercuric chloride 
(HgCl2), and  2-bromoethanamine (BEA) – studied as  part  of the  Consortium for 
Metabonomic  Toxicology [249,  250]  were re-analyzed according to the  methods 
applied to the human disorders.  
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Cisplatin is an alkylating antineoplastic agent [288] that is  known to cause 
acute renal failure  when exposed in  high  dosesand  has  been shown to inhibit faty 
acid  oxidation and the  pyruvate  dehydrogenase complex [289].   Mercuric chloride 
exposure has been shown to increase reactive oxygen species [290, 291] and result in 
oxidative stress and  nephrotoxicity [292].   Both cisplatin and  mercuric chloride 
induce acute tubular necrosis and lesions in the proximal tubule [234] and have been 
shown to  produce  Fanconi-like  urinary excretion  of  glucose and amino acids in 
animals [161,  233,  293].  Interestingly,  while  heavy-metal toxicity  does cause renal 
tubular  damage in  humans, the  major effect  of cisplatin toxicity in  humans is 
glomerular failure rather than tubular  damage [294].   2-bromoethanamine (BEA) 
induces necrosis of the renal papila and has been shown to affect the epithelial cels 
of the colecting  duct and  papila [295].   Figure  5.14 shows the  urinary  metabolic 
changes in animals exposed to these model nephrotoxins over the ful time-course of 
sample colection in the COMET protocol (see 5.2.2.3). 
These results show that both cisplatin and mercuric chloride induce significant 
urinary loss  of  glucose, lactate, and amino acids similar to that  observed in the 
congenital Fanconi Syndromes. Interestingly, many of these solutes are also excreted 
by BEA exposed animals at a level significantly higher than controls, though less than 
cisplatin and HgCl2 exposed animals. BEA exposed animals do not show significant 
diferences from controls in  glutamine and  glycine excretion, and  glycine excretion 
by cystinosis  patients showed  much lower corelations to  glucose, lactate, and the 
other amino acids characteristic of FS. Similar paterns are observed for acetate and 
creatine excretion,  with significant elevations especialy  by  HgCl2 exposed animals. 
Interestingly,  while  TMAO levels  were elevated in cisplatin and  HgCl2 exposed 
animals, significant changes in  TMAO levels  were  not  observed in  BEA exposed 
animals.   Of the  metabolites  which showed significantly altered  urinary excretion 
folowing toxin exposure, BEA exposed animals showed increased excretion of only 
methylamine and acetone relative to cisplatin and HgCl2. Methylamine was observed 
to be significantly elevated in cystinosis patients relative to both ADFS1 and ADFS2 
patients as wel as to controls. 
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Figure  5.14.  Urinary excretion  of  metabolites significantly altered in animals exposed to  model 
nephrotoxins relative to controls. White bars reflect values from control animal (N=30) at al 8 post-
dose time points. Black bars show dosed animals (cisplatin, N=10; HgCl2, N=10; BEA, N=10).  The 
height of the bars is the  mean of the log10 ratio of the  metabolites shown to CRN. Error bars, SEM; 
*P<0.05,  **P<0.005,  ***P<0.0005,  unpaired t-test,  Benjamini-Hochberg  FDR correction. 
Abbreviations:  TMAO, trimethylamine-N-oxide;  Carn, carnitine;  DMA,  dimethylamine;  MA, 
methylamine; DMG, dimethylglycine; Suc, succinate; Fum, fumarate; Pb, proline-betaine.  
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The  TCA cycle intermediates citrate, succinate and fumarate showed 
significantly  greater reductions in excretion levels in  HgCl2 relative to cisplatin 
exposed animals.   While  overal reductions in  both citrate and fumarate levels for 
cisplatin and  HgCl2 exposed animals  does  not fit  with  observations  of increased 
excretion  of  TCA cycle intermediates at  peak toxicity, analysis  of the time-course 
excretion of glucose, TMAO, and succinate (Figure 5.15) indicates that both cisplatin 
and  HgCl2 exposed animals show increases in succinate excretion folowed  by 
declines, similar to the increase and decline seen in pre-transplant cystinosis patients. 
The timing of these changes, however, difers between cisplatin and HgCl2 exposed 
animals. Cisplatin toxicity appears to result in an early increase in succinate excretion 
between  0-48  hours  post-dose folowed  by a reduction that coincides  with the 
maximal excretion of glucose and TMAO between 90-120 hours postdose, while peak 
succinate excretion resulting from  HgCl2 exposure coincides  with  peak  glucose and 
TMAO excretion at 24 hours.  
The  observations  of  Fanconi-like excretion  of  glucose, lactate, and amino-
acids as wel as increased excretion of TMAO and increases and subsequent declines 
in the excretion  of  TCA cycle intermediates resulting from acute renal failure in 
cisplatin exposed animals  match the  urinary  metabolic  profile  of the congenital 
Fanconi Syndromes and the changes in the cystinosis urinary profile over the natural 
history  of the  disease.   Cisplatin exposure  has  been  demonstrated to result in 
inhibition  of  medium chain acyl-CoA  dehydrogenase and  pyruvate  dehydrogenase 
before the  onset  of acute tubular  necrosis [289],  which is ameliorated  by treatment 
with  L-carnitine and PPARα ligands Wy-14643 and fibrate [289,  293].    The 
similarity  of these  metabolic  profiles and  previous evidence  of energetic stress in 
models of cystinosis [260-262] suggest this may play a role in the development of FS 
in cystinosis patients.  
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Figure  5.15. Trajectories  of  key  metabolites  over  nephrotoxin exposure time-course.   Mean  values 
(dark line) and standard error of the mean (SEM, lighter region) for glucose (blue), TMAO (red), and 
succinate (magenta) ratios vs. CRN show differing trajectories over time from 16 hours pre-dose to 168 
hours post-dose for cisplatin (left), HgCl2 (center), and BEA (right).  
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5.4 Conclusions 
 
  Urinary  metabolic  profiling  has  become an increasingly important tool in 
nephrology and metabolomics studies have made significant contributions, especialy 
to the toxicological [161,  221-224] and transplantation literature [217,  231,  232]. 
Metabolic  profiling  of  Dent’s  disease  and  the  Oculocerebrorenal Syndrome of Lowe 
[23] and  Autosomal  Dominant  Polycystic  Kidney  Disease (ADPKD) [24]  have 
demonstrated characteristic  urinary  metabolic  profiles resulting from  genetic 
mutations afecting the  kidney.   While it  has  previously  been suggested that 
metabolomics studies of inborn errors of  metabolism may aid toxicological research 
[235] by helping identify metabolic profiles characteristic of disruption to individual 
metabolic  pathways, the results shown  here suggest that the study  of  model 
nephrotoxins  may  help interpret the  urinary  metabolic  profiles  of  patients  with 
congenital kidney diseases. 
Unlike simple enzyme  or transporter  deficiencies for  which the  metabolic 
consequences  of  genetic  mutations are easily interpreted,  many  of these  disorders 
show a complex set of organ-specific and systemic phenotypes that both vary between 
individuals and change  over time.   As a result, comparisons  between the  metabolic 
profiles of animals exposed to nephrotoxins with known mechansims of toxicity and 
multiple related forms of congenital disorders wil likely help clarify mechanisms of 
pathology for these  more complex  genetic traits and  may suggest interventions to 
mitigate the  progression  of these  diseases.   While these  disorders are rare, the 
increasingly routine use of whole-exome and whole-genome sequencing in the clinic 
[296] together  with  more traditional  GWAS and linkage analysis  means that  new 
genetic disorders are being discovered at a rapid pace. As a result, comparisons of the 
metabolic and  biochemical changes  observed in smal  numbers  of  patients  over an 
increasingly  broad set  of  overlapping clinical  phenotypes  wil likely aid  both the 
understanding  of  gene function and  help  diagnose and treat  patients  with  genetic 
disorders.  
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CHAPTER 6 
CONCLUSIONS AND FUTURE WORK 
 
6.1 Conclusions from thesis 
 
The  work  presented in this thesis applies  metabolic  profiling technologies, 
including  Nuclear  Magnetic  Resonance and  Mass  Spectrometry, to identify the 
metabolic effects  of  genetic  mutations.   This  work focused  primarily  on identifying 
metabolic  markers resulting from the  biochemical  genetics  of  human  diseases, 
including inborn erors of metabolism and congenital diseases of the kidney, but also 
makes comparisons to  data colected from  model  organisms.   Additionaly,  new 
methods for applying metabolic profiling to clinical populations that mitigate some of 
the chalenges involved in biochemical genetics, such as smal sample sizes, unknown 
or  novel chemical structures, and the chalenge  of  providing  broader  metabolomic 
coverage,  were  developed and  presented  here.   As a result, the  work  presented 
investigates several aspects of biomarker discovery by applying metabolic profiling in 
biochemical genetics.  
 
6.1.1 2D NMR Metabolic profiling in biochemical genetics 
 
In  Chapter  3 the chalenges  of structural characterisation  of  unknown  or 
unexpected metabolites, spectral resolution, and smal sample sizes were addressed by 
applying  2D 1H-1H  NMR techniques to  profile the  metabolomes  of two  nematode 
species, C. elegans  mutant strains, and congenital  Fanconi syndrome in a single 
human pedigree. Due to the lack of computational approaches to the analysis of 2D 
NMR  data,  methods for signal  detection, alignment,  patern recognition and 
visualization were developed and presented.  These methods, including  Hierarchical 
Alignment  of  Two-Dimensional  Spectra and  Patern  Recognition (HATS-PR) [94] 
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and multivariate Differential Analysis by 2D NMR Spectroscopy (mvaDANS) [102] 
were applied to identify accumulating  very long-chain ascarosides as a result  of a 
peroxisomal β-oxidation  defect in C. elegans and elevated  urinary excretion  of 
proximal tubular transporter substrates and  TCA cycle intermediates resulting from 
mistraficking  of a  peroxisomal β-oxidation  protein to the  mitochondria in a single 
human  pedigree.   These results suggest  2D  NMR  wil  be an important tool for 
metabolic profiling when a premium is placed on structural charactization in complex 
metabolic mixtures. 
 
6.1.2 Metabolic profile screening and biomarker identification for inborn errors 
of metabolism 
 
Chapter 4 compared tandem mass-spectrometry (MS/MS) and nanospray high 
resolution  mass spectrometry (nS-HR-MS) analysis  of  DBS samples for  6,050 
unafected and  102  newborns affected  by  24 congenital  disorders  of  metabolism. 
While broader coverage of the metabolome may ofer increased diagnostic sensitivity 
and specificity in  newborn screening  programs, the trade  off  between analytical 
specificity and coverage  between  MS/MS and  nS-HR-MS  meant that for the 
population  of  phenylketonuria (PKU) and  medium-chain-acyl-CoA  dehydrogenase 
deficiency (MCADD)  patients screened in this  work  diagnostic sensitivity and 
specificity were roughly comparable. However, for both methods logistic regression 
models outperformed cutof-based diagnostics. It is possible that more advanced non-
linear,  non-parametric  machine learning  methods such as random forests,  neural 
networks,  or support-vector  machines  may  perform even  beter,  but these  methods 
tend to  be  unstable  with low sample sizes and as a result  much larger affected 
populations  would  need to  be screened to investigate the application  of these 
techniques.   The  broader coverage  provided  by  nS-HR-MS  did improve  biomarker 
identification however, as shunt metabolites in the phenylalanine metabolic pathway 
and faty acids and  glycine conjugated faty acids  were identified in the  PKU and 
MCADD populations by nS-HR-MS that were not measured by MS/MS. While low 
numbers of afected neonates limited the investigation of the metabolic consequences 
for the other 20 inborn erors for which samples were available, outlier identification 
relative to the control  population and the  other  diseases suggested that  greater 
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metabolic coverage and comparative investigation of a large set of inborn errors could 
provide important insight into the mechanisms of these diseases.  
 
6.1.3 Metabolomic investigation of congenital diseases of the kidney 
 
While biochemical genetics in clinical populations is typicaly associated with 
enzyme  deficiencies,  many  Mendelian  diseases result in complex,  progressive 
pathology that can have individual organ or systemic efects. The work presented in 
Chapter 5 compares the urinary metabolic profiles of four congenital diseases of the 
kidney with overlapping phenotypes and investigates the metabolic natural history of 
one of these diseases, cystinosis.  Additionaly, the human urinary  perturbations are 
compared to  data colected from  previous animal studies  of exposure to region 
specific  model  nephrotoxins.   These identify the  main characteristics  of  proximal 
tubular  pathology in  both  humans and animals, in  which  TCA cycle  disruption is 
folowed by loss of proximal tubular transporter substrates and an increase in markers 
of renal stress.   These results  both associate  urinary  metabolic  profiles  with region 
specific renal pathology and suggest connections with the mechanisms of pathology. 
The metabolic associations with transplantation, glomerular filtration-rate (GFR), and 
cysteamine therapy in cystinosis  may also  have ramifications for  patient care, 
especialy as  TCA cycle  disruption appears associated  with  decreased  GFR and is 
mitigated by cysteamine therapy. Comparative metabolic profiling between diseases 
with overlapping phenotypes such as those presented here may play an important role 
in the study of complex Mendelian traits.  
 
6.1.4 General conclusions and scope for extending this work 
 
  The  work  presented in this thesis, together  with the rich literature  on  NMR 
and  MS  profiling  of inborn errors and  QTL analysis suggests an important and 
growing role for  metabolic  profiling in  biochemical  genetics.   The identification  of 
accumulating  very-long-chain ascarosides in C. elegans  mutants and elevated  TCA 
cycle intermediates in Fanconi syndrome patients both show how metabolic profiling 
can help annotate the function of genes or mutations of unknown function and provide 
context  on the  mechanism and  development  of  distinct  phenotypes.   Metabolic 
profiling, typicaly  by targeted  quantification  of a smal  number  of  metabolites in 
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urine  or  blood, already  plays a large role in  medicine,  but expanding the analytical 
coverage of the metabolome in these tests could enhance diagnostics and selection of 
therapeutics in stratified or personalized medicine in the future. The identification of 
an expanded set  of  metabolic  biomarkers  of inborn errors  by an assay  with  broader 
metabolomic coverage  wil at least  provide a  beter  perspective  on  metabolic 
processes in  health and  disease.  It is likely that larger studies  wil also show 
diagnostic improvements resulting from broader coverage.  
  While the studies  presented  here  provide  useful  data for the  phenotypes 
investigated and broader context about the uses of metabolic profiling in biochemical 
genetics, these results are limited in their scope  by the smal  numbers  of afected 
individuals included in these studies.   This is  unsurprising  given  how rare these 
conditions are, and the cystinosis results in  particular indicate the additional  power 
available to larger cohort studies.   While comparisons across  phenotypes and  with 
controls enable improved biomarker discovery and interpretation, larger sample sets 
such as those available to  national  newborn screening  programs and clinical trials 
could provide greater statistical power. Greater numbers of affected patient samples 
would be particularly beneficial in the analysis of inborn erors. Large, international 
colaborations  between screening centers that alow a large  number  of cases  of 
individualy rare diseases to be colected may be promising.  
Besides an increased number of affected samples, investigating a broader set 
of diseases would be an interesting area of further exploration as wel. In the case of 
congenital  kidney  diseases,  comparison  with  related  diseases  such  as  Dent’s  disease,  
the  Oculocerebrorenal  Syndrome  of  Lowe,  polycystic  kidney  disease, and  diseases 
related to individual transporters such as cystinuria, iminoglycinuria, and  Hartnup 
disease could  help resolve the effects  of loss  of tubular transporter activity from 
broader renal stress and alow greater resolution of the metabolic profiles associated 
with individual renal structures.  The scope for an expanded set  of inborn erors  of 
metabolism is  potentialy even  greater, as the  map  of  known  genes associated  with 
Mendelian  phenotypes (Fig.  1.2) indicates.   These expanded studies  wil require 
adoption of screeningtechnologieswith broader coverage or improved bio-banking in 
rare disease research and medicine. 
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6.2Future directions of metabolic profiling in biochemical genetics 
 
Metabolomics,  despite several  decades  of  development, is stil a relatively 
young field  with substantial room for  growth in terms  of  methodology, 
standardization, and adoption.   Routine application  of  metabolic  profiling in a  non-
research seting is  hindered  by the absence  of a single analytical  platform for 
metabolome analysis, the specialized  knowledge required to interpret spectral  data 
and identify  biomarker chemical structures, and  uncertainty regarding  both 
interpretation  of  metabolome-wide  data and the  protection and  management  of 
resulting information.   Advances in instrumentation, informatics, and analytics 
software wil be necessary to resolve these outstanding chalenges [120]. 
While the development  of a highly sensitive and specific analytical  platform 
that accurately measures a substantial fraction of the metabolome would solve many 
of these chalenges, in the near term NMR and MS wil likely continue to be applied 
in  paralel and in conjunction.   Metabolic  profiling studies  would  benefit from 
improved integration  of  NMR and  MS  data as these techniques are complementary 
and both are often required for metabolite identification. Identification of metabolites 
wil  depend  on the  development  of improved  bioinformatic resources, including 
spectral databases.  However, targeted assays and improved databases wil stil miss 
the  presence  of  novel  or  unexpected  metabolites, such as shunt  metabolites. 
Acceleration and automation  of the identification  process remains the  major 
botleneck,  both  because  of limitations  described above, and  perhaps  more 
importantly,  because  of the  great chemical  diversity in  metabolism.   Protocols for 
rapid identification  of  metabolite structures  wil enhance  untargeted  metabolic 
profiling in the near term. 
As a result, continued  development  of  both analytical and computational 
methods in  metabolomic research are critical for the  widespread adoption  of these 
techniques. New institutional programs wil play an important role in translating the 
methodology  of  metabolic  phenotyping and  developing improved tools and 
procedures  for  the  colection  and  analysis  of  metabolic  profile  and  related  ‘omics data 
to support clinical  decision-making through the framework  of systems  medicine 
Large scale  metabotyping for  populations  wil  yield increasing  power to the 
identification  of  metabolic  perturbations in  disease and alow  more sensitive and 
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specific classification of disease states on the basis of metabolic changes in biofluids. 
Just as the increased availability  of  human  genome sequence  data is  providing 
important context for identifying  disease associated  variants, the availability  of 
metabolic data on large populations wil increasingly characterize normal ranges for 
reference in identifying  outliers and abnormal  metabolic  profiles.   Fulfiling the 
promise  of  metabolic  profiling in systems  medicine awaits the  day  when 
comprehensive  measurement  of  biological  variables, including  gene sequences, 
epigenetic  modifications, expression and translation levels, and  metabolite 
abundances are routine and this data is widely available.  
Genomics is curently  undergoing  yet another revolution as  next-generation 
sequencing technologies increase accuracy, coverage, read-length, and  drasticaly 
decrease the cost of whole exome sequencing (WES) and whole genome sequencing 
(WGS).   The introduction  of third-generation sequencing technologies in the  near 
future promises to continue this trend [297]. Consequently, the near term promises a 
dramatic expansion in the availability of sequence data both in the lab and clinic. The 
relevance of increased sequence data to the continued integration of metabonomic and 
genomic data is twofold: first, an opportunity for metabonomics to contribute to the 
increased  clinical  presence  of  ‘omics  sciences  led  by  genome  sequencing,  and  second,  
a chalenge to  develop  methods  of integrating  metabolic  profiles  with sequences 
rather than polymorphisms.  
Despite the significant opportunity represented by low-cost sequencing for the 
integration  of  genomic and  metabonomic  data and the identification  of  gene-
metabolite associations, several chalenges stand in the way of routine paired analysis 
of sequences and metabolic profiles. The first of these is the chalenge of discovering 
significant associations with low sample numbers. Many of the successes reported in 
clinical sequencing  have  made  use  of  data from a smal  number  of  patients, and 
sometimes only a sole patient.  In these cases, potentialy disease-causative variants 
are often identified using filtering strategies rather than statistical analysis [130, 298]. 
While the  diagnosis  of  human inborn erors  of  metabolism from single  patient 
biofluid NMR spectra demonstrates the potential of metabolic profiling to work with 
low  sample  numbers,  lack  of  statistical  validation  means  that  the  “biological  signal”  
in these cases  must  be  quite  marked.   A second chalenge is a  dearth  of tools for 
statistical analysis  of sequence  data.   While  QTL  mapping  using single  nucleotide 
polymorphisms is wel established, statistical techniques for QTL mapping with both 
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rare and common  variants are just  beginning to  be introduced [299].   As in 
metabolomics, the continued  development  of analytical and computational  methods, 
combined with institutional initiatives that expand data colection and access wil be 
necessary to overcome these chalenges.  
Of  the  ‘omics  sciences,  genomics  and  metabolomics  are  uniquely  
complementary, the strengths of each addressing weaknesses of the other. Genes are 
(mostly)  static,  an  “upstream”  blueprint  controling  dynamic  biological  processes.    
The  identities  and  quantities  of  “downstream”  metabolites  capture  both  genetic  and  
environmental influences, and can be measured serialy to assess variation through 
time. Genomic studies often struggle to establish a firm link between genetic variants 
and phenotypic observations, and while metabonomics provides a closer proxy to 
phenotype it is often dificult to infer underlying causality from variations in 
metabolism. Together, the integrated application of genomics and metabonomics 
promises a bridging of the gap between genotype and phenotype through intermediate 
metabolism to help annotate genes of unknown function, genetic controls of 
metabolism, and mechanisms of disease. 
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120. Robinette   SL,   Brü schweiler   R,   Schroeder   FC,   Edison   AS:  NMR in 
Metabolomics and Natural Products Research: Two Sides of the Same 
Coin.Acc Chem Res 2011, 45(2):288–297.. 
121.  Smith  CA,  O'Maile  G,  Want  EJ,  Qin  C,  Trauger  SA,  Brandon  TR,  Custodio 
DE,  Abagyan  R,  Siuzdak  G: METLIN:  a  metabolite  mass spectral 
database.Ther Drug Monit 2005, 27:747-751. 
122.  Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, Cheng D, Jewel K, 
Arndt D, Sawhney S, Fung C, Nikolai L, Lewis M, Coutouly M-A, Forsythe I, 
Tang P, Shrivastava S, Jeroncic K, Stothard P, Amegbey G, Block D, Hau DD, 
Wagner J, Miniaci J, Clements M, Gebremedhin M, Guo N, Zhang Y, Duggan 
GE, MacInnis GD, Weljie AM, Dowlatabadi R, Bamforth F, Clive D, Greiner 
R, Li L, Marrie T, Sykes BD, Vogel HJ, Querengesser L: HMDB: the Human 
Metabolome Database.Nucleic Acid Res 2007, 35:D521-526. 
123.  Xia J, Psychogios N, Young N, Wishart DS: MetaboAnalyst: a web server 
for  metabolomic  data  analysis  and interpretation.Nucleic  Acid 
Res2009, 37:W652-660. 
124.  Nicholson JK,  Wilson ID: High-resolution  proton  magnetic-resonance 
spectroscopy of biological fluids.Prog Nucl Magn Reson Spectrosc 1989, 
21:449–501. 
125.  Nicholson JK,  Connely J,  Lindon JC,  Holmes  E: Metabonomics:  a 
platform for studying  drug toxicity  and  gene function.Nat  Rev  Drug 
Discov2002, 1:153-161. 
 161 
126.  Schroeder FC, Gibson DM, Churchil ACL, Sojikul P, Wursthorn EJ, Krasnof 
SB,  Clardy J: Diferential  analysis  of  2D  NMR spectra:  new  natural 
products from a pilot-scale fungal  extract library.Angew Chem Int Ed 
Engl 2007, 46:901-904. 
127.  Behrends  V,  Ebbels  TMD,  Wiliams  HD,  Bundy JG: Time-resolved 
metabolic footprinting for nonlinear modeling of bacterial substrate 
utilization.Appl Environ Microbiol 2009, 75:2453-2463. 
128.  Fuchs S, Bundy JG, Davies SK, Viney JM, Swire JS, Leroi AM: A metabolic 
signature of long life in Caenorhabditis elegans.BMC Biol 2010, 8:14. 
129. Izrayelit  Y,  Srinivasan J,  Campbel  SL, Jo  Y,  von  Reuss  SH,  Genof  MC, 
Sternberg  PW,  Schroeder  FC: Targeted  metabolomics reveals  a  male 
pheromone  and sex-specific  ascaroside  biosynthesis in 
Caenorhabditis elegans.Acs Chem Biol 2012, 7:1321-1325. 
130.  Bamshad  MJ,  Ng  SB,  Bigham  AW,  Tabor  HK,  Emond  MJ,  Nickerson  DA, 
Shendure J: Exome sequencing  as  a tool for  Mendelian  disease  gene 
discovery.Nat Rev Genet 2011, 12:745-755. 
131.  Pungaliya C, Srinivasan J, Fox BW, Malik RU, Ludewig AH, Sternberg PW, 
Schroeder  FC: A shortcut to identifying smal  molecule signals that 
regulate  behavior  and  development in  Caenorhabditis  elegans.Proc 
Natl Acad Sci USA2009, 106:7708-7713. 
132.  Van QN, Issaq HJ, Jiang Q, Li Q, Muschik GM, Waybright TJ, Lou H, Dean M, 
Uitto J, Veenstra TD: Comparison of 1D and 2D NMR spectroscopy for 
metabolic profiling.J Proteome Res 2008, 7:630-639. 
133. Madsen  R,  Lundstedt  T,  Trygg J: Chemometrics in  metabolomics--a 
review in human disease diagnosis.Anal Chim Acta 2010, 659:23-33. 
134.  Koradi  R,  Bileter  M,  Engeli  M,  Güntert  P,  Wüthrich  K: Automated  peak 
picking and peak integration in macromolecular NMR spectra using 
AUTOPSY.J Magn Reson 1998, 135:288-297. 
135.  Wong JWH,  Durante  C,  Cartwright  HM: Application  of fast  Fourier 
transform  cross-correlation for the  alignment  of large 
chromatographic  and spectral  datasets.Anal  Chem2005, 77:5655-
5661. 
136.  Thompson JD,  Higgins  DG,  Gibson  TJ: CLUSTAL  W: improving the 
sensitivity  of  progressive  multiple sequence  alignment through 
sequence  weighting,  position-specific  gap  penalties  and  weight 
matrix choice.Nucleic Acid Res 1994, 22:4673-4680. 
137.  Cloarec O, Dumas M-E, Craig A, Barton RH, Trygg J, Hudson J, Blancher C, 
Gauguier  D,  Lindon JC,  Holmes  E,  Nicholson J: Statistical total 
correlation spectroscopy:  an  exploratory  approach for latent 
biomarker identification from  metabolic  1H  NMR  data sets.Anal 
Chem2005, 77:1282-1289. 
138.  Hedenstrom  M,  Wiklund  S,  Sundberg  B,  Edlund  U: Visualization  and 
interpretation  of  OPLS  models  based  on  2D  NMR  data.Chemometr 
Intel Lab 2008, 92:110-117. 
139.  Hedenström  M,  Wiklund-Lindström  S,  Oman  T,  Lu  F,  Gerber  L,  Schatz  P, 
Sundberg  B,  Ralph J: Identification  of lignin  and  polysaccharide 
modifications in Populus wood by chemometric analysis of 2D NMR 
spectra from dissolved cel wals.Mol Plant 2009, 2:933-942. 
 162 
140.  Shaka  A,  Lee  AJ,  Pines  CJ: Iterative  Schemes for  Bibear  Operators; 
Application to Spin Decoupling.J Magn Reson 1988, 77:274–293. 
141. Jones KT, Ashrafi K: Caenorhabditis elegans as an emerging model for 
studying the basic biology of obesity.Dis Model Mech 2009, 2:224-229. 
142.  McKay  RM,  McKay JP,  Avery  L,  Graf JM: C  elegans:  a  model for 
exploring the genetics of fat storage.Dev Cel 2003, 4:131-142. 
143.  Chandler  RJ,  Aswani  V,  Tsai  MS,  Falk  M,  Wehrli  N,  Stabler  S,  Alen  R, 
Sedensky  M,  Kazazian  HH,  Venditti  CP: Propionyl-CoA  and 
adenosylcobalamin metabolism in Caenorhabditis elegans: evidence 
for  a role  of  methylmalonyl-CoA  epimerase in intermediary 
metabolism.Mol Genet Metab 2006, 89:64-73. 
144.  Kenyon CJ: The genetics of ageing.Nature 2010, 464:504-512. 
145.  Butcher RA, Ragains JR, Li W, Ruvkun G, Clardy J, Mak HY: Biosynthesis 
of the  Caenorhabditis  elegans  dauer  pheromone.Proc  Natl  Acad  Sci 
USA2009, 106:1875-1879. 
146.  von  Reuss  SH,  Bose  N,  Srinivasan J,  Yim J, Judkins JC,  Sternberg  PW, 
Schroeder  FC: Comparative  metabolomics reveals  biogenesis  of 
ascarosides,  a  modular library  of smal-molecule signals in  C. 
elegans.J Am Chem Soc 2012, 134:1817-1824. 
147.  Singh I, Moser AE, Goldfischer S, Moser HW: Lignoceric acid is oxidized 
in the  peroxisome: implications for the  Zelweger  cerebro-hepato-
renal syndrome  and  adrenoleukodystrophy.Proc  Natl  Acad  Sci  USA 
1984, 81:4203-4207. 
148.  Wanders  RJA,  Waterham  HR: Biochemistry  of  mammalian 
peroxisomes revisited.Annu Rev Biochem 2006, 75:295-332. 
149.  Wang SS, Fernhof PM, Hannon WH, Khoury MJ: Medium chain acyl-CoA 
dehydrogenase  deficiency  human  genome  epidemiology 
review.Genet Med 1999, 1:332-339. 
150.  Goldfischer  S,  Colins J,  Rapin I,  Neumann  P,  Neglia  W,  Spiro  AJ, Ishi  T, 
Roels  F,  Vamecq J,  Van  Hoof  F: Pseudo-Zelweger syndrome: 
deficiencies in several peroxisomal oxidative activities.J Pediatr 1986, 
108:25-32. 
151.  Watkins PA, Chen WW, Harris CJ, Hoefler G, Hoefler S, Blake DC, Balfe A, 
Keley  RI,  Moser  AB,  Beard  ME: Peroxisomal  bifunctional  enzyme 
deficiency.J Clin Invest 1989, 83:771-777. 
152.  van  Grunsven  EG,  van  Berkel  E,  Mooijer  PA,  Watkins  PA,  Moser  HW, 
Suzuki  Y, Jiang  LL,  Hashimoto  T,  Hoefler  G,  Adamski J,  Wanders  RJ: 
Peroxisomal  bifunctional  protein  deficiency revisited: resolution  of 
its true  enzymatic  and  molecular  basis.Am J  Hum  Genet 1999, 64:99-
107. 
153.  Ferdinandusse S, van Grunsven EG, Oostheim W, Denis S, Hogenhout EM, 
IJlst  L,  van  Roermund  CWT,  Waterham  HR,  Goldfischer  S,  Wanders  RJA: 
Reinvestigation  of  peroxisomal  3-ketoacyl-CoA thiolase  deficiency: 
identification  of the true  defect  at the level  of  d-bifunctional 
protein.Am J Hum Genet 2002, 70:1589-1593. 
154.  Ferdinandusse S, Denis S, Overmars H, Van Eeckhoudt  L, Van Veldhoven 
PP, Duran M, Wanders RJA, Baes M: Developmental changes of bile acid 
composition and conjugation in L- and D-bifunctional protein single 
and  double  knockout  mice. In Developmental changes  of  bile  acid 
 163 
composition  and conjugation in  L- and  D-bifunctional  protein single  and 
double  knockout  mice,  vol.  280.  pp.  18658-18666.  City;  2005:18658-
18666. 
155.  Kaletta T, Hengartner MO: Finding function in novel targets: C. elegans 
as a model organism.Nat Rev Drug Discov 2006, 5:387-398. 
156.  Dow JAT,  Romero  MF: Drosophila  provides rapid  modeling  of renal 
development, function,  and  disease.Am J  Physiol  Renal  Physiol 2010, 
299:F1237-1244. 
157.  Kamleh  MA,  Hobani  Y,  Dow JAT,  Zheng  L,  Watson  DG: Towards  a 
platform for the  metabonomic  profiling  of  diferent strains  of 
Drosophila  melanogaster  using liquid  chromatography-Fourier 
transform mass spectrometry.FEBS J 2009, 276:6798-6809. 
158.  Gahl WA, Kaiser-Kupfer MI: Complications of nephropathic cystinosis 
after renal failure.Pediatr Nephrol 1987, 1:260-268. 
159.  Nissim I, Weinberg JM: Glycine attenuates Fanconi syndrome induced 
by maleate or ifosfamide in rats.Kidney Int 1996, 49:684-695. 
160.  Tolaymat A, Sakarcan A, Neiberger R: Idiopathic Fanconi syndrome in a 
family. Part I. Clinical aspects.J Am Soc Nephrol 1992, 2:1310-1317. 
161.  Nicholson JK,  Timbrel JA,  Sadler  PJ: Proton  NMR spectra  of  urine  as 
indicators  of renal  damage.  Mercury-induced  nephrotoxicity in 
rats.Mol Pharmacol 1985, 27:644-651. 
162.  Bourgeron  T,  Chretien  D,  Poggi-Bach J,  Doonan  S,  Rabier  D,  Letouzé  P, 
Munnich  A,  Rötig  A,  Landrieu  P,  Rustin  P: Mutation  of the fumarase 
gene in two siblings with progressive encephalopathy and fumarase 
deficiency.J Clin Invest 1994, 93:2514-2518. 
163.  Barshop  BA: Metabolomic  approaches to  mitochondrial  disease: 
correlation of urine organic acids.Mitochondrion 2004, 4:521-527. 
164.  Hamm LL: Renal handling of citrate.Kidney Int 1990, 38:728-735. 
165.  Balaban  RS,  Mandel  LJ: Metabolic substrate  utilization  by rabbit 
proximal tubule.  An  NADH fluorescence study.Am J  Physiol 1988, 
254:F407-416. 
166.  Chyla  RA,  Hu  K,  Elinger J,  Markley JL: Deconvolution  of  Two-
Dimensional  NMR  Spectra  by  Fast  Maximum  Likelihood 
Reconstruction (FMLR):  Application to  Quantitative 
Metabolomics.Anal Chem 2011. 
167.  Frydman  L,  Lupulescu  A,  Scherf  T: Principles  and features  of single-
scan two-dimensional  NMR spectroscopy.J  Am  Chem  Soc2003, 
125:9204-9217. 
168.  Tal  A,  Shapira  B,  Frydman  L: Single-scan  2D  Hadamard  NMR 
spectroscopy.Angew Chem Int Ed Engl 2009, 48:2732-2736. 
169.  Brüschweiler  R: Theory  of  covariance  nuclear  magnetic resonance 
spectroscopy.J Chem Phys 2004, 121:409-414. 
170.  Brüschweiler  R,  Zhang  F: Covariance  nuclear  magnetic resonance 
spectroscopy.J Chem Phys 2004, 120:5253-5260. 
171.  Mobli  M,  Stern  AS,  Hoch JC: Spectral reconstruction  methods in fast 
NMR: reduced  dimensionality, random sampling  and  maximum 
entropy.J Magn Reson 2006, 182:96-105. 
172.  McHugh  DMS,  Cameron  CA,  Abdenur JE,  Abdulrahman  M,  Adair  O,  Al 
Nuaimi SA, Åhlman H, Alen J, Antonozzi I, Archer S, Au S, Auray-Blais C, 
 164 
Baker  M,  Bamforth  F,  Beckmann  K,  Pino  GB,  Berberich  SL,  Binard  R, 
Boemer  F,  Bonham J,  Breen  NN,  Bryant  SC,  Caggana  M,  Caldwel  SG, 
Camilot  M,  Campbel  C,  Carducci  C,  Bryant  SC,  Caggana  M,  Caldwel  SG, 
Camilot  M,  Campbel  C,  Carducci  C,  Cariappa  R,  Carlisle  C,  Caruso  U, 
Cassanelo  M,  Castila  AM,  Ramos  DEC,  Chakraborty  P,  Chandrasekar  R, 
Ramos AC, Cheilan D, Chien Y-H, Childs TA, Chrastina P, Sica YC, de Juan 
JAC,  Colandre  ME,  Espinoza  VC,  Corso  G,  Currier  R,  Cyr  D,  Czuczy  N, 
D'Apolito  O,  Davis  T,  de  Sain-Van  der  Velden  MG,  Delgado  Pecelin  C,  Di 
Gangi IM,  Di  Stefano  CM,  Dotsikas  Y,  Downing  M,  Downs  SM,  Dy  B, 
Dymerski  M, Rueda I,  Elvers B, Eaton R, Eckerd BM, El Mougy F, Eroh S, 
Espada  M,  Evans  C,  Fawbush  S,  Fijolek  KF,  Fisher  L,  Franzson  L,  Frazier 
DM,  Garcia  LRC,  Bermejo  MSG-V,  Gavrilov  D,  Gerace  R,  Giordano  G, 
Irazabal YG, Greed LC, Grier R, Grycki E, Gu X, Gulamali-Majid F, Hagar AF, 
Han  L,  Hannon  WH,  Haslip  C,  Hassan  FA,  He  M,  Hietala  A,  Himstedt  L, 
Hofman GL, Hofman W, Hoggatt P, Hopkins PV, Hougaard DM, Hughes K, 
Hunt  PR,  Hwu  W-L,  Hynes J, Ibarra-González I, Ingham  CA, Ivanova  M, 
Jacox  WB, John  C, Johnson JP, Jónsson J,  Karg  E,  Kasper  D,  Klopper  B, 
Katakouzinos  D,  Khneisser I,  Knol  D,  Kobayashi  H,  Koneski  R,  Kozich  V, 
Kouapei R, Kohlmueler D, Kremensky I, la Marca G, Lavochkin M, Lee S-Y, 
Lehotay DC, Lemes A, Lepage J, Lesko B, Lewis B, Lim C, Linard S, Lindner 
M, Lloyd-Puryear MA, Lorey F, Loukas YL, Luedtke J, Mafitt N, Magee JF, 
Manning A, Manos S, Marie S, Hadachi SM, Marquardt G, Martin SJ, Matern 
D,  Mayfield  Gibson  SK,  Mayne  P,  McCalister  TD,  McCann  M,  McClure J, 
McGil J, McKeever CD, McNeily B, Morrissey MA, Moutsatsou P, Mulcahy 
EA,  Nikoloudis  D,  Norgaard-Pedersen  B,  Oglesbee  D,  Oltarzewski  M, 
Ombrone D, Ojodu J, Papakonstantinou V, Reoyo SP, Park H-D, Pasquali M, 
Pasquini E, Patel P, Pass KA, Peterson C, Pettersen RD, Pitt J, Poh S, Polak 
A, Porter C, Poston PA, Price RW, Queijo C, Quesada J, Randel E, Ranieri E, 
Raymond  K,  Reddic JE,  Reuben  A,  Ricciardi  C,  Rinaldo  P,  Rivera JD, 
Roberts  A,  Rocha  H,  Roche  G,  Greenberg  CR,  Melado JME, Juan-Fita  MJ, 
Ruiz  C,  Ruoppolo  M,  Rutledge  SL,  Ryu  E,  Saban  C,  Sahai I,  García-Blanco 
MIS,  Santiago-Borrero  P,  Schenone  A,  Schoos  R,  Schweitzer  B,  Scot  P, 
Seashore  MR,  Seeterlin  MA,  Sesser  DE,  Sevier  DW,  Shone  SM,  Sinclair  G, 
Skrinska  VA,  Stanley  EL,  Strovel  ET, Jones  ALS,  Sunny  S,  Takats  Z, 
Tanyalcin T, Teofoli F, Thompson JR, Tomashitis K, Domingos MT, Torres 
J,  Torres  R,  Tortoreli  S,  Turi  S,  Turner  K,  Tzanakos  N,  Valiente  AG, 
Valance  H,  Vela-Amieva  M,  Vilarinho  L,  von  Döbeln  U,  Vincent  M-F, 
Vorster BC, Watson MS, Webster D, Weiss S, Wilcken B, Wiley V, Wiliams 
SK, Wilis SA, Woontner M, Wright  K, Yahyaoui R, Yamaguchi S, Yssel M, 
Zakowicz  WM: Clinical  validation  of  cutof target ranges in  newborn 
screening  of  metabolic  disorders  by tandem  mass spectrometry:  a 
worldwide colaborative project.Genet Med 2011, 13:230-254. 
173. Dénes   J,   Szabó   E,   Robinette   SL,   Szatmári   I,   Szőnyi   L,   Kreuder   JG,  
Rauterberg EW, Takáts Z: Metabonomics of Newborn Screening Dried 
Blood  Spot  Samples:  A  Novel  Approach in the  Screening  and 
Diagnostics of Inborn Errors of Metabolism.Anal Chem2012. 
174.  Wei  R,  Li  G,  Seymour  AB: High-throughput  and  multiplexed 
LC/MS/MRM  method for targeted  metabolomics.Anal  Chem2010, 
82:5527-5533. 
 165 
175.  Shlomi  T,  Cabili  MN,  Ruppin  E: Predicting  metabolic  biomarkers  of 
human inborn errors of metabolism.Mol Syst Biol 2009, 5:263. 
176. Inouye  M,  Kettunen J,  Soininen  P,  Silander  K,  Ripatti  S,  Kumpula  LS, 
Hämäläinen E, Jousilahti  P, Kangas AJ, Männistö S, Savolainen  MJ, Jula  A, 
Leiviskä J,  Palotie  A,  Salomaa  V,  Perola  M,  Ala-Korpela  M,  Peltonen  L: 
Metabonomic, transcriptomic, and genomic variation of a population 
cohort.Mol Syst Biol 2010, 6:441. 
177.  Sims AH, Smethurst GJ, Hey Y, Okoniewski MJ, Pepper SD, Howel A, Miler 
CJ,  Clarke  RB: The removal  of  multiplicative, systematic  bias  alows 
integration  of  breast  cancer  gene  expression  datasets - improving 
meta-analysis  and  prediction  of  prognosis.BMC  Med  Genomics 2008, 
1:42. 
178.  Chen C, Grennan K, Badner J, Zhang D, Gershon E, Jin L, Liu C: Removing 
batch  efects in  analysis  of  expression  microarray  data:  an 
evaluation of six batch adjustment methods.PLoS ONE 2011, 6:e17238. 
179.  Loughrey  C,  Bennett  MJ: Screening for  MCAD  deficiency in 
newborns.BMJ 2009, 338:b971. 
180.  Blau  N,  van  Spronsen  FJ,  Levy  HL: Phenylketonuria.Lancet 2010, 
376:1417-1427. 
181.  Wilcken B, Haas M, Joy P, Wiley V, Chaplin M, Black C, Fletcher J, McGil J, 
Boneh A: Outcome of neonatal screening for medium-chain acyl-CoA 
dehydrogenase  deficiency in  Australia:  a  cohort study.Lancet 2007, 
369:37-42. 
182.  Marquardt  G, Currier  R, McHugh DMS, Gavrilov D, Magera  MJ, Matern D, 
Oglesbee  D,  Raymond  K,  Rinaldo  P,  Smith  EH,  Tortoreli  S,  Turgeon  CT, 
Lorey F, Wilcken B, Wiley V, Greed LC, Lewis B, Boemer F, Schoos R, Marie 
S, Vincent M-F, Sica YC, Domingos MT, Al-Thihli K, Sinclair G, Al-Dirbashi 
OY,  Chakraborty  P,  Dymerski  M,  Porter  C,  Manning  A,  Seashore  MR, 
Quesada J,  Reuben  A,  Chrastina  P, Hornik  P,  Atef  Mandour I,  Atty  Sharaf 
SA,  Bodamer  O,  Dy  B,  Torres J,  Zori  R,  Cheilan  D,  Vianey-Saban  C, 
Ludvigson D, Stembridge A, Bonham J, Downing M, Dotsikas Y, Loukas YL, 
Papakonstantinou  V,  Zacharioudakis  GSA,  Baráth  Á,  Karg  E,  Franzson  L, 
Jonsson J,  Breen  NN,  Lesko  BG,  Berberich  SL,  Turner  K,  Ruoppolo  M, 
Scolamiero E, Antonozzi I, Carducci C, Caruso U, Cassanelo M, la Marca G, 
Pasquini  E,  Di  Gangi IM,  Giordano  G,  Camilot  M,  Teofoli  F,  Manos  SM, 
Peterson CK, Mayfield Gibson SK, Sevier DW, Lee S-Y, Park H-D, Khneisser 
I,  Browning  P,  Gulamali-Majid  F,  Watson  MS,  Eaton  RB,  Sahai I,  Ruiz  C, 
Torres  R,  Seeterlin  MA,  Stanley  EL,  Hietala  A,  McCann  M,  Campbel  C, 
Hopkins PV, de Sain-Van der Velden MG, Elvers B, Morrissey MA, Sunny S, 
Knol D, Webster D, Frazier DM, McClure JD, Sesser DE, Wilis SA, Rocha H, 
Vilarinho  L, John  C,  Lim J,  Caldwel  SG,  Tomashitis  K,  Castiñeiras  Ramos 
DE,  Cocho  de Juan JA,  Rueda  Fernández I,  Yahyaoui  Macías  R,  Egea-
Melado JM,  González-Galego I,  Delgado  Pecelin  C,  García-Valdecasas 
Bermejo  MS,  Chien  Y-H,  Hwu  W-L,  Childs  T,  McKeever  CD,  Tanyalcin  T, 
Abdulrahman  M,  Queijo  C,  Lemes  A,  Davis  T,  Hofman  W,  Baker  M, 
Hofman  GL: Enhanced interpretation  of  newborn screening results 
without analyte cutof values.Genet Med 2012, 14:648-655. 
183.  Eastman JW,  Sherwin JE,  Wong  R,  Liao  CL,  Currier  RJ,  Lorey  F, 
Cunningham  G: Use  of the  phenylalanine:tyrosine ratio to test 
 166 
newborns for  phenylketonuria in  a large  public  health screening 
programme.J Med Screen 2000, 7:131-135. 
184.  Vinayavekhin  N,  Homan  EA,  Saghatelian  A: Exploring  disease through 
metabolomics.ACS Chem Biol 2010, 5:91-103. 
185.  Bewick  V,  Cheek  L,  Bal J: Statistics review  13: receiver  operating 
characteristic curves.Crit Care 2004, 8:508-512. 
186.  Van Hove JL, Zhang W, Kahler SG, Roe CR, Chen YT, Terada N, Chace DH, 
Iafola  AK,  Ding JH,  Milington  DS: Medium-chain  acyl-CoA 
dehydrogenase (MCAD)  deficiency:  diagnosis  by  acylcarnitine 
analysis in blood.Am J Hum Genet 1993, 52:958-966. 
187. ter Veld F, Mueler M, Kramer S, Haussmann U, Herebian D, Mayatepek E, 
Laryea  MD,  Primassin  S,  Spiekerkoetter  U: A  novel tandem  mass 
spectrometry  method for rapid  confirmation  of  medium-  and  very 
long-chain  acyl-CoA  dehydrogenase  deficiency in  newborns.PLoS 
ONE 2009, 4:e6449. 
188.  Downing M, Manning NJ, Dalton RN, Krywawych S, Oerton J: Detection of 
urinary  hexanoylglycine in the  diagnosis  of  MCAD  deficiency from 
newborn screening.J Inherit Metab Dis 2008, 31:550. 
189.  Leonard JV,  Dezateux  C: Newborn screening for  medium  chain  acyl 
CoA dehydrogenase deficiency.Arch Dis Child 2009, 94:235-238. 
190.  Dasgupta A, Sun YV, König IR, Bailey-Wilson JE, Maley JD: Brief review of 
regression-based  and  machine learning  methods in  genetic 
epidemiology: the  Genetic  Analysis  Workshop  17  experience.Genet 
Epidemiol 2011, 35 Suppl 1:S5-11. 
191.  Bagley  SC,  White  H,  Golomb  BA: Logistic regression in the  medical 
literature: standards for use and reporting, with particular attention 
to one medical domain.J Clin Epidemiol 2001, 54:979-985. 
192.  Robinette SL, Holmes E, Nicholson JK, Dumas ME: Genetic determinants 
of  metabolism in  health  and  disease: from  biochemical  genetics to 
genome-wide associations.Genome Med 2012, 4:30. 
193.  Wilson I: Top-down  versus  bottom-up-rediscovering  physiology  via 
systems biology?Mol Syst Biol 2007, 3:113. 
194.  Nicholson JK,  Holmes  E,  Lindon JC,  Wilson ID: The  chalenges  of 
modeling  mammalian  biocomplexity.Nat  Biotechnol 2004, 22:1268-
1274. 
195.  Boyle  AP,  Hong  EL,  Hariharan  M,  Cheng  Y,  Schaub  MA,  Kasowski  M, 
Karczewski KJ, Park J, Hitz BC, Weng S, Cherry JM, Snyder M: Annotation 
of functional  variation in  personal  genomes  using  RegulomeDB. In 
Annotation of functional variation in personal genomes using RegulomeDB, 
vol. 22. pp. 1790-1797. City; 2012:1790-1797. 
196.  Génin  E,  Feingold J,  Clerget-Darpoux  F: Identifying  modifier  genes  of 
monogenic  disease: strategies  and  dificulties.Hum  Genet 2008, 
124:357-368. 
197.  Vockley J,  Ensenauer  R: Isovaleric  acidemia:  new  aspects  of  genetic 
and phenotypic heterogeneity.Am J Med Genet C Semin Med Genet 2006, 
142C:95-103. 
198.  Wiliams  RA,  Mamotte  CDS,  Burnett JR: Phenylketonuria:  an inborn 
error of phenylalanine metabolism.Clin Biochem Rev 2008, 29:31-41. 
 167 
199.  Okajima  K, Inoue  M,  Morino  Y: Studies  on the  mechanism for renal 
elimination  of  N-acetylphenylalanine: its  pathophysiologic 
significance in phenylketonuria.J Lab Clin Med 1985, 105:132-138. 
200. Jelum E, Horn L, Thoresen O, Kvittingen EA, Stokke O: Urinary excretion 
of N-acetyl amino acids in patients with some inborn errors of amino 
acid metabolism.Scand J Clin Lab Invest Suppl 1986, 184:21-26. 
201.  Sack  MN,  Disch  DL,  Rockman  HA,  Kely  DP: A role for  Sp  and  nuclear 
receptor transcription factors in  a  cardiac  hypertrophic  growth 
program.Proc Natl Acad Sci USA1997, 94:6438-6443. 
202.  Gregersen  N,  Kølvraa  S,  Rasmussen  K,  Mortensen  PB,  Divry  P,  David  M, 
Hobolth  N: General (medium-chain)  acyl-CoA  dehydrogenase 
deficiency (non-ketotic  dicarboxylic  aciduria):  quantitative  urinary 
excretion pattern of 23 biologicaly significant organic acids in three 
cases.Clin Chim Acta 1983, 132:181-191. 
203.  Costa CC, Dorland L, Kroon M, Tavares de Almeida I, Jakobs C, Duran M: 3-
,  6-  and  7-hydroxyoctanoic  acids  are  metabolites  of  medium-chain 
triglycerides  and  excreted in  urine  as  glucuronides.J  Mass  Spectrom 
1996, 31:633-638. 
204.  Pitt J: Gas chromatographic-mass spectrometric  characterisation  of 
unsaturated  dicarboxylic  acids in  urine.J  Chromatogr 1990, 534:182-
189. 
205.  Chace  DH,  Hilman  SL,  Van  Hove JL,  Naylor  EW: Rapid  diagnosis  of 
MCAD  deficiency:  quantitative  analysis  of  octanoylcarnitine  and 
other  acylcarnitines in  newborn  blood spots  by tandem  mass 
spectrometry.Clin Chem 1997, 43:2106-2113. 
206.  Tyni  T,  Pihko  H: Long-chain  3-hydroxyacyl-CoA  dehydrogenase 
deficiency.Acta Paediatr 1999, 88:237-245. 
207.  Kanehisa  M,  Goto  S: KEGG:  kyoto  encyclopedia  of  genes  and 
genomes.Nucleic Acid Res 2000, 28:27-30. 
208.  Kuhara  T,  Shinka  T,  Matsuo  M,  Matsumoto I: Increased  excretion  of 
lactate,  glutarate,  3-hydroxyisovalerate  and  3-methylglutaconate 
during  clinical  episodes  of  propionic  acidemia.Clin  Chim  Acta 1982, 
123:101-109. 
209.  Simon E, Flaschker N, Schadewaldt  P, Langenbeck U, Wendel U: Variant 
maple syrup  urine  disease (MSUD)--the  entire spectrum.J Inherit 
Metab Dis 2006, 29:716-724. 
210.  Endo  F,  Tanaka  Y,  Tomoeda  K,  Tanoue  A,  Tsujimoto  G,  Nakamura  K: 
Animal models reveal pathophysiologies of tyrosinemias.J Nutr 2003, 
133:2063S-2067S. 
211.  Cerone  R,  Holme  E,  Schiafino  MC,  Caruso  U,  Maritano  L,  Romano  C: 
Tyrosinemia type III: diagnosis and ten-year folow-up.Acta Paediatr 
1997, 86:1013-1015. 
212.  Park  H-D,  Lee  DH,  Choi  T-Y,  Lee  YK,  Kim J-W,  Ki  C-S,  Lee  Y-W: Clinical, 
biochemical,  and  genetic  analysis  of  a  Korean  neonate  with 
hereditary tyrosinemia type 1.Clin Chem Lab Med 2009, 47:930-933. 
213.  Giardini O, Cantani A, Kennaway NG, D'Eufemia P: Chronic tyrosinemia 
associated  with  4-hydroxyphenylpyruvate  dioxygenase  deficiency 
with  acute intermittent  ataxia  and  without  visceral  and  bone 
involvement.Pediatr Res 1983, 17:25-29. 
 168 
214.  Yajima Y, Hirasawa T, Saheki T: Treatment of adult-type citrulinemia 
with administration of citrate.Tohoku J Exp Med 1981, 134:321-330. 
215.  Chamberlin  ME,  Ubagai  T,  Mudd  SH,  Wilson  WG,  Leonard JV,  Chou JY: 
Demyelination  of the  brain is  associated  with  methionine 
adenosyltransferase I/III deficiency.J Clin Invest 1996, 98:1021-1027. 
216.  Stöckler  S, Isbrandt  D,  Hanefeld  F,  Schmidt  B,  von  Figura  K: 
Guanidinoacetate  methyltransferase  deficiency: the first inborn 
error  of  creatine  metabolism in  man.Am J  Hum  Genet 1996, 58:914-
922. 
217.  Foxal  PJ,  Melotte  GJ,  Bending  MR,  Lindon JC,  Nicholson JK: NMR 
spectroscopy  as  a  novel  approach to the  monitoring  of renal 
transplant function.Kidney Int 1993, 43:234-245. 
218.  Neild GH, Foxal PJ, Lindon JC, Holmes EC, Nicholson JK: Uroscopy in the 
21st  century:  high-field  NMR spectroscopy.Nephrol  Dial  Transplant 
1997, 12:404-417. 
219.  Weiss RH, Kim K: Metabolomics in the study of kidney diseases.Nature 
Rev Nephrol 2011. 
220.  Kikuchi K, Itoh Y, Tateoka R, Ezawa A, Murakami K, Niwa T: Metabolomic 
analysis  of  uremic toxins  by liquid  chromatography/electrospray 
ionization-tandem  mass spectrometry.J  Chromatogr  B  Analyt  Technol 
Biomed Life Sci 2010, 878:1662-1668. 
221.  Foxal  PJ,  Bending  MR,  Gartland  KP,  Nicholson JK: Acute renal failure 
folowing accidental  cutaneous absorption of phenol: application of 
NMR  urinalysis to  monitor the  disease  process.Hum  Toxicol 1989, 
8:491-496. 
222.  Holmes E, Nicholson JK, Bonner FW, Sweatman BC, Beddel CR, Lindon JC, 
Rahr  E: Mapping the  biochemical trajectory  of  nephrotoxicity  by 
pattern recognition of NMR urinanalysis.Nmr Biomed 1992, 5:368-372. 
223.  Xu  EY,  Perlina  A,  Vu  H,  Troth  SP,  Brennan  RJ,  Aslamkhan  AG,  Xu  Q: 
Integrated  pathway  analysis  of rat  urine  metabolic  profiles  and 
kidney transcriptomic profiles to elucidate the systems toxicology of 
model nephrotoxicants.Chem Res Toxicol 2008, 21:1548-1561. 
224.  Boudonck  KJ,  Mitchel  MW,  Német  L,  Keresztes  L,  Nyska  A,  Shinar  D, 
Rosenstock M: Discovery  of  metabolomics  biomarkers for  early 
detection of nephrotoxicity.Toxicol Pathol 2009, 37:280-292. 
225.  Suhre K, Meisinger C, Döring A, Altmaier E, Belcredi P, Gieger C, Chang D, 
Milburn  MV, Gal WE, Weinberger KM, Mewes H-W, Hrabé  de Angelis M, 
Wichmann H-E, Kronenberg F, Adamski J, Ilig T: Metabolic footprint of 
diabetes: a multiplatform metabolomics study in an epidemiological 
setting.PLoS ONE 2010, 5:e13953. 
226.  Zhao L, Gao H, Lian F, Liu X, Zhao Y, Lin D: ¹H-NMR-based metabonomic 
analysis of metabolic profiling in diabetic nephropathy rats induced 
by streptozotocin.Am J Physiol Renal Physiol 2011, 300:F947-956. 
227.  Hirayama A, Nakashima E, Sugimoto M, Akiyama S-i, Sato W, Maruyama S, 
Matsuo S, Tomita M, Yuzawa Y, Soga T: Metabolic profiling reveals new 
serum  biomarkers for  diferentiating  diabetic  nephropathy.Anal 
Bioanal Chem 2012, 404:3101-3109. 
228.  Taylor  SL,  Ganti  S,  Bukanov  NO,  Chapman  A,  Fiehn  O,  Osier  M,  Kim  K, 
Weiss  RH: A  metabolomics  approach  using juvenile  cystic  mice to 
 169 
identify  urinary  biomarkers  and  altered  pathways in  polycystic 
kidney disease.Am J Physiol Renal Physiol 2010, 298:F909-922. 
229.  Kim K, Taylor SL, Ganti S, Guo L, Osier MV, Weiss RH: Urine metabolomic 
analysis identifies potential biomarkers and pathogenic pathways in 
kidney cancer.OMICS 2011, 15:293-303. 
230.  Ganti  S,  Taylor  SL,  Kim  K,  Hoppel  CL,  Guo  L,  Yang J,  Evans  C,  Weiss  RH: 
Urinary  acylcarnitines  are  altered in  human  kidney  cancer.Int J 
Cancer 2012, 130:2791-2800. 
231.  Wishart DS: Metabolomics in monitoring kidney transplants.Curr Opin 
Nephrol Hy 2006, 15:637-642. 
232.  Wishart  DS: Metabolomics:  a  complementary tool in renal 
transplantation.Contrib Nephrol 2008, 160:76-87. 
233.  Gartland  KP,  Bonner  FW,  Nicholson JK: Investigations into the 
biochemical  efects  of region-specific  nephrotoxins.Mol  Pharmacol 
1989, 35:242-250. 
234.  Ebbels  TMD,  Keun  HC,  Beckonert  OP,  Bolard  ME,  Lindon JC,  Holmes  E, 
Nicholson JK: Prediction  and  classification  of  drug toxicity  using 
probabilistic  modeling  of temporal  metabolic  data: the  consortium 
on metabonomic toxicology screening approach.J Proteome Res 2007, 
6:4407-4422. 
235.  Vangala  S,  Toneli  A: Biomarkers,  metabonomics,  and  drug 
development:  can inborn  errors  of  metabolism  help in 
understanding drug toxicity?AAPS J 2007, 9:E284-297. 
236.  Gahl  WA,  Bashan  N,  Tietze  F,  Bernardini I,  Schulman JD: Cystine 
transport is defective in isolated leukocyte lysosomes from patients 
with cystinosis.Science 1982, 217:1263-1265. 
237.  Gahl  WA,  Thoene JG,  Schneider JA: Cystinosis.N  Engl J  Med 2002, 
347:111-121. 
238.  Kalatzis  V,  Nevo  N,  Cherqui  S,  Gasnier  B,  Antignac  C: Molecular 
pathogenesis of cystinosis: efect of CTNS mutations on the transport 
activity  and subcelular localization  of  cystinosin.Hum  Mol  Genet 
2004, 13:1361-1371. 
239.  Mahoney  CP,  Striker  GE: Early  development  of the renal lesions in 
infantile cystinosis.Pediatr Nephrol 2000, 15:50-56. 
240.  Kleta  R,  Gahl  WA: Pharmacological treatment  of  nephropathic 
cystinosis  with  cysteamine.Expert  Opin  Pharmacother 2004, 5:2255-
2262. 
241.  Dohil R, Fidler M, Gangoiti JA, Kaskel F, Schneider JA, Barshop BA: Twice-
daily  cysteamine  bitartrate therapy for  children  with  cystinosis.J 
Pediatr 2010, 156:71-75.e71-73. 
242.  Brodin-Sartorius A, Tête M-J, Niaudet P, Antignac C, Guest G, Ottolenghi C, 
Charbit  M,  Moyse  D,  Legendre  C,  Lesavre  P,  Cochat  P,  Servais  A: 
Cysteamine therapy  delays the  progression  of  nephropathic 
cystinosis in late adolescents and adults.Kidney Int 2012, 81:179-189. 
243.  Charnas  LR,  Bernardini I,  Rader  D,  Hoeg JM,  Gahl  WA: Clinical  and 
laboratory findings in the  oculocerebrorenal syndrome  of  Lowe, 
with special reference to  growth  and renal function.N  Engl J  Med 
1991, 324:1318-1325. 
 170 
244.  O'Sulivan J,  Bitu  CC,  Daly  SB,  Urquhart JE,  Barron  MJ,  Bhaskar  SS, 
Marteli-Júnior H, dos Santos Neto PE, Mansila MA, Murray JC, Coletta RD, 
Black  GCM,  Dixon  MJ: Whole-Exome sequencing identifies  FAM20A 
mutations  as  a  cause  of  amelogenesis imperfecta  and  gingival 
hyperplasia syndrome.Am J Hum Genet 2011, 88:616-620. 
245.  Cho SH, Seymen F, Lee K-E, Lee S-K, Kweon Y-S, Kim KJ, Jung S-E, Song SJ, 
Yildirim  M,  Bayram  M,  Tuna  EB,  Gencay  K,  Kim J-W: Novel  FAM20A 
mutations in  hypoplastic  amelogenesis imperfecta.Hum  Mutat 2012, 
33:91-94. 
246. Jaureguiberry G, De la Dure-Mola M, Parry D, Quentric M, Himmerkus N, 
Koike T, Poulter J, Klootwijk E, Robinette SL, Howie AJ, Patel V, Figueres 
M-L, Stanescu HC, Issler N, Nicholson JK, Bockenhauer D, Laing C, Walsh 
SB,  McCredie  DA,  Povey  S,  Asselin  A,  Picard  A,  Coulomb  A,  Medlar  AJ, 
Baileul-Forestier I,  Verloes  A,  Le  Caignec  C,  Roussey  G,  Guiol J, Isidor  B, 
Logan  C,  Shore  R, Johnson  C, Inglehearn  C,  Al-Bahlani  S,  Schmittbuhl  M, 
Clauss F, Huckert M, Laugel V, Ginglinger E, Pajarola S, Spartà G, Bartholdi 
D,  Rauch  A,  Addor  M-C,  Yamaguti  PM,  Safatle  HP,  Acevedo  AC,  Marteli-
Júnior  H,  Dos  Santos  Netos  PE,  Coletta  RD,  Gruessel  S,  Sandmann  C, 
Ruehmann  D,  Langman  CB,  Scheinman  SJ,  Ozdemir-Ozenen  D,  Hart  TC, 
Hart  PS,  Neugebauer  U,  Schlatter  E,  Houilier  P,  Gahl  WA,  Vikkula  M, 
Bloch-Zupan A, Bleich M, Kitagawa H, Unwin RJ, Mighel A, Berdal A, Kleta 
R: Nephrocalcinosis (Enamel Renal Syndrome) Caused by Autosomal 
Recessive FAM20A Mutations.Nephron Physiol 2012, 122:1-6. 
247.  Wang S-K, Aref P, Hu Y, Milkovich RN, Simmer JP, El-Khateeb M, Daggag H, 
Baqain  ZH,  Hu JC-C: FAM20A  mutations  can  cause  enamel-renal 
syndrome (ERS).PLoS Genetics 2013, 9:e1003302. 
248.  Sayer JA,  Carr  G,  Simmons  NL: Nephrocalcinosis:  molecular insights 
into  calcium  precipitation  within the  kidney.Clin  Sci 2004, 106:549-
561. 
249.  Lindon JC, Nicholson JK, Holmes E, Antti H, Bolard ME, Keun H, Beckonert 
O, Ebbels TM, Reily MD, Robertson D, Stevens GJ, Luke P, Breau AP, Cantor 
GH,  Bible  RH,  Niederhauser  U,  Senn  H,  Schlotterbeck  G,  Sidelmann  UG, 
Laursen SM, Tymiak A, Car BD, Lehman-McKeeman L, Colet JM, Loukaci A, 
Thomas  C: Contemporary issues in toxicology the role  of 
metabonomics in toxicology  and its  evaluation  by the  COMET 
project.ToxicolApp Pharmacol 2003, 187:137-146. 
250.  Lindon JC, Keun HC, Ebbels TM, Pearce JM, Holmes  E, Nicholson JK: The 
Consortium for  Metabonomic  Toxicology (COMET):  aims,  activities 
and achievements.Pharmacogenomics 2005, 6:691-699. 
251.  Bohus E, Coen M, Keun HC, Ebbels TMD, Beckonert O, Lindon JC, Holmes 
E,  Noszál  B,  Nicholson JK: Temporal  metabonomic  modeling  of l-
arginine-induced  exocrine  pancreatitis.J  Proteome  Res 2008, 7:4435-
4445. 
252.  Liliefors  HW: On the  Kolmogorov-Smirnov  Test for  Normality  with 
Mean and Variance Unknown.J Am Stat Assoc 1967, 62:399-402. 
253.  Sterne JAC, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, Wood 
AM,  Carpenter JR: Multiple imputation for  missing  data in 
epidemiological  and  clinical research:  potential  and  pitfals.BMJ 
2009, 338:b2393. 
 171 
254.  Wunsch H, Linde-Zwirble WT, Angus DC: Methods to adjust for bias and 
confounding in  critical  care  health services research involving 
observational data.J Crit Care 2006, 21:1-7. 
255.  Clay RD, Darmady EM, Hawkins M: The nature of the renal lesion in the 
Fanconi syndrome.J Pathol Bacteriol 1953, 65:551-558. 
256.  Monnens L, Levtchenko E: Evaluation of the proximal tubular function 
in  hereditary renal  Fanconi syndrome.Nephrol  Dial  Transplant 2008, 
23:2719-2722. 
257.  Gougoux  A,  Zan  N,  Dansereau  D,  Vinay  P: Experimental  Fanconi's 
syndrome resulting from  4-pentenoate infusion in the  dog.Am J 
Physiol 1989, 257:F959-966. 
258.  Shofner JM,  Voljavec  AS,  Dixon J,  Kaufman  A,  Walace  DC,  Mitch  WE: 
Renal amino acid transport in adults with oxidative phosphorylation 
diseases.Kidney Int 1995, 47:1101-1107. 
259.  Thirumurugan A, Thewles A, Gilbert RD, Hulton S-A, Milford DV, Lote CJ, 
Taylor  CM: Urinary L-lactate excretion is increased in renal  Fanconi 
syndrome.Nephrol Dial Transplant 2004, 19:1767-1773. 
260.  Moran A, Ben-Nun A, Potashnik R, Bashan N: Renal cels in culture as a 
model for cystinosis.J Basic Clin Physiol Pharmacol 1990, 1:357-372. 
261.  Salmon RF, Baum M: Intracelular cystine loading inhibits transport in 
the rabbit proximal convoluted tubule.J Clin Invest 1990, 85:340-344. 
262.  Coor  C,  Salmon  RF,  Quigley  R,  Marver  D,  Baum  M: Role  of  adenosine 
triphosphate (ATP)  and  NaK  ATPase in the inhibition  of  proximal 
tubule transport with intracelular cystine loading.J Clin Invest 1991, 
87:955-961. 
263. Jackson JD,  Smith  FG,  Litman  NN,  Yuile  CL,  Latta  H: The  Fanconi 
syndrome  with  cystinossis.  Electron  microscopy  of renal  biopsy 
specimens from five patients.Am J Med 1962, 33:893-910. 
264.  Vester  U,  Schubert  M,  Ofner  G,  Brodehl J: Distal  myopathy in 
nephropathic cystinosis.Pediatr Nephrol 2000, 14:36-38. 
265.  Dixit  MP,  Greifer I: Nephropathic  cystinosis  associated  with 
cardiomyopathy: a 27-year clinical folow-up.BMC Nephrol 2002, 3:8. 
266.  Askari  A,  Vignos  PJ,  Moskowitz  RW: Steroid  myopathy in  connective 
tissue disease.Am J Med 1976, 61:485-492. 
267.  Levtchenko  EN,  de  Graaf-Hess  A,  Blom  HJ,  Monnens  LAH: Negligible 
urinary  cysteamine loss in  cystinosis  patients  with  Fanconi 
syndrome.Clin Nephrol 2002, 57:349-351. 
268.  Liu G, Wang Y, Wang Z, Cai J, Lv X, Zhou A: Nuclear magnetic resonance 
(NMR)-based  metabolomic studies on urine and serum  biochemical 
profiles after chronic cysteamine supplementation in rats.J Agr Food 
Chem 2011, 59:5572-5578. 
269.  Heinzmann  SS,  Brown IJ,  Chan  Q,  Bictash  M,  Dumas  M-E,  Kochhar  S, 
Stamler J, Holmes E, Eliott P, Nicholson JK: Metabolic profiling strategy 
for discovery of nutritional biomarkers: proline betaine as a marker 
of citrus consumption.Am J Clin Nutr 2010, 92:436-443. 
270.  Mitchel  SC,  Zhang  AQ: Methylamine in  human  urine.Clin  Chim  Acta 
2001, 312:107-114. 
271.  Nicar MJ, Skurla C, Sakhaee K, Pak CY: Low urinary citrate excretion in 
nephrolithiasis.Urology 1983, 21:8-14. 
 172 
272.  Pak CY, Peterson R, Sakhaee K, Fuler C, Preminger G, Reisch J: Correction 
of  hypocitraturia  and  prevention  of stone formation  by  combined 
thiazide  and  potassium  citrate therapy in thiazide-unresponsive 
hypercalciuric nephrolithiasis.Am J Med 1985, 79:284-288. 
273.  Sikora P, Roth B, Kribs A, Michalk DV, Hesse A, Hoppe B: Hypocitraturia 
is one of the major risk factors for nephrocalcinosis in very low birth 
weight (VLBW) infants.Kidney Int 2003, 63:2194-2199. 
274.  Wilmer  MJ,  Emma  F,  Levtchenko  EN: The  pathogenesis  of  cystinosis: 
mechanisms  beyond  cystine  accumulation.Am J  Physiol  Renal  Physiol 
2010, 299:F905-916. 
275.  Bales JR,  Higham  DP,  Howe I,  Nicholson JK,  Sadler  PJ: Use  of  high-
resolution  proton  nuclear  magnetic resonance spectroscopy for 
rapid multi-component analysis of urine.Clin Chem 1984, 30:426-432. 
276. Iles  RA,  Snodgrass  GJ,  Chalmers  RA,  Stacey  TE: Rapid screening  of 
metabolic diseases by proton NMR.Lancet 1984, 2:1221-1222. 
277.  Bird  NJ,  Henderson  BL,  Lui  D,  Balinger JR,  Peters  AM: Indexing 
glomerular filtration rate to suit  children.J  Nucl  Med 2003, 44:1037-
1043. 
278.  Slupsky CM, Rankin KN, Wagner J, Fu H, Chang D, Weljie AM, Saude EJ, Lix 
B, Adamko DJ, Shah S, Greiner R, Sykes  BD, Marrie TJ: Investigations of 
the  efects  of  gender,  diurnal  variation,  and  age in  human  urinary 
metabolomic profiles.Anal Chem2007, 79:6995-7004. 
279.  Bröer  S: Amino  acid transport  across  mammalian intestinal  and 
renal epithelia.Physiol Rev 2008, 88:249-286. 
280.  Rodenburg  RJT: Biochemical  diagnosis  of  mitochondrial  disorders.J 
Inherit Metab Dis 2011, 34:283-292. 
281.  Bain  MA,  Faul  R,  Fornasini  G,  Milne  RW,  Evans  AM: Accumulation  of 
trimethylamine  and trimethylamine-N-oxide in  end-stage renal 
disease  patients  undergoing  haemodialysis.Nephrol  Dial  Transplant 
2006, 21:1300-1304. 
282.  Le Moyec L, Pruna A, Eugène M, Bedrossian J, Idatte JM, Huneau JF, Tomé 
D: Proton  nuclear  magnetic resonance spectroscopy  of  urine  and 
plasma in renal transplantation folow-up.Nephron 1993, 65:433-439. 
283.  Holmes HC, Burns SP, Michelakakis H, Kordoni V, Bain MD, Chalmers RA, 
Rafter JE, Iles  RA: Choline  and  L-carnitine  as  precursors  of 
trimethylamine.Biochem Soc Trans 1997, 25:96S. 
284.  Zhang AQ, Mitchel SC, Smith RL: Dietary precursors of trimethylamine 
in man: a pilot study.Food Chem Toxicol 1999, 37:515-520. 
285.  Koeth RA, Wang Z, Levison BS, Bufa JA, Org E, Sheehy BT, Britt EB, Fu X, 
Wu Y, Li L, Smith JD, Didonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier 
M,  Brown JM,  Krauss  RM,  Tang  WHW,  Bushman  FD,  Lusis  AJ,  Hazen  SL: 
Intestinal  microbiota  metabolism  of l-carnitine,  a  nutrient in red 
meat, promotes atherosclerosis.Nat Med 2013, 19:576-585. 
286.  Lenz EM, Bright J, Knight R, Wilson ID, Major H: Cyclosporin A-induced 
changes in  endogenous  metabolites in rat  urine:  a  metabonomic 
investigation  using  high field  1H  NMR spectroscopy,  HPLC-TOF/MS 
and chemometrics.J Pharmaceut Biomed 2004, 35:599-608. 
287.  Kim K-B, Um SY, Chung MW, Jung SC, Oh JS, Kim SH, Na HS, Lee BM, Choi 
KH: Toxicometabolomics  approach to  urinary  biomarkers for 
 173 
mercuric   chloride   (HgCl₂)-induced  nephrotoxicity  using  proton 
nuclear  magnetic resonance (¹H  NMR) in rats.Toxicol  AppPharmacol 
2010, 249:114-126. 
288.  Cavil  R,  Kamburov  A,  Elis JK,  Athersuch  TJ,  Blagrove  MSC,  Herwig  R, 
Ebbels  TMD,  Keun  HC: Consensus-phenotype integration  of 
transcriptomic and metabolomic data implies a role for metabolism 
in the  chemosensitivity  of tumour  cels.PLoS  Comput  Biol 2011, 
7:e1001113. 
289.  Li  S,  Wu  P,  Yarlagadda  P,  Vadjunec  NM,  Proia  AD,  Harris  RA,  Portila  D: 
PPAR  alpha ligand  protects  during  cisplatin-induced  acute renal 
failure  by  preventing inhibition  of renal  FAO  and  PDC  activity.Am J 
Physiol Renal Physiol 2004, 286:F572-580. 
290.  Hussain  S,  Rodgers  DA,  Duhart  HM,  Ali  SF: Mercuric  chloride-induced 
reactive  oxygen species  and its  efect  on  antioxidant  enzymes in 
diferent regions of rat brain.J Environ Sci Health B 1997, 32:395-409. 
291.  Wiggers GA, Peçanha FM, Briones AM, Pérez-Girón JV, Miguel M, Vassalo 
DV,  Cachofeiro  V,  Alonso  MJ,  Salaices  M: Low  mercury  concentrations 
cause  oxidative stress  and  endothelial  dysfunction in  conductance 
and resistance  arteries.Am J  Physiol  Heart  Circ  Physiol 2008, 
295:H1033-H1043. 
292.  Diamond  GL,  Zalups  RK: Understanding renal toxicity  of  heavy 
metals.Toxicol Pathol 1998, 26:92-103. 
293.  Portila  D,  Li  S,  Nagothu  KK,  Megyesi J,  Kaissling  B,  Schnackenberg  L, 
Safirstein  RL,  Beger  RD: Metabolomic study  of  cisplatin-induced 
nephrotoxicity.Kidney Int 2006, 69:2194-2204. 
294.  Daugaard  G,  Rossing  N,  Rørth  M: Efects  of  cisplatin  on  diferent 
measures  of  glomerular function in the  human  kidney  with special 
emphasis on high-dose.Cancer Chemother Pharmacol 1988, 21:163-167. 
295.  Gregg  NJ,  Bach  PH: 2-Bromoethanamine  nephrotoxicity in the  nude 
mouse:  an  atypical targetting for the renal  cortex.Int J  Exp  Pathol 
1990, 71:659-670. 
296.  Berg JS, Khoury MJ, Evans JP: Deploying whole genome sequencing in 
clinical practice and public health: meeting the chalenge one bin at 
a time.Genet Med 2011, 13:499-504. 
297.  Ng  SB,  Buckingham  KJ,  Lee  C,  Bigham  AW,  Tabor  HK,  Dent  KM,  Huf  CD, 
Shannon  PT, Jabs  EW,  Nickerson  DA,  Shendure J,  Bamshad  MJ: Exome 
sequencing identifies the  cause  of  a  mendelian  disorder.Nat  Genet 
2010, 42:30-35. 
298.  Robinson PN, Krawitz P, Mundlos S: Strategies for exome and genome 
sequence data analysis in disease-gene discovery projects.Clin Genet 
2011, 80:127-132. 
299.  Yang H-C, Chen C-W: Region-based and pathway-based QTL mapping 
using  a  p-value  combination  method.BMC  proceedings 2011, 5  Suppl 
9:S43. 
 
 
 
 
 174 
Appendix A: Supplementary Tables 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Table 1. Internal standards detected by nS-HR-MS 
Internal standard Original 
conc. 
(μmol/l) 
Working 
conc. 
(μmol/l) 
m/z [M+H]+ m/z 
[M+Na]+ 
m/z [M-H]- 
 175 
15N; 2-13C-Glycine 25 10 78.04024 100.02218 76.02459 
2H4-Alanine 5 2 94.08061 116.06256 92.06496 
2H8-Valine 5 2 126.13702 148.11896 124.12137 
2H2-Ornithine 5 2 135.11026 157.09220 133.09461 
2H3-Leucine 5 2 135.12128 157.10323 133.10563 
2H3-Aspartate 5 2 137.06416 159.04611 135.04851 
2H3-Glutamate 5 2 151.07981 173.06176 149.06416 
2H3-Methionine 5 2 153.07771 175.05965 151.06206 
13C6-Phenylalanine 5 2 172.10690 194.08885 170.09125 
2H2-Citruline 5 2 178.11607 200.09802 176.10042 
2H4; 5-13C-Arginine 5 2 180.14796 202.12990 178.13231 
13C6-Tyrosine 5 2 188.10182 210.08376 186.08617 
2H9-Carnitine 1.52 0.608 171.16951 193.15145  
2H3-Acetylcarnitine 0.38 0.152 207.14241 229.12436  
2H3-Propionylcarnitine 0.076 0.0304 221.15806 243.14001  
2H3-Butyrylcarnitine 0.076 0.0304 235.17371 257.15566  
2H9-Isovalerylcarnitine 0.076 0.0304 255.22703 277.20897  
2H3-Octanoylcarnitine 0.076 0.0304 291.23631 313.21826  
2H9-Myristoylcarnitine 0.076 0.0304 381.36788 403.34982  
2H3-Palmitoylcarnitine 0.152 0.0608 403.36151 425.34346  
 
 
 
 
 
 
 
Appendix Table 2. Masses targeted in nS-HR-MS assay 
m/z Compound Name Adduct 
73.0290 Propionic acid [M-H]- 
 176 
74.0242 Glycine [M-H]- 
75.0082 Glycolic acid [M-H]- 
76.0399 Glycine [M+H]+ 
83.0221 Urea [M+Na]+ 
85.0290 2-Deoxytetronic acid [M-H]- 
87.0082 Pyruvic acid [M-H]- 
88.0399 Alanine [M-H]- 
88.9875 Oxalic acid [M-H]- 
89.0239 Lactic acid [M-H]- 
90.0555 Alanine [M+H]+ 
91.0395 Glycerol [M-H]- 
93.0340 Phenol [M-H]- 
96.9691 Phosphoric acid [M-H]- 
98.0218 Glycine [M+Na]+ 
101.0239 C4H6O3 (Acetoacetic acid; Ketobutyric acid) [M-H]- 
101.0603 C5H10O2 (Pivalic acid;  Valeric acid; Isovaleric acid;  2-Methylbutyric 
acid) 
[M-H]- 
102.0191 C3H5NO3 (Pyruvatoxime; 3-Oxoalanine) [M-H]- 
102.0555 C4H9NO2 (Aminobutyric acid; Dimethylglycine) [M-H]- 
103.0031 Malonic acid [M-H]- 
103.0144 Urea-1-carboxylate [M-H]- 
103.0395 C4H8O3 (Hydroxybutyric acid; Hydroxyisobutyric acid) [M-H]- 
104.0348 Serine [M-H]- 
105.0188 Glyceric acid [M-H]- 
106.0504 Serine [M+H]+ 
108.0449 Aminophenol [M-H]- 
111.0082 3-Furoic acid [M-H]- 
111.0195 Uracil [M-H]- 
111.0446 C6H8O2 (6-Hydroxy-2,4-hexadienal; Hexenedial; 4-Oxo-2-hexenal; etc) [M-H]- 
111.0534 N,N'-Dimethylurea [M+Na]+ 
112.0374 Alanine [M+Na]+ 
112.0511 Creatinine [M-H]- 
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113.0239 C5H6O3 (2-Hydroxy-2,4-pentadienoate; 3-Oxo-4-pentenoic acid) [M-H]- 
114.0555 Proline [M-H]- 
114.0667 Creatinine [M+H]+ 
115.0031 C4H4O4 (Maleic acid; Fumaric acid) [M-H]- 
115.0395 C5H8O3 (Keto-isovaleric acid;  Keto-valeric acid;  Methyl acetoacetate; 
Levulinic acid; 2-Ketovaline; 5-Oxo-pentanoic acid) 
[M-H]- 
115.0759 C6H12O2 (Methyl-valeric acid;  Diethyl-acetic acid;  Dimethyl-ethyl-
acetic acid; 3,3-Dimethyl-butanoic acid; etc) 
[M-H]- 
116.0348 C4H7NO3 (Aceturic acid; L-Aspartic acid b-semialdehyde; 2S-Amino-3-
oxo-butanoic acid) 
[M-H]- 
116.0712 Proline [M+H]+ 
116.0712 Valine [M-H]- 
117.0188 C4H6O4 (Methylmalonic acid; Succinic acid) [M-H]- 
117.0552 C5H10O3 (Hydroxyisovaleric acid; Hydroxyvaleric acid;  2-Methyl-3-
hydroxybutyric acid) 
[M-H]- 
118.0140 C3H5NO4 (Aminomalonic acid; 3-Nitropropionic acid) [M-H]- 
118.0504 Threonine [M-H]- 
118.0868 Valine [M+H]+ 
119.0344 C4H8O4 (Dihydroxybutyric acid;  Dihydroxyisobutyric acid; Erythrose; 
Erythrulose; etc) 
[M-H]- 
120.0661 Threonine [M+H]+ 
121.0290 Benzoic acid [M-H]- 
124.0068 Taurine [M-H]- 
124.9909 Hydroxyethanesulfonate [M-H]- 
128.0324 Serine [M+Na]+ 
128.0348 C5H7NO3 (Pyroglutamic acid; N-Acryloylglycine; 4-Oxoproline) [M-H]- 
129.0188 C5H6O4 (Mesaconic acid; Glutaconic acid; Citraconic acid; etc) [M-H]- 
129.0552 C6H10O3 (Mevalonolactone;  2-Methyl-3-ketovaleric acid;  2-
Ketohexanoic acid; etc) 
[M-H]- 
130.0504 C5H9NO3 (Propionylglycine; Hydroxyproline) [M-H]- 
130.0868 C6H13NO2 (Leucine; Isoleucine) [M-H]- 
131.0344 C5H8O4 (Ethylmalonic acid; Methylsuccinic acid; Glutaric acid) [M-H]- 
131.0457 Asparagine [M-H]- 
131.0708 C6H12O3 (2-Hydroxyisocaproic acid;  2-Hydroxy-3-methylvaleric acid; 
5-Hydroxyhexanoic acid) 
[M-H]- 
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131.0821 Ornithine [M-H]- 
132.0297 Aspartic acid [M-H]- 
132.0661 Hydroxyproline [M+H]+ 
132.0773 Creatine [M+H]+ 
132.1025 C6H13NO2 (Leucine; Isoleucine) [M+H]+ 
133.0137 Malic acid [M-H]- 
133.0613 Asparagine [M+H]+ 
133.0977 Ornithine [M+H]+ 
134.0453 Aspartic acid [M+H]+ 
135.0294 Erythronic acid; Threonic acid [M-H]- 
135.0446 Phenylacetic acid [M-H]- 
137.0239 4-Hydroxybenzoic acid [M-H]- 
137.0351 Urocanic acid [M-H]- 
138.0531 Proline [M+Na]+ 
140.0687 Valine [M+Na]+ 
141.0188 5-Hydroxymethyl-2-furoic acid [M-H]- 
142.0480 Threonine [M+Na]+ 
143.0344 C6H8O4 (3-Methylglutaconic acid; 2-Hexenedioic acid; 3-Hydroxyadipic 
acid 3,6-lactone) 
[M-H]- 
143.1072 C8H16O2 (Valproic acid; Caprylic acid) [M-H]- 
144.0661 C6H11NO3 (Isobutyrylglycine; Butyrylglycine) [M-H]- 
145.0137 2-Ketoglutaric acid [M-H]- 
145.0501 C6H10O4 (3-Methylglutaric acid; Adipic acid) [M-H]- 
145.0613 Glutamine [M-H]- 
145.0977 Lysine [M-H]- 
146.0453 Glutamic acid [M-H]- 
147.0294 Hydroxyglutaric acid [M-H]- 
147.0657 Mevalonic acid [M-H]- 
147.0770 Glutamine [M+H]+ 
147.1134 Lysine [M+H]+ 
148.0432 Methionine [M-H]- 
148.0610 Glutamic acid [M+H]+ 
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148.9909 Thiodiglycolic acid [M-H]- 
149.0086 Tartaric acid [M-H]- 
149.0450 Arabinose [M-H]- 
150.0589 Methionine [M+H]+ 
151.0256 Xanthine [M-H]- 
151.0395 Hydroxyphenylacetic acid [M-H]- 
152.0712 Dopamine [M-H]- 
153.0188 Gentisic acid [M-H]- 
154.0480 Hydroxyproline [M+Na]+ 
154.0617 Histidine [M-H]- 
154.0844 C6H13NO2 (Leucine; Isoleucine) [M+Na]+ 
155.0093 Orotic acid [M-H]- 
155.0433 Asparagine [M+Na]+ 
156.0661 C7H11NO3 (Tiglylglycine; 3-Methylcrotonylglycine) [M-H]- 
156.0773 Histidine [M+H]+ 
157.0362 Alantoin [M-H]- 
157.0501 Succinylacetone [M-H]- 
157.0865 C8H14O3 (2-Propyl-3-ketopentanoic acid; Alpha-ketooctanoic acid) [M-H]- 
158.0817 Isovalerylglycine, 2-Methylbutyrylglycine [M-H]- 
159.0294 Oxoadipic acid [M-H]- 
159.0657 C7H12O4 (3-Methyladipic acid; Pimelic acid) [M-H]- 
159.1021 C8H16O3 (2-Propyl-3-hydroxypentanoic acid; 2-Propyl-5-
hydroxypentanoic acid; 7-Hydroxyoctanoic acid) 
[M-H]- 
161.0450 C6H10O5 (3-Hydroxy-3-methylglutaric acid; 2-Hydroxyadipic acid) [M-H]- 
162.1130 Carnitine (C0) [M+H]+ 
163.0395 C9H8O3 (Phenylpyruvic acid; Coumaric acid) [M-H]- 
164.0712 Phenylalanine [M-H]- 
165.0552 Phenylactic acid [M-H]- 
166.0868 Phenylalanine [M+H]+ 
167.0205 Uric acid [M-H]- 
167.0344 C8H8O4 (Vanilic acid; Homogentisic acid) [M-H]- 
168.0661 Norepinephrine [M-H]- 
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169.0589 Glutamine [M+Na]+ 
171.0657 Octenedioic acid [M-H]- 
172.0408 Methionine [M+Na]+ 
172.0974 Hexanoylglycine [M-H]- 
172.9909 Phenyl sulfate [M-H]- 
173.0086 Aconitic acid [M-H]- 
173.0814 C8H14O4 (2-Propylglutaric acid; Suberic acid) [M-H]- 
173.1039 Arginine [M-H]- 
174.0402 N-Acetylaspartic acid [M-H]- 
174.0555 Indole-3-acetic acid [M-H]- 
174.0879 Citruline [M-H]- 
175.0243 Ascorbic acid [M-H]- 
175.1195 Arginine [M+H]+ 
176.1035 Citruline [M+H]+ 
178.0504 Hippuric acid [M-H]- 
178.0592 Histidine [M+Na]+ 
179.0344 Hydroxyphenylpyruvic acid [M-H]- 
179.0556 C6H12O6 (Galactose; Fructose) [M-H]- 
180.0661 Tyrosine [M-H]- 
181.0501 C9H10O4 (Homovanilic acid; Hydroxyphenylactic acid) [M-H]- 
181.0712 Galactitol [M-H]- 
182.0817 Tyrosine [M+H]+ 
182.0817 Epinephrine [M-H]- 
184.0950 Carnitine (C0) [M+Na]+ 
185.1178 C10H18O3 (Hydroxydecenoic acid; Oxo capric acid) [M-H]- 
187.0970 Azelaic acid [M-H]- 
188.0018 Aminophenol sulfate [M-H]- 
188.0687 Phenylalanine [M+Na]+ 
188.9858 Pyrocathechol sulfate [M-H]- 
189.0763 3-Hydroxysuberic acid [M-H]- 
191.0192 Citric acid [M-H]- 
194.0453 2-Hydroxyhippuric acid [M-H]- 
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195.0505 C6H12O7 (Gluconic acid; Galactonic acid) [M-H]- 
196.0610 L-3,4-Dihydroxyphenylalanine [M-H]- 
196.0974 Metanephrine [M-H]- 
197.0450 Vanilmandelic acid [M-H]- 
198.0855 Citruline [M+Na]+ 
199.0970 Decenedioic acid [M-H]- 
201.1127 Sebacic acid [M-H]- 
203.0532 C6H12O6 (Galactose; Fructose) [M+Na]+ 
203.0821 Trytophan [M-H]- 
204.0637 Tyrosine [M+Na]+ 
204.0661 Indolelactic acid [M-H]- 
204.1236 Acetylcarnitine (C2) [M+H]+ 
205.0348 Methylcitric acid [M-H]- 
205.0688 Galactitol [M+Na]+ 
205.0977 Trytophan [M+H]+ 
206.0817 Phenylpropionylglycine [M-H]- 
215.1032 Diacetylornithine [M-H]- 
215.1647 3-Hydroxydodecanoic acid [M-H]- 
216.9807 Hydroxybenzoic acid sulfate [M-H]- 
217.1076 Hydroxysebacic acid [M-H]- 
218.1028 Pantothenic acid [M-H]- 
218.1392 Propionylcarnitine (C3) [M+H]+ 
220.0821 N-Acetylhexosamine [M-H]- 
225.0875 Porphobilinogen [M-H]- 
226.1055 Acetylcarnitine (C2) [M+Na]+ 
227.0796 Tryptophan [M+Na]+ 
227.2011 Myristic acid [M-H]- 
230.1028 Suberylglycine [M-H]- 
232.1549 Butyrylcarnitine (C4) [M+H]+ 
232.9756 Gentisic acid sulfate [M-H]- 
238.9862 Oxoadipic acid sulfate [M-H]- 
239.0160 Cystine [M-H]- 
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239.9967 Dihydroxyquinoline sulfate [M-H]- 
240.1212 Propionylcarnitine (C3) [M+Na]+ 
242.0123 Methyldioxyindole sulfate [M-H]- 
242.9963 Coumaric acid sulfate [M-H]- 
243.0617 Uridine [M-H]- 
244.1549 Tiglylcarnitine (C5:1) [M+H]+ 
245.1389 3-Hydroxydodecanedioic acid [M-H]- 
246.1705 Isovalerylcarnitine (C5) [M+H]+ 
248.1134 Malonylcarnitine (C3DC) [M+H]+ 
249.0069 3,4-Dihydroxyphenylglycol O-sulfate [M-H]- 
254.1368 Butyrylcarnitine (C4) [M+Na]+ 
254.9811 Ascorbate sulfate [M-H]- 
255.2324 Palmitic acid [M-H]- 
259.0219 Galactose-1-phosphate [M-H]- 
260.1862 Hexanoylcarnitine (C6) [M+H]+ 
262.1291 Succinylcarnitine (C4DC) [M+H]+ 
262.1654 3-Hydroxyisovalerylcarnitine (C5OH) [M+H]+ 
263.1032 Phenylacetylglutamine [M-H]- 
266.1368 Tiglylcarnitine (C5:1) [M+Na]+ 
268.1525 Isovalerylcarnitine (C5) [M+Na]+ 
269.0661 Phenol glucuronide [M-H]- 
269.2481 Heptadecanoic acid [M-H]- 
270.0954 Malonylcarnitine (C3DC) [M+Na]+ 
273.0069 Ferrulic acid sulfate [M-H]- 
275.2011 Stearidonic acid [M-H]- 
276.1447 Glutarylcarnitine (C5DC) [M+H]+ 
277.2168 Alpha-linolenic acid [M-H]- 
279.2324 Linoleic acid [M-H]- 
281.2481 Oleic acid [M-H]- 
282.1681 Hexanoylcarnitine (C6) [M+Na]+ 
283.2637 Stearic acid [M-H]- 
284.1110 Succinylcarnitine (C4DC) [M+Na]+ 
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284.1474 3-Hydroxyisovalerylcarnitine (C5OH) [M+Na]+ 
285.0610 Pyrocathechol [M-H]- 
288.2175 Octanoylcarnitine (C8) [M+H]+ 
291.1305 Argininosuccinate [M+H]+ 
297.0974 Phenylethanol glucuronide [M-H]- 
298.1267 Glutarylcarnitine (C5DC) [M+Na]+ 
300.0389 N-Acetylhexosamine sulfate [M-H]- 
301.2168 Eicosapentaenoic acid [M-H]- 
302.1604 C6DC acylcarnitine [M+H]+ 
303.2324 Arachidonic acid [M-H]- 
305.2481 Eicosatrienoic acid [M-H]- 
306.0760 Glutathione [M-H]- 
307.2637 Eicosadienoic acid [M-H]- 
308.0916 Glutathione [M+H]+ 
309.2794 Gondoic acid [M-H]- 
310.1994 Octanoylcarnitine (C8) [M+Na]+ 
311.2950 Arachidic acid [M-H]- 
312.2175 Decadienoylcarnitine (C10:2) [M+H]+ 
314.2331 Decenoylcarnitine (C10:1) [M+H]+ 
316.2488 Decanoylcarnitine (C10) [M+H]+ 
327.2324 Docosahexaenoic acid [M-H]- 
329.2481 Docosapentaenoic acid [M-H]- 
333.2794 Adrenic acid [M-H]- 
334.1994 Decadienoylcarnitine (C10:2) [M+Na]+ 
335.2950 Docosadienoic acid [M-H]- 
336.2151 Decenoylcarnitine (C10:1) [M+Na]+ 
337.3107 Erucic acid [M-H]- 
338.2307 Decanoylcarnitine (C10) [M+Na]+ 
339.3263 Behenic acid [M-H]- 
344.2801 Lauroylcarnitine (C12) [M+H]+ 
355.2637 Tetracosahexaenoic acid [M-H]- 
355.3212 2-Hydroxydocosanoic acid [M-H]- 
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357.2794 Tetracosapentaenoic acid [M-H]- 
366.2620 Lauroylcarnitine (C12) [M+Na]+ 
367.3576 Lignoceric acid [M-H]- 
368.2801 Tetradecadienoylcarnitine (C14:2) [M+H]+ 
370.2957 Tetradecenoylcarnitine (C14:1) [M+H]+ 
372.3114 Myristoylcarnitine (C14) [M+H]+ 
373.2743 Hydroxy-cholenoic acid [M-H]- 
388.3063 3-Hydroxy-tetradecanoylcarnitine (C14OH) [M+H]+ 
389.2692 Dihydroxy-cholenoic acid [M-H]- 
390.2620 Tetradecadienoylcarnitine (C14:2) [M+Na]+ 
391.2848 C24H40O4 (Deoxycholic acid; Chenodeoxycholic acid; Ursodeoxycholic 
acid) 
[M-H]- 
392.2777 Tetradecenoylcarnitine (C14:1) [M+Na]+ 
394.2933 Myristoylcarnitine (C14) [M+Na]+ 
395.3889 Cerotic acid [M-H]- 
398.3270 Palmitoleoylcarnitine (C16:1) [M+H]+ 
400.3427 Palmitoylcarnitine (C16) [M+H]+ 
410.2882 3-Hydroxy-tetradecanoylcarnitine (C14OH) [M+Na]+ 
413.2668 Dihydroxy-cholenoic acid [M+Na]+ 
415.3212 Hydroxy-cholestenoic acid [M-H]- 
416.3376 3-Hydroxy-hexadecanoylcarnitine (C16OH) [M+H]+ 
417.3369 Hydroxy-cholestanoic acid [M-H]- 
420.3090 Palmitoleoylcarnitine (C16:1) [M+Na]+ 
422.3246 Palmitoylcarnitine (C16) [M+Na]+ 
423.2512 PA (17:0) [M-H]- 
424.3427 Linoleylcarnitine (C18:2) [M+H]+ 
426.3583 Oleylcarnitine (C18:1) [M+H]+ 
428.3740 Stearoylcarnitine (C18) [M+H]+ 
431.3161 Dihydroxy-cholestenoic acid [M-H]- 
433.3318 Dihydroxy-cholestanoic acid [M-H]- 
438.3195 3-Hydroxy-hexadecanoylcarnitine (C16OH) [M+Na]+ 
439.3188 Hydroxy-cholestenoic acid [M+Na]+ 
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440.3376 3-Hydroxy-linoleylcarnitine (C18:2OH) [M+H]+ 
441.3345 Hydroxy-cholestanoic acid [M+Na]+ 
442.3532 3-Hydroxy-octadecenoylcarnitine (C18:1OH) [M+H]+ 
444.3689 3-Hydroxy-octadecanoylcarnitine (C18OH) [M+H]+ 
445.2954 Dihydroxy-oxocholestenoic acid [M-H]- 
446.3246 Linoleylcarnitine (C18:2) [M+Na]+ 
447.3111 Trihydroxy-cholestenoic acid [M-H]- 
448.3063 Glycochenodeoxycholic acid [M-H]- 
448.3403 Oleylcarnitine (C18:1) [M+Na]+ 
449.3267 Trihydroxy-cholestanoic acid [M-H]- 
450.3559 Stearoylcarnitine (C18) [M+Na]+ 
450.3583 C20:3 acylcarnitine [M+H]+ 
452.3740 C20:2 acylcarnitine [M+H]+ 
455.3137 Dihydroxy-cholestenoic acid [M+Na]+ 
457.3294 Dihydroxy-cholestanoic acid [M+Na]+ 
461.2903 Trihydroxy-oxocholestenoic acid [M-H]- 
462.3195 3-Hydroxy-linoleylcarnitine (C18:2OH) [M+Na]+ 
463.3060 Tetrahydroxy-cholestenoic acid [M-H]- 
464.3012 Glycocholic acid [M-H]- 
464.3352 3-Hydroxy-octadecenoylcarnitine (C18:1OH) [M+Na]+ 
465.3039 Cholesterol-sulfate [M-H]- 
466.3508 3-Hydroxy-octadecanoylcarnitine (C18OH) [M+Na]+ 
469.2930 Dihydroxy-oxocholestenoic acid [M+Na]+ 
471.3086 Trihydroxy-cholestenoic acid [M+Na]+ 
473.3243 Trihydroxy-cholestanoic acid [M+Na]+ 
478.2934 C23H46NO7P (Lyso-PE (18:1); Lyso-PC (15:1)) [M-H]- 
481.2988 26-Hydroxycholesterol-3-sulfate [M-H]- 
485.2879 Trihydroxy-oxocholestenoic acid [M+Na]+ 
487.3036 Tetrahydroxy-cholestenoic acid [M+Na]+ 
496.3385 C24H50NO7P (Lyso-PC (16:0); Lyso-PE (19:0) [M+H]+ 
498.2889 Taurochenodeoxycholic acid [M-H]- 
500.2777 Lyso-PE (20:4) [M-H]- 
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514.2839 Taurocholic acid [M-H]- 
518.3205 Lyso-PC (18:3) [M+H]+ 
549.3556 PA (13:0/12:0) [M-H]- 
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ABSTRACT: Ascarosides are small-molecule signals that play
a central role in C. elegans biology, including dauer formation,
aging, and social behaviors, but many aspects of their
biosynthesis remain unknown. Using automated 2D NMR-
based comparative metabolomics, we identiﬁed ascaroside
ethanolamides as shunt metabolites in C. elegans mutants of
daf-22, a gene with homology to mammalian 3-ketoacyl-CoA thiolases predicted to function in conserved peroxisomal lipid β-
oxidation. Two groups of ethanolamides feature β-keto functionalization conﬁrming the predicted role of daf-22 in ascaroside
biosynthesis, whereas α-methyl substitution points to unexpected inclusion of methylmalonate at a late stage in the biosynthesis
of long-chain fatty acids in C. elegans. We show that ascaroside ethanolamide formation in response to defects in daf-22 and other
peroxisomal genes is associated with severe depletion of endocannabinoid pools. These results indicate unexpected interaction
between peroxisomal lipid β-oxidation and the biosynthesis of endocannabinoids, which are major regulators of lifespan in C.
elegans. Our study demonstrates the utility of unbiased comparative metabolomics for investigating biochemical networks in
metazoans.
The free-living nematode Caenorhabditis elegans is usedextensively as a model system for the study of aging and
metabolism.1−3 Recent analyses of the C. elegans metabolome
revealed a family of structurally diverse small molecules, the
ascarosides, as products of conserved peroxisomal β-oxidation
(Figure 1).4−6 The ascarosides form a modular compound
library, integrating building blocks from lipid, carbohydrate and
amino acid metabolism into small molecule signals that regulate
key aspects of C. elegans biology, including dauer formation and
social behaviors.7−10 Previous work used mass spectrometry-
based comparative metabolomics to characterize the functions
of three enzymes in ascaroside biosynthesis, the acyl-CoA
oxidase ACOX-1, the enoyl-CoA hydratase MAOC-1, and the
3-hydroxyacyl-CoA dehydrogenase DHS-28 (Figure 1b).4
However, the predicted role of the fourth enzyme in the
peroxisomal β-oxidation cascade, which is encoded by the gene
daf-22, a close homologue of mammalian 3-keto-acyl-CoA
thiolases, could not be conﬁrmed because no characteristic
shunt metabolites were found. Given the central role of daf-22
in the proposed peroxisomal β-oxidation pathway, we
hypothesized that other, yet unidentiﬁed metabolites accumu-
late in daf-22 mutants, which may help conﬁrm the biochemical
function of this enzyme and provide insight into interactions
with other biochemical pathways.
Therefore, we reinvestigated the daf-22 metabolome using
unbiased NMR spectroscopy-based metabolomics. Previously,
we had employed manual comparisons of 2D NMR spectra of
wild-type and daf-22 metabolomes to identify additional
members of the ascaroside family of signaling molecules.6,9,11
These studies highlighted the utility of 2D NMR spectra for
comparative metabolomics but also demonstrated the need for
computational tools that would enable statistical analysis of
series of spectra from diﬀerent mutants. For this purpose, we
developed multivariate Diﬀerential Analysis by 2D NMR
Spectroscopy (mvaDANS), which enables automated process-
ing and comparative computational analysis for sets of 2D
NMR spectra.
mvaDANS builds on previous eﬀorts to use 2D NMR for
metabolomic analysis by incorporating dynamic signal
detection and pattern recognition (see Methods).12−18 Figure
2 summarizes the use of this approach for identifying
compounds that are upregulated in daf-22 mutants and thus
may represent shunt metabolites or biosynthetic intermediates.
We acquired dqfCOSY spectra for metabolome extracts
obtained from two diﬀerent daf-22 alleles (m130, ok693) and
wild-type C. elegans, including four independent biological
replicates (Figure 2a, Supplementary Figures S1 and S2).
Automatic crosspeak identiﬁcation and binning (Supplemen-
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tary Figure S3) prepared the dqfCOSY spectra for statistical
analysis via Principal Component Analysis (PCA, see
Methods),19 which clustered the data by genotype (Figures
2a). Coeﬃcients from the PCA loadings were back-projected
onto the dqfCOSY spectra, which revealed a large number of
crosspeaks that are up- or downregulated in daf-22 mutants
relative to wild-type (Figures 2a, Supplementary Figures S4 and
S5).
For this study, we restricted analysis to crosspeaks that were
strongly featured in spectra from both daf-22 alleles but were
very weak or undetectable in wild-type. Furthermore, we
excluded crosspeaks also present in the E. coli food source.
Manual analysis of the remaining strongly daf-22-upregulated
crosspeaks and inputs from additional HMBC spectra
suggested a series of partial structures, including methyl
ketones, α-methyl branched fatty acids, and corresponding
ethanolamides, as well as β-keto fatty acid derivatives (Figure
2b). Considering the proposed role of daf-22 in ascaroside
biosynthesis (Figure 1b), we hypothesized that these structural
features belong to accumulated shunt metabolites. Subsequent
fractionation of the daf-22 metabolome guided by the daf-22-
speciﬁc NMR signals led to isolation of representative members
of six diﬀerent families of very long-chain ascarosides (VLCA)
that account for all of the predicted structural features (Figure
3, see Supporting Information for full spectroscopic data).
None of these daf-22 mutant-speciﬁc compounds had
previously been reported. Most prominent are a series of (ω-
1)-O-ascarosyl 2-ketones (12), as well as (ω-1)-O-ascarosyl 3-
keto fatty acid ethanolamides, which include the 2-methyl
pentacosanoic acid derivative 7 and the straight-chain
heptacosanoic acid derivative 8. Compounds 7 and 8 are
accompanied by smaller amounts of the corresponding bis-
norhomologues. Similarly, the 2-methyl pentacos-2-enoic acid
ethanolamide 9 and the two fatty acids 10 and 11 are
accompanied by bis-norhomologues. In contrast, chain lengths
of the (ω-1)-O-ascarosyl 2-ketones (12) vary more broadly and
are not preferentially odd-numbered (Figure 3c). HPLC−MS
analysis conﬁrmed the absence of these components in wild-
type samples (Figure 3a).
The incorporation of ethanolamine in the daf-22 speciﬁc
VLCAs was unexpected and suggested the possibility of
interactions between peroxisomal β-oxidation and ethanola-
mide-based signaling pathways. Recently, N-acyl-ethanolamines
(NAEs) were identiﬁed as endocannabinoid-like signaling
molecules in C. elegans and linked to dietary restriction-
dependent lifespan regulation.20 We asked whether the
upregulation of VLCAs in daf-22 mutants aﬀects NAE levels.
We found that NAE production, including the most active
endocannabinoid in C. elegans,20 eicosapentaenoyl ethanola-
mide (13, EPEA), and the ligand of mammalian cannabinoid
receptors, arachidonoyl ethanolamide (AEA, or anandamide),
was dramatically downregulated in both daf-22 alleles (Figure
3d and Supplementary Figure S6), suggesting a shift of
Figure 1. Ascarosides are signaling molecules in C. elegans. (a)
Example structures and biological functions of ascaroside-based
signaling molecules in C. elegans. (b) Model for peroxisomal
biosynthesis of ascaroside side chains and roles of peroxisomal β-
oxidation enzymes ACOX-1, MAOC-1, DHS-28, and the putative 3-
ketoacyl-CoA thiolase DAF-22.
Figure 2. mvaDANS reveals structural motifs upregulated in daf-22
mutants. (a) Schematic overview of mvaDANS for identiﬁcation of up-
and downregulated metabolites in daf-22 mutants. In the principal
component analysis (PCA), PC 1 separates the four wild-type data sets
(blue dots) from both daf-22 mutant data sets (red and brown dots),
whereas PC2 separates the two daf-22 alleles. In the back projection
(lower left), the coloring of cross speaks corresponds to the PC 1
loading coeﬃcients; blue peaks represent signals downregulated and
red peaks signals upregulated in the two daf-22 mutant strains. See
Supplementary Figure S4 for actual spectra. (b) Partial structures
inferred from manual analysis of daf-22-speciﬁc crosspeaks suggesting
α-methyl branched fatty acids, methyl ketones, and β-keto fatty acid
derivatives.
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ethanolamine utilization from the NAEs to VLCAs. Similarly,
we found greatly reduced EPEA and AEA production in
mutants of maoc-1 and dhs-28 (Figure 3d and Supplementary
Figure S6), which act directly upstream of daf-22 (Figure 1b).
EPEA-levels in acox-1 mutant worms were not signiﬁcantly
aﬀected, and AEA levels only slightly decreased, corresponding
to the much weaker eﬀect of the acox-1 mutation on
peroxisomal β-oxidation.4 EPEA and AEA production was not
rescued by growing daf-22 worms with addition of synthetic
ascarosides (Figure 3d and Supplementary Figure S6),
suggesting that the observed reduction of NAE levels in
peroxisomal β-oxidation mutants is not an indirect eﬀect of the
lack of ascaroside pheromone. These ﬁndings indicate that in C.
elegans speciﬁc defects in peroxisomal β-oxidation result in
depletion of endocannabinoid pools (Figure 3e). It is unknown
whether conditions that reduce expression of peroxisomal β-
oxidation genes in healthy animals trigger down-regulation of
endocannabinoids, which could serve as a regulatory mecha-
nism tying fat metabolism and ascaroside signaling to dietary
restriction pathways. Ethanolamides of short-chain ascarosides
serve as pheromones in a parasitic nematode species,21
suggesting that interactions of peroxisomal β-oxidation and
ethanolamide metabolism also exist in other nematode genera.
Mammalian homologues of daf-22 are thought to be
speciﬁcally required for chain shortening of branched-chain
fatty acids such as phytanic acid.22,23 However, the co-
occurrence of straight-chain and methyl-branched derivatives
among the daf-22 mutant-speciﬁc VLCAs suggests that daf-22 is
involved in processing of both branched and straight-chain fatty
acids. The chain lengths of the daf-22 mutant-speciﬁc VLCAs
indicate that 23- to 27-carbon fatty acids may represent end
points of C. elegans fatty acid biogenesis, in which the last chain-
extension step incorporates either malonate or methylmalonate.
Notably, our metabolomic analyses provided no evidence for
incorporation of methylmalonate at earlier stages in the
biosynthesis of these fatty acid derivatives. The chain lengths
of the daf-22 mutant-upregulated VLCAs in C. elegans are
similar to those of very long-chain fatty acids that accumulate in
human disorders involving defects in peroxisomal β-oxidation
such as Zellweger syndrome.22,23 However, human fatty acid
biosynthesis is not known to selectively incorporate propionate
or methylmalonate in the last chain-extension step to form α-
methyl-branched variants.
In a biosynthetic model (Figures 1b, 3e), the identiﬁed daf-
22 mutant-speciﬁc compounds plausibly represent shunt
metabolites derived from fatty-acid and β-keto-acid CoA esters,
in which the α,β-unsaturation and β-keto functionalities result
from upstream action of ACOX-1, MAOC-1, and DHS-28. The
daf-22-upregulated long-chain methyl ketones may derive from
corresponding β-keto fatty acids, which are highly prone to
decarboxylation. Although described in an earlier study,5 we
could not ﬁnd any evidence for β-keto fatty acids in our
metabolite extracts by either NMR spectroscopy or HPLC−
MS. The odd-numbered side-chain lengths of the daf-22-
upregulated ascarosyl fatty acids are consistent with the
structures of the known end products of peroxisomal β-
oxidation, the short-chain ascaroside pheromones, most of
which include side chains with 3, 5, 7, or 9 carbons (Figure
Figure 3. Long-chain ascarosides identiﬁed in the daf-22 mutant metabolome and interaction with NAE biosynthesis. (a) HPLC−MS analysis
conﬁrms long-chain ascarosides and ethanolamides in the daf-22 metabolome that are absent in wild-type. (b) daf-22 mutant-speciﬁc VLCAs
identiﬁed via mvaDANS and subsequent HPLC−MS analysis. (c) Quantitative distribution of daf-22-upregulated ascarosyl methylketones. (d)
Mutation of maoc-1, dhs-28, and daf-22 greatly reduces EPEA production and addition of ascarosides (2.5 μM ascr#3 and ascr#9, see ref 4 for
structures) to daf-22(m130) cultures does not rescue EPEA production. *P < 0.05, **P < 0.01, ***P < 0.001. (e) Interactions of peroxisomal β-
oxidation and endocannabinoid biosynthesis. Mutation of daf-22 abolishes processing of long-chain ascaroside CoA esters, whose conversion into
ethanolamides is associated with reduced endocannabinoid production,13 likely due to depletion of phosphatidylethanolamine pools.
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1a).4 These odd-numbered side chains further suggest that
ascaroside side-chain biosynthesis starts with a three-carbon
(methylmalonate-derived) template or that C. elegans elongates
odd-numbered fatty acids obtained from food.
In conclusion, mvaDANS-based comparison of daf-22 and
wild-type metabolomes revealed long-chain ascarosyl ethanola-
mides as an unexpected class of shunt metabolites in daf-22
mutant worms. The abundance of β-keto derivatives and
methyl ketones among the identiﬁed long-chain ascarosides
supports that daf-22 acts as a thiolase in ascaroside pheromone
biosynthesis, as had been suspected on the basis of homology
to mammalian peroxisomal thiolases. Our results will motivate
more detailed inspection of similarities of nematode and
mammalian fatty-acid metabolism, especially with regard to
possible interactions between endocannabinoid signaling,
phosphatidylethanolamine utilization, and peroxisomal β-
oxidation. In C. elegans, reduced NAE levels promote dietary-
restriction-induced lifespan extension,20 suggesting that defects
in peroxisomal β-oxidation may aﬀect lifespan via changes in
NAE levels.
Untargeted comparative metabolomics will form an
important tool for reinvestigating metazoan biochemistry.
mvaDANS extends the scope of 2D NMR-based metabolomic
analysis24−26 by introducing automated cross-peak identiﬁca-
tion and integration. Whereas pattern recognition techniques
have been applied previously to 2D NMR spectra, these
approaches have either relied on manual peak selection,27
parametric approaches,28 or used spectral unfolding/refolding
techniques.10,11 We expect that advances in statistical spectros-
copy will continue to accelerate the structural and functional
characterization of biogenic small molecules.
■ METHODS
C. elegans Strains and General Culture Methods. Wild-type C.
elegans (N2, Bristol), daf-22(m130), daf-22(ok693), acox-1(ok2257),
maoc-1(hj13), and dhs-28(hj8) mutant strains were obtained from the
Caenorhabditis Genetics Center (CGC). Strains were maintained at 20
°C on NGM plates with bacteria (E. coli OP50) as food.
Preparation of C. elegans Metabolite Extracts. Liquid cultures
were grown as previously reported.3 Brieﬂy, wild-type or daf-22 mutant
worms were grown for two generations on NGM plates seeded with
OP50. Three crowded 6 cm NGM plates were washed into 100 mL
solution of S-medium in a 500 mL Erlenmeyer ﬂask and grown at 22
°C and 220 rpm. Concentrated OP50 from 1 L bacterial cultures,
grown overnight, were given on day 1 and day 3. On day 5 the liquid
culture was split into two 500 mL Erlenmeyer ﬂasks, and the growth
media volume was maintained at 100 mL. An additional 1 L OP50
pellet was given as food upon splitting. The cultures were harvested on
day 7 by centrifugation at 4750 rpm. The supernatant was lyophilized,
and the residue was extracted with 95% ethanol (300 mL) at RT for 12
h. The resulting suspension was ﬁltered and evaporated in vacuo at RT
to yield the crude extracts. In this manner four extracts each of wild-
type (N2), daf-22(m130), and daf-22(ok693) cultures were prepared.
For NAE quantiﬁcation, mutant strains were grown as above in
duplicate. Liquid cultures for ascaroside mixture experiments were
prepared as described above with addition of 2.5 μM of ascr#3 and 2.5
μM of ascr#9 at day 0.
In preparation for NMR spectroscopic analysis, the crude extracts
were suspended in 1:8 methanol (MeOH)/dichloromethane (DCM),
using 7.5 mL of this solvent mixture per 1 g of crude extract. Following
centrifugation, 2 mL aliquots of supernatant of each sample were
ﬁltered over 1 g of silica (EMD Chemicals Inc.) using 10 mL of 1:8
MeOH/DCM for elution. The ﬁltrate was evaporated to dryness in
vacuo prior to analysis. For NMR spectroscopic analysis, 10−20 mg of
the resulting metabolite extracts was used.
Preparation of Bacterial Metabolite Extracts. E. coli OP50 was
grown overnight at 37 °C and 220 rpm to an OD of 1.2 in 2 L of
Lysogeny broth (LB). The bacterial broth was spun for 20 min at 4750
rpm. The supernatant was then lyophilized, crushed with mortar and
pestle, and extracted with 150 mL 95% ethanol (2 times). The extract
was ﬁltered through a sintered crucible and concentrated in vacuo prior
to analysis.
Mass Spectrometric Analysis. Metabolite extracts prepared as
described above were resuspended in 1.5 mL methanol and
centrifuged, and 30 μL of this sample was injected into HPLC−MS
for analysis. HPLC−MS analysis was performed using the Agilent
1100 Series HPLC system with an Agilent Eclipse XDB-C18 column
(9.4 mm × 250 mm, 5 μm particle diameter) connected to the
Quattro II mass spectrometer using a 10:1 split. For short chain
ascarosides, a 0.1% aqueous acetic acid−acetonitrile gradient was used.
The gradient started with 5% acetonitrile for 5 min and then increased
to 100% acetonitrile over 32 min. For long chain ascarosides, an
acetonitrile−isopropanol gradient was used, starting with 5%
isopropanol in acetonitrile for 5 min; then isopropanol was increased
to 75% over 32 min. Samples were analyzed by HPLC−ESI-MS in
negative and positive ion modes using a capillary voltage of 3.5 kV and
a cone voltage of −40 V and +20 V, respectively. The elemental
composition of the long chain ascarosides was performed by high
resolution MS and HPLC−MS using the Xevo G2 QTof.
EPEA and AEA (14) were quantiﬁed by HPLC−MS (using the
Quattro II mass spectrometer) using a water (0.1% acetic acid)−
acetonitrile gradient as described above for short chain ascarosides.
The retention time of EPEA and AEA were established by injection of
an authentic standard (Enzo Life Sciences and Cayman Chemicals,
respectively). Relative endocannabinoid content in wild-type and
mutant strains was quantiﬁed by integration of LC−MS signals from
corresponding ion traces for (M − H)− or (M + Cl)−. All integration
values were normalized by the liquid culture pellet dry weight. All
quantitative data reported in Figure 3 were from at least two
independent biological repeats.
NMR Spectrometric Analysis. NMR samples were prepared by
dissolving 10−20 mg portions of metabolite extract (see above) in 0.6
mL of CD3OD. Samples were analyzed using a Varian INOVA 600
MHz NMR spectrometer. Nongradient phase-cycled dqfCOSY spectra
were truncated at 0.4 s and acquired using the following parameters:
0.8 s acquisition time, 600 complex increments, 16 scans per
increment. For processing with mvaDANS, spectra were zero-ﬁlled
to 2048 × 1024 data points, a sine-square-shaped window function was
applied in both dimensions prior to Fourier transformation, and
spectra were converted to magnitude mode prior to transfer to
MATLAB.
For detailed analysis in phase-sensitive mode, dqfCOSY spectra
were zero-ﬁlled to 8192 × 4096 data points and a cosine bell-shaped
window function was applied in both dimensions before Fourier
transformation. Gradient and nongradient HSQCAD and HMBC
spectra of enriched fractions of daf-22-upregulated metabolites were
acquired using 8−32 scans, 0.25 s acquisition time, and 256−500
complex increments. NMR spectra were processed using Bruker
TopSpin, Varian VNMR, MestreLabs’ MestReC, and MNova software
packages.
Isolation of Major daf-22-Upregulated Metabolites. To 8 g of
Celite (prewashed with ethyl acetate) was added a solution of daf-22
metabolite extract from 16 100-mL liquid cultures. After evaporation
of the solvent, the material was dry-loaded into an empty 25 g RediSep
Rf loading cartridge. Fractionation was performed using a Teledyne
ISCO CombiFlash system over a RediSep Rf GOLD 40 g HP Silica
Column using a normal phase dichloromethane−methanol solvent
system, starting with 6 min of 100% dichloromethane, followed by a
linear increase of methanol content up to 10% at 24 min, followed by
another linear increase of methanol content up to 40% at 40 min,
followed by another linear increase of methanol content up to 95% at
45 min, which was then continued to 48 min. This yielded 70 fractions
(∼20 mL each), which were individually evaporated in vacuo and
analyzed by NMR spectroscopy (1H NMR, dqfCOSY) and HPLC−
MS. 1H NMR spectroscopic signals identiﬁed via mvaDANS as
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representing daf-22-upregulated metabolites were detected in fractions
35−45. Isolation of major daf-22-upregulated metabolites was achieved
by preparative HPLC using the same HPLC method described above
for HPLC−MS analysis of long chain ascarosides. Fractions containing
daf-22-upregulated metabolites were characterized further by
dqfCOSY, HSQC, and HMBC as well as high-resolution HPLC−
MS using the Xevo G2 QTof.
Statistical Analysis. Figure 3d and Supplementary Figure S6: we
used unpaired student’s t tests with Welch’s correction for comparing
the relative abundance of EPEA and AEA in wild type and mutant
strains. *P < 0.05, **P < 0.01, ***P < 0.001.
mvaDANS Analysis. For identiﬁcation of daf-22-upregulated
metabolites via mvaDANS, we acquired dqfCOSY spectra for
metabolome extracts obtained from two diﬀerent daf-22 alleles
(m130, ok693) and wild-type C. elegans (Figure 2, Supplementary
Figures S1 and S2). dqfCOSY spectra from four independent
biological replicates were processed in magnitude mode using the
mvaDANS algorithm in Matlab, which incorporated dynamic binning
and multivariate pattern recognition analysis (Supplementary Figure
S3). Automatic cross peak identiﬁcation and binning converted each of
the dqfCOSY spectra into a set of crosspeak integrals, which were
corrected for dilution using Probabilistic Quotient Normalization,29
mean-centered, and scaled to unit variance. This matrix of bin integrals
was then subjected to statistical analysis including two-way hierarchical
clustering, Principal Component Analysis (PCA) (Figure 2a)19 and
Partial Least Squares-Discriminant Analysis (PLS-DA) (Supplemen-
tary Figure S7).30 Coeﬃcients from PCA loadings and PLS-DA
predictors were back-projected onto the dqfCOSY spectra to enable
the detection of NMR spectroscopic signals representing compounds
diﬀerentially expressed in the three C. elegans strains (Supplementary
Figures S4, S8).
mvaDANS Automation and Spectral Interpretation. Please
see Supporting Information.
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ABSTRACT: Nuclear magnetic resonance (NMR) is the most
widely used nondestructive technique in analytical chemistry. In
recent years, it has been applied to metabolic proﬁling due to its
high reproducibility, capacity for relative and absolute quantiﬁ-
cation, atomic resolution, and ability to detect a broad range of
compounds in an untargeted manner. While one-dimensional
(1D) 1H NMR experiments are popular in metabolic proﬁling
due to their simplicity and fast acquisition times, two-dimen-
sional (2D) NMR spectra oﬀer increased spectral resolution as
well as atomic correlations, which aid in the assignment of
known small molecules and the structural elucidation of novel
compounds. Given the small number of statistical analysis methods for 2D NMR spectra, we developed a new approach for the
analysis, information recovery, and display of 2D NMR spectral data. We present a native 2D peak alignment algorithm we term
HATS, for hierarchical alignment of two-dimensional spectra, enabling pattern recognition (PR) using full-resolution spectra.
Principle component analysis (PCA) and partial least squares (PLS) regression of full resolution total correlation spectroscopy
(TOCSY) spectra greatly aid the assignment and interpretation of statistical pattern recognition results by producing back-scaled
loading plots that look like traditional TOCSY spectra but incorporate qualitative and quantitative biological information of the
resonances. The HATS-PR methodology is demonstrated here using multiple 2D TOCSY spectra of the exudates from two
nematode species: Pristionchus paciﬁcus and Panagrellus redivivus. We show the utility of this integrated approach with the rapid,
semiautomated assignment of small molecules diﬀerentiating the two species and the identiﬁcation of spectral regions suggesting the
presence of species-speciﬁc compounds. These results demonstrate that the combination of 2D NMR spectra with full-resolution
statistical analysis provides a platform for chemical and biological studies in cellular biochemistry, metabolomics, and chemical
ecology.
Nuclear magnetic resonance (NMR) is a powerful and almostuniversal detector due to its ability to analyze essentially all
types of molecules at atomic resolution. Recently, it has been
applied extensively to metabolic proﬁling in studies of human
and animal bioﬂuids,1,2 cellular biochemistry,3,4 and nonmam-
malian chemical ecology.5-8 While one-dimensional (1D) 1H
NMR spectra have been used in the majority of NMR-based
metabolic proﬁling studies, resonance overlap and lack of stru-
ctural correlations can limit the utility of the 1D approach. In
contrast, powerful multidimensional NMR methods are routi-
nely used in structural biology and natural products studies9 but
have been used much less frequently for metabolomics. Two
dimensional (2D) homonuclear (such as total correlation spectros-
copy (TOCSY) and correlation spectroscopy (COSY)) andhetero-
nuclear (such as heteronuclear single quantum coherence (HSQC)
and heteronuclear multiple-bond correlation (HMBC)) spectra
oﬀer increased dispersion of signals in two dimensions that can
overcome the problem of signal overlap, which often limits the
use of 1D 1H NMR spectra. Additionally, the information
provided by these 2D experiments through speciﬁc atomic
correlations can assist in the identiﬁcation and assignment of
known molecules and the structural elucidation of unknown
small molecules that may be signiﬁcant to the underlying biology.
The presence of novel, uncharacterized small molecules in
complex biological mixtures is a frequent occurrence, especially
in nonmammalianmetabolomics where a priori knowledge of the
metabolome is often incomplete. Even when complex biological
mixtures are composed mainly of known metabolites, the assign-
ment of a large number of spectral peaks is a signiﬁcant
complication for metabolic proﬁling. The use of 2D correlation
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spectra such as TOCSY simplify the use of semiautomated assign-
ment platforms such as MetaboMiner10 and COLMAR.11-13
While it is clear that metabolic proﬁling would beneﬁt from
more extensive use of 2D NMR spectra, preprocessing methods
such as signal alignment and visualization tools for multiple 2D
spectra have lagged behind similar methods for 1D spectra. The
importance of signal alignment for statistical analysis of spectral
data sets is widely appreciated by the metabolomics community
for both NMR14,15 and mass spectrometry.16,17 The develop-
ment of 1D alignment methods has allowed these spectra to be
analyzed with increasing accuracy and resolution. However, the
relative paucity of 2D spectral alignment18 and analysis methods
has meant that metabolomics studies making use of 2D spectra
have relied on low-resolution bins or crosspeak integrals to avoid
the problem of peak shift.19-21 While often quite successful
in mitigating the eﬀects of chemical shift variation, the use of
integrals or bins for pattern recognition causes signiﬁcant loss of
valuable information from spectral resolution, complicating
subsequent model interpretation and assignment of relevant
metabolites. Here, we present a method for hierarchical align-
ment of sets of 2D NMR spectra, thereby enabling pattern
recognition using full-resolution data; we call this overall approach
HATS-PR for hierarchical alignment of two-dimensional spectra-
pattern recognition.We demonstrate that statistical representations
of full-resolution spectra such as scaled principle component
analysis (PCA) loadings enhance the interpretation of metabolic
variation in the data set and assist in the identiﬁcation and
assignment of statistically relevant metabolites.
We have applied HATS-PR to an experimental comparison of
the exudates (i.e., exometabolomes) from two nematode species,
Pristionchus paciﬁcus and Panagrellus redivivus. Nematode chemi-
cal ecology, especially applied to the model organism Caenor-
habditis elegans, has become the subject of a number of recent
studies in development,22-25 aggregation behavior,26 mating
behavior,27,28 aging,29 chemical ecology,7,26 and functional
genomics.6,29,30,31 The discovery and structural elucidation of a
class of pheromones called ascarosides has expanded the domain
of C. elegans research well into chemical ecology.32 In a combina-
tion of chemical ecology and genetics, Pungaliya et al. used
comparative 2D NMR spectral analysis to discover new ascaro-
sides and their biological roles in C. elegans.27 By applying
standard statistical pattern recognition methods to 2D NMR
spectra, we demonstrate the utility of HATS-PR to distinguish
and characterize chemical diﬀerences between two diﬀerent
nematode species.
’EXPERIMENTAL SECTION
Collection of P. pacificus and P. redivivus Exudates. P.
pacificus and P. redivivus strains were obtained from the Sternberg
laboratory at Caltech.
P. pacificus. Ten nematode growth medium (NGM) plates
seeded with Escherichia coli (OP50 strain) were inoculated with
worms and incubated at room temperature for 3 days. Worms
were washed off the plates with 25 mL of S-complete medium
and transferred to a 250 mL Erlenmeyer flask containing 3%
(0.75 g) E. coli (HB101 strain). Worms were incubated at 22 !C
for 3 days and then transferred to a 2 L Erlenmeyer flask
containing 250 mL of S-complete medium and 3% (7.5 g)
HB101. Once the majority of worms were adults with eggs,
sucrose flotation was used to remove bacteria and other life-stage
worms. Adults with eggs were then incubated for 48 h at 22 !C at
250 rpm without food to allow the adult worms to lay the eggs
and the eggs to hatch. J2 P. pacificus were separated from adult
worms using a 20 μm nylon filter (Sefar Inc.) to obtain a
semisynchronous culture. Semisynchronized J2 P. pacificus
(2.5 million) were grown to adult stage on S-complete medium
supplemented with 3% HB101 and incubated in a shaker at 250
rpm and 22 !C. Worms from this culture were then put onto a
sucrose gradient to remove bacteria. Clean P. pacificus were
placed in M9 buffer for 30 min to clear their gut. Worms were
washed three times with double-distilled water (ddH20) and then
incubated for 1 h in ddH20 with a density of∼30 000 worms/mL
to collect worm exudates. Worm exudates were filtered with a
0.2 μmnylon syringe filter and stored at-80 !C for further analysis.
P. redivivus. P. redivivuswere cultivated similarly to P. pacificus
and transferred to liquid culture. A mixed population of
P. redivivus with worm density of 10 000 worms/mL was
incubated in 250 mL of S-complete medium supplemented with
3%HB101. P. redivivuswere cultured for 12 days, and 3%HB101
was added every third day. After 12 days of incubation, the worms
were separated from bacteria via sucrose flotation. The
P. pacificus protocol described above was also used to collect
P. redivivus exudates.
Sample Fractionation. P. pacificus and P. redivivus exudates
were each fractionated by C18 solid phase extraction using a
Varian Mega BE C18, which has a 5 mL void volume. A 50 mL
syringe was attached to the column using a rubber adapter.
Teflon tape was placed around the rubber stopper so that rubber
pieces would not contaminate the solution. Approximately
constant pressure was applied to the column by gently pressing
the syringe. Each C18 column was first washed with 50 mL of
90% methanol, followed by 50 mL of ddH20 for equilibration.
P. pacificus and P. redivivus exudates were then added to individual
columns, and the flow-through was collected. The columns were
washed with 25 mL of ddH20 and then eluted with 25 mL of 50%
methanol and 25mL of 90%methanol. All samples were collected
in glass vials with Teflon caps and stored at -80 !C.
NMR Spectroscopy. The flow-through fractions were lyoph-
ilized, dissolved in 500 μL of 99.9% D2O (Cambridge Isotope
Laboratories), and put into 5 mm NMR tubes. The 50% MeOH
fractions were lyophilized, dissolved in 110 μL of 99.95%
methanol-d4 (Cambridge Isotope Laboratories), and put into
2.5 mm NMR tubes. 1D 1H and 2D TOCSY spectra were
collected on a Bruker Avance II spectrometer operating at
600.23 MHz using a 5 mm TXI cryoprobe. NMR data were
collected with spectral widths of 11 ppm at a sample temperature
of about 300K. 1D 1H spectra were collected using a simple pulse-
acquire sequence with presaturation of residual water. TOCSY
spectra were collected with the DIPSI-2 mixing sequence33 with
water presaturation and 60 or 90 ms mixing times for the 50%
MeOHor flow-through fractions, respectively. TOCSY data were
collected with 2048 and 256 complex data points in the direct and
indirect dimensions, respectively. TOCSY data were zero filled to
2048 F2 and 1024 F1 data points, Fourier transformed, phased,
and baseline corrected in Topspin 2.0 (Bruker) before being
transferred to Matlab 2009b for alignment and pattern recogni-
tion analysis. As an additional application to a more complex
mixture, TOCSY spectra were acquired from human urine
(details provided in Supporting Information), and data were
processed similarly to the worm exudate spectra.
Hierarchical Alignment of Two-Dimensional Spectra. The
HATS alignment method presented here makes use of a guide
tree to structure the alignment process. While many existing 1D
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alignment methods have attempted to align each spectrum in a
data set to a single consensus spectrum, the quality of these “star
alignments” can suffer if there is wide chemical diversity between
spectra, as any individual spectrum chosen as a star may not
include the full complement of metabolites present in the other
data sets. The use of guide trees was a significant advance for
multiple sequence alignment in sequence bioinformatics, and
methods such as CLUSTAL-W34 have enjoyed widespread
popularity in nucleic acid and protein sequence alignment. We
suggest that the use of a guide tree will be especially important in
the alignment of 2D spectra as correlation spectra are often
collected when significant metabolic diversity is expected and the
assumptions underlying star alignments may not be appropriate.
The UPGMA agglomerative hierarchical clustering method35
was used to construct the initial guide tree for the subsequent
pairwise alignment of spectral groups. We have used the squared
distance of Pearson’s correlation coeﬃcient as a metric for
clustering (eqs 1 and 2), and the resulting dendrogram speciﬁes
the order in which alignment of the spectra proceeds.
rmn ¼
Pj
i¼ 1
ðSim - SmÞðSin - SnÞ
σsmσsn
ð1Þ
dmn ¼ 1- rmn2 ð2Þ
Here, rmn is the correlation coeﬃcient between the reshaped vectors
(1$ F1 3 F2) of spectra Sm and Sn with mean values Shm and Shn and
standard deviations σsm and σsn and dmn is a distance version of the
correlation value. At each branch point in the dendrogram, the set of
spectra speciﬁed by the branches are aligned. For the alignment
illustrated in Figure 1, the two red spectra are aligned ﬁrst, followed
by the two blue spectra; then, the two blue spectra are aligned with
the black spectrum, and ﬁnally, the two red spectra are aligned with
the three blue and black spectra. If there are multiple spectra in an
alignment group, positional adjustments are made equally to all
spectra in the group.
The alignment at each branch point of the guide tree consists
of two parts: a global alignment in which all spectral data points
are shifted equally and a local alignment in which speciﬁc cros-
speak regions are shifted individually. The global alignment step
seeks to correct defects such as miscalibration or referencing,
which produce chemical shift diﬀerences across the entire spec-
trum. One of the groups of spectra is passed over the other group
as a mask in a point-wise manner in both F1 and F2 dimensions,
and at each positional step x and y, the alignment quality is
expressed as rxy, the mean correlation between groups (eq 3).
Here, a is the number of spectra in group 1, and b is the number
in group 2, and rmn is the correlation coeﬃcient between the
reshaped vectors of spectrum m in group 1 and spectrum n in
group 2. Spectra in themask group are shifted to the pointsm and
n producing the maximal mean correlation which is identiﬁed by
a simple gradient ascent algorithm.
rxy ¼ 1a 3 b
Xa
m¼ 1
Xb
n¼ 1
rmn ð3Þ
While global alignment can resolve factors aﬀecting all reso-
nances equally, it is not capable of resolving diﬀerences in speciﬁc
resonances caused by conditions such as pH, temperature, metal
ion concentration, and osmolality. To resolve local chemical shift
variation, crosspeak regions must be aligned individually. To
identify segments of the spectrum corresponding to crosspeak
regions, a local noise surface is calculated for each spectrum.36
Initial spectral segments are identiﬁed as regions within 0.04 ppm
of a peak, deﬁned as a local maximum with intensity at least 10$
the noise value at that point. Each segment is then labeled with a
unique integer value, and these initial segments are expanded by
iterated minimum and maximum ﬁltering. Min/max ﬁltering has
the eﬀect of growing the segments until they encounter another
spectral segment or until they reach a maximum frequency range
of approximately 0.2 ppm (Figure 1S, Supporting Information).
This procedure creates spectral segments that are bounded by
Figure 1. Overall strategy of hierarchical alignment of two-dimensional spectra (HATS). Before alignment, the HATS algorithm produces a guide tree
by the UPGMA agglomerative hierarchical clustering algorithm from a matrix of pairwise correlation distances. This guide tree is used to structure the
alignment process. At each intersection of branches in the guide tree, the spectra speciﬁed by the two branches are aligned globally and locally. For the
alignment tree shown here, the two red spectra are aligned ﬁrst, followed by the two blue spectra. The two blue spectra are then aligned with the black
spectrum, and ﬁnally, the three blue and black spectra are aligned with the red spectra.
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nearby resonances yet avoid close cropping of crosspeak line-
shapes. Each crosspeak segment is then aligned individually by
maximizing the mean cross-correlation of crosspeak segments
between alignment groups in the same way as the global align-
ment but treating each crosspeak segment independently (eq 3,
where rxy is the line shape vector for a single crosspeak region
rather than the entire spectrum).
Full Resolution TOCSY Pattern Recognition. Following
alignment, HATS-PRmakes use of principal component analysis
(PCA) and partial least squares discriminant analysis (PLS-DA)
for full resolution spectral pattern recognition. PCA is an unsuper-
vised dimensionality reduction technique that is widely used in
metabolomics. PCA transforms a data set of N observations with
P features into a set of principal components that are orthogonal
linear combinations of features accounting for as much of the
variation in the original data set as possible. Each principal
component consists of N scores and P loadings, where scores
identify relationships between observations (here, TOCSY
spectra) and loadings represent the pattern of features (here,
2D NMR chemical shifts) underlying the relationships identified
by scores. We used the NIPALS algorithm37 to identify the first
five principal components of the mean-centered and univariate
scaled flow-though (N = 10) and 50% MeOH (N = 8) TOCSY
spectra.While PCA avoids the problem of overfitting by taking an
unsupervised approach to pattern recognition, it is not optimized
for class separation. Partial least-squaresmethods such as PLS-DA
are often the supervised method of choice for the analysis
of metabolic differentials. We apply SIMPLS38 PLS-DA to the
data set to help clarify the metabolic differential identified by
PCA while avoiding overfitting by the use of 4-fold cross-
validation and reportingperformance statistics for thePLS-DAmodel.
Pattern recognition of NMR spectra was done in Matlab
2009b following Probabilistic Quotient Normalization39 to ac-
count for random dilution eﬀects and alignment using the HATS
method for the TOCSY spectra and the RSPA15 algorithm for
the 1D 1H spectra. Each of the N 2048 ! 1024 TOCSY data
matrices was reshaped to a 1 ! 2 097 152 vector before the
application of PCA or PLS. This is a necessary step because it
creates an N! P matrix, where P = F1 3 F2 data points on which
pattern recognition algorithms can operate. To visualize the
resulting 1 ! P loadings, the loadings vectors for each principal
component were reshaped back into a 2048! 1024 data matrix.
Contours were deﬁned by multiplying the univariate scaled
loadings by the standard deviation along the third dimension
of the original TOCSY stack, a procedure known as back-scaling.
Contour colors were then deﬁned by the loading values them-
selves divided by the maximum loading coeﬃcient to produce a
range of-1 toþ1. This strategy produces loading spectra which
have crosspeak lineshapes similar to traditional TOCSY spectra
but include sign and intensity information related to the relation-
ships between spectra speciﬁed by the corresponding PCA
scores. PLS-DA results are presented in a similar manner, but
instead of specifying scores and loadings, only the predictive
feature vector is shown, along with performance statistics for the
model. This 2D NMR unfolding and refolding approach has
recently been applied successfully to HSQC spectra and provides
a simple methodology to apply statistical pattern recognition
approaches to 2D NMR spectra.40,41
Semi-Automated Assignment of TOCSY Loadings. To
assign the compounds represented in our back-scaled TOCSY
loadings plots, we appliedCOLMARquery11 to correlated chemical
shifts present in the loadings spectra. When COLMAR query
identified a match to a compound reference spectrum present in
the BMRB,42,43 HMDB,44 or MMCD45 databases, the reference
TOCSY spectrum for the suggested compound was downloaded
from the database web servers, processed in Topspin 2.0, and
overlaid onto an experimental spectrum for confirmation. We
considered the compound to be assigned if all reference chemical
shifts and experimental chemical shifts differ by less than 0.02 ppm
and all through-bond correlations (TOCSY crosspeaks) in the
Figure 2. Alignment results for P. redivivus (Pre) and P. paciﬁcus (Ppa) TOCSY spectra of ﬂow-through fractions from C18 solid phase extractions. (A)
The guide tree produced by HATS groups spectra from the same species, resulting in intraspecies alignment before interspecies alignment. The utility of
a guide tree-based alignment is exempliﬁed by the anomeric crosspeaks of glucose, sucrose, and trehalose in the TOCSY spectra (B, C). By aligning
spectra with similar composition ﬁrst, false positive alignments of nearby but unrelated crosspeaks, such as the anomeric crosspeaks shown above, are
avoided.
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experimental spin-system were accounted for by the reference
spectrum. It should be emphasized that for this study we did not
verify assignments by spiking natural samples with authentic
commercial or synthetic standards, a common practice for final
verification of compound identity by NMR.
’RESULTS
Previous work from our group and others has shown that
C. elegans releases a large number of ascarosides that have been
shown to have multiple functions.22-25,27,28,32 These ascarosides
typically partition into the 50% MeOH fraction of a C18 solid
phase extraction. We have also shown that C. elegans releases an
abundance of small polar molecules including amino acids, sugars,
and organic acids, many of which elute from a C18 column in the
hydrophilic ﬂow-through fraction.7 Here, we analyzed 2D
TOCSY NMR data of the ﬂow-through and 50% MeOH C18
elution fractions from P. redivivus and P. paciﬁcus exudates in
order to demonstrate our new methods and to show the utility of
this approach in metabolomics and natural product comparative
studies. In order to demonstrate the general applicability of our
approach, we have also applied it to the alignment of 2D TOCSY
spectra from human urine (Figure 1S, Supporting Information).
Alignment of TOCSY Spectra. Despite the high reproduci-
bility of NMR spectra, resonance variation, sometimes referred
to as positional noise, resulting from slight differences in sample
conditions hinder comparative studies and complicate the inter-
pretation of statistical analyses such as univariate regression and
significance testing, principal component analysis (PCA), and
partial least-squares (PLS). Previous research with 1D 1H NMR
spectra has shown that peak shift can result in both false positives
and negatives when attempting to identify metabolite biomark-
ers.46 While binning is often used to reduce positional variation,
loss of high-resolution information complicates metabolite
assignment and limits the added value of 2D experiments. The
HATS alignment methodology presented here compensates for
the effects of resonance variation, thereby increasing the accuracy
and interpretability of comparative 2D NMR analyses.
The HATS-PR approach to eliminating positional variation is
to ﬁrst cluster all of the spectra through a guide tree, as shown in
Figure 2A. The problem of positional variation in our nematode
TOCSY spectra is easily seen in the expansion of the anomeric
region of the sugars from the ﬂow-through fractions (Figure 2B,
C). In the unaligned data (Figure 2B), local diﬀerences in
resonance frequency of the anomeric protons aﬀect multiple
spectra of both P. redivivus and P. paciﬁcus samples and result in a
general “blurriness” that signiﬁcantly impacts subsequent statis-
tical analyses. Removing this variation is clearly desirable, but the
close proximity (∼0.03 ppm) and similar patterns and lineshapes
of the P. paciﬁcus glucose and P. redivivus trehalose crosspeaks
raise the possibility of inappropriate alignment of the glucose to
the trehalose crosspeaks. The use of the HATS-PR guide tree
(Figure 2A) helps avoid this possibility by aligning the most
similar before the less similar spectra. Using this approach, the
glucose and trehalose resonances are not compared for align-
ment until they have been well aligned separately. As shown in
Figure 2C, this results in the correction of positional variation
within both glucose and trehalose crosspeaks and rejection of the
inappropriate alignment of the two sugars.
P. redivivus and P. pacificus Release Different Polar
Molecules. Next, using the aligned TOCSY spectra (Figure 3A)
of C18 flow-through fractions, we conducted PCA and PLS
analysis. The PCA scores show clear, unambiguous separation of
the P. redivivus spectra from the P. pacificus spectra in the first
principal component (Figure 3B). This separation allows the PC1
loadings to be interpreted as a pattern of TOCSY crosspeaks
differentiating the two species (Figure 4). The back-scaling proce-
dure outlined above produces contours reflecting the crosspeak
lineshapes in the original spectra but colored according to the
loading coefficients. As the P. redivivus and P. pacificus PC1 scores
have opposite signs, we represent features with greater intensity in
the P. redivivus spectra in red (loadings between 0 and 1) and with
greater P. pacificus intensity in blue (loadings between-1 and 0).
The PLS predictors also agree with the PC1 loadings (Figure 2S,
Supporting Information). The assignment of the crosspeaks in the
PC1 loadings spectrum enables the identification of compounds
unique to each species as well as quantitative differences between
compound levels.
To interpret this spectral information in a chemical context, it
is necessary to assign NMR resonances to their molecules (Table
1S, Supporting Information). While assignment has traditionally
Figure 3. (A) Overlay of P. redivivus (Pre) and P. paciﬁcus (Ppa) ﬂow-
through TOCSY spectra and (B) scores plot from PCA of the ﬂow-
through TOCSY data set. P. redivivus and P. paciﬁcus spectra are clearly
diﬀerentiated by PC1, which allows the loadings of PC1 to be inter-
preted as relative quantitative spectral diﬀerences between the species.
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been one of the more diﬃcult steps in metabolomic analysis due
to the large chemical complexity in most crude biological
matrices, the establishment of reference spectra databases for
common metabolites such as the BMRB,41-43 HMDB,44 and
MMCD45 has facilitated the development of database searching
algorithms to match sets of correlated chemical shifts to a
compound ID. For example, PRIMe SpinAssign,47,48
NMRshifDB,49 MetaboMiner,10 and COLMAR12 are freely
available web utilities that oﬀer automated database matching
capabilities to aid the assignment process. The assignments
shown in Figure 4 were generated by a combination of COLMAR
query11 to identify possible matches and manual overlay of
reference spectra from the BMRB to conﬁrm identiﬁcations, as
described in the Experimental Section.While correlated chemical
shifts were identiﬁed manually for input into COLMAR query,
the back-scaled loadings matrix produced by HATS-PR should
be compatible with spectral decomposition methods such as
DemixC13 and local peak clustering.50
P. redivivus and P. pacificus Appear to Produce Different
Ascarosides. C. elegans releases at least 10 different ascarosides
important in the nematode’s chemical ecology,32 andmethods to
efficiently compare other species for ascaroside-like compounds
would be useful. The most diagnostic NMR signatures for
ascarosides are typically resonance peaks from anomeric, methyl,
and methylene protons (Figure 5) present in the eluate of C18
SPE chromatography matrix with 50% MeOH C18. As with
the flow-through fraction, PC1 separates the P. redivivus and
P. pacificus 50% MeOH fraction spectra (Figure 3S, Supporting
Information). The PC1 loadings from the 50% MeOH fractions
show numerous crosspeaks in the ascaroside signature region.
These peaks are difficult to resolve using 1D 1H NMR, and
loadings from pattern recognition on the 1D spectra are difficult
to interpret (Figure 4S, Supporting Information). Interestingly,
both P. redivivus and P. pacificus show signals representing
ascaroside-like compounds; however, differences in chemical
shift and signal intensity suggest different sets of ascarosides
produced by these species. We tried database matching the 50%
MeOH, as we did with the flow-through fractions, but we were
unsuccessful in finding any matches. Identification of these
compounds is in progress using traditional approaches and will
be reported elsewhere.
’DISCUSSION AND CONCLUSIONS
We have presented an eﬃcient method to align, statistically
analyze, and identify compounds in 2DNMR spectra. Although we
demonstrated the approach with TOCSY spectra, all of the algo-
rithms used for alignment, PCA, and PLS-DA are general and
should work without modiﬁcation for other types of 2D NMR data
sets. In addition to problems with alignment, which we have
addressed in this study, the increased acquisition time per sample
relative to 1Dexperiments remains a barrier to adoption of 2DNMR
methods in metabolic proﬁling. However, many groups are
developing rapid methods for 2D data acquisition51-53 and
designing more sensitive probes,54-56 making 2D NMR analysis
of relatively large numbers of samples increasingly feasible.
The additional structural information provided by 2D NMR
methods is often helpful for structural characterization of known
metabolites and is necessary for assignment of unknown or
novel compounds. Our use of COLMAR query for assignment
of compounds present in multiple TOCSY spectra constitutes a
Figure 4. Spectral back-projection of PC1 loadings. Here, contours are deﬁned by the back-projected intensities, while colors are deﬁned by the unit
variance-scaled loading coeﬃcients. Crosspeaks with positive loading coeﬃcients (red) represent compounds overexpressed by P. redivivus relative to P.
paciﬁcus. Blue crosspeaks represent negative loading coeﬃcients indicating P. paciﬁcus overexpressed compounds. Assignment of crosspeaks in the back-
projected loadings places the chemical information contained in the TOCSY spectra in an immediate biological context. Abbreviations: AIB,
3-aminoisobutyrate; Ala, alanine; Asn, asparagine; Asp, aspartate; Glu, glutamate; NC-Glu,N-carbamylglutamate; Pre Unk1, P. redivivus unknown 1; Pre
Unk2, P. redivivus unknown 2; Pro, L-proline; Thr, threonine.
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proof-of-principle demonstration of how metabolomic analysis can
be streamlined by integrating multi-2D statistical pattern recogni-
tion with informatics tools for compound assignment. While not
applied in this study, we suggest that the application of automated
spectral deconvolution methods, which isolate signals arising from
single molecules, such as local clustering50 and DemixC,13 to back-
scaled 2DNMR loadings matrices will result in further streamlining
of metabolomic data analysis. While automated assignment is
currently restricted to compounds for which reference data is
present in spectral databases, progress is being made on methods
to identify probable chemical structures directly from chemical shift
calculations.57 The polar metabolites present in the ﬂow-through
fraction of the nematode exudate C18 SPE extractions were
particularlywell suited for semiautomated assignment byCOLMAR
query as the reference databases contain large numbers of sugars,
amino acids, small organic acids, and other common biological
metabolites that tend to partition in the aqueous phase.
It is common practice with 2D NMR to overlay spectra with
diﬀerent colors, as shown for example in Figure 3A. There are
several advantages that HATS-PR has oversimple spectral over-
lay. First, with spectral overlay, it is very diﬃcult or impossible to
see quantitative changes in a particular compound. Using HATS-
PR, quantitative information is clearly represented by changes in
the color of the crosspeaks in the loadings plots. Second, using
overlays is not particularly amenable to evaluating statistical
replicates and comparing multiple conditions. However, with
HATS-PR, like any PCA or PLS analysis, statistical replicates
enhance the analysis and are easily visualized through the
corresponding scores plots and regression statistics. Additionally,
quantitative covariance between 2D NMR crosspeaks may
provide a means by which to identify connectivity in metabolites
with multiple spin systems.
In principle, it is possible to do PCA analysis on 2DNMR data
without alignment. However, alignment of the spectra aids in the
interpretation of individual compounds by improving the quality
of the pattern recognition analysis. Pattern recognition on
unaligned 1D spectra often results in line shapes resembling ﬁrst
derivatives rather than Lorentzian line shapes.15 In 2D NMR
spectra, misalignment often results in the duplication of peaks
(Figure 5S, Supporting Information) in the back-scaled loadings
or attenuation of loading coeﬃcients (Figure 6S, Supporting
Information) due to peak position diﬀerences and can result in
compound misidentiﬁcation. Despite making small changes in
the chemical shifts of the crosspeaks, alignment of crosspeak
lineshapes to their maximum correlation results in more inter-
pretable loadings for both the ﬂow-though and 50% MeOH
fraction, as shown by supplemental Figures S4 and S5, Support-
ing Information. HATS-PR represents, to our knowledge, the
ﬁrst usage of a guide tree in a spectral alignment method, which
removes the requirement that all compounds be present in a
Figure 5. Representative spectra and PC1 loadings for P. redivivus and P. paciﬁcus 50% MeOH fractions. The region selected is useful for ascaroside
diﬀerentiation, as crosspeaks here indicate correlations from the methylene protons on the ascaroside side chain to protons near the terminal functional
groups. PC1 loadings suggest that P. redivivus and P. paciﬁcus produce diﬀerent mixtures of ascaroside-like compounds.
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single spectrum selected as the alignment reference. We believe
guide trees will also be generally useful for peak alignment in 1D
1H NMR, chromatographic proﬁles, and LC-MS spectra as well.
HATS-PR is a relatively simple way to chemically discrimi-
nate two (or more) biological states, such as treated vs
untreated, diseased vs normal, one species vs another, etc.
Using existing database search algorithms and rapidly growing
NMR metabolomic databases, it is straightforward using
HATS-PR not only to compare biological states but also to
identify and assign the relevant compounds that diﬀerentiate
these states. In this study, we compared exudates of two
nematode species. The samples were prepared under identical
conditions, yet revealed surprisingly large diﬀerences, particu-
larly in the polar ﬂow-through fractions. In previous work, we
found thatC. elegans produces at least 40 common, mostly polar
metabolites,7 and we expected to ﬁnd a similar group of
compounds in P. redivivus and P. paciﬁcus. HATS-PR very
eﬃciently showed us that the two species produce signiﬁcantly
diﬀerent sets of polar small molecules, including sugars.
P. redivivus in general releases a less diverse set of polar
molecules but produces large amounts of the disaccharide
trehalose and their exudates also contain a large quantity of
sucrose, yet no glucose was observed. While P. paciﬁcus releases
a very diverse set of polar small molecules including glucose, the
two disaccharides sucrose and trehalose were not detected. All
of the nematodes for this study were separated from their
bacterial food using a sucrose gradient, so it is possible that
some or all of the sucrose detected in P. redivivus originates from
the sample preparation. However, we ﬁnd a comparable
amount of trehalose in the same samples, and more impor-
tantly, we ﬁnd no sucrose in P. paciﬁcus, which were prepared
with an identical sucrose gradient.
Despite the fact that spectra collected on the ﬂow-through
fractions of P. redivivus were much simpler than those from
P. paciﬁcus, the TOCSY spectra of 50% MeOH fractions from
the same worm preparations exhibited similar levels of com-
plexity but also some clear diﬀerences. Although, on the basis
of the data presented here, we are unable to determine
unambiguously whether these fractions contain ascarosides,
the spectral signatures of the 50% MeOH fractions for both
species suggest the presence of complex ascaroside mixtures,
similar to those found in C. elegans. The identiﬁcation and
assignment of these compounds requires additional work and
additional NMR spectroscopic and mass spectrometric analyses
and is beyond the scope of this study. However, it is clear that
HATS-PR is a powerfulmethod to compare small molecules from
one organism to another and as such provides a signiﬁcant bridge
between metabolomics and natural products analysis. As our use
of HATS-PR for alignment of a set of urine spectra demonstrates,
the method is broadly applicable and can successfully align arrays
of 2D spectra even in situations where sample variation leads to
signiﬁcant chemical shift diﬀerences between spectra. We expect
that this work will contribute signiﬁcantly to informatics ap-
proaches to metabolic proﬁling as well as to biological and
structural characterization of metabolic phenotypes in both
mammalian and nonmammalian models.
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†Biomolecular Medicine, Department of Surgery and Cancer, Imperial College London, United Kingdom
‡Massprom Ltd., Budapest, Hungary
§Metabolic Diagnostic Laboratory, 1st Department of Pediatrics, Semmelweis University, Budapest, Hungary
⊥Hesse Child Health Centre, Johann Wolfgang Goethe University Hospital, Giessen, Germany
*S Supporting Information
ABSTRACT: A novel, single stage high resolution mass
spectrometry-based method is presented for the population
level screening of inborn errors of metabolism. The approach
proposed here extends traditional electrospray tandem mass
spectrometry screening by introducing nanospray ionization and
high resolution mass spectrometry, allowing the selective
detection of more than 400 individual metabolic constituents
of blood including acylcarnitines, amino acids, organic acids, fatty acids, carbohydrates, bile acids, and complex lipids. Dried blood
spots were extracted using a methanolic solution of isotope labeled internal standards, and ﬁltered extracts were electrosprayed
using a fully automated chip-based nanospray ion source in both positive and negative ion mode. Ions were analyzed using an
Orbitrap Fourier transformation mass spectrometer at nominal mass resolution of 100 000. Individual metabolic constituents
were quantiﬁed using standard isotope dilution methods. Concentration threshold (cutoﬀ) level-based analysis allows the
identiﬁcation of newborns with metabolic diseases, similarly to the traditional electrospray tandem mass spectrometry (ESI-MS/
MS) method; however, the detection of additional known biomarkers (e.g., organic acids) results in improved sensitivity and
selectivity. The broad range of detected analytes allowed the untargeted multivariate statistical analysis of spectra and
identiﬁcation of additional diseased states, therapeutic artifacts, and damaged samples, besides the metabolic disease panel.
Since its introduction, electrospray tandem mass spectrom-etry (ESI-MS/MS) has become the most important and
widely applied method in newborn screening (NBS)
programs.1−3 Currently, there are more than 70 diﬀerent
metabolic diseases included in neonatal screening, with
approximately 90% of them screened by the ESI-MS/MS
method. The standard mass spectrometry newborn screening
procedure comprises the extraction of dried blood spot (DBS)
samples with a methanolic solution of stable isotope labeled
internal standards. Amino acids and acylcarnitines are semi-
quantitatively determined by detecting their n-butyl ester
derivatives in positive ion mode tandem mass spectrometry.
Amino acids are traditionally detected by neutral loss (NL 102)
scan, and acylcarnitines are detected by precursor ion (PS 85)
scan, with quantiﬁcation based generally on multiple reaction
monitoring (MRM) data.
Ionization eﬃciency and hence sensitivity is routinely
increased via butyl esteriﬁcation by eliminating the acidic
carboxyl moiety from the analyte molecules. Derivatization is
not an absolute prerequisite; however, only 30% of screening
laboratories currently use derivatization-free methods.4,5
Elimination of butyl esteriﬁcation is considered to yield more
accurate results by avoiding the formation of free amino acids
via acidic hydrolysis of protein content.
Improving the sensitivity and speciﬁcity of screening, with a
consequent reduction in the false-positive rate, is a key area of
development in the newborn screening ﬁeld. Cut-oﬀ values in
the case of the tandem mass spectrometry-based technique are
established to minimize the false negative rate to zero level. As a
result, the number of the false-positive cases can occasionally be
high, especially in the cases of certain diseases, such as
homocystinuria, methylmalonic acidemia, and propionic acid-
emia (methionine and propionylcarnitine are used as diagnostic
markers for all three diseases). Since suspected positive cases
require conﬁrmatory testing, false-positive cases involve
unnecessary stress for the family of aﬀected newborns and
increased analytical burden on the metabolic diagnostic
laboratories.6,7 Screening laboratories have used two main
strategies to reduce the false-positive rate: excluding certain
diseases from the screening (especially those, which otherwise
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do not fulﬁll the criteria for screening postulated by Wilson and
Jungner8) and introducing so-called second-tier tests9 that use
the original DBS sample for conﬁrmation of the positive result.
In these cases, the initial positive screening result is not
reported until the conﬁrmatory test validates this result,
decreasing the unnecessary stress on families.10
Development of second-tier tests by the Mayo Clinic group
provided a suﬃcient solution for the problem by minimizing
overall false-positive rates to 0.09%.9 These tests are highly
speciﬁc compared to the screening methods,11−16 but their
introduction requires additional instrumentation, trained
personnel, and an extension of the turnover time of screening,
which may be critical in the case of several diseases.
Although most of the screened metabolic disorders are
caused by the complete or partial absence of a single enzymatic
function, the missing functionality results not only in the
increase of the level of the speciﬁc substrate. Multiple metabolic
constituents, both up- and downstream in the metabolic
pathways, show changes in their concentrations; furthermore,
elevation of the concentration of certain metabolites may also
activate alternative pathways. As a result, serum proﬁles should
reﬂect broad perturbations in the metabolome characteristic of
individual diseases. While metabolomic studies traditionally
employ GC/MS or LC/MS for the untargeted analysis of
biological ﬂuids,17−19 the feasibility of direct infusion mass
spectrometry analysis has been demonstrated by a number of
recent publications.20−22 Advantages of the elimination of
chromatographic separation include shorter analysis times,
simpliﬁed data analysis, and improved reproducibility. Since the
speciﬁcity of unit resolution mass analyzers is poor, either high
resolution (HR) or tandem mass spectrometry was used, to
ensure selective detection of thousands of spectral features.
Nevertheless, these improvements do not compensate for the
suppression eﬀects of electrospray ionization, which represent
the most serious drawback for MS-only approaches.23 Besides
employing chromatographic separation prior to MS detection,
suppression eﬀects can partially be eliminated by minimizing
the diameter of electrospray emitter tips, i.e., using nano-
electrospray (or nanospray) ionization.24 Nanospray has been
demonstrated to suﬀer less from suppression eﬀects, both in the
case of large proton aﬃnity diﬀerences between diﬀerent
analytes and the presence of inorganic salts in the sample.
The combination of nanospray ionization with high
resolution mass spectrometry (nS-HR-MS) provides metab-
olome coverage comparable to that of LC/MS approaches as it
is demonstrated by the current study. The concept was
implemented by developing a high-throughput nanospray-HR-
MS method for mapping the metabolic proﬁle of DBS samples
and establishing correlation between metabolite concentrations
determined using the new approach and the traditional ESI-
MS/MS technique. Resulting metabolic proﬁles were also
correlated with the presence of various diseased statuses of the
subjects using multivariate statistical methods. The developed
method was tested for the most widely screened metabolic
diseases including phenylketonuria (PKU) and medium-chain
acyl-coenzyme A dehydrogenase deﬁciency (MCADD).
■ METHODS AND MATERIALS
Samples. Anonymous DBS samples were obtained from the
Screening Laboratory at Semmelweis University, Budapest,
Hungary, and Hesse Screening Centre, Gießen, Germany. 500
healthy and 66 abnormal samples were analyzed; for further
details, see Supporting Information.
Sample Preparation. Dried blood spot samples (d = 0.6
mm, ∼10 μL of whole blood) were placed in 96-well ﬁlter
plates (Millipore, Billerica, MA, USA) and extracted with 100
μL of methanolic (HPLC grade, Sigma-Aldrich, St. Louis, MO,
USA) solution, containing known concentrations of stable
isotope labeled standards (Cambridge Isotope Laboratories,
Andover, MA, USA); see Table S-1, Supporting Information,
for details. The samples were extracted for 30 min at room
temperature. The methanolic extracts were subsequently
ﬁltered into 96-well plates (Greiner, Frickenhausen, Germany),
diluted with water (HPLC grade, Sigma-Aldrich, St. Louis, MO,
USA) in 1:1 ratio, and analyzed by mass spectrometry.
Mass Spectrometry. High resolution mass spectrometry
was performed using LTQ Orbitrap Discovery and Exactive
instruments (Thermo Scientiﬁc GmbH, Bremen, Germany). A
high-throughput screening method was developed using the
Exactive instrument equipped with TriVersa NanoMate ion
source (Advion, Ithaca, NY, USA). Chip-based infusion mode
measurements were performed using 5 μm nominal internal
diameter nozzle chips, and a sample volume of 5 μL was
injected. Total data acquisition time was 2 min, 1 min in
negative ion mode and 1 min in positive ion mode with
automatic polarity switching. Details about the data analysis are
provided in the Supporting Information.
■ RESULTS AND DISCUSSION
Detection and Identiﬁcation of Metabolites. Nano-
spray−high resolution mass spectrometry analysis of the
methanolic extracts of newborn DBS samples results in spectra
featuring hundreds of diﬀerent metabolic constituents in both
positive and negative mode. Parameters of the instruments
were optimized to achieve the best intensity, sensitivity, and
mass resolution in the lower mass range of 70−600 m/z
(parameters are summarized in Table S-2, Supporting
Information). Since the mass spectrometry device allows one
to alternate polarity acquisition, positive and negative ion
spectra were recorded in the same experiment (Figure S-1,
Supporting Information). Positive ion mode data features ∼450
individual ion signals (excluding isotopes and adduct peaks) in
the mass range of 70−1000 m/z, being present in all 500
samples obtained from healthy newborns and analyzed by high
resolution mass spectrometry. Negative ion mode data contains
information about the presence of ∼300 molecular constituents
in the identical sample set. In addition to the core set of
frequently observed ions, several hundred ion signals are
present only in a fraction of the samples. Taking all samples
into account, a total of 1150 ion signals were registered
(without isotope and adduct signals) using a 10:1 signal-to-
noise threshold.
Identiﬁcation of ion signals was performed using accurate
masses of ions determined at 50 000−100 000 fwhm (depend-
ing on actual m/z of the ion) nominal resolution with mass
accuracy window of 1.0 ppm and tandem mass spectrometry.
The accurate mass in the given mass range at the given
precision generally allows the unequivocal determination of the
molecular formula of species detected. Given the constraints set
by the human biological origin of the species, one ion signal can
be associated with only a few isomeric metabolic constituents.
Tandem MS experiments were carried out to clarify the
isomeric composition of ion signals corresponding to multiple
known metabolites. Proper identiﬁcation was achieved for 185
species in negative ion mode and 93 species in positive ion
mode, corresponding to an overall 278 identiﬁed molecular
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constituents up to date; however, the peak identiﬁcation
process is still ongoing. Results of the identiﬁcation are
summarized in Table S-3, Supporting Information.
The observed metabolites include practically all amino acid
and acylcarnitine metabolites relevant to newborn screening in
addition to metabolites utilized for conﬁrmatory diagnostics of
metabolic diseases, including organic acids, carbohydrates,
carbohydrate phosphates, bile acids, fatty acids, eicosanoids,
phospholipids, and sphingolipids. Although single stage high
resolution mass spectrometry does not allow the diﬀerentiation
of isomers, the use of instruments with automated
fragmentation of selected peaks (LTQ Orbitrap) enables
these distinctions to be made. The resulting MS/MS spectra
often provide suﬃcient information on the isomeric composi-
tion of the corresponding peak, as it is demonstrated in the
cases of 4-hydroxyphenyllactic and homovanillic acids in Figure
S-2, Supporting Information.
One of the main concerns regarding quantitative determi-
nation using FT-MS technique is the narrow dynamic range
provided by these instruments. Limit of detection (LOD) and
linear range for a number of key metabolites was determined by
extracting parallel samples (discs punched from the same NBS
card, containing DBS from a single subject taken at the same
time) with methanol containing various concentrations of
isotope labeled internal standards. Identical DBS sample is
expected to contain a reproducible amount of the analyte, so in
this study, the native metabolite was used as internal standard.
LOD values were deﬁned as the concentration which yields 3:1
signal-to-noise ratio. Linear range was deﬁned as the widest
logarithmic concentration range where linear regression to the
Figure 1. Box charts for PKU (a,b,e,f) and MCADD markers (c,d,g,h). (a, e) Phenylalanine, (b, f) phenylalanine and tyrosine ratio, (c, g)
octanoylcarnitine (C8), and (d, h) decenoylcarnitine (C10:1). Tandem mass spectrometry screening results are shown on the left; nS-HR-MS results
are on the right, from the same data set (500 healthy, 21 PKU, 21 MCADD).
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data gives R2 > 0.990. Results are shown in Table S-4,
Supporting Information, for 12 amino acids and 8 acylcarnitines
generally used in newborn screening programs. As it is
demonstrated, the LOD values are always lower than the
physiological (or pathological if disease results in lower than
physiological concentration) levels of the metabolites. Calibra-
tion curves exceeding beyond the linear range always show
saturation phenomenon at higher concentrations (i.e., no
breakdown phenomenon was observed). This guarantees that
all pathological values will be detected as diseased, even if the
determined level falls outside of the linear range.
Validation against Traditional ESI-MS/MS Method.
Both the traditional ESI-MS/MS method and the nS-HR-MS
method presented here were able to quantify a set of 20 amino
acid and 20 acylcarnitine species. These analytes were used as a
benchmark to validate the nS-HR-MS method against the ESI-
MS/MS techniques for a set of 500 newborn samples analyzed
with both methods. Correlation plots generally reveal a linear
relationship with correlation coeﬃcients (Pearson product-
moment correlation coeﬃcient, r) in the range of 0.4−0.92.
The slope of functions obtained by linear regression was <1
when nS-HR-MS data is plotted as a function of values
measured by ESI-MS/MS, indicating that the former technique
tends to yield equal or lower values compared to the latter one
(see Figure S-3, Supporting Information). The systematic
deviation was tentatively associated with the improved
selectivity of the high resolution method, but we could not
conﬁrm this assumption due to the inability of the Orbitrap
mass spectrometer to isolate parent ions at arbitrarily narrow
m/z windows. Furthermore, while the HR-MS method detects
the unmodiﬁed molecule, the traditional method detects its
butyl-ester, raising further complications for the comparison.
The butyl-esteriﬁcation procedure may also induce the
hydrolysis of proteins, which shifts the determined amino
acid concentrations further toward higher values. Nevertheless,
both nS-HR-MS and ESI-MS/MS were validated against a
quantiﬁcation of amino acids by LC-MS/MS, and the results
for a limited number of samples clearly showed that nS-HR-MS
results gives better correlation with those of LC-MS/MS (0.87
vs 0.68 for Phe, 50 samples). These results indicate that the
traditional method gives systematically higher concentrations
caused by either interferences with similar molecular weight
and fragmentation pattern or identical metabolite produced
during sample preparation. However, this systematic shift does
not necessarily compromise the diagnostic value of concen-
trations obtained by the traditional method; while the healthy
and diseased range may be diﬀerent for the nS-HR-MS and the
traditional ESI-MS/MS approach, the separation of the ranges
is comparable or better for metabolites determined by both
methods.
Screening for PKU and MCADD. Although the set of
diseases included in newborn screening programs varies from
country to country (in some cases even between regions of the
same country), phenylketonuria and medium-chain acyl-
coenzyme A dehydrogenase deﬁciency are included in all
programs where mass spectrometry is used for screening.
Phenylketonuria is generally screened using the phenylalanine
concentration as primary parameter and Phe/Tyr ratio (and
occasionally Fischer quotient) as secondary/conﬁrmatory
parameters.25 Box plots representing the distribution of key
metabolite concentrations for healthy population and diseased
population using the two methods are shown in Figure 1 for
MCAD deﬁciency and PKU, since samples from a suﬃciently
large number of freshly diagnosed patients were available in
Figure 2. Box charts for possible markers of PKU, (a) phenylpyruvic acid and (b) phenyllactic acid. Measurements were performed in negative ion
mode for 500 healthy, 21 PKU, and 12 false-positive PKU samples. Possible markers of MCADD, (c) octenedioic acid and (d) hexanoylglycine.
Measurements were performed in negative ion mode for 500 healthy and 21 MCADD samples.
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these two cases. The box plot diagrams indicate that these
analytes diﬀerentiate between healthy and diseased population
using the nS-HR-MS method.
While both sensitivity and speciﬁcity of phenylalanine level-
based phenylketonuria screening is excellent, the rare false-
positive cases are generally associated with a transient high
phenylalanine level caused by total parenteral nutrition or
immature metabolism of prematurely born babies. Both of
these statuses are indicated in principle on the screening cards;
however, on one hand, this information is often missing, and on
the other hand, these babies require further examination
anyway, according to current existing protocols. In contrast, the
novel method oﬀers the utilization of a few additional
parameters which are analytically not associated with the
phenylalanine concentration. Phenyllactic acid and phenyl-
pyruvic acid are metabolites along an alternative catabolic
pathway of phenylalanine. Since phenylalanine is normally
converted to tyrosine by the phenylalanine hydroxylase (PAH)
enzyme, loss of this enzymatic function (i.e., in case of
phenylketonuria) dramatically increases the concentration of
the metabolites of the alternative pathway, e.g., that of
phenyllactic and phenylpyruvic acid.26 These two metabolites
along with a few others are readily detected by the nS-HR-MS
method in negative ion mode, using the same nanospray
emitter. Separation of healthy and diseased population is even
better in the case of phenylpyruvic acid than in the case of
phenylalanine. DBS samples from 12 false-positive cases
(babies screened out with Phe levels higher than 99 percentile,
but having normal PAH activity) were analyzed using nS-HR-
MS method, and the phenylpyruvic acid levels were found to be
<0.25 μM (cf. Figure 2a,b) in all cases. In 5 of these cases, the
elevated Phe level was associated with amino acid infusion,
while in 3 cases the gestational age of babies was <36 weeks.
Although our results do not fully validate phenylpyruvic acid as
a selective marker for PKU in cases of premature babies and
babies receiving amino acid infusion, the observations strongly
support its testing at the population level as an additional/
conﬁrmatory marker for PKU.
Samples of patients suﬀering from other aminoacidopathies
including tyrosinemia I, citrullinemia, and homocystinuria have
also been tested with similar results. Markers found in the case
of each disease are summarized in Table S-5, Supporting
Information.
MCAD deﬁciency is one of the most abundant mitochondrial
fatty acid beta oxidation disorders, and it is included in most of
the newborn screening programs worldwide. The deﬁciency of
medium-chain acyl-coenzyme A dehydrogenase activity inter-
rupts the stepwise beta oxidation of long- and medium-chain
fatty acids, causing problems in the general energy (ATP)
production of the body. The condition also results in the
accumulation of fatty acid metabolites produced by alternative
(i.e., to mitochondrial beta oxidation) metabolic pathways, e.g.,
peroxysomal beta oxidation or omega oxidation by cytochrome
P450. The disease is traditionally screened by ESI-MS/MS
method, monitoring the elevated level of octanoylcarnitine
(C8). While an elevated octanoylcarnitine level is a hallmark of
the disease, the sole use of this metabolite results in fairly high
(up to 3%) false-positive rates. False positives are generally
associated with the overlap of healthy (comprising also
heterozygous cases) and diseased population and adminis-
tration of valproic acid to infants with epileptic symptoms.
Since valproic acid is an isomer of caprylic acid and conjugates
with carnitine, the resulting valproylcarnitine cannot be
distinguished from C8. A further problem, pertaining to the
speciﬁcity of the method, is that other disorders of
mitochondrial fatty acid beta oxidation (e.g., Glutaric acidemia
type 2) also involve the elevation of C8 levels. Hence, in
additional to C8, other acylcarnitine concentrations (C2, C6,
C10, C10:1 or their concentration ratios) are used as additional
or conﬁrmatory markers.27,28 The nS-HR-MS method is also
able to quantify these acylcarnitine levels and ratios, as it is
demonstrated by Figure 1.
The standard, generally accepted conﬁrmatory test for
newborns screened with suspected MCAD deﬁciency is urinary
organic acid analysis, followed by genetic testing for the G985
hotspot mutation. In the case of urinary GC/MS analysis,
dicarboxylic acids, acylglycines, and fatty acid metabolites are
determined for the conﬁrmation of the diagnosis. Unlike the
standard positive ion ESI-MS/MS method, nS-HR-MS
technique is able to detect and quantify these metabolites
from the dried blood spot extracts. Since generally the urinary
concentration (normalized to creatinine level) of these
metabolites is used for diagnostics,29,30 it was a question if
whether the concentration determined in DBS samples also
serves as an acceptable marker for the disease. As the box charts
depicted in Figure 2 demonstrate, octenedioic acid and
hexanoylglycine levels determined by the nS-HR-MS technique
can serve as analytically independent markers for the MCAD
deﬁciency. Similarly to PKU, we have studied the utility of
these markers for improving the speciﬁcity of the results.
Twenty-one newborn DBS samples were selected which were
found to be positive for MCAD deﬁciency; however, the results
of the conﬁrmatory test did not support the diagnosis. For the
traditional ESI-MS/MS method, C8, C6, C10:1-acylcarnitines
and C10:1/C2-acylcarnitine ratios were used as screening
parameters, and the result was accepted as positive where at
least 3 of these parameters were higher than a predeﬁned cutoﬀ
value. The nS-HR-MS analysis of these samples yielded
conﬁrmatory metabolite concentrations lower than the ﬁrst
percentile of diseased population, between 3rd and 44th
percentile of healthy population for octenedioic acid, between
65th and 89th percentiles for hexanoylglycine, and between
40th and 51st percentile for suberic acid.
The results indicate that, using these sets of markers as
conﬁrmatory markers, the false-positive cases found by
acylcarnitine analysis can be correctly classiﬁed as healthy
newborns. Using octanoylcarnitine level combined with these
markers and accepting a case positive if all of the parameters
exceed the estimated 1 percentile value of diseased population,
100% selectivity and sensitivity was achieved for the detection
of MCAD deﬁciency in the test set; however, the tested
population (500 healthy and 21 diseased) is not suﬃciently
large to draw far-fetched conclusions regarding speciﬁcity and
sensitivity of the method in a population level screening
program.
As it has already been pointed out, the nS-HR-MS method
reveals the presence of more than a thousand molecular species,
with currently 278 compounds already identiﬁed. The group of
identiﬁed compounds includes a number of species which are
known markers of metabolic and nonmetabolic diseases as it is
discussed in detail in the Supporting Information.
Statistical Data Analysis. While the detection and
inclusion of alternative biomarkers into the mass spectrometry
screening method already provides an incremental improve-
ment in the speciﬁcity of the process, the untargeted nature of
the presented nS-HR-MS method also allows a multivariate
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statistical data interpretation approach, similar to the method
recently described for ESI-MS/MS.31 Since the removal of a
speciﬁc enzymatic function of key importance from the
metabolic machinery is expected to result in a global change
in the metabolome (vide supra), this has to be traceable by
pattern recognition approaches.32 Mass spectra can be treated
as n-dimensional data vectors where n equals the number of
possible m/z values, i.e., the peak capacity of the spectrum. This
value in the mass range of 70−600 m/z is 106 000 at high
resolution (0.01 Da bin size) or 1060 at low resolution (1 Da
bin size) for the combined positive/negative ion mode data.
Individual spectra appear as points in this 106 000 dimensional
space, potentially forming groups according to the speciﬁc
conditions. However, since in most of these dimensions the
data cloud has no extension and many of these dimensions are
not linearly independent, it is reasonable to reduce the
dimensions by appropriate mathematical tools, e.g., principal
component analysis (PCA). Dimension reduction by PCA
results in a still orthogonal data space determined by the
linearly independent principal components. Three or two-
dimensional projection of the data in the PCA space is
generally used for the demonstration of similarities and
dissimilarities. Separation of assigned data groups (i.e.,
condition speciﬁc data groups) can further be improved by
linear discriminant analysis (LDA), which is a supervised linear
transformation resulting in a nonorthogonal data space where
the distances among data groups are maximized. Similarly to
PCA, three-dimensional projection of LDA is used for the
demonstration of dissimilarity among assigned data groups.
Besides demonstration of the similarities and dissimilarities, an
assigned LDA space can also be used for the identiﬁcation of an
unknown data point by localizing it in the multidimensional
data space and determining its distance from the assigned data
groups. In the optimal case, the unknown falls into or close to
one of the clearly separated condition-speciﬁc data clouds.
Since the peaks of the important biomarker molecules have
typically low absolute intensity values, application of normal-
ization is necessary during the data analysis. While a number of
multivariate statistical tools suitable for the analysis of this type
of data exist, in the present study, we employed only
consecutive PCA and LDA analyses. Peaks in mass spectra
were reduced to the list of the identiﬁed metabolite molecules
shown in the Table S-3, Supporting Information, and peak-
speciﬁc PCA/LDA was performed on this reduced data set.
The inﬂuence of the intensive contaminant peaks, especially in
positive ion mode, and nonmetabolite peaks can be avoided
using this approach.
The results of PCA and LDA analysis of the ﬁrst 60 principal
components corresponding to a newborn cohort comprising
500 healthy newborns, 21 PKU, 21 MCADD, and 4
homocystinuria (HCY) patients, and 6 cholestatic liver diseases
(CLD) is shown in Figure 3. Figure 3a represents the data
obtained from low resolution measurements; Figure 3b shows
the high resolution analysis, and Figure 3c demonstrates the
peak-speciﬁc data analysis method. Each plot reveals complete
separation of the healthy population and individual metabolic
disorder-speciﬁc data groups.
In the model presented here, it is seemingly not critical to
use high resolution mass spectrometry since unambiguous
identiﬁcation can be obtained even using data binned to unit
resolution. However, when a statistically relevant number of
healthy samples (in the order of some 10 000s vs 500 in the
current study) and more conditions (all currently screened
inborn errors of metabolism including sample mistreatment
conditions etc.) are examined, a considerable spreading of the
data within individual subject groups is expected. Thus, the
compactness of data groups will become more critical, and a
chance of unambiguous identiﬁcation of the conditions will be
improved by high mass resolution.
Figure 3. Three dimensional LDA models representing the 60 dimensional PCA/LDA analyses of the sample sets. (a) Model of low resolution (1
Da bin size) measurements; the ﬁrst 60 components represent 96.52% of the total variance. (b) Model of high resolution (0.01 Da bin size)
measurements; the ﬁrst 60 components represent 98.22% of the total variance. (c) Model for identiﬁed peaks; the ﬁrst 60 components represent
98.81% of the total variance. (d) Model for low resolution measurements on diﬀerent types of false-positive samples.
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Sample conditions associated with false-positive cases have
also been studied using the multivariate statistical approach.
Total parenteral nutrition (TPN) cases or thermally damaged
samples obtained from healthy subjects have shown complete
separation, already in the three-dimensional projection of the
60 dimensional LDA space (Figure 3d). Although single stage
mass spectrometry is not suitable for identiﬁcation of associated
metabolites, the diﬀerences of the spectral pattern enable the
distinction between disorders and these conditions. Selective
identiﬁcation of these conditions is extremely important, since
most of the false positives are associated with these or other
similar causes.
The approach oﬀers two potential workﬂows depicted in
Figure 4. In case of workﬂow A, the screening data is evaluated
using cutoﬀ values established for a number of parameters in
the case of each condition. If the results are unambiguous (all
markers are either in the healthy or in the diseased range), then
the result is established. However, if some values are in the
healthy range while others are in the diseased range, then PCA/
LDA analysis is performed using a model which comprises all
relevant conditions. For instance, if octanoylcarnitine is found
to be elevated, then a model comprising MCADD, Glutaric
acidemia type 2 cases, false positives, babies receiving valproate,
and damaged cards would be used.
In case of workﬂow B, the data points corresponding to
screened newborns are localized in the universal model
(containing all true positives, normal healthy newborns, and
nonmetabolic conditions) and evaluation is performed in a
single step. While workﬂow B seems to be simpler, the large
number of assigned data groups may compromise selectivity,
which makes the utilization of workﬂow A safer.
Due to the limited number of positive samples, the system
was tested only in cases of PKU, MCADD, and HCY using
both workﬂows and also the ESI-MS/MS method used for
population level screening in western and central Hungary. The
cutoﬀ values used in the national screening program are
harmonized with those established by the international
collaborative study coordinated by Rinaldo et al. at Mayo
Clinic.33 Performance of the three approaches was compar-
ed,and it was concluded that both workﬂows A and B operate
ﬂawlessly using these limited numbers of samples and
conditions, while the traditional method yields a low, but still
signiﬁcant, number of false positives (∼0.65%). The required
analysis time is comparable for each method, but signiﬁcant
increase of overall turnaround time occurs, when second-tier
tests are included. The necessity of second-tier tests in the case
of the ESI-MS/MS method is well expressed through the
reduced false-positive rate (0.09%), which is expected to reach
even lower values in the herein reported method (estimated
value: 0.05%).
■ CONCLUSIONS
The presented nS-HR-MS method oﬀers a promising
alternative to the traditionally used ESI-MS/MS approach at
the population level screening of newborn babies for inborn
errors of metabolism. Thereby, the chip-based nanoelectrospray
system oﬀers several advantages compared to an ESI
autosampler, most notably the lack of cross-contamination
resulting in a signiﬁcantly reduced number of false-positive
results. Besides the detection of amino acids and acylcarnitines,
the novel method is also capable of the semiquantitative
determination of highly speciﬁc disease markers including
various organic acids, acylglycines, or even carbohydrates. The
untargeted nature of the novel method also allows multivariate
pattern recognition analysis of the resulting spectral informa-
tion, which results in improved speciﬁcity at the recognition of
screened conditions, and also the identiﬁcation of interferences
caused by the medical treatment of babies or damaged DBS
samples. Routine application of the method is expected to
decrease the number of second samples requested as well as the
number of second-tier or conﬁrmatory tests (amino acid
chromatography, GC/MS proﬁling of urinary organic acids,
succinylacetone, etc).
In principle, the method also has potential in the screening of
galactosemia (monitoring hexose and hexose-phosphate),
biotinidase deﬁciency, congenital hypothyroidism, lysosomal
storage disorders, certain hemoglobinopathies, and a number of
other diseases involving global changes in the metabolome. The
sample set used for this pilot study was a limited collection of
healthy and diseased neonates, which represents neither the
statistical variance of healthy population nor the prevalence of
the examined disorders yet. The data presented here already
shows signiﬁcant diﬀerences between normal and abnormal
samples, indicating the suitability of the proposed methodology
for the neonatal screening of DBS samples at proof-of-principle
level. The study is being extended for a larger, statistically
relevant set of samples, and the validation at population level is
already in progress.
Figure 4. Diﬀerent workﬂows of the newborn screening process suggested for the application of the nS-HR-MS approach.
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 Abstract 
 Background/Aims: Calcium homeostasis requires regulat-
ed celular and interstitial systems interacting to modulate 
the activity and movement of this ion. Disruption of these 
systems in the kidney results in nephrocalcinosis and neph-
rolithiasis, important medical problems whose pathogene-
sis is incompletely understood. Methods: We investigated 
25 patients from 16 families with unexplained nephrocalci-
nosis and characteristic dental defects ( amelogenesis im-
perfecta, gingival hyperplasia, impaired tooth eruption) . To 
identify the causative gene, we performed genome-wide 
linkage analysis, exome capture, next-generation sequenc-
ing, and Sanger sequencing.  Results: Al patients had bi-
alelic FAM20A mutations segregating with the disease; 20 
diferent mutations were identified. Conclusions: This au-
tosomal recessive disorder, also known as enamel renal
syndrome, of FAM20A causes nephrocalcinosis and amelo-
genesis imperfecta. We speculate that al individuals with 
bialelic FAM20A mutations wil eventualy show nephrocal-
cinosis.  Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Nephrocalcinosis (NC), diagnosed by radiographs, 
CT, or increased echogenicity on ultrasound, represents 
an important renal complication because it can accom-
pany progressive deterioration of glomerular function or 
nephrolithiasis [ 1] .I n some cases, NC provides a clue to 
an underlying genetic disorder such as hyperox aluria or 
distal renal tubular acidosis with or without deafness [ 2, 
3] .I n other cases, NC is a side efect of chronic treatment 
with various drugs, including loop diuretics and vitamin 
D. I n general, the pathogenesis of NC has not been ade-
q uately elucidated, although hypercalciuria appears to be 
a common finding.
 Often, rare genetic diseases reveal previously unrecog-
nize d mechanisms of action regarding physiology, cel bi-
ology, and metabolism. Here, we present genetic studies 
into a rare human disease of NC combined with amelo-
genesis imperfecta (AI ), a disorder of abnormal enamel 
formation and impaired tooth eruption.
 Methods 
 Patients and families were identified in our rare disease renal 
tubular or dental/craniofacial reference centers and gave informed 
consent. This study was approved by the institutional review 
boards and ethics commitees of the various centers. Al patients 
had NC confirmed by either ultrasound, X-ray or CT, and al 
showed characteristic teeth findings with AI  and delayed or miss-
ing tooth eruption.
 In short, multipoint parametric linkage analysis utiliz ing 2,000 
highly polymorphic markers (DeCode, Iceland) across the whole 
genome in 4 informative families as wel as homoz ygosity mapping 
for another consanguineous family was used to determine the lo-
cus linked to this trait, as published before [ 4 , 5] . Nex t-generation 
seq uencing using ex ome capture (Perkin Elmer, USA;  Leeds 
Translational Genomics Unit, UK) was performed on 5 patients 
from 5 unrelated families; 4  were part of the linkage analysis. Sub-
seq uent data analysis was restricted to novel seq uence variants 
within the linked region. The freq uency of each variant was ex am-
ined in > 100 ethnicaly matched aleles available in public data-
bases (1000 Genomes, release 12 – May 2012). Sanger seq uencing 
was performed as described, and mutations were seq uenced in 
family members for segregation analysis.
 In detail, genomic DNA was isolated from peripheral blood 
lymphocytes for al subj ects using standard protocols. Genotypes 
from polymorphic markers for 4 families were generated by De-
Code, Iceland. Analyses were carried out as published before 
with modifications [ 4 ] .I n short, genotypes were ex amined using 
a multipoint parametric linkage analysis and haplotype recon-
struction was performed via Alegro and Genehunter for an au-
tosomal recessive model with complete penetrance, disease alele 
freq uency of 0.001 (DeCode map with appropriate alele fre-
q uencies). The data were formated using Mega2 (version 4.0) 
through Alohomora (version 0.30, Win32);  non-informative 
markers were filtered out. Mendelian inconsistencies were 
checked using PedCheck (version 1.1); unlikely genotypes were 
identified and filtered using Merlin (version 1.1 alpha 3). The 
Alegro haplotype output files were visualiz ed with Haplopaint-
er. I n addition and in paralel, whole-genome SNP microarray 
analysis was performed on genomic DNA for another consan-
guineous family by AROS Applied Technology; resulting data 
were analyz ed using I BD finder software [ 5 ] .Whole-ex ome se-
q uencing was performed using 3 μg of genomic DNA, which was 
sheared and ligated to Ilumina adapters, according to Agilent’ s 
SureSelect Library Prep protocol. The sample was then siz e se-
lected (200–300 bp) by agarose gel electrophoresis and enriched 
for 12 cycles, using PCR prior to hybridiz ation to the SureSelect 
reagent for 24  h at 65    °   C. The library was denatured using NaOH 
and diluted to a concentration of 12 p M ,of which 120 μl was hy-
bridiz ed onto a v5  single-read flow cel (I lumina, San Diego, 
Calif., USA). Samples were prepared for seq uencing according 
to Ilumina’ s standard amplification, lineariz ation, blocking and 
primer hybridiz ation protocols. The flow cel was then loaded 
onto an Ilumina GAI I x  and seq uencing performed for 8 0 cycles 
after which the raw data were processed using the Ilumina pipe-
line. The data (q seq ) files generated were aligned to the human 
reference seq uence (hg19 /GRCh37) using Novoalign short-read 
alignment software (Novocraft Technologies, Selangor, Malay-
sia). Duplicate reads and reads mapping to multiple locations 
were ex cluded from any analysis. SAMtools and the Genome 
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Analysis Toolkit were used to further process the alignment files 
for variant caling [ 6, 7] .
 For confirmation of variants detected by ex ome capture/nex t-
generation seq uencing and for mutation detection in additional 
cases, we amplified al coding ex ons and ex on-intron boundaries 
of FAM20A using standard PCR methodology with intronic (ge-
nomic) primers. PCR products were separated on 1%  agarose gels 
with ethidium bromide using electrophoresis and visualiz ed un-
der UV  light. Specific bands were cut and DNA was isolated and 
purified using standard procedures. Bi-directional seq uencing of 
al ex ons and ex on-intron boundaries were performed using a 
Beckman Coulter CEQ 8 000 or an Applied Biosystems 3130x l 
capilary seq uencer per the manufacturer’ s protocol. Seq uencing 
data was analyz ed and compared with the published reference 
seq uence for  FAM20A (NG_ 029 8 09 , April 2012, NCBI  build 
37.3).
 Results 
 We ascertained 25  patients (12 males, 13 females; age 
12–64 ) in 16 families with NC and characteristic dental 
findings, i.e., the triad of AI , gingival thickening and im-
pairment of tooth eruption ( table  1 ). The diagnosis of NC 
was made predominantly by nephrologists based upon 
characteristic imaging findings. Generaliz ed hypoplastic 
AI  was evident from eruption of the deciduous teeth early 
in childhood with subseq uent impaired eruption of the per-
manent teeth and development of gingival enlargement. 
Clinical details of some patients have been published [ 8 –
11] .None of the parents or ofspring of our patients had AI .
 From the 16 families with this disorder, we selected 
four informative families ( fig.  1 A) for whole-genome 
Table 1. FAM20A mutations in patients with NC and AI
Family Age, years Gender FAM20A mutations
1 21 male c.9 15 –9 18 delCTTT; p.F305 fsX 38 0
2 27 female I V S2 + 1G> A/c.9 13–9 14 delTT; p.F305 fsX 378
31 male I V S2 + 1G> A/c.9 13–9 14 delTT; p.F305 fsX 378
3 23 male I V S4  + 1G> C/c.134 8 –134 9 delTC; p.S4 5 0fsX 4 69
25 female I V S4 + 1G> C/c.134 8 –134 9 delTC; p.S4 5 0fsX 4 69
4 5 9 male c.14 75 –14 8 2dupAACCCCAC; p.L4 9 5 fsX 5 09
64 female c.14 75 –14 8 2dupAACCCCAC; p.L4 9 5 fsX 5 09
5 12 female c.4 06C> T;  p.R136X
6 20 male c.34 –35 delCT; p.L12fsX 78
7 16 female c.15 13delA;  p.I 5 05 fsX 5 06
22 male c.15 13delA; p.I 5 05 fsX 5 06
8 20 male c.14 32C> T;  p.R4 78 X
9 13 male c.5 18 T> G;  p.L173R
10 29 female c.727C> T/c.1228 –1229 delGA; p.R24 3X /p.D4 10fsX 4 14
11 19 female c.217C> T/c.727C> T; p.R73X /p.R24 3X
20 male c.217C> T/c.727C> T; p.R73X /p.R24 3X
12 18 female c.1369 A> T; p.K4 5 7X
13 14 female c.75 5 –75 7delTCT/c.64 1–719 del79 bp; p.F25 2del/p.I 214 fsX 25 9
16 male c.75 5 –75 7delTCT/c.64 1–719 del79 bp; p.F25 2del/p.I 214 fsX 25 9
14 21 female I V S5 + 2T> G
15 24 male c.9 07–9 08 delAG; p.S303fsX 378
31 male c.9 07–9 08 delAG; p.S303fsX 378
37 female c.9 07–9 08 delAG; p.S303fsX 378
16 17 female c.34 –35 delCT/c.612delC; p.L12fsX 78 /p.A204 fsX 215
18 female c.34 –35 delCT/c.612delC; p.L12fsX 78 /p.A204 fsX 215
 Mutations are described on the cDNA and predicted protein levels. Listing of one alele indicates homoz ygosity; two aleles indicate 
compound heterozyg osity. Every patient had bialelic mutations involving insertions, deletions, essential splice sites, missense changes 
or nonsense changes.
Do
wnl
oa
de
d b
y: 
NIH
 Li
bra
ry 
    
    
    
    
    
    
    
    
    
    
   
12
8.2
31.
25.
17
1 - 
6/2
0/2
01
3 1
0:2
8:5
4 P
M
 Jaureguiberry et al. Nephron Physiol 2012; 122: 1–6
DOI : 10.115 9 /00034 9 9 8 9
4
parametric multipoint linkage studies. Using dense
(2 cM) polymorphic markers, we identified a single linked 
locus on chromosome 17q 24  with a LOD score of 3.1 
( fig.  1 B). Haplotype reconstruction placed the locus
between flanking markers D17S1821 (97.3 cM) and 
D17S1797 (106.2 cM), a region of 5.3  milion bases con-
taining 41 annotated genes (NCBI  build 37.3, October 
2011). I ndependently, homoz ygosity mapping identified 
the same locus in another consanguineous family (data 
not shown).
 To identify the disease-causing gene, we performed 
massive paralel seq uencing using ex ome capture on 5 
unrelated patients. Using an autosomal recessive model, 
limiting our analysis to the linked region, and filtering 
variants to eliminate common polymorphisms, we 
found homoz ygous or compound heteroz ygous muta-
tions in al 5 patients in only one gene, FAM20A .A total 
of 20 diferent mutations (deletions, insertions, and 
splice site, missense and nonsense mutations) were 
identified in the homoz ygous or compound heteroz y-
gous state, confirmed by Sanger seq uencing, and dem-
onstrated to segregate with the disorder in our 16 fami-
lies ( table  1 ).  FAM20A (cDNA 1,626 bp, protein 54 1 
amino acids, 11 coding ex ons) is a member of a family 
of kinase-encoding genes that includes  FAM20B and 
 FAM20C .
D17S2200 ENDC17
DG17S14 D17S668
D17S745 D17S784
D17S1847 D17S836
D17S802 D17S674
D17S937
D17S1603 D17S2192
D17S1864 D17S929
D17S515 D17S1862
D17S1797 D17S1351
D17S949 D17S1350
D17S789 D17S940
D17S1874 D17S1816
D17S957 D17S1290
D17S787 D17S1799
D17S1795 D17S1319
D17S1859 D17S1868
D17S1299 D17S1563
D17S1818 D17S1814
D17S927 D17S1867
D17S1857 D17S2196
D17S969 D17S1803
D17S520 D17S1303
D17S945 D17S804
D17S952 D17S1791
D17S595 D17S1832
D17S919 D17S1876
STARTC17 D17S849
D17S794 D17S924 D17S944
D17S1821
D17S916
D17S788
D17S1842
D17S1293
D17S2194
D17S798
D17S1800
D17S1824
D17S1871
D17S918
D17S839
D17S922
D17S799
D17S1844
D17S960
D17S1854
D17S831
D17S2181
D17S1529
cM
4.0
3.0
2.0
1.0
0
–1.0
–2.0
–3.0
–4.0
–5.0
–6.0
–7.0
–8.0
–9.0
–10.0
–11.0
–12.0
–13.0
–14.0
–15.0
–16.0
–17.0
–18.0
–19.0
LOD
A
B
 Fig. 1.  A Pedigrees used for multipoint 
parametric linkage analysis. Black symbols 
indicate afected, white unafected, sq uares 
males and circles females.  B LOD score 
analysis for chromosome 17. Note the sin-
gle significant peak at 17q 24 . 
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 Discussion 
 Calcium plays many critical roles in human physiolo-
gy, serving as an intracelular messenger, an ex tracelular 
neuromuscular ex citatory ion, and a structural compo-
nent of bone and teeth. For ex ample, tooth enamel (cal-
cium hydrox yapatite) is the hardest human tissue and can 
function into old age, despite being the only mineraliz ed 
tissue with no capacity for celular repair. Hence, the tem-
poro-spatial concentration of calcium must be ex q uisite-
ly regulated in diferent compartments, bound to albu-
min within the circulation, seq uestered by calbindin 
within cels, including teeth  [ 12] ,and ex creted under 
tight control by the kidney [ 13] .Within the vasculature, 
calcium availability is closely modulated by an intricate 
interplay between bones and regulatory hormones that 
involves positive and negative feedback mechanisms 
(e.g., vitamin D, PTH, calcitonin) [ 14,  15] . Conseq uences 
of dysregulated calcium homeostasis include nephrolithi-
asis and NC, i.e., precipitation of calcium in the urinary 
colecting system and renal interstitium, respectively.
 The processes that normaly maintain calcium balance 
in renal tissues can be delineated by studying genetic dis-
orders involving NC. A prime ex ample lies in an autoso-
mal recessive disorder of NC combined with AI . Linkage 
analysis and focused ex ome seq uencing performed on af-
fected families identified the causative gene as FAM20A ,
previously associated only with a disorder of AI  [ 16, 17] .
 Previous causes of NC have involved epithelial and 
paracelular disturbances in calcium transport, predomi-
nantly caused by mutations in calcium-specific channels 
and proteins [ 18– 20] .These systems either reabsorb fil-
tered calcium from the filtrate (urine) across the renal 
tubular cel or release calcium from the tubular cel into 
the interstitial compartment. When they malfunction, in-
creased urinary calcium precipitates within the renal tu-
bule (leading to nephrolithiasis and urolithiasis) or with-
in the interstitium (leading to NC); this is invariably ac-
companied by hypercalciuria.
 Our 25  patients ex hibited NC and AI , but ascertain-
ment of other patients with bialelic FAM20A  mutations 
wil ex pand the phenotype and define the entire spectrum 
of this rare disease. Also, two diferent Fam20a  knock-out 
mouse models ex hibited diferent findings; in one, no 
kidney findings were reported, whereas the other showed 
arterial calcification without NC  [ 21, 22] .The patients 
previously reported with FAM20A mutations and AI may 
also prove to have NC.
 Conclusions 
 Our findings have implications for diagnosis and treat-
ment. FAM20A is a localy secreted protein with low 
abundance in saliva [ 23] and blood [ 24 ] ,suggesting that 
replacement therapy could provide an option for a treat-
ment or prophylax is.
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Statistical Spectroscopic Tools for Biomarker Discovery and
Systems Medicine
Steven L. Robinette, John C. Lindon, and Jeremy K. Nicholson*
Computational and Systems Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London,
Sir Alexander Fleming Building, South Kensington, London SW7 2AZ, U.K.
ABSTRACT: Metabolic proﬁling based on comparative, statistical analysis
of NMR spectroscopic and mass spectrometric data from complex
biological samples has contributed to increased understanding of the
role of small molecules in aﬀecting and indicating biological processes.
To enable this research, the development of statistical spectroscopy has
been marked by early beginnings in applying pattern recognition to nuclear
magnetic resonance data and the introduction of statistical total correlation
spectroscopy (STOCSY) as a tool for biomarker identiﬁcation in the past
decade. Extensions of statistical spectroscopy now compose a family of
related tools used for compound identiﬁcation, data preprocessing, and
metabolic pathway analysis. In this Perspective, we review the theory and
current state of research in statistical spectroscopy and discuss the growing
applications of these tools to medicine and systems biology. We also
provide perspectives on how recent institutional initiatives are providing new platforms for the development and application of
statistical spectroscopy tools and driving the development of integrated “systems medicine” approaches in which clinical decision
making is supported by statistical and computational analysis of metabolic, phenotypic, and physiological data.
The connection between the chemistry of tissues andbiological ﬂuids and health has been recognized since
the beginning of medicine as a discipline. The color, smell,
and taste of urine, for example, were used as diagnostics by
physicians from ancient Greece through to the Middle Ages.1
While metabonomics,2 and the related ﬁeld of metabolomics,3
have replaced human chemosensation with modern analytical
chemistry techniques, the basic insight that chemical patterns
are indicative of biological processes underlying both
physiological and pathological states remains the same. Several
terms are used interchangeably and employ essentially the same
technologies and procedures: metabonomics, metabolomics,
metabolic proﬁling, and metabolic phenotyping. Metabonomics
employs a so-called top down systems biology philosophy and
is deﬁned as “the quantitative measurement of the dynamic
multi-parametric metabolic response of living systems to
pathophysiological stimuli or genetic modiﬁcation”.2
Technological developments in nuclear magnetic resonance
(NMR) spectroscopy and mass spectrometry (MS) have
played a key role in facilitating the large-scale measurement
of low-molecular weight metabolites.4 While these techniques
feature varying strengths in coverage, sensitivity, selectivity for
various chemical classes, reproducibility, provision of structural
information, and sample preparation requirements, both stand
out in their capacity to measure a large number of small
molecule analytes in an untargeted fashion from complex bio-
logical mixtures such as human bioﬂuids.5 While the application
of these technologies to characterize human biochemical matrices
including bioﬂuids and tissues is not new, the combination of
untargeted proﬁling with ‘omics experimental designs and
multivariate statistical pattern recognition in metabonomics and
metabolomics has led to signiﬁcant improvements in under-
standing of the role of small molecules in controlling and marking
biological processes in toxicology,6 microbiology,7 and in human
health and disease.8 Protocols for these techniques, including
sample preparation, acquisition parameters, and resulting
information content have been published previously.9−13
The development of statistical spectroscopy14 and the
ongoing reﬁnement and extension of statistical spectroscopy
tools are signiﬁcantly increasing the utility of the metabonomics
approach as a general-purpose tool in analytical chemistry. Over
20 years ago, Noda developed the concept and theory of
statistically correlating peak intensities across sets of spectra
and applied it to IR data.15−17 In a later development,
Brüschweiler and co-workers published the application to the
rows or columns of a 2D NMR spectrum and termed it
covariance spectroscopy.18−21 While chemical identiﬁcation has
historically been dependent on puriﬁcation and separation
sciences, the combination of biological replicates and
correlation based approaches for NMR and MS together with
improved compound databases are increasingly enabling the
identiﬁcation of unknown compounds and even novel chemical
structures without prerequisite isolation.22 These approaches are
being extended to support the integration of metabolic proﬁles
with parallel data sets from genomics and proteomics, yielding a
framework for “global” systems biology in which organism level
Received: March 9, 2013
Accepted: April 24, 2013
Published: April 24, 2013
Perspective
pubs.acs.org/ac
© 2013 American Chemical Society 5297 dx.doi.org/10.1021/ac4007254 | Anal. Chem. 2013, 85, 5297−5303
human biological networks are mapped by identifying associations
between human genes, gut microﬂora, proteins, and metabolites.23
Additionally, the combination of metabolic proﬁling with statistical
spectroscopy and predictive modeling is increasingly being
incorporated into clinical practice, both as diagnostics, to monitor
patients, and to support clinical decision-making.24−26
To date, metabonomics has signiﬁcantly impacted the
practice of toxicology,6 microbiology,7 drug discovery,27 and
the study of metabolic regulation and disease.8 In this
Perspective, we review the origins and theory of statistical
spectroscopy, major milestones in the development of the ﬁeld,
and survey the landscape of statistical spectroscopic tools
currently available. We then discuss how the framework of
statistical spectroscopy is being applied to global systems
biology through the identiﬁcation of gene-metabolite and other
systems level associations. Just as the development of systems
biology has advanced research in the life sciences, we are
currently seeing an analogous development of “systems
medicine”, the integrated study of system level metabolic,
phenotypic, and physiological changes in response to disease
processes or therapies by application of computational and
statistical approaches to support clinical decisions. We discuss
applications of statistical spectroscopy toward the development
of a systems medicine, especially in surgical metabonomics and
patient journey monitoring. We conclude with a perspective
on how statistical spectroscopy will continue to contribute to
analytical chemistry and major institutional initiatives that will
advance this science in the near term.
Statistical Spectroscopy As a Tool for Biomarker
Discovery and Disease Modeling. Early metabonomics
studies in which pattern recognition was applied to NMR spectra
frequently noted complex, coordinated multianalyte responses
between biological states and through time.28 The application of
dimensionality reduction techniques such as principal component
analysis (PCA) and later supervised learning methods including
partial least-squares (PLS) and orthogonal projection onto latent
structures (OPLS)29 spurred an interest in using metabolic
proﬁles as a multivariate descriptor of an underlying biological
state, resulting in now widespread application of chemometric
tools in metabonomics.30,31 While individual metabolites were
often assigned in representative spectra, discussions involving the
application of pattern recognition in metabonomics frequently
highlighted the ability to distinguish spectra from two or more
biological states based on diﬀerences between metabolic proﬁles
and of “metabolic trajectories” over time.32
While these methods focused on identifying correlations
between signal and state (phenotype), the introduction of new
methods in the past decade signiﬁcantly enhanced metabolite
identiﬁcation by identifying correlations between signals. 2D
Fourier transform NMR, 2D-correlation IR spectra,15−17 and
covariance NMR18−21 identify correlations between spectroscopic
signals by making use of systematic variation in a sequence of
one-dimensional spectra to improve chemical characterization,
but these methods all make use of measurements collected
from a single sample. With the introduction of statistical total
correlation spectroscopy (STOCSY),14,33 this approach was
extended to identify covariance in peak intensities across
multiple, independent samples that can generate associations
between signals rising from the same molecular structure
independent of through-bond or through-space connectivity
(Figure 1). While STOCSY is typically applied to identify signal-
signal rather than signal-state correlations, like most statistical
spectroscopy tools it can be combined with chemometrics as a
two stage process as was noted in the original presentation.14
The theoretical framework of STOCSY (see Box 1) was
recognized to be ﬂexibly extendable beyond 1H NMR both to
other metabolic proﬁling techniques and to multiple ‘omics
technologies. This recognition has led to sustained development
of a diverse set of tools in statistical spectroscopy (Table 1).
Statistical spectroscopy is now composed of a family of related
tools that perform a range of functions in metabonomic research
(Figure 2). While initial applications of STOCSY sought to
Figure 1. Statistical total correlation spectroscopy (STOCSY): (A) one-dimensional (1D) and (B) two-dimensional (2D) STOCSY correlation/
covariance plots of a urinary NMR data set. Here, lineshapes are calculated by covariance ([−∞,∞]) while colors are set by correlation ([−1,1]).
One-dimensional STOCSY plots (A) are traces of the two-dimensional STOCY (B, black box) at a given chemical shift taken from the “driver” peak.
For the maxima of the doublet of 3-hydroxybutryic acid at 1.2 ppm (“driver” peak), high positive correlation coeﬃcients are both sensitive and
speciﬁc indicators of structural connectivity, and “pathway” connectivities show mostly negative correlations. For other metabolite signals seen in the
2D STOCSY, high positive correlations such as those between lactate (1.33 ppm), alanine (1.48 ppm), and glucose (∼3.5−4 ppm) indicate
coordinated excretion rather than structural relationships.
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identify structural relationships between 1D 1H NMR signals,
oﬀshoots quickly appeared applying and modifying the
STOCSY methodology to preprocess spectroscopic data sets,
to reveal structural relationships between multiple analytical
platforms and to identify coregulation resulting from biological
and pathway relationships between metabolites. Figure 2 maps
out a statistical spectroscopy “family tree” outlining these
various techniques and their primary applications.
One of the major drivers of the development of new tools in
statistical spectroscopy is the ablility of these tools to detect
both associations across spin-systems that are not visible
using traditional correlation NMR spectroscopy and weaker
“pathway” correlations between compounds of interest and
related compounds whose expression is modulated by associ-
ated biological pressures.33 One of the initial key challenges
in statistical spectroscopy involved diﬀerentiating between
these two sources of correlations. As a result, substantial eﬀort
has been applied to characterizing the range of correlations
from within-compound “structural” associations and between-
compound “biological” correlations.34 Extensions of statistical
spectroscopy beyond biomarker identiﬁcation have sought to
make use of these properties to (1) improve diﬀerentiation
of structural correlations by local clustering, subset selection,
and stoichiometric relationships,35−37 (2) query networks of
biological coregulation of metabolites,35,38−40 and (3) improve
preparatory processing of spectroscopic data for subsequent
statistical analysis.41−43
Statistical spectroscopy is ﬂexibly applied to nearly any
analytical technique that results in quantitative or semiquantitative
measurements of molecular features. Because of this ﬂexibility,
statistical spectroscopy versions of many correlation spectroscopy
experiments have been formulated, including Het-STOCSY
(heteronuclear STOCSY) for 1H−31P44 and 1H−19F45 correla-
tions, diﬀusion-ordered projection spectroscopy (DOPY),46 and
statistical heterospectroscopy (SHY) to identify associations
between NMR and MS data,47 which often prove challenging
to identify using hyphenation techniques such as LC−NMR−MS.
Advantages of these correlation techniques include higher
resolution and sensitivity relative to direct experimental observa-
tion and an extended range of correlations, both positive and
negative.
It is our perspective that many applications of analytical
chemistry will beneﬁt from recent advances in statistical
spectroscopy. By combining the direct observation of complex
mixtures with postprocessing to highlight and correlate signals
of interest, statistical spectroscopy suggests a new, four-stage
approach to biomarker and compound identiﬁcation, repre-
sented schematically in Figure 3. In the ﬁrst stage, spectral
features are correlated with a given biological state or response
by applying pattern recognition analysis to individual data
sets generated by NMR spectroscopy or mass spectrometry
(Figure 3A). Subsequently, STOCSY, SHY, and other statistical
spectroscopy tools are then used to associate masses,
fragments, and NMR spectral features (Figure 3B). In a
third stage, the set of correlated features, including mass,
retention time, fragmentation patterns, chemical shifts, and
through-bond correlations are searched in-silico for matching
compounds using metabolite libraries and reference spectral
data (Figure 3C). While individual MS m/z values and single
NMR chemical shifts are often non-speciﬁc, only a small
number of structural isomers will give rise to similar NMR
spectra and MS-MS fragments. To conclusively verify database
matches, metabolite candidates of interest may be conﬁrmed by
direct spiking of pure chemical standards into the biological
matrix for NMR or comparison of parent masses, retention
times, and fragmentation patterns of pure standards by mass
spectrometric analysis (Figure 3D). Several web-based computa-
tional tools to support biomarker and compound identiﬁcation,
including Metlin, XCMS Online, the BMRB and HMDB
databases, and MetaboAnalyst, have been introduced in recent
years,48−52 and additional support will be provided by continued
integration of statistical spectroscopy and pattern recognition
with spectral databases.
Applications of Statistical Spectroscopy in Systems
Biology and in Medicine. High-throughput measurement
and analysis of genes, transcripts, proteins, and others in addition
to metabolites have enabled the simultaneous monitoring of
many elements of biological networks. It is our perspective that
statistical spectroscopy will play an important role in the develop-
ment of top-down and “global” systems biological approaches.23
These expand the framework of statistical spectroscopy to
identify associations across multiple omits sciences (see Box 1).
Examples include the development of metabolomic quantitative
trait loci mapping (mQTL)53−55 and related metabolomic
Box 1. Theory of Statistical Spectroscopy
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In eq 1, rmn is the correlation coeﬃcient between the intensities
x of signal m and signal n across all spectra i through j, where
these signals have mean intensity xm̅ and xn̅ and standard
deviations σxm and σxn. When signals m and n arise from the
same chemical structure, rmn will tend to approach unity. When
signals m and n arise from diﬀerent chemical structures, the
magnitude of rmn will depend on the extent to which the
metabolites giving rise to signals m and n are subject to the same
metabolic perturbations (e.g., pathway connectivity). As a result,
the correlation coeﬃcient rmn can be used to assess both
structural and pathway connectivity, though in the case of strong
metabolic perturbations or poor signal resolution there may be
ambiguity between the underlying origin of correlations.
Equation 2 is mathematically equivalent to eq 1, but the
matrix notation emphasizes diﬀerences between data sets rather
than signals. Here, R is a matrix of correlation coeﬃcients
between two autoscaled data sets X1 and X2, each of which is
composed of j observations. When X1 and X2 are the same
matrix, R is homospectroscopic. When X1 and X2 are matrices
derived from diﬀerent analytical techniques, such as hetero-
nuclear NMR or mass spectrometry, R is heterospectroscopic.
The framework of statistical spectroscopy is ﬂexibly extended in
cases in which X2 is data derived from genomics, proteomics, or
transcriptomics as well. In these cases R will reﬂect metabolite−
nonmetabolite associations as opposed to the traditional
metabolite−metabolite associations. When X2 is not a second
data set but is instead a vector of phenotypic traits Y (eq 3), R
reﬂects metabolite−phenotype associations.
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genome wide association studies (mGWAS),56−59 metabolome−
microbiome associations, and work integrating genome, trans-
criptome, and metabolome variation to identify functional
networks governing human homeostasis.60
Developments in genomics and metabonomics have now
enabled the large-scale proﬁling of both genetic variants and
metabolic proﬁles necessary to draw ﬁrm statistical associations
between genes and metabolites. As statistical power grows with
sample sizes, the relatively small set of known associations
between single nucleotide polymorphisms (SNPs) and bioﬂuid
metabolite concentrations identiﬁed by NMR or MS is growing
rapidly. New mQTL/mGWAS publications are both replicating
and expanding the set of known gene−metabolite associations.58
Many of these discovered associations make immediate bio-
logical sense. Many “cis” associations between polymorphisms
in metabolic enzymes and adjacent metabolites (urine glycerate
and glycerate kinase54) and transporters and transporter
substrates (serum urate and SLC2A9 urate transporter58) are
immediately comprehensible. Other “pathway” associations can
be more diﬃcult to explain at ﬁrst but are no less informative.
These associations are likely to annotate unknown gene
functions and help explain human metabolic networks in both
physiological and pathological states. The nearly simultaneous
discovery of a statistical association between the NT5E gene,
encoding a vascular epithelial enzyme, and serum inosine con-
centration58 and the identiﬁcation of a human vascular calciﬁ-
cation phenotype cause by rare mutations in the NT5E gene
and resulting disruption of adenosine metabolism61 indicates the
potential power of this approach.
In addition to mammalian genomic determinants of meta-
bolism, the global systems biology approach enables the
identiﬁcation of gut microbiota impacts on host metabolism.
Sensitivity to intestinal microbes is especially important for
organism-level networks as our microbiota includes over a
thousand species of symbionts with a total genetic contribution
of probably more than 100 times the ∼20 000 predicted human
genes. This “second genome” coordinates extensively with host
metabolic and physiological systems, especially the liver and
immune system.62 Associations of microbe populations with
metabolites have been enabled by semiquantitative character-
izations of bacterial species using techniques such as ﬂuorescent
in situ hybridization (FISH) and denaturing gradient gel electro-
phoresis (DGGE) and have been used to identify associations
between bacterial populations, related metabolites, and obesity.63
While extensions of statistical spectroscopy to nonmetabolite
data sets is a promising area of research, weaker associations
between levels of biological organization (e.g., gene regulation
and metabolite abundance) require increased statistical power
to detect. Population-level studies are increasingly necessary to
identify signiﬁcant associations in top-down systems biology.
The recently established MRC-NIHR National Phenome
Centre in the U.K. will play an important role in developing
the scale necessary to do this kind of science.
Figure 2. Statistical spectroscopy family tree. Statistical spectroscopy is
based on the quantitative correlation of spectral signals derived from
analytical chemistry data and can be applied to identify metabolite−
metabolite associations, metabolite−nonmetabolite associations, and
metabolite−phenotype assocations. STOCSY and its extended family
of methodologies are typically applied to assign chemical structures,
prepare spectroscopic data sets for pattern recognition analysis, and
identify coregulation between metabolites. Branches in the tree show
diﬀerent statistical spectroscopic tools and indicate the major
applications of these tools. Additional information about individual
tools and relevant citations are shown in Table 1.
Table 1
statistical spectroscopic tool analysis platform purpose ref(s)
statistical total correlation spectroscopy
(STOCSY)
1H/1H NMR assign biomarker chemical structure by identifying structural correlations in
1D NMR
14, 33
subset optimization by reference matching
(STORM)
1H/1H NMR identify structural correlations from minor peaks in large NMR data sets 36
diﬀusion ordered projection spectroscopy (DOPY) 1H/1H DOSY NMR improve resolution of correlated signals 46
statistical total regression spectroscopy (STORSY) 1H/1H JRES NMR identify stoichiometric relationships between NMR signals 37
statistical total correlation mass spectrometry
(STAMSY)
LC−MS/LC−MS identify isotope/adduct correlations in mass spectrometry
statistical heterospectroscopy (SHY) 1H NMR/LC−MS identify corresponding signals in NMR and MS 47
heteronuclear STOCSY (Het-STOCSY) 1H/19F, 1H/31P NMR correlation of heteronuclear NMR signals 44, 45
cluster analysis statistical spectroscopy (CLASSY) 1H/1H NMR distinguish structural/pathway correlations and identify metabolic
perturbations
35
kinetic STOCSY (K-STOCSY) 1H/1H NMR follow sequences of biotransformations on short time scales 76
iterative STOCSY (I-STOCSY) 1H/1H NMR trace network of pathway correlations 38
recoupled STOCSY (R-STOCSY) 1H/1H NMR identify sets of pathway relationships in perturbed metabolic networks 40
orthogonal ﬁltered recoupled STOCSY
(OR-STOCSY)
1H/1H NMR identify metabolites in weakly perturbed networks 39
STOCSY-editing (STOCSY-E) 1H/1H NMR remove signals from exogenous compounds 42
STOCSY-scaling (STOCSY(S)) 1H/1H NMR scale statistical variance of compound signals 43
statistical recoupling of variables (SRV) 1H/1H NMR adaptive binning of signals to reduce dimensionality 41
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While metabonomics continues to promise a signiﬁcant
potential for translating biomarkers identiﬁed by association
studies into clinical tests, the advent of “surgical metabonomics”
has seen signiﬁcant contributions in identifying downstream
biochemical consequences of surgical interventions and in
tracking metabolic perturbations and subsequent biochemical
journeys toward recovery.64,65 Metabonomics has been applied
to study experimental models of bariatric surgery,66 laparotomy,67
ischemia/reperfusion,68 and the identiﬁcation of complex impacts
on gut micoﬂora from these interventions. Growing appreciation
for the utility of metabonomics in patient monitoring following
surgery has led to eﬀorts toward applying metabolic proﬂing
to analyze “patient journeys” from disease through surgical
interventions and subsequent recovery, applications and prospects
of which have been recently reviewed.65,69
Application of metabonomic monitoring real-time during
surgery is also a growing area of interest. Development of
“intelligent knife” technology coupling molecular ion generat-
ing surgical techniques, such as electrocautery, laser surgery,
or ultrasonic aspiration, with mass spectrometry has shown
signiﬁcant promise for the rapid identiﬁcation and guided
excision of pathological tissues.26,70 Here, mass spectrometry acts
as a biochemical sensor, sampling tissues in situ to provide real
time information guiding surgical decisions. Ionization con-
ditions under electrosurgery or laser surgery generally lead to loss
of chemical stability and the mass spectrometry instrumentation
suitable for in-theater use may not provide suﬃcient resolution
or separation to conclusively identify individual biomolecules.71
However, rather than attempting to identify individual markers
and make tissue classiﬁcation decisions based on levels of these
markers, classiﬁcation of real-time mass spectra is done on the
basis of pattern recognition of spectral features, biochemical
“ﬁngerprints”.72,73
Proof-of-principle demonstrations for the intelligent-knife
technology began with sampling and analysis of nonhuman, ex
vivo tissues.70−72 This early work demonstrated classiﬁcation of
tissue types and various tumors is possible on the basis of mass
spectrometric ﬁngerprints. Subsequent work identiﬁed brain
tumors as a good candidate for early application of the
intelligent knife, and several groups have reported ex vivo
sampling and classiﬁcation of human brain tissue and tumor
types.25,74,75 Recent work has demonstrated surgical mass
spectrometric diﬀerentiation of both gray matter and white
matter from meningeoma and glioblastoma74 and distinguishing
of multiple gliomas, including oligodendroglioma, astrocytoma,
and oligoastrocytoma.25
The recently established Imperial Clinical Phenotyping
Centre will play an important role in extending surgical
metabonomics, intelligent knife technology, and the framework
of patient journey monitoring into clinical practice. Combining
metabolic proﬁle measurement over the course of the patient
journey including diagnosis, intervention, and postintervention
with statistical spectroscopy and predictive modeling will provide
important information to guide clinical decision-making.
Future Directions for the Field. Direct, quantitative com-
parison of spectra generated by analytical chemistry techniques
is a basic cornerstone of current practice in metabonomics/
metabolomics. The application of pattern recognition techni-
ques to spectral data has driven over 20 years of metabonomic
science that has led to a renewed appreciation for the role of
small molecules and transformed our approach to research in
toxicology, functional genomics, microbiology, and pathology.
In the past decade, the introduction and continued development
Figure 3. Strategy for unknown compound identiﬁcation using statistical spectroscopy. Signals of interest are identiﬁed from an experimental data set
(a). Statistical spectroscopy tools, such as STOCSY and SHY, are used to identify correlations between the signal of interest and additional signals in
the same or other spectral data sets collected from the same set of samples (b). Candidate compounds are identiﬁed using database search tools to
match the set of correlated spectral features with structures (c). A candidate compound is conﬁrmed by spiking a solution of the candidate into the
original mixture (d).
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of statistical spectroscopy has further extended the reach of this
approach to compound identiﬁcation, providing rapid diag-
nostics in a clinical setting, and the study of biochemical
organization at the systems level. Despite these advances, routine
application of metabolic proﬁling in a nonresearch setting is
hindered by the absence of a single analytical platform for
metabolome analysis, the specialized knowledge required to
interpret spectral data and identify biomarker chemical
structures, and uncertainty regarding both interpretation of
metabolome-wide data and the protection and management of
resulting information. Advances in instrumentation, informatics,
and analytics software will be necessary to resolve these out-
standing challenges.
These challenges are not insurmountable, and in the U.K. the
recently established MRC-NIHR National Phenome Centre
and the Imperial Clinical Phenotyping Centre at St. Mary’s
Hospital in London will play an important role in translating
the methodology of metabolic phenotyping and developing
improved tools and procedures for the collection and analysis
of metabolic proﬁles and related ‘omics data to support clinical
decision-making through the framework of systems medicine.
We anticipate the day when comprehensive measurement of
biological variables, including gene sequences, epigenetic
modiﬁcations, expression and translation levels, and metabolite
abundances are routine and this data is widely available.
Developments in statistical spectroscopy and integration with
the related ﬁelds of genomics and proteomics will lead to an
important role for analytical chemistry in paving the way to this
future.
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Introduction
e last few decades have witnessed a radical change in 
the biological sciences, as the advent of the ‘omics’ era 
has brought large-scale measurement of genes [1,2], 
transcripts [3], proteins [4,5] and metabolites [6-8]. 
Genetics has undergone a high-throughput revolution, 
with genomic sciences enabling the rapid acquisition of 
genome-wide gene-expression proﬁles, polymorphisms 
and, more recently, whole genome sequences [9]. ese 
advances have been matched by advances in the measure-
ment of smal-molecule metabolites in the associated 
ﬁelds of metabonomics [10,11] and metabolomics [8,12]. 
Like genomics, these ﬁelds aim for comprehensive 
measurement and analysis of variations, but in the 
complement of low-molecular-weight compounds within 
a cel, tissue or bioﬂuid.
For the past 20years, developments in genomics and 
metabonomics have progressed on paralel tracks, ex-
changing experimental designs, data-analysis techniques 
and applications in basic biology and medicine [13-16]. 
Yet genes and metabolites are intrinsicaly co-infor-
mational, each shedding light on complementary bio-
logical processes. e genome encodes the metabolic 
capacities of the cel (the microbiome also inﬂuences 
mammalian metabolism), and changes in the activity and 
function of enzymes, transporters and transcription 
factors resulting from genetic variations have a direct 
impact on the identities and quantities of both intra-
celular and extracelular metabolites. Metabolite concen-
tra tions are ultimately quantitative, phenotypic traits, the 
genetics of which are described by the quantitative trait 
locus (QTL) - a DNA sequence controling the pheno-
typic outcome of the quantitative trait, such as a metabo-
lite concentration. Since the origins of biochemical 
genetics over a century ago, the integrated study of 
genetics and metabolism has produced signiﬁcant 
advances in the understanding of basic biological pro-
cesses and in the diagnosis and treatment of human 
disease [17].
Metabolic proﬁling of single gene mutations [18] and 
QTL mapping of single metabolic traits [19] both 
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represent early attempts at identifying gene-metabolite 
associations through omic sciences, by regressing one 
gene against many metabolites or one metabolite against 
many genes. In more recent studies, metabolome-wide 
profiling of biofluids by nuclear magnetic resonance 
(NMR) spectroscopy or mass spectrometry (MS) is 
combined with whole-genome profiling of single nucleo-
tide polymorphisms (SNPs) to identify many gene-
metabolite associations simultaneously, by regressing 
many metabolite levels against many polymorphisms 
[20]. While these studies, termed metabolomic quanti-
tative trait locus (mQTL) mapping, or metabolomic 
genome-wide association studies (mGWAS), are often 
applied to human genes and human biofluid profiles, 
these techniques hold the additional promise of 
investigating interactions between gut microflora genes 
and biofluid metabolites. By regressing metagenomic 
sequences against metabolic profiles, metagenome-wide 
metabolome-wide associations provide insight into the 
metabolic cross-talk of bacterial and human genomes in 
the larger human superorganism [21,22]. !is review 
discusses the highly analogous methods and applications 
of genomics and metabolomics, as well as recent attempts 
at integrating the two fields towards a more compre-
hensive and holistic understanding of gene function and 
the control of metabolic processes.
Developments in instrumentation and 
experimental design in metabonomics parallel 
those in genomics
Increases in the speed, accuracy and coverage of genomic 
analysis have been mirrored by technological develop-
ments in the large-scale measurement of low-molecular-
weight metabolites, using the two major analytical plat-
forms of NMR spectroscopy and MS [23]. While these 
techniques feature varying strengths in coverage, sensi-
tivity, selectivity for various chemical classes, repro-
ducibility, provision of structural information, and 
sample-preparation requirements, both stand out in their 
capacity to measure a large number of small-molecule 
analytes in an untargeted fashion from complex 
biological mixtures, such as human biofluids [24].
One of the most popular analytical chemistry tech-
niques, NMR spectroscopy has a long history of applica-
tion in organic chemistry for structural identification and 
is used extensively in metabonomics. NMR spectroscopy 
is characterized by the following key properties, which 
are fit for purpose: (i) high dynamic range, with several 
biological nuclei, such as 1H, 13C, 15N or 31P, being 
accurately measured over a large range of concentrations; 
(ii) high linearity of signal intensity with concentration; 
and (iii)  high reproducibility. In particular, 1H NMR 
spectro scopy is robust, provides a high degree of 
structural information for both one-dimensional 1H and 
two-dimensional 1H-1H NMR, and is flexibly applied to 
extracts, biofluids and solid tissues using high-resolution 
magic angle spinning, and in vivo using magnetic 
resonance spectroscopy. Technological advancements in 
magnetic field strength with the introduction of 600, 800 
and, recently, 1,000  MHz NMR spectrometers, pulse 
sequence experiments, and cryogenically cooled probes 
have increased the sensitivity and coverage for small-
molecular-weight metabolites and lipid components 
from urine, plasma, serum and tissue samples [11].
MS, coupled to either liquid (LC) or gas (GC) 
chromatography, is also frequently applied to profile the 
metabolome [25-27]. LC- and GC-MS both boast high 
sensitivity to low-concentration analytes, as well as high-
resolution chromatographic separation. While these 
tech niques have faced challenges in compound identi fi-
cation, reproducibility and bias towards certain com-
pound functional groups, the rapid pace of technological 
development in MS has sought to address many of these 
challenges. Advances in chromatography, including ultra-
high-performance liquid chromatography (UPLC) and 
multidimensional gas chromatography (GC×GC, 3D-GC), 
have increased the speed and reproducibility of chroma-
tography-coupled MS [28]. Additionally, advances in MS, 
including high-resolution time-of-flight (ToF) and quad-
ru pole time-of-flight (qTOF) instruments, along with 
serial ion fragmentation (MS-MS, MSn) have improved 
resolution, coverage and identification of low-molecular-
weight species [29].
While many comparisons have been made between the 
utility of these techniques for metabolite analysis [30], 
advances in both have paralleled advances in speed, 
accuracy and coverage in genomics. As a result, broad-
coverage metabolite profiling using NMR spectroscopy 
and MS has been increasingly used to answer the same 
questions as genomics, especially in the search for risk 
factors for disease at the population level and predictors 
of drug metabolism in personalized medicine [13-16]. 
!ese are mirrored in parallel developments in experi-
mental design and data analysis.
Just as the introduction of the genome-wide association 
study (GWAS) began the search for associations between 
genome-wide polymorphisms with disease phenotypes in 
large population cohorts [15,31], the metabolome-wide 
association study (MWAS) has used large numbers of 
biofluid spectra and statistical regression to search for 
associations between metabolites present in human 
biofluids and both quantitative and binary physiological 
and pathological traits [16]. Two-class experimental 
designs, in which metabolite associations with disease 
are identified by statistical regression of metabolic 
profiles against binary variables for aﬀected and control 
individuals, are common, and associations between 
meta bolites and disease have been reported for obesity 
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and insulin resistance [32], prostate cancer [33], autism 
[34], ulcerative colitis [35] and more [36]. However, the 
recent application of metabolic profiling to large popu-
lation cohorts, quantitative traits and population diﬀer-
ences (termed MWAS) has revealed metabolite asso-
ciations with diet and blood pressure [37], region and 
cardiovascular risk [38] and ethnicity [39].
In addition to studies of disease risk, both metabolites 
and genes have been queried to predict drug metabolism. 
Paralleling previous work in pharmacogenomics, the 
introduction of pharmaco-metabonomics has demon-
strated that drug metabolism can be predicted from the 
metabolite composition of urinary biofluids before drug 
administration [13,40]. Recent applications of pharmaco-
metabonomics have highlighted metabolic predictors of 
acetominophen toxicity in animals [13] and humans 
[41,42], capecitabine toxicity [43] and microbial influ-
ences on drug detoxification [41].
Early integration: metabolic pro!ling of Mendelian 
traits and QTL mapping of single metabolites
Since the discovery of alkaptonuria by Archibald Garrod 
in the early 20th century, the measurement of metabolites 
has been used as a proxy to identify human genetic 
diseases, especially inborn errors of metabolism. Uniform 
newborn screening for multiple inborn errors of 
metabolism, including urea-cycle disorders and amino- 
and organic-acidurias, using heel-prick testing with GC-
MS-MS exemplifies the power of targeted metabolomic 
analysis to diagnose these diseases and enable the inter-
ruption of pathological processes resulting from genetic 
mutations [44]. More recently, untargeted NMR spectro-
scopy and MS have been used to diagnose known inborn 
errors [45-48], identify novel inborn errors using biofluid 
profiling [49,50] and identify complex downstream 
metabolic consequences [51-53] and biomarkers of organ 
pathology resulting from genetic mutations [54-56].
Untargeted metabolic profiling of biofluids, especially 
urine and serum, is a powerful technique for diagnosing 
inborn errors of metabolism with often non-specific 
clinical presentation, as metabolic intermediates accu-
mulated in biofluid compartments can be easily identified 
[18,57,58]. As a result, diagnosis of suspected inborn 
errors has been reported for many Mendelian diseases 
[45-50], especially using NMR spectroscopy. In some 
cases, metabolic profiling of biofluids from patients with 
suspected inborn errors has led to the discovery of 
previously undescribed diseases, with the identification 
of causal genes following the description of metabolic 
perturbations, as occurred with aminoacylase  1 defi-
ciency and beta-ureidopropionase deficiency [49,50].
While mutations in enzymes and transporters can 
often be readily diagnosed by biofluid profiling, and a 
strong mechanistic link is easily inferred between the 
disruption of a metabolic pathway and resulting accu-
mulation or depletion of metabolic intermediates, many 
Mendelian diseases result in more complex, progressive 
organ-specific or multi-organ pathology [59]. In these 
cases, metabolic profiling has been applied to identify 
sites of lesions, describe progression and attempt to 
identify proxy small-molecular biomarkers of the disease. 
Examples of this include the identification of markers of 
autosomal dominant polycystic kidney disease [55], 
comparison of the urinary profiles of several genetic 
forms of renal Fanconi syndrome [56] and description of 
abnormal brain metabolism in Smith-Lemli-Optiz syn-
drome [54]. Additionally, metabolite flux analysis using 
isotopically labeled metabolites suggests an additional 
way to apply metabolic profiling techniques to study the 
impact of genetic mutations [59].
#e genomic corollary of using metabolic profiling to 
study Mendelian genes is QTL mapping of single meta-
bolic traits. #e advent of whole-genome SNP analysis 
and the use of QTL mapping for quantitative traits, such 
as height [60], led to interest in identifying genetic loci 
associated with quantitative variation in individual meta-
bolite levels [19]. Examples of this include mapping of 
serum leptin levels to genes on human chromosome 2 in 
multiple human populations [61,62], associations with 
plasma triglyceride levels [63,64] and identification of 
genetic variants associated with high-density lipoprotein 
(HDL) levels [65,66]. Recent studies have investigated 
associations between serum lipid fractions and polymor-
phisms, constituting an intermediate between traditional 
metabolite QTL mapping and mQTL/mGWAS [67]. Like 
many QTL mapping studies, attempts to identify loci 
significantly associated with biofluid levels of single 
metabolites frequently indicate a large number of genetic 
associations. #is is almost certainly an indication of 
complex, multigenic control processes regulating energy 
metabolism and homeostasis, and the identification of 
large numbers of multiple loci provides an important 
documentation of genes involved in complex metabolic 
pathways. However, a large number of loci each contri-
buting to a potentially small percentage of observed 
variance in metabolite levels complicates direct inter-
pretation of genotype-phenotype relationships in these 
cases. Figure  1 shows a schematic illustration of gene-
metabolite correlations in biochemical genetics, tradi-
tional QTL mapping, and mQTL/mGWAS.
Identifying the genetic determinants of the 
metabolome: mQTL and mGWAS
GWAS currently requires increasingly large cohorts to 
ensure discovery of new genes associated with disease 
phenotypes [68]. Although this approach is very eﬃcient, 
the biological relevance of these associations can be 
diﬃcult to assess. #e identification of phenotypes 
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related to disease mechanism, onset and progression 
represents a promising research avenue.
e systematic search for molecular endophenotypes 
(that is, internal phenotypes) that can be mapped onto 
the genome began with the quantitative genetic analysis 
of gene-expression proﬁles, referred to as genetical 
genomics [69] or expression QTL (eQTL) mapping [70]. 
Treating genome-wide gene-expression proﬁles as 
quantitative traits was originaly developed in model 
organisms and applied to humans [70,71]. In  eQTL map-
ping, cis-regulatory associations between genomic varia-
tions and gene-expression levels are discovered by 
integrated analysis of quantitative gene-expression pro-
ﬁles and SNP s. e identiﬁcation of a SNP  at a gene locus 
aﬀecting its own expression represents a powerful self-
validation. H owever, eQTL mapping presents a series of 
drawbacks:  (i)  frequently analyzed cel lines often have 
altered gene expression, and access to biopsy samples 
from organs directly relevant to pathology is often 
impossible;  and (i)  due to the gene-centric nature of 
eQTL mapping, this approach bypasses the biological 
conse quences of the endophenotypes generating the 
association.
Imme diately folowing the success of the eQTL map-
ping approach [70], in which cis-regulatory associations 
between genomic variations and gene-expression levels 
are discovered by integrated analysis of quantitative 
gene-expression proﬁles and SNP s, metabolic proﬁles 
were included as endophenotypic quantitative traits. is 
led to mapping of multiple quantitative metabolic traits 
directly onto the genome to identify mQTLs in plants 
[72,73], then in animal models [74,75]. In  mQTL 
mapping, individuals are genotyped and phenotyped in 
paralel and the resulting genome-wide and metabolome-
wide proﬁles are then quantitatively correlated (B ox  1). 
mQTL mapping presents a signiﬁcant advantage over 
gene-expression products such as transcripts [70] or 
proteins [76]: the ever-increasing coverage of the meta-
bolome alows a glimpse at the real molecular endpoints, 
which are closer to the disease phenotypes of interest. 
Folowing the success of mQTL mapping in plants [72,73] 
and then in mammalian models [75], this approach was 
quickly folowed by the development of mGW AS in 
humans cohorts ([77-83], see also the review by 
J  Adamski [84]).
O ne of the distinctive features of mGW AS is the 
intrinsicaly paralel identiﬁcation of associations between 
monogeneticaly determined metabolic traits and their 
causative gene variants (see Table  1 for a list of human 
mQTL-metabolite associations).
e mechanistic explanation of gene/ metabolite 
associations identiﬁed by mQTL mapping can be 
diﬃcult. e simplest case corresponds to associations 
between genes encoding enzymes and metabolites, which 
are either substrates or products of the enzyme they are 
associated with [74,75] (Figure  2). is corresponds to a 
direct cis-acting mechanism. Also, one of the interesting 
discoveries from results obtained by Suhre et al. is that a 
number of gene variants causing metabolic variation 
correspond to solute transporter genes, as the maj ority of 
the genes in this category belong to the solute carrier 
(SLC) family [78,81,82]. Again, this corresponds to a 
direct mechanistic link. In  other cases, the link between 
gene variants and their associated metabolites can 
demon strate pathway, rather than direct, connectivity, 
such as polymorphisms in enzymes associated with 
Figure 1. Three experimental designs integrating genomic and metabolomic analysis. (a) Metabolic proﬁling applied to the diagnosis and 
study of human Mendelian diseases frequently identiﬁes direct, casual relationships between genetic variants and downstream accumulation 
or deﬁciency of metabolic intermediates, which may vary or progress over time. (b) QTL mapping of single quantiﬁed metabolites can identify 
strong associations between metabolite concentration and polymorphisms, though frequently additional, weaker associations with other aleles 
are discovered as wel. (c) mQTL and mGWAS studies are conceptualy similar to QTL studies of individual metabolites, but search for associations 
between many metabolites and many genes, frequently yielding a larger set of associations between genetic polymorphisms and metabolite 
concentrations or ratios.
et al Genome Medicine 4
metabolites several reactions downstream of the com-
pound directly acted upon by the enzyme itself (as 
observed with NT5E polymorphisms and inosine).
More opaque associations may be trans-acting in a 
broader sense: the causative gene variant can be a 
molecular switch, and the metabolite it is associated with 
is in fact regulated indirectly by this molecular switch 
(further down in the regulation events). !is is 
particularly the case when the causative gene variant 
encodes a transcription factor, inducing the medium- to 
long-term expression of entire gene networks, or when 
the gene variant encodes a kinase or a phosphatase 
regulating entire pathways on much shorter time-scales. 
Unlike cis-acting mQTL/metabolite associations, which 
can be seen as self-validation of the causative gene at the 
locus, trans-acting mQTL associations present the 
challenge of identification of the most relevant causative 
gene at the locus. If a SNP is associated with a metabolite, 
the closest gene at the locus is not necessarily the most 
relevant candidate, and further investigation of a larger 
biological network, such as protein-protein interactions 
[85], may be necessary to identify mechanistic relation-
ships between genetic variants and downstream meta-
bolism. Despite these challenges, which are familiar to 
practitioners of biochemical genetics, statistical identi-
fication of gene-metabolite associations by mQTL and 
mGWAS promises to significantly advance current 
under standings of gene function, metabolic regulation 
and mechanisms of pathology.
A glimpse of our extended genome with 
microbiome-metabolome associations
!e functional genomic association studies and data-
integration approaches described above rely predomi-
nantly on mammalian genome sequences and their 
annotation (excluding MWAS, which makes use only of 
metabolite profiling data and does not, as such, require 
genomic data). However, human phenotypes result from 
the interaction of several sets of genes: the karyome, the 
chondriome and the microbiome, respectively corres-
ponding to eukaryotic chromosomes, mitochondrial 
chromo somes and, finally, gut bacterial prokaryotic 
chromosomes. !e latest human gut microbiome gene 
catalogue identified 3.3 million non-redundant genes 
[86], which was dubbed ‘our other genome’, and the 
bacterial species composition of the gut microbiome 
varies from one individual to another, but this variation is 
stratified, not continuous, and suggests the existence of 
stable bacterial communities, or ‘enterotypes’ [87].
!e classical identification of associations between gut 
bacteria and metabolites has been performed on a case-
by-case basis for decades. However, the correlation of 
metabolic profiles with multiple gut bacterial abundance 
profiles was initiated a few years ago with the intro-
duction of bacteria/metabolite association networks [21]. 
Semi-quantitative characterizations of microbial popula-
tions using denaturing gradient gel electrophoresis 
(DGGE) and fluorescent in situ hybridization (FISH) 
have yielded associations with obesity and related 
metabolites [88]. Recently, the introduction of high-
throughput sequencing of bacterial 16S rDNA profiles 
and correlation with metabolic profiles has greatly 
increased the coverage and quantification of microbial 
species [89]. !e correlation of metabolic profiles with 
16S rDNA microbiome profiles provides a strategy for 
the identification of co-variation between metabolites 
and bacterial taxa, and such associations point to the 
production or regulation of metabolic biosynthesis by 
these microbes.
Given these early successes, the integration of meta-
bolome-wide experimental profiles with metagenome-
wide metabolic reconstruction models obtained from full 
microbiome sequencing should provide a clear insight 
into the functional role of the gut microbiome, especially 
the synthesis of metabolites and resultant impacts on 
human metabolism. !is critical need for a marriage 
between metabolomics/metabonomics and metagenomics 
has been clearly identified for several years [90]. How 
Box 1. Mathematical modeling for mQTL identi!cation
The statistical analysis involved in mQTL mapping and mGWAS 
does not currently diﬀer substantially from the statistical 
methods used to identify genetic loci associated with single 
quantitative traits. mQTL and mGWAS involve independent 
QTL mapping of each metabolite identified by metabolic 
profiling, though accurate analysis is dependent upon proper 
preprocessing of both genomic and metabonomic data. 
Associations are identified using techniques such as Haley-Knott 
regression implemented in the R/QTL package, which uses 
local information about surrounding markers [103], or typical 
univariate association tests such as χ2 or Cochrane-Armitage 
trend tests implemented in PLINK [104]. The results of mQTL and 
association mapping are typically displayed using a logarithm of 
odds (LOD, -log10(P value)) score, which allows establishment of 
genome/metabolome LOD score maps [74,75], or more classical 
Manhattan plots [77,78,81,82] (Figure 2).
The main challenge in mQTL data modeling is multiple 
correlation testing. Assuming the use of high-resolution 
metabolic profiles (1,000 to 10,000 features) and genome-wide 
SNP coverage (600,000 SNPs), a typical metabolome-wide GWAS 
can apply between 600,000,000 and 6,000,000,000 univariate 
tests. Given the number of tests involved, there are numerous 
opportunities for false discoveries and multiple testing 
corrections are required to account for this. Genome-wide 
significance levels can be estimated using Bonferroni correction 
[77], but also using Benjamini and Hochberg or Benjamini and 
Yakutieli corrections [105]. Finally, permutation and resampling 
methods also provide empirical estimates for false discovery 
thresholds [74,79].
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associations, several challenges stand in the way of 
routine paired analysis of sequences and metabolic 
profiles. !e first of these is the challenge of discovering 
significant associations with low sample numbers. Many 
of the successes reported in clinical sequencing have 
made use of data from a small number of patients, and 
sometimes only a sole patient. In these cases, potentially 
disease-causative variants are often identified using 
filtering strategies rather than statistical analysis [98,99]. 
While the diagnosis of human inborn errors of 
metabolism from single-patient biofluid NMR spectra 
demonstrates the potential of metabolic profiling to work 
with low sample numbers, lack of statistical validation 
means that the ‘biological signal’ in these cases must be 
quite marked. A second challenge is a dearth of tools for 
statistical analysis of sequence data. While QTL mapping 
using SNPs is well established, statistical techniques for 
QTL mapping with both rare and common variants are 
just beginning to be introduced [100]. It is likely that 
increased availability of large-scale population sequence 
data from initiatives such as the 1000 Genomes Project 
[101,102] and ClinSeq [103] will spur the development of 
statistical methods that can be deployed to identify gene-
metabolite associations.
Of the omics sciences, genomics and metabolomics are 
uniquely complementary, the strengths of each addressing 
Table 1. Human gene-metabolite associations identi!ed by mQTL/mGWAS
Metabolite Bio!uid SNP ID Local gene P-value Reference(s)
Trimethylamine Urine rs7072216 PYROXD2 (C10orf33) 7.90E-15 [79]
N-acetylated compound(s) Urine rs9309473 ALMS1, NAT8, TPRKB, DUSP11 1.40E-11 [79]
3-Amino-isobutyrate Urine rs37369 AGXT2 1.1E-06  [79]
    3.17E-75 [82]
2-Hydroxyisobutyrate Urine rs830124 WDR66, HPD 1.59E-15 [82]
Dimethylamine Plasma rs6584194 PYROXD2 (C10orf33) 8.10E-03 [79]
Sphingomyelin SM C14:10 Serum rs9309413 PLEK 1.95E-09 [77]
Lysine Serum rs992037 PARK2 1.20E-07 [77]
Sphingomyelin SM(OH,COOH) C18:2 Serum rs1148259 (rs1200826) ANKRD30A 3.04E-09 [77]
Phosphatidylcholine PC aa C36:4 Serum rs174548 FADS1 4.52E-08 [77]
Phosphatidylethanolamine PE aa C38:6 Serum rs4775041 LIPC 9.66E-08 [77]
C0 Serum rs7094971 SLC16A9 3.80E-20 [78]
N-Acetylornithine Serum rs13391552 NAT8 5.40E-252 [81]
5-Oxoproline Serum rs6558295 OPLAH 1.50E-59 [81]
Androsterone sulfate Serum rs17277546 CYP3A4 8.70E-40 [81]
Urate Serum rs4481233 SLC2A9 5.50E-34 [81]
Glycine Serum rs2216405  CPS1 1.60E-27  [81]
  rs7422339 CPS1 2.12E-24 [83]
Succinylcarnitine Serum rs2652822 LACTB 7.20E-27 [81]
Isobutyrylcarnitine Serum rs662138 SLC22A1 7.30E-25 [81]
Aspartylphenylalanine Serum rs4329 ACE 8.20E-20 [81]
Serine Serum rs477992 PHGDH 2.60E-14 [81]
Inosine Serum rs494562 NT5E 7.40E-13 [81]
Proline Serum rs2023634 PRODH 2.00E-22 [81]
α-Hydroxyisovalerate Serum rs2403254 HPS5 1.00E-20 [81]
Bradykinin, des-arg(9) Serum rs4253252 KLKB1 6.60E-18 [81]
Glutamine Serum rs2657879 GLS2 3.10E-17 [81]
Isovalerylcarnitine Serum rs272889 SLC22A4 7.40E-16 [81]
Decanoylcarnitine Serum rs8396 ETFDH 5.50E-15 [81]
Carnitine Serum rs7094971 SLC16A9 3.40E-14 [81]
S h ow n h e re  are  th e  S N P-m e taboli te  associ ati ons w i th  th e  h i g h e st stati sti cal si g n i !cance, as i n [77,79,81-83]. Associ ati ons w i th  m e taboli te  conce ntrati on w e re  re porte d  
for a total of 28 uni que  S N Ps, as sh ow n above. Associ ati ons w i th  rati os of m ulti ple  m e taboli te s w e re  re porte d  for an ad d i ti onal 30  uni que  S N Ps, but are  not i nclud e d  i n 
th i s table.
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weaknesses of the other. Genes are (mostly) static, an 
‘upstream’ blueprint controlling dynamic biological pro-
cesses. !e identities and quantities of ‘downstream’ 
metabolites capture both genetic and environmental 
influences, and can be measured serially to assess 
variation through time. Genomic studies often struggle 
to establish a firm link between genetic variants and 
phenotypic observations, and while metabonomics pro-
vides a closer proxy to phenotype, it is often diﬃcult to 
infer underlying causality from variations in metabolism. 
Together, the integrated application of genomics and 
metabonomics promises a bridging of the gap between 
genotype and phenotype through intermediate metabo-
lism, to help annotate genes of unknown function, genetic 
controls of metabolism, and mechanisms of disease.
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CONS P EC TU S
S mall molecules are central to biology, mediatingcritical phenomena such as metabolism, signal
transduction, mating attraction, and chemical defense.
The traditional categories that define small molecules,
such as metabolite, secondary metabolite, pheromone,
hormone, and so forth, often overlap, and a single
compound can appear under more than one functional
heading. Therefore, we favor a unifying term, biogenic
small molecules (BSMs), to describe any small mole-
cule from a biological source.
In a similar vein, two major fields of chemical
research,natural products chemistry and metabo-
lomics, have as their goal the identification of
BSMs, either as a purified active compound
(natural products chemistry) or as a biomarker of a
particular biological state (metabolomics). Natural products chemistry has a long tradition of sophisticated techniques that allow
identification of complex BSMs, but it often fails when dealing with complex mixtures. Metabolomics thrives with mixtures and uses
the power of statistical analysis to isolate the proverbial “needle from a haystack”, but it is often limited in the identification of active
BSMs. We argue that the two fields of natural products chemistry and metabolomics have largely overlapping objectives: the
identification of structures and functions of BSMs, which in nature almost inevitably occur as complex mixtures.
Nuclear magnetic resonance (NMR) spectroscopy is a central analytical technique common to most areas of BSM research.
In this Account, we highlight several different NMR approaches to mixture analysis that illustrate the commonalities
between traditional natural products chemistry and metabolomics. The primary focus here is two-dimensional (2D) NMR;
because of space limitations, we do not discuss several other important techniques, including hyphenated methods that combine
NMR with mass spectrometry and chromatography.
We first describe the simplest approach of analyzing 2D NMR spectra of unfractionated mixtures to identify BSMs that are
unstable to chemical isolation. We then show how the statistical method of covariance can be used to enhance the resolution of 2D
NMR spectra and facilitate the semi-automated identification of individual components in a complex mixture. Comparative studies
can be used with two or more samples, such as active vs inactive, diseased vs healthy, treated vs untreated, wild type vs mutant,
and so on. We present two overall approaches to comparative studies: a simple but powerful method for comparing two 2D NMR
spectra and a full statistical approach using multiple samples. The major bottleneck in all of these techniques is the rapid and
reliable identification of unknown BSMs; the solution will require all the traditional approaches of both natural products chemistry
and metabolomics as well as improved analytical methods, databases, and statistical tools.
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1. The Common Theme: Biogenic Small
Molecules
The identification and functional analysis of biogenic small
molecules (BSMs) form the primary objectives of both nat-
ural products chemistry andmetabolomics: natural products
chemists are traditionally interested in the identification of
new molecular structures with biological activity, whereas
metabolomics and the related field of metabonomics have
focused on correlating known BSMs with specific biological
properties. Despite similar objectives, application of similar
techniques, and frequent study of the same organisms,
natural products and metabolomics research have re-
mained largely separate fields, lacking regular interaction
and exchange of ideas.
BSMs control intracellular processes (metabolism), inter-
cellular processes (nervous system and hormonal regulation),
intraspecific communication (e.g., via pheromones), and inter-
specific interactions (e.g., viadefensive compounds); asa result,
many drugs are derived from BSMs.1 Many biogenic small
molecules function at multiple levels, making it difficult and
often artificial to differentiate between “metabolites”, that is,
compounds that are part of primarymetabolism, and “second-
ary metabolites”, that is, compounds not necessarily required
for metabolic functioning. Similarly, functional categorizations
such as “hormone”, “pheromone”, “biosynthetic intermediate”,
or “catabolite” canbeproblematic. For example, citric acid cycle
intermediatesare ligandsofGPCRs that function in intercellular
signaling.2 Therefore, for the purpose of this review, we use
“biogenic smallmolecules” (BSMs) as a unifying term to refer to
all “metabolites”, “secondary metabolites”, and “natural pro-
ducts”. Small molecules generally havemolecular weights less
than 1500 Da, but it should be noted that BSMs are further
distinguished from larger biomolecules such as proteins and
nucleic acids in that they are not strictly derived from a small
number of known building blocks. As a result, the molecular
structuresofBSMscanbehighlydiverseand irregular, and their
identification and characterization can present great analytical
challenges.
This separation of natural products research and meta-
bolomics appears ultimately rooted in differences of experi-
mental design. The basic goal of both fields is to take
complex mixtures of BSMs and identify a subset of com-
pounds that describe a biological process or possess intrinsic
biological activity. Whereas natural products research has
relied on activity guided fractionation to isolate simple
mixtures or individual compounds, metabolomics research-
ers have replaced chemical isolationwith direct comparative
analysis of complex mixtures to statistically identify subsets
of BSMs relevant in a specific biological context.
We think that the fields of metabolomics and natural
products are essentially “two sides of the same coin” and
would both benefit froman increased exchange of expertise
and approach. In natural products research, the process of
isolating individual components can lead to chemical mod-
ification or degradation of the BSMs of interest. Furthermore,
activity-guided fractionation necessarily risks losing impor-
tant biological information that was encoded in the original
BSM mixture, because most of the sample is not analyzed.
The use of activity-guided fractionation therefore often fails
in cases where several BSMs act in synergy. For example, a
family of BSMs recently identified in the model organism
Caenorhabditis elegans act synergistically as a mate-attracting
pheromone, but most of this activity is lost when individ-
ual components of the pheromone are separated during
fractionation.3
On the other hand, metabolomics uses statistical analysis
of NMRandmass spectra of complex BSMmixtures to detect
spectral features that correlate to a phenotype or biological
property of interest and their response to stimuli. One of the
most pressing challenges inmetabolomics is the subsequent
chemical identification of the BSMs represented by the
detected spectral features. This problem of assigning peaks
to BSMs is a major bottleneck in the typical metabolomics
workflow. Structure elucidation techniques commonly ap-
plied in natural products research, especially integrated use
of 2D NMR spectroscopy and mass spectrometry, may hold
the key to increasing the number of identifiable compounds
in metabolomic analyses.
2. Experimental Techniques That Bridge
Natural Products and Metabolomics
In this Account, we focus on several approaches to mixture
analysis by NMR. Each uses different sampling strategies,
data sets, and computational algorithms, but they all illus-
trate methods that bridge natural products and metabolo-
mics.We startwith themost chemically intuitive approachof
simply using 2D NMR spectra to analyze unfractionated
mixtures for unstable BSMs. Next, we show that the statis-
tical method of covariance can be used to enhance the
resolution of 2D NMR spectra and thus enable in silico
separation of BSMs in a mixture for database or ab initio
identification using individual spectra. We then describe a
comparative approach in which 2D NMR spectra from two
different organisms with different genetic backgrounds are
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compared to highlight unique BSMs. The final section high-
lights some of the powerful methods of statistically extract-
ing specific chemical information from 1D and 2DNMR data
of a particular biological state using tools of multivariate
analysis. Specific technical aspects of NMR spectroscopy,4
hyphenated techniques,5 statistical analysis,6,7 and overall
protocol development8 have been reviewed elsewhere.
2.1. Direct Observation of Mixtures. Two-dimensional
NMR spectroscopy is arguably the most important spectro-
scopic technique for the elucidation of novel or unexpected
structures.4,9 Two-dimensional NMR spectra are unique in
that they provide direct evidence for atom connectivity and
spatial arrangements. In contrast to metabolomics, which
routinely uses 1D NMR spectra for the characterization of
complex, often entirely unfractionated, BSM mixtures,10
natural product researchers traditionally relied on pure,
isolated samples for analysis, whereas definite identification
of novel compounds fromcomplexmixtureswas usually not
pursued or deemed possible. However, recent examples
have demonstrated that identification of new compounds
via 2D NMR spectroscopy of complex mixtures not only is
feasible but frequently offers significant advantages over
fractionation-based approaches.
Development of methods for identifying novel structures
via 2D NMR analyses of mixtures was motivated by several
instances in which traditional activity-guided fractiona-
tion failed to reveal the BSMs of interest. In one of the first
examples, the poison gland secretion of Myrmicaria ants
was suspected to contain highly toxic alkaloids; however,
chromatographic fractionation revealed only nontoxic
monoterpene hydrocarbons in some samples. Subsequent
2D NMR analyses of unfractionated ant venom then re-
vealed the highly unstable heptacyclic alkaloid myrmicarin
430A, representing one of the first examples for natural
products based on the oligomeric assembly of several
similarly functionalized fatty-acid chains.11,12 Myrmicarin
430A, whose intriguing structure and biogenesis has
spawned several efforts toward its total synthesis,13 repre-
sents one of the first examples of BSMs that were identified
without ever having been isolated. Similarly, a 2D NMR
spectroscopic screen of a library of spider venom samples
revealed that sulfated nucleosides, which despite their struc-
tural simplicity had not previously been found in nature,
form major venom components in several spider species,
including the infamous brown recluse, Loxosceles reclusa
(Figure 1).14,15 These arthropod examples showed that
high-resolution 2QF-COSY spectra are well suited for detect-
ing and characterizing unknown BSMs from complex
mixtures because they provide detailed structural informa-
tion and often permit interpretation of overlapping signals,
one primary challenge for using NMR spectroscopy for
mixtures.
2.2. Statistical Methods for Identification of BSMs from
Single Biological Mixtures. The popularity of 1D 1H NMR in
metabolomics and metabonomics applications is primarily
founded on the simplicity and efficiency of data collection.
Natural product research, on the other hand, has adopted
fromearly on the powerful repertoire of 2DNMR techniques.
Due to the narrowNMR linewidths of smallmolecules, 1D 1H
NMR spectra of mixtures can provide some rather speci-
fic information about the mixture components. They are
particularly useful in situations where the pool of compo-
nent candidates is limited, for example in the case of a urine
sample.16 In such cases, the observation of a single non-
overlapping peakmultiplet of amixture component permits
identification of the component and determination of its
relative concentration with high confidence. On the other
hand, 1D 1H NMR spectra of mixtures containing unknown
components permit neither the determination of the 1D
spectral traces that belong to individual components nor the
assignment of peaks to specific atoms. In such cases, the use
of 2DNMRmethods becomes indispensible. J-resolvedNMR
spectra17 are useful for simplifyingoverlap in 1D 1HNMRbut
lack important atomic correlations that are the cornerstone
of structure determination via 2D NMR; therefore, this
approach is not included in this Account.
The main drawback of 2D Fourier transform (FT) NMR
spectroscopy is the time required to collect the indirect
second dimension at high digital resolution. This dimension
is acquired in the time domain by repeating the same pulse
FIGURE 1. Structures of BSMs (biogenic small molecules) identified via
NMR-spectroscopic analysis from largely unfractionated metabolite
mixtures. Myrmicarin 430A (1) and bacillaene (3) represent members of
a small but growing class of natural products that have never been
isolated in pure form.11,12,15,35 The sulfated nucleoside 2was identified
from spider venom.15 The xanthurenic acid derivative 4 is a natriuretic
identified from partially fractionated human urine samples.49
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sequence N1 times with the evolution time t1 incremented
from experiment to experiment. Because the digital spectral
resolution is determined according to the Nyquist theorem
by Δν = SW/N1, where SW is the spectral width, a relatively
large number of increments, N1 > 256, is required to obtain
acceptable spectral resolution along the indirect dimen-
sion. This sampling requirement, which is independent of
sensitivity, becomes more severe at higher magnetic field
strengths B0 as SW ! B0.
Covariance NMR18,19 represents an alternative approach
to 2D FT that overcomes some of these limitations. Instead
of applying FT along the indirect dimension, the 2D correla-
tion information is reconstructed by statistical means
through covariance yielding a symmetric spectrum C that
has the same high resolution along the indirect and direct
dimensions. In this way, the minimal number of t1 incre-
ments required can be reduced to N1 < 100.
20 It can be
shown that C is mathematically related to the 2D FT spec-
trum F through C = sqrtm(FT 3 F)
19 where sqrtm denotes the
matrix square root, which can be efficiently computed via
singular valuedecomposition (SVD).21 The covariancemeth-
od can be directly applied to TOCSY and NOESY-type spec-
tra, whereas for COSY an additional regularization step
should be applied.22
While for short mixing times the information content of
TOCSY and COSY spectra are similar, for longermixing times
(∼100 ms) typically all protons that belong to the same
molecule or spin system show 2D cross-peaks to each other.
This property conveniently permits the spectral deconvolu-
tion of the mixture into 1D NMR traces that correspond to
individual components. Such a decomposition can be
achieved by non-negative matrix factorization (NMF)23 or
bottom-up clustering of all 1D cross sections of a covariance
TOCSY spectrumusing theDemixCmethod.24 Application of
the method to the analysis of a single defensive spray
milking from an adult female walking-stick insect Anisomor-
pha buprestoides using a 1-mm high-temperature supercon-
ducting NMR probe revealed that it contains, in addition to
glucose, two stereoisomeric terpenes, each with a dialdehyde
and a diol in slow chemical exchange (Figure 2).25
DemixC traces can be treated like 1D NMR spectra, and
hence, they are well suited for compound identification by
database searching. For this purpose, a peak list is generated
for a given DemixC trace, which is then queried against
the peak lists of the components of an NMR database, such
as themetabolomics BMRB26 or HMDB,27 as implemented in
the COLMAR suite of web servers28,29 (http://spinportal.
magnet.fsu.edu). NMR databases26,27,30 are improving and
expanding rapidly, and correspondingly, their importance for
metabolomics and natural products research is growing.
Detailed descriptions of these databases are available at
the listed Web sites.
FIGURE 2. (A) Aliphatic section of covariance proton TOCSY spectrum of defensive secretion of a single walking stick insect. (B) One-dimensional 1H
NMR spectrum of the mixture. The six black spectra are covariance TOCSY traces extracted from covariance TOCSY of panel A using the DemixC
approach. The bottom three red spectra are reference 1D spectra of purified components. Each reference spectrum contains two species, R-glucose
(trace 1) and β-glucose (trace 2); dialdehyde and diol forms of the anisomorphal (traces 4 and 3, respectively); and the peruphasmal (traces 5 and 6,
respectively) monoterpenes. Chemical structures of the anisomorphal and peruphasmal and their corresponding geminal diols are shown as insets.
Figure is adapted from ref 25.
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Database matching has also been demonstrated for
heteronuclear 2D 13C!1H HSQC31 and HSQC-TOCSY NMR32
spectra of mixtures. Although at natural 13C abundance the
intrinsic sensitivity of HSQC is lower than for TOCSY, along
the 13C dimension the fully decoupled HSQC spectrum dis-
plays very sharp peaks with low probability of cross-peak
overlap. Moreover, HSQC spectra only yield correlations
between directly bonded 1H!13C nuclei and are therefore
unsuitable to trace the carbon backbones of individual
mixture components. This objective can be achieved by
the doubly indirect covariance NMR method combining a
2D COSY spectrum Y with a 2D HSQC spectrum H via basic
matrix operations: D = H 3Y 3H
T.33 D is a symmetric ultra-
high resolution 13C!13C correlation spectrum that can be
analyzed using graph theory to identify the carbon skele-
tons of individualmixture components, as shown in Figure 3.
In case of proton overlap, additional connectivities do occur.
They can be suppressed by an unsupervised “moment”
FIGURE 3. Doubly indirect covariance spectroscopy ofmodelmixture containing carnitine, lysine, isoleucine, and shikimate: (A) 2QF-COSYspectrum;
(B) 13C!1H HSQC spectrum; (C) doubly indirect covariance spectrum; (D) absolute value cross sections along 1H dimension of COSY and HSQC for the
overlap at ω2 = 1.45 ppm (traces 1!4 belong to COSY and traces 5 and 6 to HSQC); (E) carbon!carbon connectivity graphs of mixture components.
Dashed lines indicate extraneous connectivities to nodes 15 and 16 due to 1H overlap at 1.45 ppmas indicated by arrows in panels A and B. They are
identified by filtering according to differential peak positions and shapes (1st and 2ndmoments) (panel E) or, alternatively, by diffusion order spectro-
scopy (DOSY). The labels a, b, c, andd inpanels E andF belong to carnitine, lysine, shikimate, and isoleucine, respectively. Figure is adapted from ref 33.
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filtering method34 that removes false correlations based on
differential peak positions and peak widths (Figure 3). Be-
sides the carbon backbone topology, the method also
provides 13C and, via HSQC, 1H chemical shifts, which are
useful reporters on the nature of additional chemical groups,
for example, a phosphate or amino group, attached to these
carbons that are not directly visible in the COSY and HSQC
spectra. The doubly indirect covariance approach is de-
signed for studying samples from uncharted territories
where not only the concentrations of mixture components
but also their chemical structures are not a priori known,
thereby bridging the fields of natural product research and
metabolomics.
2.3. Comparative Analysis of Biological Mixtures. Sta-
tistical techniques used in comparativemetabolomicswill be
particularly useful for identifying new BSMs associated with
specific phenotypes or genotypes, perhaps the largest loom-
ing challenge in chemical biology and natural products
chemistry. For most known BSMs in nonmammalian sys-
tems, their biological functions andbiosynthetic heritage are
not known, and correspondingly, many genes believed to
play a role in small molecule biosynthesis have remained
orphans. The recent identification of the antibiotic bacil-
laene from Bacillus subtilis using differential analyses of 2D
NMR spectra (DANS) illustrates the potential for adapting
comparative approaches to natural products research.35,36
Previous studies had shown that the very large pksX
gene cluster (∼2% of the B. subtilis genome) encodes an
unusual hybrid PKS/NRPS (polyketide synthase/nonribosomal
peptide synthetase) that produced a small molecule with
antibiotic properties. Despite copious production of this
metabolite, its structure had remained undetermined be-
cause all isolation attempts had failed as a result of chemical
instability. Ultimately, bacillaene was identified via 2D NMR
spectroscopic comparison of the unfractionated metabo-
lomes of a pksX knockout and a pksX-expressing strain.
DANS analysis of 2QF-COSY spectra obtained for these two
metabolite samples enabled straightforward identification
of spectral features that were present in the pksX-expressor
but absent in the knockout, which formed the basis for
subsequent identification of bacillaene's complete structure
(Figure 1).35
A similar approach was used for the identification of a
component of the male-attracting pheromone of the nema-
tode Caenorhabditis elegans. Earlier studies based on activity-
guided fractionation of wormmetabolite extracts had shown
that C. elegans hermaphrodites produce a male-attracting
blend of derivatives of the dideoxysugar ascarylose.3
However, due to strong synergism, not all components of
this pheromone blend could be identified via fractionation.
Based on the observation that daf-22 mutant worms do not
produce the male attractant, Pungaliya et al. employed
DANS to compare the C. eleganswild-type and daf-22mutant
metabolomes, which revealed the unanticipated p-amino-
benzoic acid derivative ascr#8 as an important component
of the male-attracting pheromone (Figure 4).37 The identifi-
cation of ascr#8 from C. elegans and bacillaene from B.
subtilis illustrate that using comparative approaches for the
analysis of whole-metabolome 2D NMR spectra offers sig-
nificant opportunities for natural products chemistry and
chemical biology.
2.4. Statistical Methods for Identifying BSMs fromMul-
tiple Biological Mixtures. The combination of untargeted
spectral analysis of complex small molecule mixtures with
statistical pattern recognition techniques for direct spe-
ctral comparison has transformed the study of meta-
bolite associations with disease, gene function, and drug
metabolism.38,39 Quantitative comparisons of spectra from
two or more distinct biological states has been a defining
feature of an approach that has been referred to as “meta-
bolomics”, “metabonomics”, and “metabolic profiling”.38,39
As such, the statistical data analysis methodology for com-
paring spectra is as significant a part of metabolomics as the
underlying analytical chemistry technique that is used to
generate data sets. Two major classes of statistical tools are
used in metabolomics: those that identify relation-
ships between biological states and spectral signals and
those that look for correlations between spectral signals
themselves.
Most metabolomics studies make use of statistical tech-
niques to look for correlations between spectral signals and
the biological states of the analyzed samples. Examples of
these tools include principal component analysis (PCA),
partial least squares (PLS), orthogonal projection onto latent
structures (O-PLS), anddiscriminant analysis (PCA-DA, PLS-DA,
O-PLS-DA).6 In the general implementation of a metabo-
lomics study, two biological states are chosen such that the
majority of BSMs are unchanged, but certain BSMs that are
sensitive to differences in the two biological states are
quantitatively or qualitatively different. Pattern recognition
tools then act as a filter to remove the spectroscopic signals
from the shared metabolites from consideration while high-
lighting the signals arising from the metabolites present in
one state or the other (Figure 5).6
Although the use of 2D NMR spectra in metabolomics
has generally lagged behind the use of 1D NMR or mass
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spectra,40 a recent example demonstrates that full-resolu-
tion 2D NMR spectra can be used for statistical analysis (e.g.,
via PCA) following proper alignment. Using a peak align-
ment algorithm termed HATS-PR (hierarchical alignment of
two-dimensional spectra - pattern recognition), Robinette
et al. compared sets of TOCSY spectra derived frommetabo-
lome samples of two nematode species, Pristionchus pacificus
and Panagrellus redivivus.41 The method combined the
strengths of traditional 1D statistical methods and 2D NMR
data, illustrating how a combination of natural products and
metabolomics approaches can be used together and provid-
ing a framework for applying comparative statistical anal-
ysis to BSM discovery.
While themajority of the statistical tools inmetabolomics
seek to identify correlations between signals and biological
states, in the past 5 years there have been a number of
methods developed to identify correlations of spectroscopic
signals to other signals. The best known of these methods
is statistical total correlation spectroscopy (STOCSY).42,43
While covariance TOCSY18,19,21 (see section 2.2) identifies
correlations between signals by assessing their covariances
acrossmultiple t1-increments collected froma single sample,
STOCSYuses1Dspectraofmultiple biological replicates in the
place of t1-increments. Because all the signals from a given
compound increase and decrease together with the concen-
tration of the compound, peaks arising from the same com-
pound exhibit high positive statistical correlations. Because
STOCSY does not depend on physical phenomena such as
magnetization transfer, it can correlate signals even across
multiple spin systems that could not be correlated by TOCSY.
Though STOCSY was applied to identify correlations
between protons within the same spectrum, it was quickly
realized that statistical correlations could be identified
across multiple types of spectra. Heteronuclear STOCSY, or
Het-STOCSY, has beenapplied to identify 1H!19F and 1H!31P
correlations frommultiple biological replicates of 1D 1H and
1D 19F or 31P spectra.44,45 Additionally, peaks from NMR and
mass spectra have been correlated using statistical hetero-
spectroscopy (SHY).46 This approach is particularly promising
given thatwhile ascertaining bothmolecular formula and the
FIGURE 4. Identification of male-attracting pheromones in C. elegans via differential analysis of 2D NMR spectra (DANS): (A) overlay of COSY spectra
from C. elegans wild-type and daf-22 mutant metabolomes reveals daf-22-dependent signals; (B) structures of two new metabolites, ascr#7 and
ascr#8, that were identified from additional analysis of the daf-22-dependent signals.37
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structural restraints encoded in NMR spectra are critical for
structural elucidation, there are few methods for correlating
nuclear resonances with molecular weights in mixtures.
One drawback of these techniques is that any small mole-
cules that covary in concentration due to biological factors
such as coregulation will exhibit statistical correlations as well,
which can lead toambiguity aboutwhether agiven correlation
between two peaks represents a structural or biological
relationship.47 A recent extension of STOCSY termed cluster
analysis statistical spectroscopy (CLASSY) has focused on using
the network structure of correlations to resolve local clusters of
tightly correlated peaks.48 In the future, clustering both signals
and states using two-way or biclustering techniques should
provideameansofboth identifying signals specific toanactive
biological state andgrouping correlated signals as a first step in
the identification of BSMs. While “signal!state” correlation
tools are useful for identifying signals arising from a biologi-
cally active smallmolecule, theyalso couldbeextremelyuseful
in structure elucidation.
3. Conclusion/Future Perspectives
Long-establishedNMR techniques innatural product research
and the more recent statistical techniques of metabolomics
both strive to identify BSMs and correlate them to activity.
As described in this Account, several approaches using
NMR take advantage of the strengths of both approaches
in solving important biological problems. Advances in analy-
tical instrumentation in NMR and mass spectrometry as well
as improved databases and computational resources are
fueling these new capabilities. However, a great amount of
work remains. Some important challenges include the
following:
• Improved integration of NMR and MS data. The two
techniques are complementary and both are often
required for BSM identification. However, they have
very different sensitivities and dynamic ranges. MS is
very sensitive, but not all compounds are easily de-
tected. NMR is almost a universal detector, but it
suffers from low sensitivity. Despite advances, such
as SHY,46 this is still a difficult problem that limitsmany
studies.
• Improved Databases. This has improved significantly in
the past few years, but the size of NMRdatabases is still
relatively small, and many NMR chemical shifts are
dependent on solvent, sample concentration, and
other acquisition parameters, which makes exact
matching a challenge.
FIGURE 5. When two biological mixtures (blue and red ovals) share most compounds (colored spheres) but differ in biological activity, pattern
recognition techniques applied to NMR spectra of the mixtures can identify the spectral signatures of the differential compounds. Multivariate
statistical tools such as PCA and PLS decompose a set ofmixture spectra into a score for each sample spectrum and loadings for each chemical shift in
the NMR data set. When pattern recognition produces scores that separate the active (red circles) and inactive mixtures (blue circles), the loadings
indicate which signals arise from compounds specific to the active (red cross-peaks) and inactive (blue cross-peaks) mixtures.
296 ’ ACCOUNTS OF CHEMICAL RESEARCH ’ 288–297 ’ 2012 ’ Vol. 45, No. 2
NMR in Metabolomics and Natural Products Research Robinette et al.
• Rapid Identification of BSMs. Ultimately, the goal in
virtually every natural products or metabolomics
study is the identification of active BSMs. Acceleration
and automation of the identification process remains
the major bottleneck, both because of limitations
described above, and perhaps more importantly, be-
cause of the great chemical diversity in BSMs.
Although comparison to experimental reference spec-
tra may enable identification of common abundant
metabolites, a large number of minor and trace com-
ponents, especially organism-specific metabolites,
usually remain unidentified in automated analyses.
There is no universal identification algorithm or pro-
tocol that can be robustly applied to all classes of
molecules, and thus exists amajor need for the further
development of methods that can build on the recent
progress made, including the work described in this
Account.
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Detection of a large number of low molecular weight meta-bolites in complex mixtures has become an important tool
to study human disease and the eﬀects of drug therapy, to identify
biochemical functions of unknown genes and assess the impact
of mutations, and to investigate the interactions of genes and
environment to produce observable phenotypes at the cell
and organism level.1!3 This approach, often referred to as
metabonomics,4 metabolomics,1 or metabolic proﬁling, aims to
improve understanding of physiology and metabolism by using
analytical chemistry techniques to assess metabolic changes in
bioﬂuids, tissues, and cell extracts following an experimental
perturbation. Unlike microarray based “omics” platforms, meta-
bonomics relies on established analytical chemistry techniques
such as liquid chromatography/mass spectrometry (LC/MS),
gas chromatography/mass spectrometry (GC/MS) and nuclear
magnetic resonance spectroscopy (NMR) to obtain metabolic
signatures.1!3 The recent introduction of ultraperformance
LC (UPLC/MS) has greatly enhanced chromatographic perfor-
mance, increasing the sensitivity and throughput of LC/MS
measurements. Although the determination of the exact number
of metabolites which can be measured by untargeted UPLC/MS
is complicated by sample preparation, chemical diversity of the
matrix, and the presence of isotopes and fragment and adduct
ions, UPLC/MS routinely detects thousands of features repre-
sentative of hundreds to thousands of metabolites in biological
mixtures.5
While these analytical chemistry techniques boast high sensi-
tivity and reproducibility and are capable of untargeted detection
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ABSTRACT: Ultra-performance liquid chromatography coupled to mass spectrometry
(UPLC/MS) has been used increasingly for measuring changes of low molecular weight
metabolites in bioﬂuids/tissues in response to biological challenges such as drug toxicity
and disease processes. Typically samples show high variability in concentration, and the
derived metabolic proﬁles have a heteroscedastic noise structure characterized by
increasing variance as a function of increased signal intensity. These sources of
experimental and instrumental noise substantially complicate information recovery
when statistical tools are used. We apply and compare several preprocessing procedures
and introduce a statistical error model to account for these bioanalytical complexities. In
particular, the use of total intensity, median fold change, locally weighted scatter plot
smoothing, and quantile normalizations to reduce extraneous variance induced by
sample dilution were compared. We demonstrate that the UPLC/MS peak intensities of
urine samples should respond linearly to variable sample dilution across the intensity
range. While all four studied normalization methods performed reasonably well in reducing dilution-induced variation of urine
samples in the absence of biological variation, the median fold change normalization is least compromised by the biologically
relevant changes in mixture components and is thus preferable. Additionally, the application of a subsequent log-based
transformation was successful in stabilizing the variance with respect to peak intensity, conﬁrming the predominant inﬂuence of
multiplicative noise in peak intensities from UPLC/MS-derived metabolic proﬁle data sets. We demonstrate that variance-
stabilizing transformation and normalization are critical preprocessing steps that can beneﬁt greatly metabolic information recovery
from such data sets when widely applied chemometric methods are used.
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of a large number of diverse chemical species, the collection and
comparison of a large number of NMR or mass spectra pose
formidable data analysis challenges regardless of whether NMR,
GC/MS, or LC/MS is applied. While the capabilities of these
techniques have been compared elsewhere, spectra generated by
each require similar preprocessing steps before comparative
analysis.6 The signatures of thousands of metabolites generated by
UPLC/MS require extensive preprocessing prior to comparative
statistical analysis.7!10 A key step in the analysis of UPLC/MS data
sets is the transformation of ion intensities resolved by elution time
into a matrix of features (m/z!retention time pairs; columns)
present in each sample (rows) by peak detection, alignment, and
area extraction algorithms. A number of open source tools such as
XCMS,10 MAVEN,11 MZmine,12,13 OpenMS,14,15and XAlign,16
as well as proprietary software packages such as MarkerLynx
(Waters Corp), Mass Proﬁler (Agilent), and others from
Thermo Scientiﬁc and Applied Biosystems, are currently avail-
able to achieve these objectives. Subsequent statistical analysis
tools operate on this matrix of ion intensities.
Despite the signiﬁcant attention paid to peak identiﬁcation
methods, instrumental and experimental challenges complicating
the direct interpretation of ion intensities as metabolite concen-
trations have been largely neglected in the experimental
literature.17,18 This is especially true with respect to the urinary
matrix commonly used in metabonomics studies. While urine is
an ideal bioﬂuid for metabonomics studies since it is obtained
noninvasively, and its composition is aﬀected by genetic and
environmental factors reﬂecting the physiology of multiple
organs, urine dilution eﬀects and instrumental variation from
the analytical method play a signiﬁcant confounding role when
one attempts to characterize these biological and physiological
factors through NMR and MS measurements of small molecule
concentrations.19 Ensuring that NMR- and MS-generated urin-
ary proﬁles are directly comparable by reducing the impact of
variance associated with dilution and noise by data normalization
and transformation are critical steps in MS data preprocessing
prior to multivariate statistical analysis.18,20
Normalization is used to identify and remove sources of
systematic variation between sample proﬁles due to factors that
are irrelevant with regard to biological processes, such as sample
dilution or variation in instrument detector sensitivity, in order to
ensure that spectra are comparable across runs and across related
sample sets.20 Up to 15-fold changes in urine volume are
commonly observed under normal conditions, resulting in sig-
niﬁcant variation in dilution of metabolite concentrations across
many samples.21 Additionally, disease or toxic eﬀects may cause
further changes in overall urine volume, further complicating
interpretation of changes in observed metabolite concentrations.
Technical variation in UPLC/MS arises from sources such as
diﬀerences in LC separation eﬃciency (e.g., due to column
aging), and drifts in ionization and detector eﬃciencies (e.g.,
due to source contamination). In order to obtain repeatable and
interpretable LC/MS metabolic proﬁling data, the chromato-
graphic retention time, ion signal intensity, and mass accuracy
must be stable both within a sample batch and between multiple
batches. It is well-known that the ﬁrst few injections of sample on
an LC/MS system give unrepresentative results for global
metabolic analysis, due to small changes in chromatographic
retention time and/or signal intensity. Usually after 5!10
injections of the matrix, retention times stabilize as the column
becomes “conditioned” and the system then shows little varia-
bility through the remainder of the run. Additionally, the source
of the mass spectrometer can become contaminated, leading to
gradual changes in instrument sensitivity over time. Providing
that these changes are not major, the subsequent data treatment
will not be too adversely aﬀected, provided that careful ran-
domization of the samples has been performed to ensure that all
of the experimental groups are aﬀected to the same extent.
Quality control samples, ideally a pooled sample consisting of
aliquots from all samples in a study batch, can be used to
condition the column at the start of the run and are then injected
periodically, for example, every 10 samples throughout the run to
assess instrument stability. These QC samples can also be used to
assess stability across multiple instruments.
In order to ensure that samples are comparable within a batch
and betweenmultiple sets of samples, a variety of methods can be
employed to estimate normalization factors.17,20,22!24 Each
technique relies on a set of assumptions about the analytical
measurements and the biological variability of a data set in
question. The normalization approaches applied to LC/MS
metabolic data sets have been thus far largely limited to basic
techniques that scale all spectra by a common factor, usually the
total metabolite peak intensity or physiological variables such as
urine volume, osmolality, or creatinine level.24 However, both
the total metabolite concentration and physiological variables of
urine can vary considerably with reference to a variety of factors
such as age, gender, diet, and time of urine collection. The
instrumental eﬀects of ion suppression and detector saturation
can also cause highly abundant metabolite peaks to respond
diﬀerentially to dilution, and thus the same scaling factor may not
necessarily be required across the peak intensity range.20 More
recently, a normalization method was developed to correct for
UPLC/MSpeak intensity attenuation of serumproﬁles with respect
to the order of injection based onQCdata.25 It is a robustmethod to
account for technical variance due to factors such as loss of
instrumental sensitivity, but it is not directly applicable to urine
studieswhere additional and oftenmore substantial variation of total
urinary volume (and hence metabolite concentrations) is expected.
In addition, the UPLC/MS peak intensities of metabolic
proﬁles are subject to noise from various sources and hence of
diﬀerent types resulting in a heteroscedastic noise structure,
characterized by increasing technical variance as a function of
increased signal intensity.17,18 This can adversely aﬀect stan-
dard statistical and pattern recognition tools,26,27 which assume
the data noise to be consistent across the whole intensity range
(i.e., homoscedastic). This issue can be addressed either by
modifying a statistical model to accommodate heteroscedastic
noise structure26,28 or by validating an appropriate variance-stabi-
lization transformation tomake peak intensity consistent across the
whole intensity range.27Where possible, the last is often a preferred
option. Here, we introduce a statistical model for UPLC/MS peak
intensities of metabolite levels that comprises data normalization
and quantiﬁcation of measurement noise. The objective is to
remove sources of systematic variation between sample proﬁles
due to factors that are irrelevant with regard to biological processes
such as sample dilution (normalization) and to stabilize the
technical variance as a function of signal intensity (variance-stabiliz-
ing transformation). Four diﬀerent normalization techniques
[locally weighted scatter plot smoothing (LOESS), quantile,
median fold change, and total intensity] are compared for adjusting
peak intensities between samples to a common scale. The choice is
made to cover a range of assumptions regarding UPLC/MS meta-
bolic measurements and biological variability of a data set. The utility
of logarithmic-based variance-stabilizing transformations is evaluated.
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The proposed approach could be adapted for use in other types of
biochemical mixtures and is thus generally applicable to a wide range
of analytical chemistry applications.
’MATERIALS AND METHODS
Study Details. Urine samples analyzed as part of a study on
gender differences in rat metabolic profiles were used to assess
the different preprocessing procedures. After 1 week of acclima-
tization, 40 Wistar rats (20 males and 20 females), aged 9 weeks,
were housed individually in metabolism cages for 24 h under a
conventional environmentwith controlled conditions [temperature
20!24 !C, relative humidity 40!70%, 12-h light cycle (7 a.m. to
7 p.m.)]. Filtered tap water was available ad libitum. Food
[sterilized A04C-10 feed pellets from SAFE (Villemoisson-sur-
Orge, France)] was available ad libitum for the first 8 h, and then
the animals were fasted for the subsequent 16 h. Urine was
collected over the intervals 0!8 h and 8!24 h into refrigerated
tubes protected from light containing sodium azide (500 μL of
1% solution). After collection, all samples were centrifuged and
225 μL aliquots were stored at!40 !C until UPLC/MS analysis.
Sample Preparation.Water (150 μL) was added to 50 μL of
urine. Samples were vortexed and centrifuged (16000g, 10 min),
and 140 μL of supernatant was transferred into MS 96-well plates.
A quality control (QC) sample, representative of the sample batch,
was prepared by combining 40μLof each sample. Dilutions 1/2, 1/
4, and 1/8 of this QC sample in water were also prepared.
UPLC/MS Analysis. Analyses were performed on an Acquity
UPLC system (Waters, Elstree, U.K.) coupled to a LCT Premier
time-of-flight mass spectrometer (Waters, Manchester, U.K.),
operated in the positive electrospray ionization (ESIþ) mode.
Chromatography was carried out at 40 !C with a 0.5 mL/min
flow rate on a Waters Acquity UPLC HSS T3 column (1.8 μm,
2.1 # 100 mm), with the following solvent system: A = 0.1%
formic acid in water, B = 0.1% formic acid in acetonitrile. A
10 min gradient was used, followed by a 2 min re-equilibration
phase (0!1 min, hold at 0% B; 1!3 min, 0!15% B (linear); 3!
6 min, 15!50% B (linear); 6!9 min, 50!95% B (linear); 9!
10 min, hold at 95% B; 10.1!12 min, hold at 0% B). Gradient
type = 6 (Waters). Samples were kept at 4 !C in the autosampler
during the analysis. The injection volume was 5 μL. ESI condi-
tions were as follows: source temperature 120 !C, desolvation
temperature 350 !C, cone gas flow 25 L/h, desolvation gas flow
900 L/h, capillary voltage 3200 V, cone voltage 35 V. The
instrument was operated in V optics mode and set to acquire
data over the m/z range 50!1000 with scan time of 0.2 s and an
interscan delay of 0.01 s. Data were collected in centroid mode.
Leucine enkephalin (MW = 555.62) (200 pg/μL in acetonitrile/
water 50:50) was used as a lock mass for accurate mass
measurements. The instrument was calibrated before analysis
by use of 0.5 mM sodium formate solution. The run order was
randomized to minimize its correlation with the factors of the
experimental design (gender and collection time point). The QC
sample was injected regularly throughout the run (after every
10 samples) to monitor the stability of the analytical platform.5,9,29
This QC sample was also used to condition the column at the
beginning of the UPLC/MS run,5,9 because the first injections of a
batch are often not reproducible.
Raw Data Preprocessing. UPLC/MS raw data files were
converted to netCDF format by use of the DataBridge tool
implemented in MassLynx4.1 software (Waters). They were then
preprocessed by use of the freely available XCMS software.10
The CentWave algorithm30 was used for peak picking with a
peak width window of 3!15 s; the m/z width for the grouping
step was changed to 0.1 Da; and the bandwidth parameter was
kept to default (30 s) for the first grouping and then determined
from the retention time deviation profile after retention time
correction. This preprocessing step produced an output table of
time-aligned detected features with their retention time, m/z
ratio, and intensity in each sample. Isotope peaks, fragments, and
adducts were treated as separate metabolite features. For the
work carried out in this paper, the urine samples of the collection
interval 8!24 h only were used, resulting in 40 urine samples
(20 males and 20 females) plus the QC samples.
Statistical Model.An UPLC/MS data set following the above
routine preprocessing stages can be represented by a rectangular
table (X) of real number elements (xik). The rows and columns
of X represent, respectively, samples and metabolite peak in-
tensities. Due to a variety of experimental, instrumental, envir-
onmental, and signal processing influences, the resulting peak
intensities are a combination of real signal and noises of varying
characteristics, which are generally of additive or multiplicative
nature18,31 and thus can be modeled by
xik ¼ βik þ niksikeηik ð1Þ
where xik is the measured peak intensity (level) of the ith
metabolite in the kth sample, sik is the expected peak intensity
(level), βik is the random background (electronic) noise, ηik is
the multiplicative random noise (for example, due to sample
preparation variation or fluctuations in the ion source or the
sample-introduction equipment), and nik is the normalization
scaling factor of signal intensities of the kth sample as a result of
variable sample dilution assumed to be either fixed (nk) or peak-
intensity-dependent (nik). Additive noise is characterized by
random fluctuations in the baseline, irrespective of the presence
of metabolite signals, and is derived from electronic noise in the
equipment. Conversely, multiplicative noise grows with the
signal intensity of a metabolite and is often proportional to it.
As a result of the influence of multiplicative noise, metabolites
with higher peak intensities would exhibit larger variability when
repeatedly measured, and thus weak signals can be buried in the
noise of strong signals. The objective of the preprocessing
strategies considered here is to remove the systematic variation
due to differences in overall sample concentration (normalization)
and to convert multiplicative noise into additive noise (variance-
stabilizing transformation):
vst
xik
nik
! "
' μik þ εik ð2Þ
where vst denotes a variance-stabilizing transformation, μik is the
transformed peak intensity, and εik is the random noise. The
overall procedure is quite straightforward. The fixed or peak-
intensity-dependent normalization factor is initially estimated for
each sample profile. The peak intensity is then divided by the
sample-dependent normalization factor. The generalized loga-
rithm or logarithm variance-stabilizing transformation is finally
applied to convert multiplicative noise into additive noise.
Normalization: Accounting for Systematic Bias between
Samples. Four different normalization techniques were selected
for adjusting peak intensities between samples to a common
scale. The choice was made to cover a range of assumptions
regarding UPLC/MS metabolic measurements and biological
variability of a data set. The first two approaches considered here
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are the total intensity and median fold change normalizations.
Both methods assume that measured peak intensities are directly
proportional to concentrations of metabolites in solution. Under
this assumption, the change in intensity of a profile due to
variable sample dilution and/or inconsistency of UPLC/MS
acquisition parameters is expected to be uniform across all peaks
and thus a fixed scaling factor is employed.
Total intensity normalization forces all samples in a set of
experiments to have equal total intensity:
nkTI ¼ ∑
i
xik ð3Þ
where nk
TI is the total intensity of the kth sample.24 This
technique assumes that the total concentration for all metabolites
in a sample does not vary across samples in a data set. This
assumption is not generally fulﬁlled in urinary metabolic studies,
due to changes in the number and concentration of small
molecules excreted.32 Changes in the peak intensities of a few
high-concentration metabolites can compromise noticeably the
normalization performance because of their substantial contribu-
tion to the total peak intensity.
Median fold change normalization adjusts themedian of log fold
changes of peak intensities between samples in a set of experi-
ments to be approximately zero:
nkMFC ¼ median xikxir
! "
ð4Þ
where nk
MFC is the median fold change of peak intensities
between the kth sample and the target sample. This normal-
ization is based on the reasonable premise that metabolite peaks
aﬀected purely by dilution will exhibit the same fold changes
between two sample proﬁles. This should be the case if peak
intensities are directly proportional to metabolite levels in solution.
The median value of fold change between sample and target proﬁles
has been shown to be a robust estimate of this dilution factor.32 The
performance of this method is robust against at least 50% peak
intensities exhibiting asymmetrical increase or decrease in response
to biological factors such as disease or toxic challenge. The choice of a
target proﬁle has been shown not to be crucial for the method
performance; it can be any sample of a given data set or, as typically
selected, the median proﬁle.
The other two approaches considered here are quantile and
LOESS normalizations. These methods assume that systematic
sample-to-sample variation is peak-intensity-dependent, that is, not
necessarily the same scaling factor is used over the peak intensity
range. This variation may arise due to the eﬀects of ion suppression
and detector saturation on measured metabolite levels.
Quantile normalization enforces all samples in a set of experi-
ments to have identical peak intensity distribution:22
nikQN ¼ xikxrðiÞt ð5Þ
where nik
QN is the quantile-intensity-dependent normalization
factor of the kth sample and the subscript (i) enclosed in
parentheses indicates the order statistic of the ith peak intensity
of the kth sample and xt is a target sample. Each peak intensity of
a sample by the quantile normalization is simply substituted by
the peak intensity with the same order statistic r(i) of a target
sample. For example, the highest intensity in a given sample takes
the value of the highest peak intensity in the target sample, the
second highest peak intensity takes the second highest in the
target sample, and so on. The target proﬁle is typically selected to
be the mean or median proﬁle of a data set. The method assumes
that the distribution of peak intensity across a data set is nearly
the same for all samples and can be problematic with high-
intensity values since they typically vary noticeably from sample
to sample. It is also assumed that there is a similar number of
metabolites with increased and decreased signals across the peak
intensity range.
Locally weighted scatter plot smoothing (LOESS) normalization
adjusts the local median of log fold changes of peak intensities
between samples in a data set to be approximately zero across the
whole peak intensity range:23,33
nikLOESS ¼ fðxikÞ ð6Þ
where nik
LOESS is the LOESS-intensity-dependent normalization
factor of the kth sample calculated by nonlinear mapping of
sample intensities into those of a reference sample. It is assumed
that the proportion of metabolic changes across biological
samples is relatively small or that there is a similar number of
metabolites with increased and decreased signals across the peak
intensity range.
Variance-Stabilizing Transformation: Accounting for Het-
eroscedastic Noise Structure. To account for heteroscedastic
noise structure observed in UPLC/MS metabolite measure-
ments, two logarithm-based transformations are chosen on the
basis of the model (eq 1). It is first assumed that the noise is
mainly multiplicative in nature, that is, the influence of back-
ground random noise is negligible (i.e., βki≈ 0). This assumption
has been previously used in modeling UPLC/MS data17
and other types of high-throughput data generated by, for
example, microarray technology.26,34 In this noise model,
the standard deviation of peak intensity is proportional to its
expected value. The logarithm is an appropriate variance-stabiliz-
ing transformation, as it makes peak intensity variance indepen-
dent of its expected value by transforming multiplicative error
into additive error:
log
xik
nik
! "
$ log ðsikÞ þ ηik ð7Þ
It is second assumed that the error structure of UPLC/MS
measurements has both additive and multiplicative noises (eq 1).
The additive random component may arise from the integration of
count-based signal inherent in the majority of MS instrumentation
and/or the presence of a small basal unspecific background signal
component. The variance of peak intensity under this model is a
quadratic function of its expected value.26 The samemodel has been
previously considered in modeling LC/MS data18 and is commonly
used in gene expression studies.26,27,31 The inverse generalized
logarithm transformation has been derived as an appropriate
variance-stabilizing transformation in this case:27
glog
xik
nik
! "
$ μik þ εik ð8Þ
glog ðxÞ ¼ log xþ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
x2 þ cp
2
 !
ð9Þ
where c is a fitted parameter. This transformation (eq 9) coincides
with the logarithm for large intensities but is approximately linear for
low intensities and interpolates smoothly in between. The scripts for
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performing variance-stabilizing normalizations described above are
available, upon request, in the open source statistical language R.
Principal Component Analysis. Formally, principal compo-
nent analysis (PCA) summarizes the data matrix in terms of
scores and loadings:35
X ¼ TP0 þ E ð10Þ
where X is a data matrix of sample profiles,T is a matrix of scores,
P is a matrix of weights (loadings) of spectral variables into the
scores, E is a residual, and the prime (0) denotes a transpose
operation. PC scores summarize interrelationships between
observations, for example, groupings according to physiological
traits or gender and dose- or time-dependent changes. A subset of
metabolites correlated with PC scores can be identified by use of
the corresponding PC loadings. PCAwas performed by using the
built-in function of Matlab for eigenvalue decomposition
(http://www.mathworks.com/).
’RESULTS AND DISCUSSION
Performance of Logarithmic-Based Variance Stabilizing
Transformations. To evaluate the changes in variation of peak
intensities across the entire measurement intensity range, repli-
cate injections of a quality control (QC) sample, obtained by
pooling equal aliquots of each urine sample in the study, were
used, as this QC sample represents all metabolites present in the
experimental set and can serve as a measure of technical
variability. The QC sample was measured eight times in the
experimental run. The standard deviation as a function of the
rank of the mean of peak intensity for replicate injections of the
QC sample is shown in Figure 1A. In the absence of hetero-
scedastic noise structure, the running median of the standard
deviation should approximate a horizontal line with minor
fluctuations but no overall trend. This is not the case for the
UPLC/MS data, where the variation of peak intensity grows with
the rank of mean intensity, that is, as intensity increases. As a
consequence for replicate measurements, larger peak intensities
are progressively more variable. This means that assumptions
underlying many widely applied statistical methods are not valid,
and this in turn could lead to incorrect statistical inferences,
having consequences for metabolic information recovery. To
correct for heteroscedastic noise structure, the log and glog
transformations were applied. Both transformations performed
comparatively well in stabilizing the variance of transformed peak
intensities across the entire measurement intensity range
(Figure 1B,C). This indicates the negligible influence of back-
ground additive noise and the predominant influence of multi-
plicative noise in the UPLC/MS peak intensity data. Such a
dominating influence of multiplicative noise has been previously
observed in LC/MS measurements of protein levels.18
Performance of NormalizationMethods in the Absence of
Biological Variation. To assess the ability of normalization to
account for dilution effects, the QC sample was systematically
diluted, ranging from 2- to 8-fold. An 8-fold dilution of urine
samples is quite common in metabolic studies. The objective
here is to evaluate whether sample dilution is likely to induce
uniform or peak-intensity-dependent changes in metabolic pro-
files. The uniform change due to sample dilution occurs when
measured peak intensities are directly proportional to metabolite
levels in solution (e.g., 2-fold sample dilution would result in
2-fold decrease in all peak intensities). However, various
instrumental influences can potentially introduce peak-inten-
sity-dependent biases between samples. As a result of ion
suppression or detector saturation, for example, the peak
intensities of highly abundant peaks may respond differently
to sample dilution or not be affected by it at all. One way to test
this is to visualize the log fold changes of peak intensities
between diluted and undiluted samples as a function of log peak
intensity; in microarray analysis this referred to as the M versus
A plot. Typical behavior of peak intensities in response to 2- and
4-fold dilutions is shown in Figure 2 panels A and B, where red
curves (calculated by the nonlinear LOESS regression) capture
the adjustment required for a particular intensity range between
diluted and undiluted samples. Clearly, the dilution-induced
adjustment of peak intensities is comparable across the entire
peak intensity range (e.g., the scaling factor of around 2 is
necessary to bring all peak intensities of the 2-fold diluted
sample to a common scale with the undiluted sample). The
majority of peak intensities are thus likely to respond linearly to
sample dilution. This is further confirmed by the fact that the
reduction of the percentage of dilution-induced variation for
individual peak intensities (calculated by one minus ratio of
variance of transformed peak intensity after and prior to
application of normalization) is comparable (on average
70%95%) over the peak intensity range between four studied
normalization methods (Figure 2C). It should be noted that
high sample dilution might limit the detection of low-abun-
dance metabolites in biological samples by UPLC/MS.
Figure 1. Standard deviation as a function of the rank of mean signal intensity for QC samples: (A) nontransformed data, (B) logarithm- (log-)
transformed data, and (C) generalized logarithm- (glog-) transformed data. The runningmedian of the standard deviation is shown as a dotted red line in
the plot. In the absence of heteroscedastic noise structure, it should be approximately a horizontal line with minor ﬂuctuations but no overall trend.
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However, this issue relates only to the instrumental data
acquisition and not to the subsequent data normalization.
Comparison of NormalizationMethods in the Presence of
Biological Variation. A robust normalization method not only
must account for dilution effects in samples of the same
composition but also must be applicable to experimental data
where changes in mixture composition are to be expected.
Certain assumptions with regard to the nature of biological
variance are inherent to all normalization methods (see the
Materials and Methods section for a detailed description). As
all four studied methods performed comparatively well in the
absence of biological variation, a method whose performance is
robust to biologically induced changes in peak intensity would be
of comparative advantage. The total intensity, quantile, and
LOESS normalizations rely heavily on the assumption that there
are similar numbers of metabolites with increased and decreased
signals.22,23 This assumption may not generally be fulfilled in
metabolic studies since the increases in the level of one metabo-
lite in response to stimuli may not necessarily be accompanied by
the decreased level of another metabolite. The application of the
LOESS and quantile methods is thus limited to cases in which a
low percentage of metabolites have asymmetrically increasing or
decreasing abundances. The performance of total intensity
normalization can be compromised by a single large metabolite
peak that varies substantially from sample to sample.32 By
contrast, the median fold change normalization allows at least
half of metabolite peak intensities to exhibit asymmetrical
changes between samples. This is a relaxed assumption with
regard to the nature and proportion of differentially abundant
metabolite peaks, which is generally applicable to data from
metabolic studies.
The performance of normalization methods in the presence of
biological variance can be diagnosed by use of summary statistics
of sample peak intensity distributions via box plots. If it is
assumed that up to a quarter of peak intensities are asymme-
trically increased or decreased due to biological eﬀects, the log
ratios of nondiﬀerentially abundant metabolite peaks should
have a comparably small spread around zero across samples
(noted by the box in Figure 3) and a median of zero (a black
diamond in the box in Figure 3). This is illustrated on a urine data
set of controlWistar rats, in which themajority of peak intensities
are expected not to be diﬀerentially abundant. The peak inten-
sities of nonnormalized samples exhibit large variation in overall
concentration within sample types of male (red) and female
(blue) rats (Figure 3A). This variation is within the 8-fold
dilution range of the QC sample (green). The eﬀect of this
dilution-induced variation is that any informational changes in
metabolite concentration between sample types would need to
be very large to be detected. As a result, a large set of biomarker
candidates would simply not be identiﬁed by statistical
Figure 2. Assessment of peak-intensity-dependent bias due to variable sample dilution in UPLC/MS metabolic measurements. The log fold change in
peak intensities between diluted and undiluted samples as a function of log peak intensity is shown for (A) 2-fold and (B) 4-fold sample dilutions. Red
curves (calculated by nonlinear LOESS regression) capture the adjustment required for a particular intensity range between diluted and undiluted
samples. (C) Reduction of the percentage of dilution-induced variation for individual log- or glog-transformed peak intensities across peak intensity
range. Reduction of dilution-induced variation is calculated by 1! varnorm/varnon-norm, where varnorm and varnon-norm are variances of transformed peak
intensities after and prior to application of normalization, respectively. The sorted mean intensity values for 4453 peaks were divided into ﬁve
approximately equal-sized data subsets, denoted by low, low/medium,medium,medium/high, and high peak intensity ranges. The upper edge of the box
is the 75th percentile and the lower edge is the 25th percentile of values.
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techniques. The median fold change, quantile, and LOESS
normalizations successfully reduce dilution-induced variance, as
shown by the near zero log ratios of nondiﬀerentially abundant
peaks, indicating the negligible inﬂuence of peak intensity biases
between samples (Figure 3B and Figure S1, Supporting In-
formation). Total intensity normalization, however, shows in-
ferior performance as indicated by the remaining sample-to-
sample variation. This is most likely due to small changes in total
metabolite excretion between samples. We suggest that while
quantile and LOESS show similar performance to median fold
change, the median fold change normalization should be pre-
ferred because of its relaxed assumption with the proportion of
asymmetric metabolic marker changes.
Impact of Variance-Stabilizing Normalization on Explora-
tory Data Analysis via PCA. Principal component analysis
(PCA) is the most commonly used method to explore relation-
ships between samples in metabolic profiling studies. It aims to
extract a small number of latent components that summarize the
measured data with minimal information loss by taking ad-
vantage of the correlation structure of peak intensities. The
information content in PCA is measured as a sum of variances
of individual peak intensities, referred to as the total variance. In
the presence of multiplicative noise, metabolites with higher peak
intensities are progressively more variable when measured re-
peatedly and therefore constitute a larger share of the total
variation. The resulting PC scores are impacted heavily by the
random variation of these high-intensity metabolites and there-
fore can poorly represent the complete variation structure of a
data set. This effect is illustrated on the urine data set of control
Wistar rats in Figure 4. The sample scores of the first two PCs
(raw peak intensities, Figure 4) are scattered, indicating a
dominant influence of random variation. As a consequence, the
assessment of overall similarities and differences between sam-
ples is quite poor; the grouping of technical replicates with
respect to the degree of dilution is not even clear. The normal-
ization of raw peak intensities by median fold change results in
only slight changes in the PC scores because of the dominant
impact of multiplicative noise in high-concentration mixture
components (normalized peak intensities, Figure 4). After
application of log-based variance-stabilizing transformations,
the first two components clearly capture the systematic variation
due to the difference in sample composition and variable sample
dilution (log/glog-transformed peak intensities, Figure 4). The
dispersion in the scores of bothmale and femaleWistar rats along
PC1 and PC2 parallel to the QC dilution series indicates a range
in concentration similar to the 8-fold dilution changes of the
QC sample. Normalization successfully removes this dilution-
induced variation, leading to tight clustering of technical
replicates and improved clustering of biological replicates. In
addition, all clusters of sample types are clearly distinguishable
(log/glog-transformed and normalized peak intensities, Figure 4).
The sample scores of the first two PCs between log- and glog-based
transformations across four normalization methods are somewhat
comparable (Figure S2, Supporting Information). This confirms the
results of the previous sections: that multiplicative noise is the most
significant source of background variation inMSmetabolic profiling
and that all four normalization methods remove the majority of
dilution-induced variation from the data.
Figure 3. Box plots of the log 2-fold change in peak intensities relative to the median proﬁle calculated across a data set: (A) nonnormalized and (B)
median fold change normalized data. The upper edge of the box is the 75th percentile and the lower edge is the 25th percentile of relative intensity values
and points noted by ‘.’ are metabolite features which exhibit relative changes. The median is shown as a black diamond in the box. The boxes are colored
by sample types. QC, quality control urine samples of Wistar rats; QCD2, 2-fold diluted quality control urine samples; QCD4, 4-fold diluted quality
control urine samples; QCD8, 8-fold diluted quality control urine samples.
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’CONCLUSIONS
We have compared several variance-stabilizing normalization
strategies based on a statistical error model in order to account
for systematic sources of variation, such as that induced by
variable sample dilution, and in order to stabilize the technical
variance as a function of peak intensity observed in UPLC/MS
metabolic proﬁles of urine.
It can be concluded that the UPLC/MS peak intensities of
urine metabolic proﬁles are likely to respond linearly to variable
sample dilution across the intensity range. In other words, peak-
intensity-dependent biases between samples as a result of ion
suppression or detector saturation that would cause highly
abundant peaks to respond diﬀerentially to dilution were not
observed. This indicates that the majority of urinary metabolites
are within the detector dynamic range.
Second, all four studied normalization methods (LOESS, quan-
tile, total intensity, and median fold change) performed compara-
tively well in reducing dilution-induced variation of urine samples in
the absence of biological variation.However, themedian fold change
normalization is least compromised by biologically relevant changes
in mixture components and is thus preferable
Third, the higher peak intensities of urine proﬁles exhibit
larger variability when repeatedly measured, mainly due to the
presence of multiplicative noise. This violation of constant
variance across the measurement range imposes a serious
challenge when standard statistical techniques are applied, as
demonstrated by principal component analysis. The UPLC/MS
peak intensity of urine samples can be brought in line with this
assumption by applying a log-based transformation, which success-
fully stabilizes the technical variance across the intensity range.
Finally, variance-stabilizing transformation and normalization
are critical preprocessing steps that can greatly beneﬁt the
metabolic information recovery from urine UPLC/MS data sets
via commonly used pattern recognition tools.
Although applied to urine studies, the proposed framework for
assessing the performance of normalization methods and var-
iance-stabilizing transformation is general in scope and thus can
be applied to other biological sample types.
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